Molecular cloning and characterisation of GABA-B receptors from Xenopus laevis. by James, R.
1Molecular cloning and 
characterisation of GABAb 
receptors from X
Robert James
UMI Number: U591606
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591606
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
2I, Robert James, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this 
has been indicated in the thesis.
Signed
Printed  ROBERT JAMES
Dated K . fig.. o?
3Abstract
Gamma-amino butyric acid (GABA) is the principal inhibitory neurotransmitter in the adult 
central nervous system (CNS) and signals via ionotropic GABAa receptors and 
metabotropic GABAb receptors. GABAb receptors are obligate heterodimers comprised of 
GABAB(1) and GABAB(2) subunits, members of the Family 3 G-protein coupled receptors 
(GPCRs). GABAbl is an orphan Family 3 GPCR of unknown function, most closely related 
to GABAb receptors.
To investigate the functions of these genes during vertebrate development, Xenopus 
laevis GABAB(d, GABAB(2) and GABAbl cDNAs were isolated, and their spatiotemporal 
expression patterns during embryogenesis analysed by RT-PCR and in situ hybridization. 
Maternal GABAB(2) transcripts were detected by RT-PCR in blastulae, whereas GABAB(1) 
and GABAbl transcripts were not detected until gastrulation and neurulation respectively. 
In situ hybridization revealed that GABAB(i) and GABAB{2) transcripts were co-expressed in 
most brain regions, although areas of unique GABAB(i) expression also existed, and 
GABAbl transcripts were located primarily in the brain and otic vesicle of the tailbud 
embryo.
Co-expression of GABAB(1) and GABAB(2) transcripts suggests a role for metabotropic 
GABA receptor signalling in the developing brain of Xenopus embryos. However, 
overexpression of GABAB(1) and GABAB(2) transcripts together or in isolation, during 
embryonic development did not generate a distinct morphological phenotype. In contrast, 
embryos overexpressing GABAbl during embryonic development exhibited a significant 
body truncation phenotype. Animal cap assays indicated that GABAbl overexpression 
interferes with mesodermal convergent extension, whilst RT-PCR shows that the 
expression of mesoderm-specific markers is not affected, demonstrating morphogenetic 
but not biochemical activity of GABAbl.
Whilst the temporal expression pattern of GABAbl does not support an endogenous role in 
the regulation of convergent extension in Xenopus, these experiments demonstrate that 
GABAbl is a functional protein that acts in a manner reminiscent of a GPCR by disrupting 
intracellular signalling cascades.
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1.1 The G-protein coupled receptor (GPCR) superfamily
1.1.1 GPCRs make up the largest class of cell-surface receptors
G-protein (guanine-nucleotide-binding protein) coupled receptors (GPCRs) belong to the 
largest known protein family, encoded by over 1000 genes in the human genome, and 
make up the largest class of cell-surface receptors (Howard,A.D et al. 2001). They are 
activated by a vast array of extracellular signals including small molecules such as amino 
acids and peptides, inorganic ions, nucleotides, neurotransmitters, hormones, cytokines, 
and even photons of light. GPCRs are responsible for the regulation of numerous 
physiological processes and carry out a multitude of tasks in the central nervous system 
(CNS) and the periphery, making them extremely important drug targets (George,S. R et 
al. 2002). Indeed, around 50% of all modern drugs modulate GPCR activity in some way 
(Howard,A.D. et al. 2001). Despite this, the majority of putative GPCRs identified from the 
human genome remain ‘orphan’ receptors whose endogenous ligands or downstream 
effector systems are yet to be identified, and as such, the ‘de-orphanisation’ of these 
receptors remains a primary objective in GPCR research (Okuno.Y et al. 2006).
1.1.2 GPCRs signal via both heterotrimehc and monomeric G-proteins
Most GPCRs transduce information by acting as guanine nucleotide-exchange factors 
(GEFs) for heterotrimeric G-proteins, whereby agonist binding brings about conformational 
changes in the GPCR that promote the exchange of guanosine 5’-diphosphate (GDP) for 
guanosine 5’-triphosphate (GTP) on the G-protein Gor subunit. Activation of the G-protein
21
in this way is thought to bring about its dissociation into Gcr and G/3y subunits which are 
then able to positively or negatively regulate various downstream effectors, where the 
intrinsic GTPase activity of the Gcr subunit acts as a molecular switch resulting in the 
deactivation of the subunit upon hydrolysis of bound GTP to GDP. There are several 
families of heterotrimeric G-proteins whose specificity for a particular downstream 
signalling cascade is conferred by the identity of the Gcr subunit. Activated Gcrs and Gofi/0 
subunits, for example, stimulate or attenuate adenylate cyclases respectively, regulating 
the cyclic AMP/protein kinase A (cAMP/PKA) pathway, whilst Gorq/11 subunits stimulate 
phospho-lipaseC-j3 (PLC-/3), activating the Ca2+/protein kinase C (Ca2+/PKC) pathway. 
G/3y subunits are also able to regulate intracellular events through the direct activation or 
inhibition of ion channels.
In addition to heterotrimeric G-proteins there are over 100 different monomeric G-proteins, 
or small GTPases, which are classified into five families according to structural similarity 
(Takai.Y et al. 2001). The Ras and Rho family GTPases regulate signalling cascades that 
affect gene transcription events, the latter family acting as the principal regulators of the 
actin cytoskeleton. Rab and Arf family GTPases primarily regulate vesicular movement 
between intracellular compartments, whilst the Ran GTPases regulate microtubule 
organisation and nucleocytoplasmic protein transport (Bhattacharya.M et al. 2004). 
Recent studies have demonstrated that GPCRs are able to modulate monomeric G- 
protein signalling events indirectly through activation of upstream heterotrimeric G-proteins 
(Seasholtz.T.M et al. 1999, Sah.V.P et al. 2000, Marinissen, M.J et al. 2001). For 
example, activation of Gai2/13 subunits by GPCRs in response to the binding of agonists, 
such as acetylcholine and lysophosphatidic acid (LPA), can trigger Rho GTPase-mediated 
cytoskeletal reorganisation through the stimulation of RhoGEFs (Kozasa.T et al. 1998, 
Hart,M.J et al. 1998). Also, G/3y subunits are able to couple to Ras GTPases indirectly
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through the stimulation of Src-dependent activation of matrix metalloproteinases (MMPs), 
which can in turn indirectly activate receptor tyrosine kinases (RTKs) and trigger Ras 
GTPase signalling (Bhattacharya.M et al. 2004).
1.1.3 GPCRs may be classified into five distinct families
Whilst all GPCRs are transmembrane proteins, possessing seven membrane-spanning a- 
helices, they may be easily classified into five distinct, phylogenetically unrelated families 
according to sequence homology (Bockaert.J et al. 1999) (see Figure 1.1). Family 1 
GPCRs, themselves broken down into type 1a, 1b and 1c, constitute by far the largest 
group of receptors. They are characterised by relatively short N- and C-termini and exhibit 
several highly conserved amino acid residues, including a C-terminal palmitoylated 
cysteine residue (George,S.R et al. 2002). Type 1a receptors, such as rhodopsin and the 
j02-adrenergic receptor O82-AR), bind their ligands in a pocket formed by their seven- 
transmembrane domains, whereas type 1b and 1c coordinate ligands via their N-terminal 
domains and extracellular loops. The latter two families include receptors for peptides and 
glycoprotein hormones respectively, where type 1c receptors are characterised by much 
larger N-terminal domains. Family 2 GPCRs, which include receptors for high molecular 
weight ligands such as glucagon, exhibit a similar morphology to type 1c receptors and 
possess multiple N-terminal cysteine residues, which presumably form a network of 
disulphide bridges (George,S.R et al. 2002).
Family 3 GPCRs include the metabotropic glutamate receptors (mGluRs), the calcium- 
sensing receptor (CaSR), metabotropic GABA (GABAb) receptors, a family of putative 
mammalian taste receptors (T1Rs), a promiscuous L-a-amino acid receptor (GPRC6A),
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and a host of putative orphan receptors. They are characterised by a very large N- 
terminal extracellular ligand-binding domain, structurally related to bacterial periplasmic 
binding proteins (PBPs), a long intracellular C-terminal tail and a highly conserved third 
intracellular loop containing the molecular determinants required for G-protein activation, 
equivalent to the second intracellular loop in Family 1 GPCRs (Yamashita.T et al. 2001). 
Many Family 3 GPCRs possess cleavable N-terminal secretion signal peptides and most 
exhibit a cysteine-rich linker region between their extracellular domain (ECD) and seven- 
transmembrane domains, with the notable exception of the GABAb receptors.
A model for ligand-binding, originally proposed for the bacterial L-arabinose binding 
protein (ABP) (Mao.B et al. 1982) and known as the ‘venus-flytrap’ model, describes open 
and closed conformations of ABP corresponding to unliganded and liganded states 
respectively. It is proposed that a ‘venus-flytrap’ model for receptor activation may be 
conserved across Family 3 GPCRs, whereby the N-terminal ECD switches between open 
and closed states according to ligand-binding (O’Hara,P.J et al. 1993, Galvez,T et al. 
2001, Kniazeff.J et al. 2002). Indeed, site directed mutagenesis studies have identified 
residues involved in ligand coordination in the leucine/isoleucine/valine-binding protein 
(LIV-BP) that are conserved across Family 3 GPCRs (Galvez,T et al. 1999).
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Figure 1.1 Schematic diagram showing structure of A. Family 1, B. Family 2, C. Family 3, 
D. Family 4, and E. Family 5 G-protein coupled receptors, showing approximate location of key 
cysteine residues (red) and ligand-binding sites (blue).
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A single family of putative pheromone receptors (VNs) constitute the Family 4 GPCRs. 
These receptors exhibit short N- and C-termini and share a high level of amino acid 
sequence identity. The expression of each member of the gene family is restricted to a 
small, distinct subpopulation of vomeronasal organ (VMO) neurons. (Dulac.C et al. 1995). 
Family 5 GPCRs include the Frizzled (Fzd) and Smoothened (Smo) receptors: regulators 
of developmental processes such as neurulation, somite and limb formation, and cell 
polarity (Strutt,D et al. 2003, Alcedo,J et al. 1997).
1.1.4 GPCR signalling regulates important processes during development
The events that occur during development are complex and highly regulated. Intercellular 
signalling molecules in the form of secreted or transmembrane proteins, of which there are 
six main families, regulate key developmental process by binding to cell-surface receptors 
and initiating signal transduction cascades in neighbouring cells (Wolpert.L et al. 1998). 
The fibroblast growth factors (FGFs) are secreted proteins that bind to RTKs and are 
responsible for induction of the spinal cord in vertebrates (Smith, J.C et al. 1993), whilst the 
transforming growth factor-jS (TGF-/3) family of proteins, which includes activin and bone 
morphogenetic proteins (BMPs), have roles in mesoderm formation and dorsoventral 
patterning, and signal via receptor serine-threonine kinases (RSTKs) (Dale,L et al. 1999). 
Ephrins are membrane-tethered ligands for Eph receptors, the largest known family of 
RTKs, and are involved in events such as cell adhesion and migration (Klein,R et al. 
2004). The ligands Delta, Serrate and Jagged, involved in cell recognition events, all 
signal via a single-transmembrane receptor called Notch which, upon ligand-binding, is 
proteolytically processed leading to the nuclear translocation of the receptor’s intracellular
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domain and the transcriptional regulation of target genes (Weinmaster.G et al. 1997, 
Artavanis-Tsakonas.S et al. 1999).
The hedgehog and Wnt families of secreted glycoproteins have important roles during 
embryonic development and both mediate their effects by GPCR signalling. Whilst there 
is only one hedgehog gene (hh) in Drosophila, there are three mammalian proteins, 
named sonic hedgehog (Shh), Indian hedgehog (Ihh) and desert hedgehog (D/7/7), which 
are responsible for a host of developmental functions including specification of regional 
characteristics of the gut, dorsoventral polarity of the neural tube, anterior-posterior 
patterning of the limbs, endoderm formation and spermatogenesis (Ramalho-Santos.M et 
al. 2000, Maye,P et al. 2000, Bitgood.M.J et al. 1996). Hedgehog protein signals by 
binding to its cell-surface receptor, a twelve-transmembrane protein called Patched (Ptc), 
which brings about the disinhibition of a constitutively active Family 5 GPCR called 
Smoothened (Smo), which activates a signal transduction cascade mediated by the 
proteins cubitus interuptus (Ci), fused kinase (Fu), and costal-2 (Cos-2), resulting in the 
transcriptional regulation of target genes.
Wnt proteins are involved in embryonic cell patterning, adhesion, proliferation, 
differentiation and survival, and signal via multiple intracellular signalling pathways (see 
Figure 1.2) (Du.S.J et al. 1995, Moon.R.T et al. 1993, Christian,J.L et al. 1993). The 
canonical Wnt pathway regulates gene transcription through /?-catenin, whereby Wnt 
binding to the Family 5 GPCR Frizzled (Fzd) and its co-receptor LRP-5/6 activates the 
multi-module protein Dishevelled (Dsh) via a G-protein, which in turn inhibits glycogen 
synthase kinase-3/3 (GSK-3/3), leading to the dephosphorylation of /3-catenin and the 
transcriptional regulation of target genes (Peters,J.M et al. 1999). In contrast, non- 
canonical Wnt signalling is mediated by two distinct intracellular cascades: the Wnt/Ca2+ 
pathway, where activation of Fzd/LRP-5/6 stimulates PLC-/3 activity, presumably via
Gofq/n, leading to the release of Ca2+ from intracellular stores and the activation of PKC 
(Slusarski.D.C et al. 1997, Kuhl.M et al. 2000), and the Wnt/PCP (planar cell polarity) 
pathway, where Fzd/LRP-5/6-mediated activation of Dsh brings about activation of Rho 
GTPases, such as RhoA and cdc42, which in turn leads to the activation of c-Jun N- 
terminal kinase (JNK) and the transcriptional regulation of target genes (Tada.M et al. 
2000, Li,F et al. 2005). The Wnt/PCP pathway has been implicated in signalling in the 
developing vertebrate eye field (Cavodeassi.F et al. 2005, Lee,H-S et al. 2005, De 
longh.R.U et al. 2006), and is known to be responsible for the regulation of important 
gastrulation movements, such as convergent extension, in Xenopus and zebrafish 
embryos (Heisenberg,C.P et al. 2000, Wallingford, J.B et al. 2000, Darken,R.S et al. 2002, 
Park.M et al. 2002, Tada.M et al. 2002, Wallingford,J.B et al. 2002, Kilian,B et al. 2003, 
Takeuchi.M et al. 2003, Veeman.M.T et al. 2003, Wang,J et al. 2006).
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Figure 1.2 Signalling pathways initiated by Wnt ligand-binding to the Family 5 GPCR Fzd, showing Wnt 
ligand-binding and cysteine-rich region; and its co-receptor LRP5/6, showing N-terminal (epidermal growth 
factor) EGF repeats. A. The canonical Wnt pathway: DIX domain of the Fzd-activated Dsh protein inhibits 
the GSK-3/3 protein complex bringing about accumulation of /3-catenin (red). B. Non-canonical Wnt/PCP 
pathway: PDZ and DEP domains of the Fzd-activated Dsh protein can activate Rho GTPases either 
directly, or via the Dsh-associated activator of morphogenesis 1 protein (Daaml), leading to JNK activation 
(green). C. Non-canonical Wnt/Ca2+ pathway: stimulation of PLC-/3 by Fzd-activated G-proteins leads to 
diacylglycerol (DAG) and IP3 synthesis, release of Ca2+ from intracellular stores, and activation of PKC and 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) (purple).
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1.2 Y~amino butyric acid (GABA) and its receptors
12 .1 GABA signals via ionotropic and metabotropic receptors
Gamma-amino butyric acid (GABA) is the principal inhibitory neurotransmitter in the adult 
central nervous system (CNS). During fast synaptic transmission GABA signals through 
ionotropic GABAa and GABAc receptors that initiate inhibitory post-synaptic potentials 
(IPSPs) through rapid, chloride-mediated post-synaptic membrane hyperpolarization. 
GABAa receptors, responsible for the majority of fast inhibitory signalling in the 
mammalian CNS, are ion channels comprised of five subunits that can belong to one of 
eight different classes a-, p-, y-, 6-, £-, 0-, tt- and p- (Barnard,E.A et al. 1998, Whiting,P.J 
et al. 1999). To date, at least six different mammalian a-subunit subtypes have been 
reported, and three subtypes within each of the p-, y- and p- subunit classes. Whilst most 
GABAa receptors appear to be comprised of two a-subunits, two p-subunits and one y- 
subunit, several minor subunit compositions have been proposed, including homo- or 
hetero-oligomers of p-subunits (Sieghart.W et al. 1999). Subunit subtypes exhibit distinct 
and widespread expression patterns indicating the existence of multiple GABAa receptor 
variants in the brain, perhaps as many as 500, each with distinct pharmacological and 
electrophysiological properties, generating an extraordinary degree of receptor 
heterogeneity (Sieghart.W et al. 1995).
GABA also signals via the metabotropic GABAb receptor, a Family 3 GPCR that 
modulates synaptic transmission via intracellular signal transduction cascades. The 
GABAb receptor was first described as a slow acting GABA receptor unaffected by GABAa 
receptor antagonists and responsible for the late phase of biphasic IPSPs (Hill.D.R et al.
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1981). GABAb receptor agonists such as Baclofen, an anti-convulsant drug available 
since 1972, had proved to be promising therapeutic agents, but often generated unwanted 
side effects such as tolerance and sedation (Bowery,N.G et al. 1993). As such, there was 
significant commercial interest in isolating GABAb receptor cDNA in the hope of designing 
more selective drugs. However, this proved to be difficult, and the GABAb receptor 
remained the last major neurotransmitter receptor to be cloned.
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1.3 Cloning of GABAb receptor complementary DNAs (cDNAs)
1.3.1 GABAB(1) cDNA was first isolated by expression cloning
The isolation of cDNAs encoding GABAe receptors was problematic and their nucleotide 
sequence remained elusive seventeen years after their existence was first postulated 
(Bowery,N.G et al. 1980). The difficulties associated with the cloning of GABAB receptors 
are now well understood and arose from the heterodimeric nature of these receptors, 
which is discussed later in this chapter (see Section 1.5). Prior to cloning there were no 
radioligands available that bound with high affinity to GABAb receptors, making purification 
of receptor protein difficult, and as a consequence it was not possible to raise antibodies 
against GABAb receptors. Frustratingly, functional responses were typically lost upon 
solubilization of receptor protein during purification, or when splitting active cDNA pools 
into smaller ones, this easily ascribed in retrospect to the separation of the subunits 
required to form functional heterodimeric receptors.
The isolation of an immunoaffinity-purified putative GABAb receptor protein was, however, 
reported in 1993 (Nakayasu.H et al. 1993) upon the development of an antiserum that 
specifically recognised an 80kDa GABA-binding protein. Whilst the researchers were able 
to demonstrate GABAb receptor agonist and antagonist binding to the purified receptor, 
and modulation of adenylate cyclase activity upon their application to the purified protein 
reconstituted into a phospholipid membrane, no amino acid sequence was disclosed. It is 
now clear that the molecular weight of this protein differs from that of the GABAb receptors 
cloned subsequently, and a relationship with the latter now seems unlikely.
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Ultimately GABAb receptor cDNA was isolated by expression cloning, four years later, 
upon the development of the high-affinity radiolabelled antagonist [125I]CGP64213 
(Kaupmann,K et al. 1997). This approach was successful primarily because it did not 
require functional coupling of the receptor, but merely the availability of the high-affinity 
binding site. Rat cortex and cerebellum tissues, shown to contain a high density of 
GABAb receptor binding sites, were used as a source to construct a cDNA library and 
clones were screened for [125I]CGP64213 binding in transfected COS1 cells. Following 
serial subdivisions of positive cDNA pools, a single 4.4kb cDNA clone was isolated 
containing an open reading frame encoding a 960 amino acid protein, sharing low 
sequence identity with metabotropic glutamate receptors (mGluRs). This protein was 
named GABAB(ia). By using the GABAB(1a) cDNA as a probe to screen the cDNA library at 
low stringency, several additional clones were isolated including a 2.9kb cDNA encoding 
an 844 amino acid protein, which was named GABAB(1b). Both isoforms were predicted to 
be seven transmembrane proteins, most closely related to Family 3 GPCRs, exhibiting 
structural similarity to bacterial periplasmic amino acid binding proteins in their N-terminal 
ECD.
The GABAB(1a) and GABAB(1b) proteins share 797 C-terminal amino acids but exhibit 
dissimilarity at their N-termini, possessing 163 and 47 unique N-terminal amino acid 
residues respectively. The N-terminus of GABAB(1a) contains a pair of sushi domains, or 
short consensus repeats (SCRs), which is absent in GABAB(ib) (Blein.S et al. 2004). 
Originally identified in complement proteins as a module involved in protein-protein 
interactions, sushi domains had not been observed previously in any other GPCR. 
However it has been recently suggested that, in fact, all Family 1b GPCRs possess an 
SCR module in their N-termini, further identified as the major site of peptide hormone 
interaction (Grace,C.R et al. 2004). The GABAB(1a) and GABAB(1b) isoforms were shown to
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be conserved across vertebrates, this demonstrated by photoaffinity labelling of brain 
membrane preparations of several species, and several full-length and partial GABAB(ia) 
and GABAeob) clones were isolated from numerous rat brain and spinal cord cDNA 
libraries (Kaupmann.K et al. 1997).
Whilst the cloned GABAB(i) isoforms exhibited many of the expected properties of GABAb 
receptors, neither GABAB(1a) nor GABAB(1b) were able to couple efficiently to their effector 
systems, and exhibited around 100-fold lower affinity for agonists compared to native 
receptors. It was soon demonstrated that recombinant GABAB(1) receptors were retained 
as immature glycoproteins on intracellular membranes (Couve.A et al. 1998). The search 
for an associated factor or chaperone responsible for maturation and trafficking of 
GABAB(1) to the plasma membrane quickly ensued.
1.3.2 GABAB(2) shares sequence identity with GABAbu) and was first identified through 
homology searches
In an effort to identify additional GABAb receptor subunits, a number of research groups 
began by mining expressed sequence tag (EST) databases with GABAB(1) cDNA 
sequence and simultaneously isolated cDNA encoding a novel 941 amino acid protein, 
sharing 35% amino acid identity with GABAB(1b), termed GABAB(2). When co-expressed 
with GABAB(i) in mammalian cell lines, GABAB(2) promoted the cell surface expression of a 
functional receptor that coupled robustly to the expected effector systems and exhibited 
an affinity for agonists comparable to native GABAb receptors. This discovery led to three 
separate research groups publishing consecutive papers in the same volume of Nature, 
each postulating that native GABAb receptors existed as functional heterodimers
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comprised of GABAB(d and GABAB(2) subunits (Kaupmann.K et al. 1998a, Jones,K et al. 
1998, White,J et al. 1998). Three further publications shortly followed also reporting the 
molecular identification of GABAB(2) (Martin,S et al. 1999, Kuner.R et al. 1999, Ng,G et al. 
1999). The requirement for heterodimer formation in facilitating the proper function of a 
GPCR had not previously been described, and so the findings of these studies uncovered 
an intriguing new paradigm in GPCR biology (Marshall,F et al. 1999, Couve.A et al. 2000).
1.3.3 GABAbl shares sequence identity with GABAb receptors and was identified
through homology searches
Whilst the cloning of GABAB(1) and GABAB(2) cDNAs permitted the pharmacological 
characterisation of the GABAb receptor, the existence of a single GABAB(i/2) heterodimer 
did not satisfactorily account for the receptor heterogeneity predicted by native studies, 
and so efforts to isolate cDNAs encoding additional putative GABAb receptor subtypes 
continued. In 2003, a cDNA encoding an 814 amino acid, putative seven transmembrane 
protein related to GABAB(1) and GABAB(2) was isolated, and named GABAbl (GABAB-like) 
(Calver,A.R et al. 2003). The human G A B A bl gene was initially identified by searching the 
GenBank sequence database using the GABAB(1b) protein sequence as a query. Analysis 
of overlapping genomic contigs and subsequent prediction of exons facilitated the 
assembly of a putative full-length cDNA clone, which was then independently isolated from 
numerous human and rodent tissues.
Despite exhibiting striking sequence similarity to GABAB(i) and GABAB(2) across the seven 
transmembrane domains, sharing 27% and 31% amino acid identity respectively, GABAbl 
lacked the large N-terminal extracellular domain and signal peptide sequence
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characteristic of most Family 3 GPCRs, and possessed an unusually long C-terminal 
intracellular domain. However, GABAbl exhibited many key features shown to be critical 
for GABAb receptor function, and so it was postulated that GABAbl might be a novel 
GABAb receptor subunit (Calver,A.R et al. 2003, Charles,K.J et al. 2003, Martin,S.C et al
2004).
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1.4 GABAb receptor gene structure and transcript variants
1.4.1 GABAB(d, GABAB(2) and GABAbl are encoded by three distinct genes
The recent progress that has been made in sequencing the genomes of several model 
organisms has allowed researchers to investigate the structure of genes with ease. 
Analysis of human genomic sequence reveals that GABAB(i), GABAB(2) and GABAbl 
transcripts are encoded by three distinct genes, located on chromosomes 6, 9 and 3 
respectively, from which exon and intron sizes have been deduced (Goei.V.L et al. 1998, 
Peters,H.C et al. 1998, Martin,S.C et al. 2001, Hubbard,T.J.P et al. 2007). Analysis of 
human GABAB(1) and GABAB(2) genes reveals that they have a similar genomic 
organisation, indicating that they may derive from a common ancestral gene. Also, 
comparisons between human and Drosophila melanogaster GABAB(1) and GABAB(2) genes 
reveals several comparable intron locations, demonstrating a high degree of sequence 
conservation between vertebrates and invertebrates, despite the fact that D.melanogaster 
GABAb receptors exhibit a unique pharmacology compared to their vertebrate 
counterparts (Martin,S.C et al. 2001, Mezler.M et al. 2001). An investigation into the 
organisation of the GABAbl gene and its conservation across the species is lacking.
1.4.2 GABAB(1a) and GABAB(1b) mRNAs are generated by alternative transcription 
initiation sites
GABAB(1a) and GABAB(ib) are the most abundantly expressed GABAB(1) transcript variants 
and are highly conserved among vertebrate species (Kaupmann, K et al. 1997). Analysis
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of the GABAB(d gene reveals that GABAB(ia) and GABAB(ib) transcripts are generated by 
alternative transcription initiation sites (Martin, S.C et al 2001) and are not N-terminal 
splice variants, contrary to the initial assumption (Kaupmann, K et al. 1997). Putative 
promoter regions for GABAB(ia) and GABAB(1b) have been identified in the human GABAB(d 
gene, the latter residing within intron sequence downstream of the GABAB(1a)-specific exon 
1a4 (Steiger,J.L et al. 2004). The initiation of transcription from the GABAB(ib) promoter 
results in the extension of GABAB(d exon 1 at its 5’ end and generates a transcript 
encoding 47 N-terminal amino acids specific to GABAB(1b). Whilst several studies have 
uncovered distinct temporal and spatial expression patterns for GABAB(ia) and GABAB(ib) 
(Kaupmann,K et al. 1997, Kaupmann,K et al. 1998a, Kaupmann,K et al. 1998b, Benke.D et 
al. 1999, Fritschy.J.M et al. 1999, Bischoff,S et al. 1999, Billinton.A et al. 1999), 
recombinant GABAB(ia) and GABAB(1b) receptor subunits are pharmacologically 
indistinguishable when expressed in mammalian cells (Kaupmann,K et al. 1998a, 
Malitschek.B et al. 1999, Brauner-Osbourne.H et al. 1999a, Green,A et al. 2000). The 
discovery of separate promoters and differential expression patterns is, however, 
indicative of distinct functional roles for GABAB(1a) and GABAB(ib), and recent work has 
succeeded in separating these isoforms by functional means (see Section 1.6.2).
1.4.3 Additional GABAB(1) transcript variants are generated by exon skipping
In the years following the cloning of GABAB(1a) and GABAB(1b), a number of additional 
GABAB(1) transcript variants were isolated as cDNA from human and rodent tissues. 
GABAB(1C) is a human isoform of GABAB(1) that is identical to GABAB(1a) except for the 
skipping of exon 1a3, resulting in the deletion of the second sushi domain that is present 
in GABAB(1a) (Calver.A.R et al. 2001, Martin,S.C et al. 2001). This isoform is particularly
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abundant and its expression pattern typically parallels that of GABAB(ia). the transcription 
of both variants presumably regulated by the same promoter. Two transcript variants 
isolated from rat brain cDNA libraries, both also originally named GABAB(1C), are identical 
to rat GABAB(1a) and GABAB(1b) respectively, except for the extension of exon 15 by 63pb 
through an alternative splicing event (Isomoto.S et al. 1998, Pfaff.T et al. 1999). Whilst 
these isoforms are functional when co-expressed with rat GABAB{2) in mammalian cell 
lines, the additional sequence present in these isoforms is not conserved in humans. 
These transcripts are referred to here as GABAB(10.a) and GABAB(10.b) for simplicity, based 
on the N-terminal sequence they share with rat GABAB(ia) and GABAB(1b) respectively. 
GABAB(1d) is an additional transcript variant isolated from rat that is identical to rat 
GABAB(1b) except for a divergent C-terminus derived from the failure to splice out intron 17 
of the GABAB(i) gene, resulting in an alternative C-terminus and the deletion of half of the 
coiled-coil domain (Isomoto.S et al. 1998).
GABAB(1e) is transcript variant encoding a truncated receptor that shares its N-terminus 
with GABAB(1a) (Schwarz,D.A et al. 2000). It arises from the skipping of exon 10 of the 
GABAB(i) gene resulting in a frameshift in exon 11 that generates a premature termination 
codon and deletes both the seven transmembrane and C-terminal intracellular domains. 
GABAB(1e) is particularly intriguing in that it is found in both humans and rats, and appears 
to be the principal GABAB{1) isoform expressed in peripheral tissues. Recombinant 
GABAB(1e) protein is soluble and is secreted into the medium when expressed in 
mammalian cells, and it also forms stable heterodimers with GABAB(2). GABAB(if) is a 
transcript variant isolated from rat that is identical to rat GABAB(1c-a) except for the in-frame 
deletion of exon 1a4 (Isomoto.S et al. 1998, Wei,K et al. 2001a). Exon 1a4 is 21 bp in 
length and encodes 7 amino acids that reside between the sushi domains and the PBP- 
like domain. Finally GABAB(1g) is a variant isolated from rat that arises from the failure to
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splice out intron 1 of the GABAB(i) gene, resulting in the extension of exon 1 at its 3’ end 
(Wei.K et al. 2001b). This splice variant encodes a truncated receptor that lacks the PBP- 
like, seven transmembrane and C-terminal intracellular domains.
It is important to note that the existence of isoforms GABAB(iC) to GABAB(ig) at the protein 
level has not been demonstrated and, as such, their physiological significance remains 
enigmatic. However, the generation of each of these transcripts can be explained by 
known splicing mechanisms, and are unlikely to be artefacts of cDNA synthesis or PCR. 
A schematic diagram showing the exon structure of each of the GABAB(1) transcript 
variants, indicating the regions encoding key protein domains, is shown in Figure 1.3.
1.4.4 There are no confirmed GABAb l  transcript variants
The concomitant publications reporting the cloning of GABAB(2) describe a single transcript 
encoding a 941 amino acid protein (Kaupmann,K et al. 1998a, Jones,K et al. 1998, White,J 
et al. 1998, Martin,S et al. 1999, Kuner.R et al. 1999, Ng,G et al. 1999). Two additional 
isoforms were isolated from human tissue, named GABAB(2b) and GABAB(2c), which 
exhibited dissimilarity from GABAb(2) in their C-terminal tails (Clark,J.A et al 2000). 
However, the temporal and spatial expression patterns described for GABAB(2b) and 
GABAB(2C) where found to be near-identical to that of GABAB(2) (Calver,A.R et al. 2000), 
and analysis of the GABAB(2) gene revealed that consensus sequences for canonical 
splice junctions were lacking at the locations required to generate these alternative 
transcripts (Martin,S.C et al. 2001). Taken together, these data suggest that GABAB(2b) 
and GABAB(2c) are most likely artefacts of cDNA synthesis and do not occur in vivo. The 
records for these transcripts have been removed from the GenBank database at the
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submitter's request. A schematic diagram showing the exon structure of these GABAbl 
transcript variants, indicating the regions encoding key protein domains, is shown in 
Figure 1.3.
1.4.5 There are no confirmed G A B A bl transcript variants
The paper reporting the cloning and characterisation of GABAbl describes a single cDNA 
encoding an 814 amino acid protein, although evidence of additional transcripts of 
differing size is provided by northern analysis using RNA isolated from testes (Calver.A.R 
et al. 2003). A human GABAbl transcript variant is found in the GenBank sequence 
database (accession number: AB209362), although no expression pattern is disclosed 
(Totoki.Y et al. 2005). Analysis of the human GABA bl gene reveals that this transcript 
variant, termed here GABABL(b), is generated by the skipping of exons 3 to 7. The resulting 
frameshift in exon 8 generates an immediate termination codon, and the transcript 
encodes a truncated protein lacking six transmembrane domains and the intracellular C- 
terminal tail of GABAbl- Whilst it is apparent that this transcript derives from a canonical 
splicing event, in the absence of any expression data its physiological relevance cannot 
be ascertained. A diagram showing the exon structure of these GABAbl transcript 
variants, indicating the regions encoding key protein domains, is shown in Figure 1.3.
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C. GABAbl, showing the location of intron/exon boundaries and key protein domains.
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1.5 GABAb receptor heterodimerization
1.5.1 Functional GABAb receptors are obligate heterodimers
The discovery that co-expression of two distinct receptor subunits was required for GABAb 
receptor function was remarkable. Whilst it had recently been suggested that the /32- 
adrenergic receptor (jSrAR) might exist as a homodimer in vivo, following the 
demonstration that recombinant /32-AR homodimers exhibited agonist responses and 
desensitization behaviour equivalent to that of wild-type ^ A R s  (Hebert,T.E et al. 1998), 
GPCR heterodimers had not been proposed before. Shortly after the cloning of GABAb 
receptors, it was demonstrated that a heterodimer comprised of k- and 5-opioid receptor 
subunits, both fully functional homodimeric receptors in their own right, was shown to yield 
a novel and pharmacologically distinct opioid receptor (Jordan,B.A et al. 1999). There are 
now at least 20 known examples of functional GPCR heterodimers and it is broadly 
accepted that receptor hetero-oligomerization is an important aspect of GPCR biology, 
contributing to receptor diversity in a way not anticipated prior to the characterisation of 
GABAb receptors (Devi.L.A et al. 2001, George,S.R et al. 2002).
The GABAb receptor is peculiar in that it mediates agonist-induced G-protein activation 
through a process known as transactivation, whereby the two GABAb receptor subunits 
play distinct roles. GABAb(1), isolated by its ability to bind a high-affinity antagonist, is 
responsible for the binding of all GABAb receptor agonists and antagonists, whereas 
GABAB(2) appears not to bind any endogenous ligands (Kaupmann,K et al. 1998a, Jones,K 
et al. 1998, White,J et al. 1998, Galvez,T et al. 2000, Kniazeff,J et al. 2002). Alignment of 
GABAB(d and GABAB(2) protein sequences reveals that key residues, implicated in ligand
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coordination by mutagenesis studies, are not conserved in GABAB(2) (Franek.M et al. 
1999, Galvez,T et al. 1999, Galvez,T et al. 2000). Conversely, the molecular determinants 
required for the activation of G-proteins by the GABAb receptor are found in the 
intracellular segments of GABAB(2) and are not conserved in GABAB(1) (Robbins,M et al. 
2001, Galvez,T et al. 2001). It is possible to substitute intracellular segments of GABAB(1) 
with their GABAB(2) or mGluR counterparts, or even random coil peptides, without any loss 
of receptor function (Margeta-Mitrovic.M et al. 2001a, Margeta-Mitrovic.M et al. 2001b).
1.5.2 A trafficking checkpoint regulates the assembly of GABAb receptor heterodimers
Early studies with recombinant GABAb receptors demonstrated that, whilst GABAB(2) 
subunits were correctly trafficked and expressed at the surface of mammalian cells in the 
absence of GABAB(i), GABAB(1) subunits were retained on intracellular membranes when 
expressed alone (Kaupmann,K et al. 1998a, White,J.H et al. 1998, Couve.A et al. 1998, 
Martin,S.C et al. 1999). Analysis of the GABAB(1) protein sequence revealed a conserved 
RSR motif in the C-terminal tail, immediately downstream of the coiled-coil domain, 
reminiscent of the ER retention/retrieval motif RKR identified in subunits of the ATP- 
sensitive K+ channel (Zerangue.N et al. 1999). Analysis of the surface expression of 
several GABAB(1) C-terminal deletion constructs indicated that this sequence, extended to 
RSR(R), was responsible for the intracellular retention of GABAB(1), and it was postulated 
that heterodimerization with GABAB(2) in the ER via a coiled-coil interaction resulted in the 
masking of this motif, facilitating the efficient trafficking of functional GABAb receptor 
heterodimers to the cell-surface (Margeta-Mitrovic.M et al. 2000, Pagano.A et al. 2001, 
Calver.A.R et al. 2001). Indeed, mice expressing a C-terminally truncated GABAB(2)
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subunit do not express functional GABAb receptors at the cell-surface, as the GABAB(i) 
RSR(R) motif remains exposed upon heterodimer formation (Thuault.S.J et al. 2004).
More recently, it was shown that sequences upstream of the RSR(R) signal also affect 
GABAb receptor function, and the full ER retention/retrieval motif in GABAB(1) was 
extended to QLQSRQQLRSRR, which includes part of the coiled-coil domain 
(Grunewald.S et al. 2002). Deletions in this upstream sequence drastically reduce the 
effectiveness of the coat-protein I complex (COPI), a factor which is shown to bind to the 
RSR(R) motif and which promotes c/s-Golgi-ER retrograde trafficking of monomeric 
GABAB(1) subunits in the absence of GABAB(2) (Brock,C et al. 2005, Gassmann.M et al.
2005). A di-leucine motif, known to be important in the regulation of protein trafficking 
between the endosomal and trans-golgi network (Petris.M.J et al. 1998, Kirchhausen.T et 
al. 1999), was identified at the N-terminal end of the coiled-coil domain in GABAB(1) and 
was also shown to modulate intracellular retention (Margeta-Mitrovic.M et al. 2000, 
Margeta-Mitrovic.M et al. 2001a). More recently it was demonstrated that msec7-1, a GEF 
for the ARF family of GTPases which are regulators of vesicular membrane trafficking, 
interacts with GABAB(1) via this di-leucine motif and modulates the cell surface expression 
of GABAb receptors (Restituito.S et al. 2005).
1.5.3 The extracellular domain of GABAB(1) is sufficient to bind agonists and 
antagonists
The GABAB(d splice variant GABAB(ie) encodes a soluble truncated receptor 
corresponding to the N-terminal ECD of GABAB(ia). Recombinant GABAB(1e) was shown to 
be secreted into the medium, when expressed in mammalian cells, and was capable of
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heterodimerizing with GABAB(2) at the cell surface, indicating that the intracellular coiled- 
coil interaction between GABAB(i) and GABAB(2) C-termini is not the sole 
heterodimerization interface in the GABAb receptor (Schwarz,D.A et al. 2000). Whilst it 
was demonstrated that GABAB(ie/2) heterodimers were unable to couple to downstream 
effector systems, GABAB(1e) was shown to successfully compete with GABAB(ia) for 
GABAB(2) binding and disrupt normal GABAB(ie/2) heterodimer formation. This suggested 
that, should GABAB(1e) protein occur in vivo, it might regulate GABAb receptor activity in a 
dominant negative manner (Bettler.B et al. 2004). Whilst Schwarz and colleagues were 
unable to demonstrate binding of the radiolabelled GABAb receptor antagonist 
[3H]CGP54626A to GABAB(ie), another group showed that comparable artificially truncated 
GABAB(ia) and GABAB(1b> proteins, comprising only of extracellular residues, bound 
agonists and antagonists with a greater affinity than their full-length wild-type counterparts 
when expressed in insect cells (Malitshek.B et al. 1999). These experiments showed that 
the ECD of GABAB(1) is sufficient to bind GABAergic ligands with high affinity, and also 
implied that crystallization of liganded and unliganded ECD might be feasible.
1.5.4 Allosteric interactions between GABAB(i) and GABAbl subunits are necessary for 
optimal G A B A b receptor function
The analysis of various chimeric GABAb receptors has revealed that considerable ‘cross­
talk’ occurs between GABAB(1) and GABAB(2) domains during optimal GABAb receptor 
function. For example, the ECD of GABAB(2) is shown to increase the agonist affinity of 
GABAB(i) and is required for agonist activation of the receptor, whilst the seven- 
transmembrane domain of GABAB(i) dramatically improves coupling efficacy (Galvez,T et 
al. 2001, Margeta-Mitrovic.M et al. 2001a, Kniazeff.J et al. 2002).
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1.6 GABAb receptor signalling
1.6.1 Pre- and post-synaptic GABAb receptors have distinct roles
The GABAb receptor couples negatively to adenylate cyclase through the activation of 
Pertussis toxin-sensitive Gor^ G-proteins when expressed in mammalian cells 
(Kaupmann,K et al. 1997, Filippov,A.K et al. 2000). Whilst the physiological relevance of 
this adenylate cyclase inhibition is unclear, GABAb receptor-activated Gfiy subunits 
mediate GABABergic effects through the inactivation of high voltage-activated Ca2+ 
channels, inhibiting neurotransmitter release in pre-synaptic neurons; and through 
activation of inwardly rectifying K+ channels (GIRKs), perpetuating IPSPs in post-synaptic 
neurons (see Figure 1.4). Pre-synaptic GABAb receptors may be subdivided into 
populations of autoreceptors, which inhibit the release of GABA into the synapse, and 
heteroreceptors, which inhibit the release of other neurotransmitters, for example, at 
glutamatergic terminals.
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Figure 1.4 Schematic diagram showing GABAb receptor signalling at the synapse.
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1.6.2 The GABAB(ia) and GABAB(ib) isoforms contribute to GABAb receptor diversity
Evidence from native studies is indicative of considerable heterogeneity in the GABAb 
receptor system and so, prior to cloning, researchers were expecting to discover multiple 
GABAb receptor subtypes, each exhibiting differential expression patterns and coupling to 
distinct effector systems, analogous to the closely related metabotropic glutamate 
receptors (mGluRs). However, it is now broadly accepted that all metabotropic GABA 
signalling is mediated by a heterodimeric receptor comprised of GABAB(d and GABAB{2) 
subunits, and that the only highly conserved and abundant transcript variants are those of 
GABAB(ia) and GABAB(ib), generating only two receptor subtypes (Bettler.B et al. 2006).
Whilst GABAB(ia) and GABAB(ib) exhibit near identical pharmacological profiles when 
expressed in mammalian cells (Kaupmann,K et al. 1998a, Malitschek.B et al. 1999, 
Brauner-Osbourne.H et al. 1999a, Green,A et al. 2000), numerous reports demonstrate 
differential temporal and spatial expression patterns (Kaupmann,K et al. 1997, 
Kaupmann,K et al. 1998a, Kaupmann,K et al. 1998b, Malitshek.B et al. 1998, Benke,D et 
al. 1999, Billinton,A et al. 1999, Bischoff,S et al. 1999, Fritschy,J-M et al. 1999, Towers,S 
et al. 2000), and pre- versus post-synaptic localisations have been suggested for both 
variants (Benke.D et al. 1999, Billinton.A et al. 1999, Ng.G.Y et al. 2001). There have also 
been isolated reports of separation of GABAB(1a/2) and GABAB(ib/2) receptors by 
pharmacological means, such as the suggestion that the anticonvulsant drug gabapentin 
was an agonist at GABAB(ia/2) receptors but not GABAB(1b/2) receptors (Ng.G.Y et al. 2001, 
Bertrand,S et al. 2001). However, such reports remain controversial as other groups were 
unable to reproduce these findings (Lanneau.C et al. 2001, Patel,S et al. 2001, 
Jensen,A.A et al. 2002) and, ultimately, a clean dissection of the distinct physiological
49
roles of GABAB(ia) and GABAB(ib) was only made possible upon the development of 
transcript variant-specific knock-out mice.
Taking advantage of the fact that GABAB(1a) and GABAB(ib) are regulated by different 
promoters, Bettler and colleagues recently produced GABAB(1a)- and GABAB(1b)-deficient 
mice using a ‘knock-in’ approach, whereby the initiation codon for one isoform was 
converted to a stop codon whilst leaving the other isoform intact (Vigot.R et al, 2006, 
P6rez-Garci,E et al. 2006). Using a combination of immunohistochemistry and two-photon 
laser scanning microscopy, it was demonstrated that GABAB(ia) was localised primarily at 
glutamatergic terminals, whereas GABAB(1b) was found in dendritic spines opposite the site 
of glutamate release. Furthermore, GABAB(ia)-/- mice were found to lack GABAb 
heteroreceptors, whilst GABAB(ib)-/- neurons exhibited greatly reduced slow IPSPs in 
response to incubation with the agonist Baclofen (Vigot,R et al. 2006). Together these 
results strongly suggest that GABAB(1a) mainly assembles presynaptic heteroreceptors, 
whilst GABAB(1b/2) receptors mainly mediate postsynaptic inhibition.
Given that GABAB(1a) and GABAB(1b) differ only in the presence of a pair of sushi domains 
in the GABAB(1a) N-terminus, it is postulated that interactions between these domains and 
unidentified extracellular factors might be responsible for the retention of GABAB(1a/2) 
heterodimers at specific sub-cellular locations. To date, only one such interaction has 
been proposed, between sushi domain 1 of GABAB(1a) and the extracellular matrix protein 
fibulin-2 (Ginham.R.L et al. 2002, Blein.S et al. 2004), however, it is not currently possible 
to integrate this observation into a coherent model to explain the situation in vivo.
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1.6.3 Atypical responses are occasionally observed when GABAb(i) or GABAB(2) are 
expressed alone
Recently, the disabling of GABAB(i) and GABAB(2) genes in mice has helped to clarify the 
roles of native GABAb(d and GABAB(2) subunits predicted by the pharmacological 
characterisation of cloned receptors. In general, the behaviour of GABAe(i)-deficient mice 
is consistent with the hypothesis that functional GABAb receptors are GABAB(1/2) 
heterodimers. The overt phenotype of GABAB(i)-/- mice includes spontaneous epileptic 
seizures, hyperalgesia, impaired memory and loss of all detectable biochemical and 
electrophysiological pre- and post-synaptic GABAb receptor responses (Prosser,H.M et al. 
2001, Schuler,V et al. 2001, Queva.C et al. 2003). GABAB(2) is also heavily 
downregulated, implying that most GABAB(2> is associated with GABAB(1) in vivo.
In contrast, experiments with GABAB(2)-deficient mice appear to challenge the 
conventional understanding of GABAb receptor function. Whilst GABAb(2>-/- mice exhibit 
spontaneous seizures, hyperalgesia, impaired memory and hyperlocomotion analogous to 
GABAbo)-/- mice, atypical GABABergic electrophysiological responses are detected in 
GABAB(2)-/- hippocampal slices (Gassmann.M et al. 2004). These data suggest that it is 
feasible that GABAB(1) mediates GABAb receptor responses, on its own or in conjunction 
with other subunits, in neurons that lack GABAB(2).
Similarly, it has been demonstrated that GABAB(2) is expressed at the cell surface and 
couples to adenylate cyclase in the absence of GABAB(1) (Kaupmann.K et al. 1998a, 
Martin,S.C et al. 1999), implying that GABAB(2) might be responsible for constitutive 
GABAb receptor activity in vivo when expressed alone.
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Several groups have demonstrated differential expression patterns for GABAB(i) and 
GABAB(2), revealing areas of unique expression for both subunits (Ng.G.Y et al. 1999, 
Clark,J.A et al. 2000, Charles,K.J et al. 2001, Kulik.A et al. 2002, Sands,S.A et al. 2003, 
Fritschy.J.M et al. 2004, Lopez-Bendito.G et al. 2004, Martin,S.C et al 2004). A notable 
example of this phenomenon is found in some peripheral tissues, where GABAB(d is 
clearly expressed in the absence of GABAB(2) despite the presence of functional peripheral 
receptors (Ong.J et al. 1990, Calver.A.R et al. 2000). These data, together with the 
proposal that both GABAB(1) and GABAB(2) are capable of forming homodimers (Ng.G.Y et 
al. 1999), suggest that both subunits might function alone in vivo, either as receptor 
homodimers, or through interactions with additional, hitherto unidentified, factors.
1.6.4 Interacting proteins may modulate GABAb receptor activity
Whilst cloning efforts have been unable to identify pharmacologically distinct receptor 
subtypes that satisfactorily account for the diversity of native GABAb receptors, it is still 
feasible that further GABAb receptor subunits remain undiscovered. However given the 
availability of the human genome sequence and the fact that all GABAB-related isoforms 
that have been isolated do not form functional GABAb receptors when expressed with 
either GABAb(1) or GABAB(2) (Cheng,Y et al. 1998, Robbins,M.J et al. 2000, Brauner- 
Osborne.H et al. 2000, Brauner-Osborne.H et al. 2001, Calver.A.R et al. 2003, 
Charles,K.J et al. 2003), the likelihood of discovering other GABAb receptor genes is 
small. It is possible that further heterogeneity of GABAb receptor responses is achieved 
by coupling to differential downstream effector systems, facilitated by interactions with 
intracellular factors or through association with other transmembrane partners. Indeed, a 
number of specific interactions with intracellular proteins are reported, including
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interactions between the C-terminus of GABAboj and members of the ATF/CREB and 
CCAAT/enhancer-binding protein (C/EBP) families of transcription factors (Nehring.R.B et 
al. 2000, Vernon,E et al. 2001, White,J.H et al. 2000, Sauter.K et al. 2005), two members 
of the 14-3-3 family of signalling proteins (Couve.A et al. 2001), and a novel RNA-binding 
protein called Marlin-1 (Couve.A et al. 2004). However, none of these interactions have 
been shown to affect GABAb receptor function and, as such, may simply represent 
artefacts of the yeast-2-hybrid system used to identify them. In contrast, a highly 
significant interaction between GABAB(i) and the y2s subunit of the ionotropic GABAa 
receptor was recently reported, whereby the latter was demonstrated to recruit GABAB(1) to 
the plasma membrane in the absence of GABAB(2) and enhance agonist-induced GABAb 
receptor internalisation (Balasubramanian.S et al. 2004).
This association, combined with increasing evidence that GABAb receptors associate with 
lipid rafts (Becher.A et al. 2001), indicate that GABAb receptor heterogeneity might derive 
from association with other receptor proteins, or intracellular factors, as part of diverse 
oligomeric signalling assemblies at the cell surface. Indeed, a host of hetero-oligomeric 
interactions between a number of receptors have recently been described, and GPCR 
signalling is increasingly being considered in terms of receptor oligomers (Bouvier.M et al. 
2001, George,S.R et al. 2002, Milligan,G 2004, Prinster.S.C et al. 2005). The various 
GABAB-related orphan GPCRs that have been isolated, including GABAbl and the GPRC5 
family of receptors, may yet be found to contribute to such oligomeric assemblies and 
modulate coupling to downstream signalling cascades.
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Figure 1.5 Schematic diagram showing reported GABAb receptor-interacting proteins, fibulin-2, marlin-1, 
msec7-1, ATF/CREB family transcription factors, 14-3-3 signalling molecules, coat-protein I complex 
(COPI), heterotrimeric Gj/0 G-proteins and the GABAa receptor y2s subunit, showing approximate sites of 
interaction with GABAB(d (red), GABAb(2) (blue), and GABAB(iarspecific (green) protein domains.
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1.7 The GABAbl receptor
1.7.1 GABAbl is a transmembrane protein most closely related to GABAb receptors
The molecular cloning and characterisation of novel human and rodent orthologues of a 
GABAb receptor-related seven-transmembrane protein, termed GABAbl (GABAB-like), was 
reported in 2003 (Calver.A.R et al. 2003). GABAbl possesses several key features known 
to be of importance to GABAb receptor function, such as a C-terminal coiled-coil domain, a 
di-leucine motif, and several RXR-type ER retention/retrieval motifs. However, unlike 
most Family 3 GPCRs, GABAbl is predicted not to have an N-terminal signal peptide 
sequence and only possesses 48 extracellular amino acids, lacking the characteristic N- 
terminal extracellular ‘venus-flytrap’ domain. GABAbl failed to elicit any response in 
a calcium mobilisation assay, when transfected with a cocktail of promiscuous G-proteins 
and screened against over 2500 ligands, and is unable to substitute for either GABAB(i) or 
GABAB(2) when co-expressed in HEK293 cells (Calver.A.R et al. 2003). Nevertheless, 
phylogenetic analysis indicates that GABAbl is indeed a Family 3 GPCR most closely 
related to the GABAb receptors, and GABAbl mRNA was shown to be widely expressed in 
the human CNS and peripheral tissues, particularly the testis where several additional 
transcript variants were identified by northern analysis (Calver,A.R et al. 2003).
1.7.2 GABAbl may not be functionally related to GABAb receptors
GABAbl expression was demonstrated at the protein level in rat brain by 
immunohistochemistry, upon development of a polyclonal antibody, revealing several
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areas of co-expression with GABAb receptor proteins (Charles,K.J et al. 2003). Real-time 
quantitative PCR also indicated a high level of GABAbl mRNA expression in areas such 
as the striatum and olfactory bulb, where GABAB(1) transcripts are abundant and GABAB{2) 
transcripts are rare, indicating that GABAbl could function as a partner for GABAB(1) in 
these regions (Martin,S.C et al. 2004). However, evidence of a physical association 
between GABAbl and GABAb receptor subunits is distinctly lacking, and a functional 
relationship with the latter now seems unlikely. Indeed, despite its name, GABAbl is 
almost certainly not a GABA receptor, and may simply be described as a seven- 
transmembrane protein of unknown function that is endogenously expressed at the protein 
level in the brain.
1.7.3 GABAbl is not conserved in invertebrates
GABAb receptors have been described in several invertebrate species including 
echinoderms, arthropods and molluscs (Fischer,Y et al. 1996, Azatian.K.V et al. 1997, 
Devlin,C.L 2001), and cDNAs encoding the Drosophila melanogaster (d)GABAb receptors 
have been cloned (Mezler.M et al. 2001). Like their mammalian counterparts, c/GABAB(1) 
and c/GABAB(2) form functional heterodimeric receptors and regulate K+ and Ca2+ currents 
through activation of Gi/0 G-proteins. However, dGABAB receptors exhibit a unique 
pharmacology, and the dGABAB(D gene also lacks the sushi domains found in the 
mammalian GABAB(ia) isoforms. Intriguingly, a third GABAb receptor was discovered in 
Drosophila: a paralogue, termed dGABAB(3), which encodes a transmembrane protein of 
unknown function. Like GABAbl, dGABAB(3) is unable to substitute for either dGABAB(1) or 
dGABAB(2) to form a functional heterodimer, nor is-able to modulate normal dGABAe 
receptor function when co-expressed with both dGABAB(i } and dGABAB(2) in mammalian
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cells (Mezler.M et al. 2001). It is tempting to speculate that GABAbl might represent the 
mammalian orthologue of c/GABAB(3) given these functional similarities, and indeed 
hGABAei and dGABAB(3) share greater amino acid identity in their transmembrane 
domains (32%) than hGABAB(2) and hGABABL share (31%) (Calver.A.R et al. 2003). 
However, dGABAB(3) encodes a protein 1305 amino acids in length, compared to the 814 
amino acids encoded by hGABABL, and exhibits a large putative N-terminal venus-flytrap 
domain characteristic of other Family 3 GPCRs, unlike GABAbl. Given these major 
differences in morphology, it is unlikely that these two proteins share the same function 
and, as such, are not considered to be orthologous.
These data indicate that, unlike the GABAb receptors, GABAbl may have arisen during the 
evolution of vertebrates. However, as studies of GABAbl in non-mammalian vertebrates 
are absent, it has yet to be ascertained whether the GABAbl gene is conserved 
throughout the vertebrate kingdom.
1.8 The role of GABA and its receptors during development
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1.8.1 GABA is demonstrated to act chemotropically in vitro
While GABA is the major inhibitory neurotransmitter in the adult vertebrate brain, both 
GABA and its receptors are present before GABAergic synapses are formed during 
development (Roberts.A et al. 1987, Rozenberg.F et al. 1989, Lopez-Bendito,G et al. 
2002, Fritschy.J.M et al. 2004). GABA, like other neurotransmitters, has been shown to 
act chemotropically to influence the trajectory of extending axons in vitro, suggesting that it 
may play a similar role in vivo (Redburn.D.A et al. 1996), and GABA has even shown to be 
excitatory in some developing brain regions (Chen.G et al. 1995). Retinal ganglion cell 
(RGC) axons have been shown to grow alongside GABAergic cells in Xenopus laevis 
(X.laevis) embryos and both GABA and Baclofen stimulate RGC neurite outgrowth in 
culture, whilst the GABAb receptor antagonist CGP54626 causes a dose dependent 
shortening of the developing optic projection in Xenopus embryos (Ferguson,S.C.D et al. 
2001). These data point to a role for GABAb receptors in the organisation of developing 
neurons in vivo.
1.8.2 GABAb receptor subunits are differentially expressed during development
Several groups have examined the expression patterns for GABAb receptor subunits 
during rat brain development, at both the mRNA and protein level (Fritschy.J.M et al. 
2004, Lopez-Bendito.G et al. 2002, Lopez-Bendito,G et al. 2004, Martin,S.C et al. 2004). 
Consistent with observations from the adult brain, gene expression patterns for GABAB(1)
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and GABAB(2) are not identical during development, and RNase protection assays indicate 
that GABAB(i) transcripts greatly outnumber those of GABAB(2) in many developing brain 
regions (Martin, S.C et al. 2004). Immunohistochemistry and immunofluorescence 
experiments reveal areas of unique expression for both subunits at early stages of 
development; where GABAB(d protein is prominent in non-neuronal (glial) cells, such as 
astrocytes, and GABAb(2) is selectively detected in specific axonal pathways such as the 
corticothalamic projection (Fritschy.J.M et al. 2004). These data point to the possibility of 
separate roles for GABAB(1) and GABAB(2) in the immature brain, perhaps in neuron-glial 
cell interactions or axonal maturation, in addition to their contribution to GABAb receptor 
heterodimers.
The two principal GABAB(i) isoforms, GABAB(1a) and GABAB(ib), also exhibit dissimilar 
temporal and spatial expression patterns in the developing rat brain. There is strong 
agreement, at both the mRNA and protein level, that GABAB(ia) is the principle isoform 
expressed during early development, whereas GABAB(1b) is predominant adult isoform 
(Malitschek.B et al. 1998, Fritschy.J.M et al. 1999, Fritschy.J.M et al. 2004, Martin,S.C et 
al. 2004, Steiger,J.L et al. 2004). Indeed, GABAB(ib) is barley detectable in the neonatal 
rat brain but is heavily up-regulated during the third postnatal week and broadly co­
expressed with GABAb(2), generating a more ‘adult-like’ subunit distribution (Fritschy.J.M 
et al. 2004). This changeover occurs during a major period of synaptogenesis, and at a 
time when ionotropic GABAa receptors switch from being mediators of excitatory signals to 
inhibitory ones (Ben-Ari,Y. 2002). It remains to be seen whether the early predominance 
of GABAB(1a/2) heterodimers is key to the specification of GABABergic neurons, or 
determines the future sub-cellular location of GABAB(1b/2) heterodimers, perhaps through 
interactions with extracellular factors via the sushi domains unique to the GABAB(1a) 
subunit N-terminus.
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Whilst the presence of functional GABAb receptors is clearly not essential for the normal 
development of the brain, demonstrated by the viability of GABAB(ir /- and GABAB{2)-/- 
mice (Prosser,H.M et al. 2001, Schuler,V et al. 2001, Queva.C et al. 2003, Gassmann.M 
et al. 2004), the high level of expression of GABAb receptor subunits throughout ontogeny, 
and particularly prior to the formation of synapses, is highly indicative of developmental 
functions.
1.8.3  The gene expression pattern for G ABA bl suggests a possible role in development
Real-time quantitative PCR analysis indicates that GABAbl mRNA is highly abundant in 
the human testis and is expressed at around 20-fold higher levels in human foetal brain 
than in adult brain, suggesting possible roles in gametogenesis and/or neuronal 
development (Calver.A.R et al. 2003). A recent study also shows that GABAbl mRNA is 
five times more highly expressed in the rat embryonic brain than the adult brain, further 
supporting this hypothesis (Martin,S.C et al. 2004).
1.8.4 Studies o f GABA signalling during vertebrate embryogenesis
The functions of GABA signalling in developing vertebrate embryos has been studied 
previously in model organisms such as chick, zebrafish and Xenopus (Maderdrut.J.L. et al. 
1986, Roberts,A et al. 1990, Sandell.J.H et al. 1994, Ferguson,S.C.D et al. 2001, 
Lambert,T.D et al. 2004, Mueller,T et al. 2006). The distribution of GABAergic cells in the 
early developing vertebrate nervous system has been demonstrated by 
immunohistochemistry, using antibodies specific to glutaraldehyde fixation complexes of
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GABA, and is indicative of a role for GABA during embryogenesis (Roberts,A et al. 1987, 
Perrins,R et al. 2002, Mueller,T et al. 2006).
Behavioural studies indicate that GABAa receptor agonists, and to a much lesser extent 
GABAb receptor agonists, are capable of reducing motility of chick and Xenopus embryos 
when applied exogenously (Maderdrut.J.L. et al. 1986). It was postulated that the reduced 
responsiveness and immobility observed in some developing embryos, such as the 
X.laevis hatchling tadpole, might result from GABA-mediated inhibition of neuronal circuits 
(Boothby.K.M et al. 1992). Sensory trigeminal neurons, innervating tissues in the head of 
Xenopus tadpoles, can initiate swimming in response to touch. However, application of 
constant pressure upon these regions, for example through attachment to objects by 
mucus secreted from the cement gland on the front of the head, reduces spontaneous 
swimming activity (Clarke,J.D et al. 1984, Roberts,A et al. 1990). Several studies now 
indicate that trigeminal sensory neurons, firing in response to pressure exerted at the skin, 
activate GABAergic mid-hindbrain reticulospinal neurons (MHRs) which, in turn, initiate 
GABAa receptor-mediated IPSPs in spinal neurons and inhibit swimming activity 
(Perrins,R et al. 2002, Li,W-C et al. 2003, Lambert,T.D et al. 2004).
The contribution of GABAb receptor signalling to the inhibition of swimming in Xenopus 
tadpoles is not well characterised, but experiments in chick using GABAb receptor 
agonists indicate only minimal effects on motility (Maderdrut.J.L. et al. 1986). However, 
there is evidence to suggest that GABAb receptors might be involved in neuronal 
organisation in the developing brain (Fritschy.J.M et al. 2004), and GABAb receptor 
agonists and antagonists have been demonstrated to act chemotropically in vitro, by 
regulating Xenopus RGC neurite outgrowth in culture (Ferguson,S.C.D et al. 2001). To 
date, no non-mammalian vertebrate GABAb receptors have been cloned, precluding any
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analysis of developmental functions by gain- or loss-of-function approaches, through 
GABAb receptor gene overexpression or knock-down, in model organisms such as 
zebrafish or Xenopus tadpoles. Such experiments might give rise to observable changes 
in the behaviour or morphology of these embryos, which could provide insight into the 
developmental functions of GABAb receptors in the immature vertebrate brain.
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1.9 Xenopus as a model organism for the study of vertebrate embryo development
1.9.1 X. laevis and X. tropical is are model organisms commonly used for the study of
vertebrate embryo development
The African clawed frog X.laevis has for decades been widely used for research within the 
field of early embryo development and cell biology. The external development and large 
size of X.laevis embryos (approximately 1mm in diameter at fertilisation) makes them 
straight-forward to manipulate for microinjection and tissue transplants, for example, and 
their rapid rate of development allows experimental results to be obtained quickly. 
Furthermore, X.laevis can be induced to ovulate repeatedly any time of the year, unlike 
most frog species, and females will lay eggs when exposed to the human chorionic 
gonadatrophin (HCG) hormone. HCG is present in the urine of pregnant women and 
X.laevis embryos were, in fact, commonly used as an indicator for human pregnancy tests 
in the 1950s (Jones,C.M et al. 1999).
Whilst the use of X.laevis in research is still widespread, the closely related frog 
X.tropicalis is increasing being used in preference, particularly for the study of post- 
metamorphic effects, since it has a much shorter generation time of four to six months. By 
comparison, it takes up to two years for X.laevis to reach maturity (see Figure 1.6A). 
X.tropicalis was also selected for genomic sequencing by the U.S. Department of Energy 
Joint Genome Institute (JGI) since it is the only true diploid frog among the 14 Xenopus 
species and has a relatively small genome of around 1,700 million base pairs, roughly half 
the size of its larger relative, X.laevis (Showell.C et al. 2007).
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Figure 1.6 A. The mature African clawed frog X.laevis (left) and its close relative, X.tropicalis (right), 
courtesy of The Wellcome Trust Sanger Institute and Enrique Amaya Institute of Cancer and 
Developmental Biology. B. Development of the X.laevis embryo from stage 1-40, based upon the Normal 
table of Xenopus laevis (Nieuwkoop.P.D and Faber, J. 1967), adapted from image © Cebra-Thomas 
(2003). Abbreviations: ap (animal pole), bp (blastopore), eg (cement gland), jc (jelly coat), tb (tailbud).
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The early development of X.laevis embryos has been well characterised and a staging 
system, based upon morphological criteria, was prepared in 1967 by Nieuwkoop.P.D and 
Faber, J. Stages 1-40 correspond to the development of the fertilised embryo (stage 1) 
into a free swimming and feeding tadpole (stage 40) through the early developmental 
processes of gastrulation (stages 10-12), neurulation (stages 13-18), and organogenesis 
(stages 18-40) (see Figure 1.6B).
The Xenopus embryo exhibits a distinct polarity prior to fertilisation, with a pigmented 
animal pole containing the nucleus and cytoplasm and a vegetal pole containing the yolk. 
The antero-posterior axis is related to the animal-vegetal axis, and is thus already laid 
down in the unfertilised egg; the dorso-ventral axis, by contrast, is established according 
to the site of sperm entry. Following fertilisation, the plasma membrane and the 
pigmented cortex beneath it rotate towards the site of sperm entry and the Nieuwkoop 
centre forms at the opposite side of the embryo in the vegetal region. The first cleavage 
passes through the point of sperm entry and the Nieuwkoop centre, dividing the embryo 
into left and right halves; the second cleavage takes place perpendicular to this lateral axis 
and divides the embryo into to dorsal and ventral halves. The Nieuwkoop centre, located 
in the dorsal half, is essential for normal embryo development, and is responsible for 
specifying another signalling centre, the Spemann Organiser, which is located at the lip of 
the blastopore and coordinates both dorso-ventral and antero-posterior aspects of the 
body plan and induces neural tissue from the ectodermal cells in the animal pole (De 
Robertis.E.M et al. 1997, Jones,C.M et al. 1999)..
The onset of gastrulation is characterised by major cell movements inside the blastula 
embryo, and the arrangement of the germ layers - ectoderm, mesoderm and endoderm - 
to the positions where they will develop into larval body structures (see Figure 1.7).
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During gastrulation the blastopore also forms through the invagination of local endodermal 
cells; animal pole cells undergo epiboly and converge at the blastopore, and marginal 
cells move inwards as they reach the dorsal lip of the blastopore. Neurulation is 
characterised by the formation of the neural tube from the ectoderm directly overlying the 
notochord, whereby the flat neural plate folds up either side of the midline to form a neural 
groove and ultimately fuse together to form the neural tube. This process is regulated by 
signals such as chordin, noggin and follistatin that are released by the notochord and 
inhibit the activity of bone morphogenic protein 4 (BMP4) in ectodermal cells, a signalling 
molecule that is produced by the ectoderm and otherwise specifies an epidermal fate 
(Dale.L et al. 1999, De Robertis,E.M et al. 2004).
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Figure 1.7 Schematic diagram showing rearangement of the presumptive germ layers during gastrulation 
and neurulation in X.laevis, showing A. the arrangement of germ layers in the blastula embryo at stage 9 
prior to gastrulation, and B. the arrangement of germ layers in the embryo at stage 24, following
gastrulation and neurulation.
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1.9.2 A fate map for Xenopus blastulae can be used to direct injected molecules to 
specific tissues in the differentiated embryo
A fate map for the 32-cell X.laevis embryo, which describes the fate of each blastomere in 
terms of tissue types and spatial localisation, has been prepared previously (Dale.L et al. 
1987). Whilst exact targeting is problematic, due to mixing of cell populations, the fate 
map can be used as a guide to direct injected molecules, such as nucleic acids or 
proteins, towards particular tissues in the later embryo following microinjection into 
specific blastomeres at the 4, 8, 16 or 32-cell stage. For example, to direct expression of 
a protein of interest towards the CNS of the tadpole embryo, synthetic mRNA can be 
injected into the anterior dorsal blastomeres at the 8-cell stage (see Figure 1.8). This 
approach has been used previously to demonstrate the differential effects of a several 
genes in dorsal or ventral tissues (Sokol,S et al. 1991, Jones,C.M et al. 1992, Dale.L et al. 
1992).
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Figure 1.8 X.laevis embryo at stage 4 (8-cells) indicating orientation of the embryo and future 
fate of the blastomeres in the later embryo. Electron micrograph courtesy of Jurgen Berger, Max
Planck Institute for Developmental Biology.
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1.10 Principal aims and objectives of this project
This project aims to pursue a novel avenue of investigation into the possible functions of 
GABAb receptors during vertebrate development, by making use of the model organism 
X.laevis. Investigations into the in vivo functions of metabotropic GABA signalling in 
developing Xenopus tadpoles are distinctly lacking, and non-mammalian vertebrate 
GABAb receptors have yet to be been cloned. A primary objective of this project is to 
address areas of contention in GABAb receptor research wherever possible, through the 
cloning and characterisation of X.laevis GABAb receptors, and contribute further to our 
understanding of GABAb receptor physiology during vertebrate development. 
Furthermore, this research aims to elucidate a possible function for the putative orphan 
GPCR, GABAbl, though functional analysis of a non-mammalian orthologue 
overexpressed in its host organism.
Whilst a discussion of the rationale behind approaches used during this project appears at 
the beginning of each Results Chapter, below is an outline of the four principal objectives 
of this piece of research.
1.10.1 Molecular cloning of cDNAs encoding X.laevis GABAb receptors
In the first instance, this project aims to isolate cDNAs encoding X.laevis GABAb 
receptors, analyse their amino acid sequences, and compare them to their mammalian 
orthologues through multiple sequence alignments and phylogenetic analysis.
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Subsequent cloning of these cDNAs into expression vectors is hoped to facilitate further 
investigation of X.laevis GABAb receptor function at the molecular level.
1.10.2 Comparisons of mammalian and Xenopus GABAb receptor gene structures
Analysis of the gene structure of Xenopus GABAb receptors is to be explored through 
mapping the cloned X.laevis GABAb receptor nucleotide sequences onto available 
genomic DNA sequences belonging to the closely related frog Xenopus tropicalis 
(X.tropicalis). This analysis is hoped to identify the location of intron/exon boundaries in 
the Xenopus GABAb genes, and account for any possible transcript variants isolated 
through molecular cloning. The deduced gene structures shall be used to evaluate the 
conservation of intron/exon sizes and boundary locations between mammalian and 
Xenopus GABAb genes.
1.10.3 Investigation into the expression pattern of GABAb receptor mRNAs during 
Xenopus laevis embryonic development
Molecular methods will be used to identify temporal and spatial expression patterns for 
GABAb receptor mRNAs during X.laevis embryonic development. These expression 
patterns will be used to infer possible functional roles for GABAb receptors during 
Xenopus development, and identify possible targets for further functional analysis.
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1.10.4 Investigation into the function of GABAb receptors during X.laevis embryonic 
development through gene overexpression or knock-down
It is envisaged that in vivo functions of the cloned X.laevis GABAb receptors will be 
explored primarily through use of a gain-of-function bioassay, whereby GABAb receptor 
proteins will be overexpressed during embryonic development by microinjection of in vitro 
transcribed mRNA into cleavage-stage embryos. Morphological changes will be 
characterised and, where possible, loss-of-function approaches will be considered. The 
causes of any reproducible developmental changes in overexpressing embryos will also 
be explored at the molecular level.
Materials and Methods
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2.1 Molecular Biology Methods
2.1.1 Preparation of competent E.coli cells
To prepare chemically competent cells, 5ml Luria Bertani (LB) broth (10g/L NaCI, 10g/L 
tryptone, 5g/L yeast extract) was inoculated with a single colony of an appropriate E. coli 
strain and incubated overnight at 37°C with shaking. The overnight culture was used to 
inoculate 100ml LB, which was incubated at 37°C with shaking until its OD550 reached 0.4. 
The culture was then divided into 25ml aliquots in 50ml tubes, incubated on ice for 10 
mins and centrifuged at 2500rpm (700rcf) for 10 mins at 4°C. Pellets were resuspended 
in 15ml ice-cold solution FB (100mM KCI, 50mM CaCI2, 10mM KAc, 10% (v/v) glycerol) 
and incubated on ice for a further 20 mins. Cells were then centrifuged again at 5000rpm 
(2800rcf) for 10 mins at 4°C, and pellets were resuspended in 1ml ice-cold solution FB. 
200pl aliquots were flash frozen in liquid nitrogen and stored at -80°C.
2.1.2 Transformation of competent E. coli cells
For each transformation, a 200pl vial of competent cells was thawed on ice and 50-1 OOng 
of plasmid DNA was typically added. Cells were incubated on ice for 30 mins, briefly 
heat-shocked at 42°C for 60-90 secs and immediately returned to ice. Following the 
addition of 250pl salt optimised (SOC) broth (0.5g/L NaCI, 5g/L MgS04, 20g/L Tryptone, 
5g/L yeast extract, 20mM dextrose), cells were incubated at 37°C with shaking for 30-60 
mins to permit expression of the antibiotic resistance gene. Cells were spread onto LB
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agar plates, containing the appropriate antibiotic (e.g. 100pg/ml Ampicillin, 50pg/ml 
Kanamycin or 10pg/ml tetracycline), and incubated at 37°C overnight.
2.1.3 Preparation of plasmid DNA from E.coli cells (mini-prep)
Single colonies of E.coli were used to inoculate 2.5ml overnight cultures in LB broth 
containing an appropriate antibiotic. 1ml of culture was centrifuged at 13,000rpm 
(14,200rcf) for 2 mins to pellet the cells. Pellets were resuspended in 100pi solution I 
(50mM glucose, 25mM Tris-HCI (pH8.0), 10mM EDTA (pH8.0)), and 200pl solution II 
(0.2M NaOH, 1.0% (w/v) SDS) was added, mixed by inversion and incubated at room 
temp for 5 mins. 150pl ice-cold solution III (3M KAc, 11.5% (v/v) glacial acetic acid) was 
added, mixed by inversion and incubated at 4°C for 5 mins. Following centrifugation at 
13,000rpm (14,200rcf) for 5 mins at 4°C, supernatant was removed and mixed with 250pl 
phenol:chloroform:isoamyl alcohol saturated with TE (10mM Tris-HCI, 1mM EDTA (pH 
8.0)). Following centrifugation at 13,000rpm (14,200rcf) for 1 min at 4°C, the upper 
aqueous phase was transferred to a fresh tube and 1ml ice-cold ethanol was added. 
Precipitated plasmid DNA was centrifuged at 13,000rpm (14,200rcf) for 15 mins at 4°C 
and, after briefly washing with 500pl 70% (v/v) ethanol, pellets were resuspended in 30- 
50pl distilled water (dH20), or TE + 10pg/ml RNaseA, depending on future application. 
Where necessary, equal quantities of bacterial culture and glycerol were mixed and stored 
at -80°C for future use.
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2.1.4 Preparation of plasmid DNA from E. coli cells (maxi-prep)
For each preparation, 1ml of an overnight culture was used to inoculate 500ml LB, 
containing the appropriate antibiotic, and incubated overnight at 37°C with shaking. The 
overnight culture was decanted into a 500ml flask and centrifuged at 10,000rpm 
(11,200rcf) for 20 mins at 4°C in a Sorvall RC-5B centrifuge. Supernatant was poured off 
and the bacterial pellet resuspended in 20ml solution I (50mM glucose, 25mM Tris-HCI, 
pH8.0), 10mM EDTA (pH8.0)). 40ml solution II (0.2M NaOH, 1.0% (w/v) SDS) was added 
and the preparation incubated at room temp for 5 mins. Next, 20ml ice-cold solution III 
(3M KAc, 11.5% (v/v) glacial acetic acid) was added, mixed gently, and the preparation 
was incubated on ice for 15 mins. Following the addition of 5ml dH20, the preparation 
was centrifuged at 10,000rpm (14,200rcf) for 20 mins at 4°C in a Sorvall RC-5B 
centrifuge. Cleared supernatant was filtered through a double layer of gauze and 
transferred to a 250ml flask, mixed with 45ml isopropanol, and centrifuged at 12,000rpm 
(12,900rcf) for 30 mins at 4°C in a Sorvall RC-5B centrifuge. Pellets were resuspended in 
10ml TE, to which a further 150pl 0.5M EDTA was added, and pH was adjusted to ~7.5 
with 2M TRIZMA base. CsCI was added to a final concentration of 1.2g/ml and ethidium 
bromide to a final concentration of 0.5mg/ml. Preparations were loaded into a Beckman 
Coulter 10ml NVT centrifuge tubes, heat-sealed and centrifuged at 55,000rpm 
(200,000rcf) for at least 24 hours at 4°C in a Beckman Coulter Optima™ L-100XP 
Ultracentrifuge. Intact supercoiled plasmid DNA was extracted from the NVT tube using a 
19 gauge needle and syringe, and ethidium bromide was removed by extraction with 
butan-2-ol. The preparation was then dialysed in TE to remove the CsCI, incubated with 
RNaseA at a final concentration of 10pg/ml, at 65°C for 60 mins, followed by incubation 
with Proteinase K at a final concentration of 100pg/ml, 0.2% (w/v) SDS, at 37°C for 60 
mins. Protein was removed by extraction with phenol:chloroform:isoamyl alcohol
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(saturated with TE at pH 8.0) and transfer of the upper phase was transferred to glass 
centrifuge tubes. NaCI was added to a final concentration of 250mM and plasmid DNA 
was precipitated with the addition of ethanol at -20°C prior to centrifugation at 12,000rpm 
(12,100rcf) for 30 mins at 4°C in a Sorvall RC-5B centrifuge. The pellet was resuspended 
in approximately 250-500pl TE or dH20  and the concentration determined 
spectrophotometrically (see Section 2.1.5).
2.1.5 Quantitation of nucleic acids
Nucleic acid concentrations were routinely determined spectrophotometrically, either by 
measuring the absorbance at 260nm of a diluted sample and applying the formula pg/ml = 
O D 26o x dilution factor x C, where C is the molar extinction coefficient specific to the 
species of nucleic acid (ss-DNA = 37; ss-RNA = 40; ds-DNA = 50), or by using a 
NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop) according to the 
manufacturer’s instructions.
2.1.6 Agarose gel electrophoresis of nucleic acids
For routine use, agarose gel electrophoresis was performed using 1% (w/v) agarose 
1xTAE (40mM Tris-acetate, 1mM EDTA) gels, containing ethidium bromide at a final 
concentration of 0.5pg/ml. Nucleic acid samples were typically combined with 5xDNA 
BlueRun™ loading dye (Hybaid) and loaded alongside a molecular weight marker, 
typically 1Kb Plus DNA Ladder (Invitrogen). Gels were immersed in 1xTAE in gel tanks
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and electrophoresed at 120-130V for 15-60 mins, depending on application, before being 
visualised on an UV transilluminator.
2.1.7 Restriction endonuclease digestions of DNA
Plasmid DNA was routinely digested by incubation with restriction endonuclease at a final 
concentration of around 10units/pl DNA in the appropriate 1x restriction enzyme digest 
buffer. 1xBSA (bovine serum albumin) was included where required. Digests were 
typically incubated for 60-90 mins at 37°C. Digested plasmid DNA was routinely analysed 
by separation on an agarose gel (see Section 2.1.9).
2.1.8 Extraction of total RNA
Total RNA was extracted and purified from X.laevis embryos or animal cap explants using 
either the RNeasy Mini Kit (Invitrogen) or Trizol® Reagent (Invitrogen) according to the 
manufacturer’s instructions. Samples of 10 snap-frozen embryos, or anterior, posterior, 
dorsal or ventral explants, were homogenized using a Pellet Pestle® (Kimble-Kontes) or by 
pipetting up and down; samples of 20 snap-frozen animal cap explants were 
homogenized by vortexing. Total RNA was resuspended in 30pl dH20  and the 
concentration was determined spectrophotometrically (see Section 2.1.5).
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2.1.9 Reverse transcriptase (RT)
Reverse transcriptase (RT) was routinely carried out in 20pl reactions using the 
Omniscript RT kit (Qiagen) or Improm II® RT kit (Promega) according to the 
manufacturer’s instructions. Total RNA, at a final concentration of 50-100ng/pl, was 
incubated with random hexamer oligonucleotide primers (at a final concentration of 1 pM), 
dNTPs (at a final concentration of 0.5mM each), RNase inhibitor (at a final concentration 
of 0.5units/pl), and reverse transcriptase (at a final concentration of 0.2units/pl). 
Reactions were incubated for 90 mins at 37-42°C.
2.1.10 Reverse transcriptase polymerase chain reaction (RT-PCR)
For routine use, reverse transcriptase polymerase chain reaction (RT-PCR) was carried 
out in 25pl reactions using 1units/pl BIOTAQ™ DNA polymerase (BioMix™ Red, 
BIOLINE), or 1.25units/pl HotMaster Taq DNA Polymerase (Eppendopen reading frame), 
containing 1mM MgCI2 and dNTPs (at a final concentration of 0.5mM each). Where RT- 
PCR was used for cloning purposes, 25pl reactions were carried out using 1unit/pl 
ACCUZYME™ high-fidelity proofreading DNA polymerase (ACCUZYME™ Mix, BIOLINE) 
containing 1mM MgS04 and dNTPs (at a final concentration of 0.5mM each). Template 
cDNA was included at a final concentration of around 2ng/pl, oligonucleotide primers were 
included at a final concentration of 0.4pmoles/pl and, where necessary, DMSO was added 
to a final concentration of 2% (v/v). PCR was carried out using a PCR Express thermal 
cycler (Hybaid), using the following conditions: Four mins at 94°C, followed by 24-30 
cycles of 30 secs at 94°C, 30 secs at the optimal annealing temperature for the primers 
used, and 1 min/kb of the amplicon (or 2min/kb when using the ACCUZYME™
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proofreading DNA polymerase) at the optimal elongation temperature of the polymerase 
used. A final elongation step of 5 mins was performed. Optimal primer annealing 
temperatures were calculated using MacVector 7.2 (Accelrys).
Where RT-PCR was performed to analysis the expression of transcripts in X.laevis 
tissues, a 228bp amplicon was also amplified from the Xenopus gene encoding orthinine 
decarboxylase (x/ODC), which is uniformly expressed during development, to act as a 
positive control as described previously (Agius.E. et al. 2000). As a negative control, PCR 
was conducted concomitantly on samples containing total RNA that had not been 
converted to cDNA by reverse transcriptase.
2.1.11 Rapid amplification of 5’ cDNA ends (5’RACE)
The amplification of 5’ cDNA sequences was performed using the 5' RACE System for 
rapid amplification of cDNA ends v2.0 (Invitrogen). First strand synthesis was performed 
in 24pl reactions containing template total RNA (at a final concentration of 0.2pg/pl) and 
gene-specific oligonucleotide primers (at a final concentration of 0.1pmol/pl), and 
reactions were incubated for 90 mins at 42°C. Following heat-inactivation and RNase 
treatment, ss-cDNA was purified using the Wizard® DNA Clean-Up System (Promega) 
according to the manufacturer’s instructions. Following the poly-dC-tailing of ss-cDNA, 
and heat-inactivation of the TDT enzyme, ds-cDNA was amplified by PCR in 25pl 
reactions including 5pl template poly-dC-tailed ss-cDNA, 1 unit/pl ACCUZYME™ 
proofreading DNA polymerase, and nested 5’RACE abridged anchor and gene-specific 
oligonucleotide primers (see Section 2.1.10 for conditions). 1pl of this PCR product was 
used as a template for a further 30 cycles of PCR, the product from which was separated
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on an agarose gel (see Section 2.1.9), excised and purified (see Section 2.1.17) and 
ligated into a plasmid vector (see Section 2.1.18).
2.1.12 Dideoxy sequencing of plasmid DNA
Plasmid DNA was sequenced by the Sanger dideoxy method using the BigDye® 
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) according to the 
manufacturer’s instructions. PCR was performed in 25pl reactions containing template 
plasmid DNA (at a final concentration of 50ng/pl), oligonucleotide primers (at a final 
concentration of 0.4pmoles/pl), and DMSO (at a final concentration of 5% (v/v)). PCR 
was carried out using a PCR Express thermal cycler (Hybaid), using the following 
conditions: Five mins at 98°C, followed by 25 cycles of 30 secs at 96°C, 20 secs at the 
optimal annealing temperature for the primers used, and 4 mins at 60°C. A final 
elongation step of 5 mins at 60°C was performed. Optimal primer annealing temperatures 
were calculated using MacVector 7.2 (Accelrys).
The PCR product was precipitated in 6pM NaAc, 250nM EDTA, with 3 volumes of ethanol, 
incubated at -20°C for 10 mins and centrifuged at 13,000rpm (14,200rcf) for 15 mins at 
4°C. The pellet was washed with 50pl 70% (v/v) ethanol and resuspended in 10pl 
formamide prior to loading on an automated capillary DNA sequencer (ABI Applied 
Biosystems 3100-Avant Genetic Analyzer). Sequences were viewed using Chromas Lite 
2.0 (Technelysium Pty Ltd), exported in FASTA format and analysed using MacVector 7.2 
(Accelrys).
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2.1.13 PCR-based site-directed mutagenesis
PCR-based site-directed mutagenesis was used to introduce or remove restriction 
endonuclease recognition sequences from plasmid DNA. PCR was carried out in 25pl 
reactions using 1unit/pl ACCUZYME™ proofreading DNA polymerase and two 
complementary gene-specific oligonucleotide primers (at a final concentration of 
0.4pmoles/pl) containing the appropriate mutation(s). Following the addition of Dpn1 
nuclease to a final concentration of 0.4units/pl and incubation for 3 hours at 37°C, 1 pi of 
the PCR product was used to transform competent E.coli cells (see Section 2.1.2). 
Plasmid DNA was isolated from the E.coli (see Section 2.1.6), digested using the 
appropriate restriction endonuclease(s) (see Section 2.1.7), and separated on an agarose 
gel by electrophoresis (see Section 2.1.9) to indicate presence of the mutation(s). 
Mutations were also verified by sequence analysis (see Section 2.1.12).
2.1.14 Isolation and purification of DNA from agarose gels
Linear fragments of DNA were electrophoresed on agarose gels, visualised on a UV 
transilluminator and excised using a scalpel blade. DNA was purified from excised gel 
fragments using either the Wizard® PCR Preps DNA Purification System (Promega) or the 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. DNA 
fragments, purified using either method, were eluted in 30pl dH20  at 70°C and a small 
amount was run on an agarose gel (see Section 2.1.9) to verify the quality of the purified 
fragment.
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2.1.15 Ligation of DNA fragments into piasmid vectors
DNA fragments were routinely ligated into linearised plasmid vectors with compatible 
sticky or blunt ends. Plasmid vectors were purified using the Wizard® DNA Clean-Up 
System (Promega), according to the manufacturer’s instructions, and DNA fragment 
inserts were isolated and purified from agarose gels (see Section 2.1.14), following 
digestion of each with the appropriate restriction endonuclease(s) (see Section 2.1.7). To 
generate blunt ends from 5’-overhangs, purified DNA fragments were incubated with 
1unit/pg (of DNA) T4 DNA polymerase (New England Biolabs), and dNTPs (at a final 
concentration of 100pM each), at 37°C for 5 mins. Ligations were performed with a 
vector:insert ratio of approximately 1:1 in a 10pl reaction containing 100ng vector 
fragment, 1x Ligase buffer and 400units T4 DNA Ligase (Promega). Reactions were 
incubated for a minimum of 4 hours at 14°C and then used to transform competent E.coli 
cells (see Section 2.1.2).
2.1.16 In vitro transcription of cRNA probes
In vitro transcription of complementary RNA (cRNA), from template plasmids containing 
promoters for the bacteriophage RNA polymerases T3, T7 or Sp6, was performed to 
generate DIG (digoxygenin)-labelled sense and anti-sense probes for use in wholemount 
in situ hybridization experiments (described in Section 2.3.5). Purified template plasmid 
DNA, linearised by the appropriate restriction endonuclease (see Section 2.1.7), was 
incubated in 20pl transcription reactions (at a final concentration of 50ng/pl) containing 1x 
transcription buffer (Promega), dithiothreitol (DTT) (at a final concentration of 10mM), 
0.5units/pl RNase inhibitor, and T3, T7 or Sp6 RNA polymerase (Promega) (at a final
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concentration of 1unit/|jl). Ribonucleotides were included at a final concentration of 1mM 
except for rUTP, which was included at a final concentration of 0.65mM and DIG-11-rllTP 
at a final concentration of 0.35mM. Reactions were incubated for 3-4 hours at 37°C, and 
then for a further 30 mins at 37°C following the addition of RQ1 DNase to a final 
concentration of 0.05units/pl. Transcripts were precipitated in 6pM NaAc with 3 volumes 
of ethanol, incubated at -20°C for 10 mins and centrifuged at 13,000rpm (14,200rcf) for 15 
mins at 4°C. After washing with 100pl 70% (v/v) ethanol, the pellet was resuspended in 
30pl RNase-free dH20  and the quality of the cRNA was assessed using agarose gel 
electrophoresis (see Section 2.1.6).
2.1.17 In vitro transcription of 5’-capped, polyadenylated cRNA for microinjection
5’-capped, poly-adenylated complementary RNA (cRNA), suitable for microinjection into 
X.laevis embryos (see Section 2.3.7), was synthesized using the mMessage mMachine kit 
(Ambion) according to the manufacturer’s instructions. The cRNA was purified using the 
RNeasy Mini Kit (Invitrogen) according to the manufacturer’s instructions, and the quality 
of the cRNA was assessed by agarose gel electrophoresis (see Section 2.1.6).
2.1.18 Producing radiolabelled cDNA probes
Radiolabelled complementary DNA (cDNA) probes were synthesised using the Prime-a- 
Gene® Labelling System (Promega) according to the manufacturer’s instructions. 25ng of 
heat-denatured template DNA was incubated in a 50pl reaction containing, 62.5pCi a- 
[32P]CTP, 1pM random hexamer oligonucleotide primers, dATP, dGTP and dTTP (at a
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final concentration of 20|jM each), and 5 units DNA polymerase (Klenow fragment). 
cDNA probes were separated from unincorporated dNTPs by size exclusion 
chromatography using NICK™ Sephadex™ G-50 columns (GE Healthcare) as described 
in the manufacturer’s instructions.
2.1.19 Determining stringency through calculation of Tm values
The Tm values for duplexes were routinely estimated using the formulae: Tm = 81.5 + 
16.6(log10[Na+]) + 0.41(%G:C/100) - 0.63(% (v/v) formamide) - (600/I), for DNA:DNA 
hybrids, and Tm = 79.8 + 18.5(log10[Na+]) + 0.58(%G:C/100) + 11.8(%G:C/100)2 - 0.5(% 
(v/v) formamide) - (820/I), for DNA:RNA hybrids, where I = length of oligonucleotide probe 
in bp. Hybridizations were typically carried out at Tm -5°C, low stringency washes were 
typically carried out at Tm -10°C, and high stringency washes were typically carried out at 
Tm +10°C
2.1.20 Colony hybridization
E.coli colonies were screened by colony hybridization, using a radiolabelled cDNA probe, 
to isolate clones containing the desired plasmid DNA. Colonies were streaked onto 
duplicate LB agar plates and incubated overnight at 37°C. Colonies from one of the 
duplicate plates were transferred onto labelled 80mm Hybond-N+ nylon filters (GE 
Healthcare). Filters were soaked in denaturing solution (500mM NaOH) for 5 mins and 
neutralization solution (1M Tris-HCI pH8.0) twice for 5 mins, air-dried, and pre-incubated 
in hybridization solution (50% (v/v) formamide, 5x SSC, 1x BFP, 0.1 mg/ml sheared
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salmon sperm DNA, 20mM Tris-HCI (pH8.0), 0.5% (w/v) SDS) for 60 mins at the 
appropriate hybridization temperature. Following the removal of cellular debris, filters 
were incubated in hybridization solution containing heat-denatured radiolabelled cDNA 
probe (see Section 2.1.18), for at least 8 hours at the appropriate temperature. Filters 
were washed three times at low stringency (2x SSC, 0.1% (w/v) SDS), and twice at high 
stringency (0.2x SSC, 0.1% (w/v) SDS), 20 mins per wash. Damp filters were wrapped in 
SaranWrap® and placed in a cassette and exposed to photographic film. Positive colonies 
were picked from the duplicate plate and used to inoculate overnight cultures, from which 
plasmid DNA was isolated (see Section 2.1.6) for PCR (see Section 2.1.13) or restriction 
enzyme analysis (see Section 2.1.10).
2.1.21 Southern hybridization
The identity of DNA fragments amplified by RT-PCR (see Section 2.1.10) was confirmed 
by Southern analysis in Section 5.2.1. DNA fragments separated by agarose gel 
electrophoresis (see Section 2.1.9) were denatured by immersion of the gel in denaturing 
solution (500mM NaOH) for 5 mins. Gels were immersed in neutralization solution (1M 
Tris-HCI pH8.0) twice for 5 mins, and then inverted onto Whatman® 3MM blotting paper 
pre-soaked in 10xSSC. A Hybond-N+ nylon filter (GE Healthcare) was laid upon the 
inverted gel, followed by sheets of pre-soaked blotting paper, dry blotting paper, and 
paper towels to yield a semi-dry blotting stack. A weight was placed on top of the stack 
and the DNA was allowed to transfer onto the filter overnight. After rinsing briefly with 
2xSSC, DNA was cross-linked to the filter by irradiation with UV for 5 mins on a 
transilluminator, and filters were pre-incubated in pre-hybridization solution (50% (v/v) 
formamide, 5x SSC, 1x BFP, 0.1 mg/ml sheared salmon sperm DNA, 20mM Tris-HCI
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(pH8.0), 0.5% (w/v) SDS) for 60 mins at the appropriate hybridization temperature. Heat- 
denatured radiolabelled cDNA probe (see Section 2.1.21) was then added and 
hybridization carried out for at least 8 hours at the appropriate temperature. Following 
hybridization, filters were washed three times at 42°C, 20 mins per wash, in 2x SSC 
containing 0.1% (w/v) SDS, followed by two high stringency washes, 20 mins per wash, in 
0.2x SSC containing 0.1% (w/v) SDS. The damp filters were wrapped in SaranWrap®, 
placed in a cassette and exposed to photographic film.
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2.2 Protein Methods
2.2.1 In vitro translation of radiolabelled protein
Recombinant protein was translated in vitro using a nuclease-treated Rabbit Reticulocyte 
Lysate kit (Promega), and radiolabelled through incorporation of l35]S-labelled methionine, 
as described in the manufacturer’s instructions. 5’-capped, poly-adenylated 
complementary RNA (cRNA) was included in each reaction at a final concentration of 
25ng/pl, and reactions were incubated at 30°C for 90 mins. Translated proteins were 
analysed by separation on an SDS polyacrylamide gel and visualised on an 
autoradiograph (see Section 2.2.2).
2.2.2 Separation of proteins by SDS polyacrylamide gel electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was routinely 
carried out using hand-cast gels comprised of a 4% stacking gel (4% (w/v) acrylamide, 
0.1% (w/v) bis-acrylamide, 125mM Tris-HCI (pH 6.8), 0.1% (v/v) SDS, 0.05% (w/v) 
ammonium persulphate, 0.1% (v/v) TEMED) on top of a 7.5% resolving gel (7.5% (w/v) 
acrylamide, 0.2% (w/v) bis-acrylamide, 375mM Tris-HCI (pH 8.8), 0.1% (v/v) SDS, 0.1% 
(w/v) ammonium persulphate, 0.1% (v/v) TEMED). Once set, gels were clamped into a 
Mini-PROTEAN II electrode assembly and electrophoresis chamber (BIORAD) and 
immersed in SDS-PAGE running buffer (25mM Tris-HCI (pH6.8), 192mM glycine, 0.1% 
(v/v) SDS). Protein samples were combined with a 2x Laemmli sample buffer concentrate 
(Sigma) (20% (v/v) glycerol, 4% (v/v) SDS, 10% (v/v) p-mercapto-ethanol, 125mM Tris-
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HCI (pH 6.8)) and heat-denatured at 95°C for 10 mins, before loading into the gel 
alongside a pre-stained molecular weight marker such as SeeBlue® Plus2 (Invitrogen). 
Proteins were electrophoresed at 170V for approximately 1 hour. Where appropriate, 
separated proteins were visualised by direct staining of the gel with Coomassie Blue, 
whereby gels were immersed in the stain for up to an hour, then repeatedly washed in 
destaining solution (40% (v/v) methanol, 10% (v/v) acetic acid) until protein bands were 
clearly visible. To visualise radiolabelled protein, gels were dried in a vacuum gel drier, 
wrapped in SaranWrap®, and placed in a cassette and exposed to photographic film.
2.2.3 Western blotting of SDS polyacrylamide gels
Proteins separated by SDS-PAGE were transferred to a PVDF membrane by western 
blotting as follows. Gels were soaked in a transfer buffer (25mM Tris-HCI (pH6.8), 
192mM Glycine, 10% (v/v) methanol) and inverted onto sheets of Whatman® 3MM blotting 
paper pre-soaked in transfer buffer. A Hybond-P PVDF membrane (GE Healthcare), pre­
rinsed in methanol and then dH20, was and placed on top of the gel, followed by more 
pre-soaked blotting paper, and placed in a Trans-Blot® SD semi-dry transfer cell 
(BIORAD). Proteins were transferred by electrophoresis at 15V for 30 mins. Proteins 
were visualised by direct staining of the PVDF membrane with Ponceau Red.
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2.2.4 Immuno-detection of proteins on blotted membranes
Proteins were specifically detected on blotted PVDF membranes by incubating the 
membrane in 5% blocking solution (5% (w/v) Marvel® milk powder, TBS-T (1xTBS, 0.1% 
(v/v) Tween-20)) overnight at 4°C, briefly rinsing in TBS-T, and incubating in a sealed bag, 
containing diluted primary antibody in 2.5% blocking solution, for 2 hours at 4°C. 
Membranes were washed, with agitation, at least 4 times in 100ml TBS-T then incubated 
in a sealed bag, containing a 1:4000 dilution of HP-conjugated anti-goat IgG secondary 
antibody in 2.5% blocking solution, for 1 hour at 4°C. Membranes were then washed, with 
agitation, at least 4 times in 100ml TBS-T. Immuno-detected protein was visualized using 
an ECL-Plus enhanced chemiluminescence kit (GE Healthcare) according to the 
manufacturer’s instructions. Following exposure to light for 5 mins, excess liquid was 
removed and the membrane was wrapped in SaranWrap®, placed in a cassette and 
exposed to photographic film.
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2.3 Embryology Methods
2.3.1 Fertilisation ofX.laevis oocytes
Ovulation was induced in mature female X.laevis frogs by subcutaneous injection of 750 
units human chorionic gonadatrophin (HCG) (Chroulon, Intervet) into the dorsal lymph 
sac. After 12-16 hours, oocytes were squeezed from injected frogs into a Petri dish and 
fertilised with a piece of freshly dissected, macerated X.laevis testis suspended in a little 
tap water. Fertilised embryos were incubated at room temperature in NAM/20 (5.5mM 
NaCJ, 0.1 mM KCI, 0.05mM Ca(N03)2, 5nM EDTA, 2mM HEPES, 25pg/ml gentamicin) and 
left for up to 2 hours to allow for the cortical rotation of fertilised embryos to occur. 
Embryos were subsequently incubated in 2% (w/v) cysteine hydrochloride (pH8.2) for 5- 
10 mins to break down the jelly coats, and were washed several times with large volumes 
of tap water. After the removal of dead or unfertilised oocytes, embryos were incubated in 
NAM/20 at the desired temperature, typically 14.5°C, and allowed to develop.
2.3.2 Maintenance ofX.laevis embryos in normal amphibian medium (NAM)
Developing embryos were maintained in NAM/20, or NAM/2 (55mM NaCI, 1mM KCI, 
0.5mM Ca(N03)2, 0.05mM EDTA, 2mM HEPES, 7pg/ml gentamicin) post-gastrulation, at 
the desired temperature (typically 13-18°C). Stages of embryonic development were 
assigned according to the Normal Table of Xenopus Development by Nieuwkoop.P.D and 
Faber,J (1967).
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2.3.3 Snap-freezing ofX.laevis embryos and animal cap explants
When preparing embryos or animal cap explants for extraction of total RNA (see Section 
2.1.11) or protein, medium was removed from samples which were then snap-frozen on 
dry-ice prior to storage at -20°C. Cell lysates were prepared by macerating samples in 
homogenization buffer (20mM Tris-HCI (pH 7.6), 100mM NaCI, 1% (v/v) Triton X-100) 
containing Complete Mini protease inhibitor cocktail (Roche), centrifuged at 13,000rpm 
(14,200rcf) for 15 mins to clear the lysate, and snap-frozen on dry ice prior to storage at - 
20°C.
2.3.4 Fixing of X. laevis embryos
When preparing embryos for wholemount in situ hybridization (see Section 2.3.5) or wax- 
sectioning (see Section 2.3.6), healthy embryos were selected at the desired stage of 
development and incubated in 1x MEMFA (10% (w/v) formaldehyde, 0.1M MOPS (pH 
7.4), 2mM EGTA, 1mM MgS04) for 60 mins. After washing briefly with methanol, 
embryos were stored in fresh methanol at -20°C until required.
2.3.5 Wholemount in situ hybridization
Wholemount in situ hybridization was carried about as described previously (Harland.R.M. 
1991) with several modifications. Fixed X.laevis embryos (see Section 2.3.4) were slowly 
re-hydrated and washed with PBS-T (1xPBS, 0.1% (v/v) Tween-20), bleached with 10% 
peroxide solution (10% (v/v) H20 2, 5% (v/v) formamide, 0.5x SSC), rinsed in 0.1 M
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triethanolamine (pH 7.8) containing 0.625% (v/v) 1.25% (v/v) acetic anhydride, and re­
fixed in 10% (w/v) formaldehyde. Embryos were incubated in hybridization solution (50% 
(v/v) formamide, 5x SSC, 1x BFP, 1 mg/ml sheared torula RNA, 100pg/ml heparin, 10mM 
EDTA, 0.1% (w/v) CHAPS, 0.1% (v/v) Tween-20) for at least 6 hours, at the appropriate 
hybridization temperature (calculated as described in Section 2.1.19). DIG-labelled sense 
or anti-sense cRNA probe (see Section 2.1.19) was added to a final concentration of 0.3- 
1 .Opg/rnl and embryos were incubated for at least 8 hours, at the appropriate hybridization 
temperature.
Following hybridization, used probe solution was retained and stored at -80°C for re-use, 
and embryos were washed three times, 30 mins per wash, at 60°C in 2x SSC containing 
0.1% (v/v) Tween-20). Embryos were then washed twice, 30 mins per wash, at high 
stringency in 0.2x SSC containing 0.1% (v/v) Tween-20, and then incubated in RNase T1 
solution (2x SSC, 10units/ml) for 15 mins at 37°C to degrade any remaining single­
stranded RNA. Following washes with maleic acid buffer (pH7.8) (100mM maleic acid, 
150mM NaCI, 0.1% (v/v) Tween-20), embryos were incubated in blocking solution 1 (2% 
blocking solution (Roche) in maleic acid buffer) for 2 hours at room temperature, blocking 
solution 2 (20% (v/v) lamb serum in blocking solution 1) for 2 hours at room temperature, 
and finally in blocking solution containing a 1:2000 dilution of affinity-purified 
antidigoxygenin-AP Fab fragments (Roche) at 4°C overnight. Following at least six 
washes in 3-5ml maleic acid buffer, 1 hour per wash, embryos were rinsed briefly in 
alkaline phosphatase buffer (100mM TRIZMA base, 100mM NaCI, 100mM MgCI2, 5mM 
tetramisole, 0.1% (v/v) Tween-20), and then incubated with BM Purple AP-substrate 
precipitating solution (Roche) until dark blue staining became visible. Embryos were 
stored in methanol at -20°C.
2.3.6 Wax sectioning and histology
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Fixed X.laevis embryos (see Section 2.3.4) were incubated in Borax Carmine stain 
overnight, then in acid alcohol solution (70% (v/v) ethanol, 1% (w/v) HCI) for at least 2 
hours. Stained embryos were dehydrated incrementally through the following series of 
washes: 80% (v/v) EtOH for 15 mins, 80% (v/v) EtOH:BuOH (3:1 ratio by volume) for 15 
mins, 90% (v/v) EtOH:BuOH (1:1 ratio by volume) for 15 mins, 100% (v/v) EtOH/BuOH 
(1:3 ratio by volume) for 15 mins, and 100% BuOH for 30 mins. Embryos were brought to 
60°C and butanol was exchanged for molten Fibrowax (TAAB Laboratories Equipment) 
maintained at 60°C, and individual embryos were loaded into plastic trays on a hotplate. 
Trays were transferred to a coldplate to solidify the wax. Embedded embryos were fixed 
to wooden blocks with molten wax, loaded into a vice, and 12pm sections were cut using 
a Microm HM325 rotary microtome. Wax sections were transferred to wet slides and 
incubated over a hotplate overnight to dry. Wax sections were cleared by dipping slides 
into Histoclear™ solution (Ward’s Natural Science), hydrated using a series of 100% - 0% 
(v/v) ethanol solutions, then counterstained for 30 secs in Piero Blue. Following 
counterstaining, sections were alcohol dehydrated and cleared using Histoclear™ 
solution, and cover slips were applied to slides and left to set overnight.
2.3.7 Microinjection ofX.laevis embryos with cRNA
Embryos were selected for microinjection at the 2-cell or 8-cell stage and were placed in 
NAM/20 (5.5mM NaCI, 0.1 mM KCI, 0.05mM Ca(N03)2, 5nM EDTA, 2mM HEPES, 25pg/ml 
gentamicin) containing 2% (w/v) Ficoll. Micropipettes were produced by pulling 1mm 
outer diameter x 0.58mm inner diameter x 100mm borosilicate glass capillaries (Intrafil) in
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a Narishige PC-10 pipette puller, and attached to a PLI-100 microinjection rig (Medical 
Systems) connected to pressurised N2(g). The micropipette was backfilled with 2-3pl in 
vitro transcribed, 5’-capped, polyadenylated cRNA (see Section 2.1.17), containing a 1/25 
dilution of Dextran Fluorescein (Molecular Probes) where appropriate, and calibrated by 
injecting into mineral oil and measuring the bubble produced with an eye-piece graticule; 
A diameter of 4.0 eye-piece units (epu) at 1.6x magnification corresponded to a 8.6nl 
volume. Injection pressure and duration was adjusted until the required volume of 8.6nl 
was obtained. Following microinjection, embryos were maintained as described in 
Section 2.3.2. For each construct, in vitro transcribed cRNA was microinjected into 
batches of around fifty cleavage-stage embryos per experiment, and experiments were 
performed at least twice to account for batch variability. Representative batches were 
then selected for scoring and photography in order to generate figures (see Sections 2.3.9 
and 2.3.10). To facilitate direct comparison between the effects of microinjection of 
distinct cRNAs, or distinct cRNA concentrations, experiments were carried out upon the 
same batch of fertilised embryos from a single X.laevis frog to eliminate the potentially 
misleading effects of batch variability. Furthermore, to eliminate the possibility of variance 
between separate in vitro transcribed cRNA preparations, a single preparation was used 
for the overexpression experiments shown in Sections 6.2 and 6.3 for each construct 
analysed.
2.3.9 Scoring of embryos according to morphological phenotype
In order to quantify the phenotypic variability observed within batches ofX.laevis embryos, 
and to thus facilitate direct comparison of the morphological defects in embryos injected 
with distinct cRNAs, a graded scoring system was developed and adopted throughout
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Sections 6.2-5). Using this system, a greater score represented an increase in the 
severity of the morphological defects observed, and thus an increased departure from the 
wild-type morphology of X.laevis embryos. A score of 1 was assigned to embryos 
exhibiting wild-type morphology with no observable morphological defects. A score of 2 
was assigned to embryos exhibiting a near wild-type morphology but with minor defects, 
such as a slight decrease in the size of the head or eyes (microcephaly), minor body 
truncation, or a significant kink in the tail. A score of 3 was assigned to embryos 
exhibiting moderate head defects, such as limited eye or cement gland development or 
severe microcephaly, and/or minor gastrulation defects, significant body truncation or loss 
of fin structures. A score of 4 was assigned to embryos exhibiting major head defects, 
such as loss of specification of eyes or cement gland, or complete loss of all head 
structures (acephaly), and/or major gastrulation failures, major body truncation, or loss of 
identifiable tail or fin structures. An example of the application of this scoring system, 
showing the calculation of percentage proportions and graphical representation as a 
stacked column chart, is shown in Figure 2.1. Stacked column charts were produced 
using Excel 2002 (Microsoft).
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1 3 13.6
2 2 9.1
3 9 40.9
4 8 36.4
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Figure 2.1 A. A sample of 22 embryos at stage 40, following microinjection of 0.4ng x/GABAeL(a) cRNA at 
the 2-cell stage, showing assignment of scores 1-4, where embryos scoring 4 are indicated by an 
unlabelled dark grey spot. B. Pictorial representation of the scoring system used.
C. Table showing number of embryos (n) assigned scores 1-4, and percentage proportion of the total 
sample. D. A stacked column chart showing percentage proportion of embryos scoring 1-4.
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2.3.9 Animal cap isolation and use in mesoderm extension assays
Animal caps were removed by micro-dissection from stage 8 embryos using a pair of 
sharp forceps. Vitelline membranes were removed from embryos prior to dissection, and 
special care was taken to remove only ectodermal cell populations and not prospective 
mesodermal cells from the marginal zone. Animal caps were maintained in NAM/2 
(55mM NaCI, 1mM KCI, 0.5mM Ca(N03)2, 0.05mM EDTA, 2mM HEPES, 7pg/ml 
gentamicin), containing 0.1% (w/v) bovine serum albumin (BSA) when conducting 
mesoderm extension assays. Assays were repeated three times in order to account for 
batch variability, and representative batches were selected for photography to generate 
figures (see Section 2.3.10).
2.3.10 Photography
Embryos were viewed under a Leica MZFLIII Stereo Microscope, images were captured 
using the associated IM50 Image Manager software (Imagic Bildverarbeitung AG), and 
figures were prepared using Photoshop 5.5 (Adobe) and Word 2002 (Microsoft).
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Results
Chapter One
Cloning and characterisation of complementary DNAs encoding 
Xenopus laevisGABAb receptors
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3.1 Introduction
3.1.1 Background
In order to begin to explore the functional significance of GABAb receptors during X.laevis 
development, three avenues of investigation are open. Firstly, analysis of the 
physiological roles of metabotropic GABA signalling in Xenopus frogs is possible through 
application of specific GABAb receptor agonists and antagonists to particular tissues (for a 
review of available GABAb receptor ligands see Bowery,N.G et al. 2002), an approach 
that has been adopted previously (see Section 1.8). x/GABAb receptors will exhibit a 
pharmacology that can be used to characterise the binding of known radiolabelled GABAb 
receptor ligands to native receptors. For example, the distribution of GABAb receptor 
binding sites in X.laevis embryos might be revealed through photoaffinity labelling of 
tissue using the ligand [125I]CGP71872, which has previously been shown to bind to 
Xenopus GABAb receptors (Kaupmann.K et al. 1997). However, identification of GABAb 
receptors through ligand-binding requires only the cell-surface expression of the GABAB(1) 
subunit (Kaupmann.K et al. 1997, Malitshek.B et al. 1999). Such analyses do not directly 
demonstrate the presence of the GABAB(2) subunit, nor are pharmacological approaches 
able to distinguish between the various GABAB(1) receptor isoforms (see Section 1.4). In 
addition, the characterisation of GABAbl, an orphan whose ligand(s) awaits identification 
(see Section 1.7) is not presently possible using radioligand-binding.
A second approach to the in vivo characterisation of x/GABAb receptors during X.laevis 
development would be to use receptor-specific antibodies. The use of antibodies for the 
molecular identification of gene products that are orthologous to cloned human or rodent
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genes is not uncommon, since many antibodies exhibit species cross-reactivity where 
epitope amino acid sequence is conserved. However, in the absence of x/GABAb 
receptor protein sequences, it is not clear whether any of the commercially available 
GABAb receptor antibodies would recognise x/GABAb receptor subunits. One example of 
the use of a GABAB(d antibody in the detection of x/GABAB(1) protein appears in the 
literature, however, the immunoblot presented shows only a single 100kDa protein band 
using a C-terminal antibody that should recognise multiple x/GABAB(1) isoforms 
(Ferguson,S.C.D et al. 2002). The detection of either x/GABAB(2) or x/GABAbl using 
existing antisera has not previously been reported. The use of antibodies as an initial 
approach to identify x/GABAb receptors therefore represents an unattractive option, in the 
absence of known x/GABAb receptor protein sequences.
Clearly, the most informative avenue to pursue is a third option, the isolation of cDNAs 
encoding x/GABAb receptors, as this would facilitate the exploration of multiple avenues of 
investigation. Knowledge of x/GABAb receptor sequences would permit the design of 
oligonucleotide primers for use in reverse transcriptase polymerase chain reaction (RT- 
PCR), or the raising of specific antisera, to investigate gene expression. Cloning of 
x/GABAb receptor cDNAs into expression vectors would also make possible the in vitro 
transcription of labelled cRNA probes, for in situ hybridization experiments, or synthetic 
mRNAs (5’-capped, polyadenylated cRNAs), for micro-injection into X.laevis oocytes or 
embryos. The latter could be used to manipulate the expression of x/GABAb gene 
products in developing embryos, or to express functional x/GABAb receptors at the cell 
surface of Xenopus oocytes for pharmacological studies. Perhaps most importantly, 
molecular cloning of x/GABAb receptor cDNAs would allow the investigation of the roles of 
the distinct GABAb receptor isoforms, through the identification of specific temporal or 
spatial expression patterns, or through their misexpression during development.
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The development of public domain expressed sequence tag (EST) databases, containing 
thousands of short nucleotide sequences derived from expressed mRNA transcripts, has 
dramatically reduced the time necessary to identify new genes in recent years. The 
identification of new orthologous genes is often straight-forward when nucleotide or 
protein sequences have already been identified in other organisms. In the case of both 
X.laevis and X.tropicalis, there are several large collections of clones in the public domain, 
such as the NIH Xenopus Gene Collection (XGC) and the NIBB Xenopus Database 
(XDB). Many of these clones may contain complete open reading frames, and most can 
be obtained by members of the biomedical research community through distributors. 
Clearly, the availability of complete Xenopus cDNA clones makes this an ideal place to 
search for putative full-length x/GABAb receptor cDNAs, and offers a time advantage over 
other approaches such as the in-house screening of cDNA libraries. Where complete 
clones are not available, missing sequence may be isolated using rapid amplification of 
cDNA ends (RACE) from an RNA template, using gene-specific oligonucleotide primers 
derived from a partial cDNA sequence or EST, and amplified by PCR. Similarly, if it is 
possible to design flanking oligonucleotide primers, using partial cDNA sequences or 
ESTs, missing sequence may be amplified by reverse transcriptase PCR (RT-PCR), using 
template cDNA generated from mRNA by reverse transcriptase.
3.1.2 Aims
The aim of this chapter was to isolate complete cDNA clones encoding the Xenopus 
laevis orthologues of the principal mammalian GABAb receptor subunit isoforms, 
GABAB(1a), GABAB(ib), GABAB(2) and GABAbl, and generate constructs that might facilitate 
the investigation of x/GABAb receptor gene expression and functionality.
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3.2 Isolation and sequence analysis of X.laevis GABAB(i) cDNAs
3.2.1 Homology searches to identify Xenopus ESTs sharing sequence identity with 
human GABAB(ia)
In order to search specifically for Xenopus clones encoding GABAB(ia), and not GABAB(ib), 
the 164 N-terminal amino acids from the human (h)GABAB(ia) protein sequence (GenBank 
accession number: NP_001461) were used as a query to search against the GenBank 
non-human, non-mouse expressed sequence tag (EST) database using TBLASTN 2.2 
with Blosum62 similarity matrix and parameters: Open Gap Penalty = 11.0, Extend Gap 
Penalty = 1.0, and an Expect threshold value of 1x1 O'10. Six significant alignments with 
ESTs belonging to X.tropicalis cDNA clones were generated; EST GenBank accession 
numbers and Clone IDs are listed in Table 3.1. The clones identified come from cDNA 
libraries that were derived from embryos at stages 51-62 of development or from adult 
frogs.
The 5’ EST sequences belonging to the these clones map to the 5’ end of the f7GABAB(1a) 
coding region, as shown in Figure 3.2. In each case the corresponding 3’ EST sequences 
did not share identity with the /7GABAB(1a) protein sequence when translated in any 
reading frame, suggesting that they may correspond to the 3’ untranslated region (UTR) 
downstream of the coding sequence. Whilst this would suggest that these clones contain 
entire open reading frames, encoding putative X.tropicalis GABAB(1a), the aim here was to 
isolate clones belonging to X.laevis, and so efforts were made to first identify X.laevis 
GABAB(1b) sequence, which might later facilitate the isolation of X.laevis GABAB(1a) 5’ 
sequence by 5’RACE.
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Clone ID Species cDNA library Dev. 5'EST 3'EST 5'EST 3'EST
(Xenopus) Stage Acc.# Acc.# e value e value
IMAGE:7726051 Tropicalis XGC adult heart adult DN004963 DN004962 3.0E-44 none
IMAGE:7660047 Tropicalis XGC adult brain adult CX840283 CX840282 1.0E-44 none
IMAGE:7655261 Tropicalis XGC adult brain adult CX824734 CX824733 4.0E-31 none
IMAGE:7660975 Tropicalis XGC adult brain adult CX841475 CX841474 3.0E-26 none
IMAGE:7661788 Tropicalis XGC adult brain adult CX843223 CX843222 1.0E-21 none
xtbs11M17 Tropicalis xtbs CNS 51-62 CN075982 CN075981 2.0E-15 none
Table 3.1 Table summarising the Xenopus ESTs generating significant alignments with the 164 N- 
terminal amino acids of the /iGABAB(ia) protein sequence, showing GenBank accession numbers (Acc.#)
and Expect (e) values.
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Figure 3.2 Schematic diagram mapping the Xenopus ESTs against the ftGABAecia) coding sequence. 
Exons and principal protein domains of hGABAe(U) are indicated. Location of orthologous region of each 
EST is shown by thick green bars. Scale bar shown represents 500bp.
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3.2.2 Homology searches to identify Xenopus ESTs sharing sequence identity with
human GABAB(ib)
The /7GABAB(ib) protein sequence (GenBank accession number: NP_068703) was used 
as a query to search against the GenBank non-human, non-mouse expressed sequence 
tag (EST) database using TBLASTN 2.2, with the parameters used in Section 3.2.1, and 
an Expect threshold value of 1x1 O'20. Nineteen significant alignments with ESTs 
belonging to Xenopus cDNA clones were generated; EST GenBank Accession numbers 
and Clone IDs are listed in Table 3.3. Of the nineteen clones identified, twelve belong to 
X.tropicalis and seven to X.laevis, and all are from cDNA libraries that were derived from 
embryos at the taiibud stage of development onwards.
The 5’ EST sequences belonging to the these clones map to the hGABABm coding region 
as shown in Figure 3.4. The 3’ EST belonging to the NIBB XL104k16 cDNA clone also 
maps to /?GABAB(ib) coding sequence, whereas all other 3’ EST sequences either did not 
share identity with the hGABABm protein sequence when translated in any reading frame, 
or were absent from the GenBank database.
The X.laevis cDNA clone IMAGE:6948709, highlighted in Table 3.3, has a 5’ EST 
sequence that maps to the 5’ end of the hGABABm coding region (see Figure 3.4). The 
corresponding 3’ EST sequence does not share identity with the hGABAB(1b) protein 
sequence when translated in any reading frame, suggesting that it may correspond to the 
3’UTR. It was thus considered possible that the IMAGE:6948709 cDNA clone might 
contain an entire open reading frame encoding putative X.laevis GABAB(ib), and so this 
clone was selected for sequencing.
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Clone ID Species cDNA library Dev. 5'EST 3'EST 5’EST 3’EST
{Xenopus) Stage Acc.# Acc.# e value e value
TTpA053e21 Tropicalis XGC tadpole 35-40 BX731212 BX731213 1.0E-144 none
IMAGE:7626861 Tropicalis XGC tadpole 36-41 CX380106 CX380105 2.0E-138 none
IMAGE:7657125 Tropicalis XGC adult brain adult CX828604 CX828603 3.0E-130 none
IMAGE-.7758165 Tropicalis XGC adult oviduct adult DR876353 n/a 4.0E-130 n/a
TTbA035104 Tropicalis XGC tailbud 28-30 CR431304 CR431305 7.0E-124 none
IMAGE:7623730 Tropicalis XGC tadpole 36-41 CX373111 CX373110 9.0E-121 none
TT pA048e24 Tropicalis XGC tadpole 35-40 BX727166 n/a 1.0E-118 n/a
IMAGE:7669211 Tropicalis XGC adult brain adult CX875595 CXD875594 1.0E-117 none
IMAGE:7633700 Tropicalis XGC tadpole 36-41 CX375310 DR901755 1.0E-106 none
THdA053o04 Tropicalis XGC tailbud head 28-30 CR587667 CR587668 2.0E-102 none
IMAGE:7647232 Tropicalis XGC adult brain adult CX805495 CX805494 6.0E-86 none
IMAGE:7659620 Tropicalis XGC adult brain adult CX839966 CX839965 2.0E-77 none
IMAGE:6955724 Laevis XGC adult eye adult CD303148 n/a 6.0E-75 n/a
IMAGE:6948354 Laevis XGC adult eye adult CD325871 CD519862 9.0E-73 none
XL104k16 Laevis NIBB tailbud 25.0 BJ057636 BJ076108 2.0E-71 1.0E-29
XL061g15 Laevis NIBB tailbud 25.0 BJ059055 BJ077572 1 OE-33 none
IMAGE:6950579 Laevis XGC adult brain adult CD328305 CD328989 3.0E-23 none
IMAGE:6950580 Laevis XGC adult brain adult CD327533 CD329668 3.0E-23 none
Table 3.3 Table summarising the Xenopus ESTs generating significant alignments with the /7GABAe(ib) 
protein sequence, showing GenBank accession numbers (Acc.#) and Expect (e) values. IMAGE:6948709 
cDNA clone, selected for sequencing, is highlighted in red.
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Figure 3.4 Schematic diagram mapping the Xenopus ESTs against the fiGABAB(ib) coding sequence. 
Exons and principal protein domains of hGABAeeib) are indicated. Location of orthologous region of each 
EST is shown by thick red bars. ESTs belonging to the same clone are connected by a thin black bar. 
IMAGE:6948709 cDNA clone, selected for sequencing, is boxed. Scale bar shown represents 500bp.
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3.2.3 Sequence analysis of IMAGE:6948709 cDNA clone
The X.laevis cDNA clone IMAGE:6948709, highlighted in Table 3.3, has a 5’ EST 
sequence that shares 82% identity with amino acids 48-107 of the /7GABAB(1b) protein 
sequence when translated. This cDNA clone was acquired from the IMAGE Consortium 
and manually sequenced using the dideoxy method (see Section 2.1.12) with the 
oligonucleotide primers shown in Table 3.22A.
Sequence analysis revealed a 3653bp cDNA insert with an open reading frame encoding 
a protein 842 amino acids in length, sharing 78% amino acid identity with the /7GABAB(1b) 
protein sequence. The optimal translation initiation codon was identified using the ATGpr 
program (www.hri.co.jp/atqpr/). which uses the preference for the sequence A/GXXATGG 
(Kozak,M et al. 1987) to predict the most probable ATG initiation codon. The full cDNA 
sequence, showing the coding region with deduced protein sequence, is presented in 
Figure 3.5.
It should be noted that, whilst the sequence analysis of the IMAGE:6948709 cDNA clone 
performed here reveals that it encodes a protein orthologous to /7GABAB(ib), the 3’ EST 
sequence for this clone deposited into GenBank (accession number: CD325726), 
indicated with an asterix (*) in Table 3.3, is instead homologous to the 3’ end of a X.laevis 
beta A1 crystallin cDNA clone (GenBank accession number: BC053794).
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10 20 30 40 50 60 70 80 90
GCACCTCATCCTGGGGCTGTCACGCTCAGTTATCCCTTCTTGTCTGACTGCATCCTTTTCTATCTTTCTGGGGCTGCTTTCCTCCCATTT
100 110 120 130 140 150 160 170 180 
TCCAACTAAGATTGTTTCTTTCTTTTCTGCAGTGCAGCTATTCTATCCTCTTTCCTCATTTTGCTCCTCATCTTTATTCCTTGTCTTTCC
190 200 210 220 230 240 250 260 270  
TGCAGTTTTCCTGTTTTTTTCTCATTTAACCCATTTAACCCTTTTACTTGCATTCTCCTGTTGATCTCTGCTGCTGCCTTTTTGTGTCTA
280 290 300 310 320 330 340 350 360 
TCATTTTACCTATCATCTGCCATTATCTCATATTTTTCTTTCCTTCTGCACTTGGTGATACTCCTCAAACCCCCATTTTCTGTTCTCTGC
370 380 390 400 410 420 430 440 450 
ACTCTCTCTGGCTTATTAATGCCCCATTTTCTATTTTCCACCACTTTCGCTGCCTTCTGAAAACCTTATGTTCTGTTCCTTTCACTTTTG
460 470 480 490 500 510 520 530 540 
CTGGCTTATCATGTCTCTCCCAGCTTCCAGTCTTCCAGGCCGCTTTCTACTCTTTAGTTCTCCCACCCAGTGATGCATCCTCATTTGGTC
M H P H L V 6
7
550 560 570 580 590 600 610 620 630 
ATGTCTGTCTCTCTGTGTGTGCCTCTACTGATGCTCTTGCTGTGTGCTGCTGTCTCAGGTAAGAGAGCACTACACGTGGGTGCTCTATTC 
M S V S L C V P L L M L ' L L C A A V S G K R A L H V G A L F 36
37
640 650 660 670 680 690 700 710 720 
CCAATGAGTGGGGGATGGCCCGGTGGACAGGCCTGCCAGCCTGCTGCACAGATGGCTCTGGAGGATGTCAATAATAGACGGGACATCTTG 
P M S G G W P G G Q A C Q P A A Q M A L E D V N N R R D I L 66
67
730 740 750 760 770 780 790 800 810 
CCGGAGTATGAACTGAGGCTTATTCACCATGACAGCCAGTGTGACCCTGGCCAGGCAACACGATACCTATATGAGTTACTGTATAATGAC 
P E Y E L R L  I  H H D S Q C D P G Q A T R Y L Y E L L Y N D 96
97
820 830 840 850 860 870 880 890 900 
CCCATAAAGATCATGCTAATGCCAGGATGCAGCAGTGTCTCTACCCTAGTGGCAGAAGCAGCAAGAATGTGGCATCTTATTGTGCTCTCT 
P I K I M L M P G C S S V S T L V A E A A R M W H L I V L S 126
127
910 920 930 940 950 960 970 980 990 
TATGGGTCCAGCTCTCCAGCACTTTCAAACCGACAGAGATTCCCCACTTTCTTCCGCACTCATCCGTCAGCCACCTTACACAATCCTACC 
Y G S S S P A L S N R Q R F P T F F R T H P S A T L H N P T 156
157
1000 1010 1020 1030 1040 1050 1060 1070 1080  
AGAGTACAGCTCTTCAAAAAGTGGGGATGGACTAAAATTGCCACCATACAGCAGACCACTGAGGTCTTCACTTCCACCCTGGATGATTTG 
R V Q L F K K W G W T K I A T I Q Q T T E V F T S T L D D L 186
187
1090 1100 1110 1120 1130 1140 1150 1160 1170  
GAAGAGCGAGTGAAGGAAGCTGGCATTGAGATAACTTTTCGACAGAGCTTTTTCTCTGACCCAGTTATCCCAGTGAAAAACCTGAAGAGG 
E E R V K E A G I E I T F R Q S F F S D P V I P V K N L K R 216
217
1180 1190 1200 1210 1220 1230 1240 1250 1260  
CAAGATGCAAGAATAATAGTTGGACTATTCTATGAAACTGAAGCACGAAAAGTCTTCTGTGAGGTTTATAAAGAACGTTTATTTGGTAAG 
Q D A R I  I V G L F Y E T E A R K V F C E V Y K E R L F G K 246
247
1270 1280 1290 1300 1310 1320 1330 1340 1350 
AAATATGTGTGGTTTTTGATTGGCTGGTATGCAGACAACTGGTTTAAGATCCCTGACCCAGCCATTAACTGCACCGTGGAGGAAATGACA 
K Y V W F L I G W Y A D N W F K I P D P A I N C T V E E M T 276
277
1360 1370 1380 1390 1400 1410 1420 1430 1440 
CAGGCGGTGGAAGGTCATGTGACCACAGAAATTGTCATGCTTAACCCCGAAAACACACGAGGAATCTCAAACATGACATCTCAGGAGTTC 
Q A V E G H V T T E I V M L N P E N T R G I S N M T S Q E F 306
307
1450 1460 1470 1480 1490 1500 1510 1520 1530  
ATGGAAAAGTTGGAAAAACGTCTTGGAGAAAACCCAGAAATGACAGGGGGGTTACAAGAAGCTCCCCTCGCATATGATGCTATTTGGGCC 
M E K L E K R L G E N P E M T G G L Q E A P L A Y D A I W A 336
337
1540 1550 1560 1570 1580 1590 1600 1610 1620 
CTTGCTCTTGCACTTAATAAAACTGCCTATGAATTATCAAAGAAGGGTAAACGGTTGGAAGATTTCAATTATAACAATAAAATGATTAGT 
L A L A L N K T A Y E L S K K G K R L E D  F N Y N N K M I  S 366
367
1630 1640 1650 1660 1670 1680 1690 1700 1710  
GAAGAAATCTACAGGGCAATGAACTCCTCTTCATTTGATGGTGTTTCAGGTCATGTGGTCTTTGATGCCAGTGGTTCCAGAATGGCCTGG 
E E I  Y R A M N S S S F D G V S G H V V F D A S G S R M A W 396
397
1720 1730 1740 1750 1760 1770 1780 1790 1800 
ACTCTTATTGAACAGCTACAAGGTGGTGTTTACAAGAAAATTGGGTATTATGACAGCACCAAGGACAACCTCTCGTGGTATAACAATGAC 
T L I  E Q L Q G G V Y K K I G Y Y D S T K D N L S W Y N N D 426
continued overleaf...
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1810 1820 1830 1840 1850 1860 1870 1880 1890
AAGTGGATTGGAGGATCCCCTCCAGCTGACCACACCAAAGTGATCATTACATTCCGCTATGTCTCTCAGAAGCTTTTCATCTCTATCTCT 
427 K W I G G S P P A D H T K V I I T F R Y V S Q K L F I S I S  456
1900 1910 1920 1930 1940 1950 1960 1970 1980
GTGCTTGCTGGTCTTGGAATACTTCTGGGATTTGTGTGTCTGTCATTTAACATCTACAACAGTCATGTGAGGTATATCCAGAACTCTCAG 
457 V L A G L G I L L G F V C L S F N I Y N S H V R Y I Q N S Q  486
1990 2000 2010 2020 2030 2040 2050 2060 2070
CCCCATCTGAATGATATGACTGCAGCAGGATGTATTTTGTCTCTCGCTGCTGTGTTTCCACTTGGTCTTGACGGACGCCACATTGAGACA 
487 P H L N D M T A A G C I L S L A A V F P L G L D G R H I E T  516
2080 2090 2100 2110 2120 2130 2140 2150 2160
TGGCACTTTCCACTTGTGTGTCAGGCACGTCTTTGGCTTCTAGGTCTGGGATTCAGTCTGGCATATGGCAGCATGTTTACCAAAATCTGG 
517 W H F P L V C Q A R L W L L G L G F S L A Y G S M F T K I W  546
2170 2180 2190 2200 2210 2220 2230 2240 2250
TGGATACATACAGCATTTACCAAGAAGGAAGATAAGAAGGAAAGGAGAAAGCTGTCCCAAACTCTAGAGCCATGGAAGCTCTACACTACA 
547 W I H T A F T K K E D K K E R R K L S Q T L E P W K L Y T T  576
2260 2270 2280 2290 2300 2310 2320 2330 2340
GTCTCACTTTTGCTGGGCCTGGATGTCATAACACTAGGGATCTGGCAGATAGTGGACCCCCTACAGCGTTCTATTGAGGAATTCACCAAA 
577 V S L L L G L D V I T L G I W Q I V D P L Q R S I E E F T K  606
2350 2360 2370 2380 2390 2400 2410 2420 2430
GAAGAACCTCGTGGTGACCTGGATGTTCTCATACTCCCGCAGCTGGAACACTGCAGTTCTCTCAAGATGAACACATGGCTTGGTATAGTA 
607 E E P R G D L D V L I L P Q L E H C S S L K M N T W L G I V  636
2440 2450 2460 2470 2480 2490 2500 2510" 2520
TATGGCTCTAAAGGGCTACTCCTTTTGCTTGGTATATTCTTGGCCTATGAGACCAAGAGTGTTTCAACTGAGAAGATCAATGACCACCGT 
367 Y G S K G L L L L L G I F L A Y E T K S V S T E K I N D H R  666
2530 2540 2550 2560 2570 2580 2590 2600 2610
GCTGTGGGGATGGCTATATACAATGTGGCTGTCCTTTGCCTCATCACCGCTCCAGTGACAATGATCCTCAGTAGCCAGCAGGACGCTTCC 
667 A V G M A I Y N V A V L C L I T A P V T M I L S S Q Q D A S  696
2620 2630 2640 2650 2660 2670 2680 2690 2700
TTTGCATTCTCCTCTCTTGCCATTGTATTCTCAGCCTACATCACTCTTGTTGTGCTCTTTGTGCCCAAGATGAGGCGCCTTATTACAAGA 
697 F A F S S L A I V F S A Y I T L V V L F V P K M R R L I T R  726
2710 2720 2730 2740 2750 ' 2760 2770 2780 2790
GGAGAGTGGCAGTCTGAACAACAGGACACCCTTAAGACTGGATCATCTACAAATAACAATGAGGAGGAGAAGTCTCGTCTATTGGAGAGA 
727 G E W Q S E Q Q D T L K T G S S T N N N E E E K S R L L E R  756
2800 2810 2820 2830 2840 2850 2860 2870 2880
GAGAATCAGGAATTAGGAAGGATCATTGCTGAGAAAGAAGAAAGGGTCATGGAGCTTCGTCAGCAGCTGCGCTCCCGTAGGAGACCTTCT 
757 E N Q E L G R I  I A E K E E R V M E L R Q Q L R S R R R P S  786
2890 2900 2910 2920 2930 2940 2950 2960 2970
GTACCGGCCCGGGAAAACTGTTCTGACAATCACTTCCCTAACTCTTCAGGGGCAGTTTCTTCTCTCTACCAGCCTGGCCTACCTCTTGCC 
787 V P A R E N C S D N H F P N S S G A V S S L Y Q P G L P L A  816
2980 2990  3000 3010 3020 3030 3040 3050 3060
AGGTGTCTTGTAGCAGAGGGAGGAGACAAACTGGGTAGGAATAGTTGTGATGGGAGCAGAGTGCACCTTTTGTACAAGTAGACCCTGAGA 
817 R C L V A E G G D K L G R N S C D G S R V H L L Y K * >  842
3070 3080 3090 3100 3110 3120 3130 3140 3150
GTAGTGAGGCAATATAGTCATGTACATAACTGTAAAAATACTGAGTCTCCTCTCTGTGTCTCTCTGCTGGCCAGTCTTTTCTTTCCTCTT
3160 3170 3180 3190 3200 3210 3220 3230 3240
GTTTGGCTTTTCCATTGCTGACAAGTCCCCCTTGCAGGTATAATTATTTTTCTGCCATTTAGCTTTAATTTCTATCCATTGATAGATGCC
3250 3260 3270 3280 3290 3300 3310 3320 3330
TTATTATTGCTTCCTATCAATGCCATCCCTCCCTTCTGGCTCTGCTGTTATAGTTCATGTATTCTTTCTTTATGTGCATCCAACTTTCTT
3340 3350 3360 3370 3380 3390 3400 3410 3420
GGCTTTTTGTTTTCCAATCCTGGATATCTTTATCAGTAAGGCCCCTTATATTTCATTCAAGCCAATTGCAAAAGCACCCACATAATACCC
3430 3440 3450 3460 3470 3480 3490 3500 3510
TGACTCCCCCCACACACAGTCATATGATGCACTATTATTCTCCCCTTCTGCTGGAAGAAGTCACTTCCCCTCATCATTGATATCCCTTTT
3520 3530 3540 3550 3560 3570 3580 3590 3600
ATAAGGAAAGCCAAACATCAACTTCTTAGTACAAAGGGACATCACTACATTAGCACTTGTCACCCTCCCAATGTTTTCTAAACTGTGATT
3 61 0  3620 3630 3640 3650
GGCTGTTGCAATAAATACATTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Figure 3.5 The complete nucleotide sequence for IMAGE:6948709 cDNA clone encoding putative 
x/GABAB(ib), showing the deduced protein sequence.
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3.2.4 Rapid amplification of cDNA ends to isolate xlGABAB(ia) 5' sequence
Since there were no X.laevis cDNA clones identified by homology searches that shared 
sequence identity with the 164 N-terminal amino acids from the human GABAB(ia) protein 
sequence, rapid amplification of 5’ cDNA ends (5’RACE) was used to obtain a X.laevis 
cDNA encoding the N-terminus of x/GABAB(1a). This was accomplished using gene 
specific oligonucleotide primers designed from the x/GABAB(ib) cDNA sequence shown in 
Figure 3.5. 5’RACE was carried out, as described in Section 2.1.11, using total RNA 
extracted from embryos at stage 36 of development, and the cloned PCR product was 
sequenced via the dideoxy method (see Section 2.1.15). The oligonucleotide primers 
used for 5’RACE and dideoxy sequencing are shown in Table 3.22B.
Sequence analysis revealed a 1088bp amplicon containing an open reading frame 
encoding putative x/GABAB(1a) N-terminal protein sequence1. The deduced protein 
sequence was 218 amino acids in length and shared 60% identity with amino acids 1-213 
of the hGABAB(1a) protein sequence. Assembly of a complete nucleotide sequence for 
x/GABAB(ia), using the cDNA isolated here by 5’RACE and the x/GABAB(1b) cDNA 
sequence shown in Figure 3.5, generates a cDNA with an open reading frame encoding a 
987 amino acid protein that shares 79% identity with the /7GABAB(1a) protein sequence. 
The optimal translation initiation codon was identified using the ATGpr program 
(www.hri.co.jp/atqpr/). as described previously (see Section 3.2.3). This assembled 
x/GABAB(1a) cDNA sequence, showing the coding region with deduced protein sequence, 
is presented in Figure 3.6.
1 Three distinct cDNAs encoding the putative x/GABAB(1a) N-terminus were isolated by 5’RACE, 
termed variants 1, 2 and 3, and are discussed in Section 4.3.2. Variant 1 was used to assemble a 
full-length x/GABAB(ia) cDNA clone, in Section 3.5.2, for use in all subsequent experiments.
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10 20  30  40 50 60 70 80 90
AGCTATGGATGAGACAGCTTGAGACAACCTGTCTGCCTTGCTGTTGTACGGAGGCCTGAGGTACAGGCCGAGACTGAGTGCCGGGCAATG
100  110  120 130 140  150  160  170  180
AGCGTGTGGTGAGGGCAGAGAAGGGCAAAGGGGAGAGGCTGTCATTGAAGCCAAAGCTTCACGTGCCATGAGACAGACCGGCTGGATATT
190  20 0  21 0  22 0  2 3 0  2 4 0  2 5 0  2 6 0  270
GGGCTAAAGAGACCGCGAAGGCAAGAAAGAGACACCGACGGATGCAGGGAGTCAGTGACAAGCCAACGTGAAGGCGTAACTTTCAGAGGC
28 0  2 9 0  300  310  32 0  3 3 0  34 0  3 5 0  360
CATAGTGTCGGAGAGAGAGAGAGAGAGCATCCTCCATCCCCACCCAAGAGCAAGCAGGTAATGTGACCTCCCTTCATCCTTTGGATAGAG
370  380  39 0  400 410  4 2 0  43 0  440  450
CATCATGGGACATAAAGCACTATAGGAAGTGAACAGGCTTTGCCGTGTGGAAAATACAAGACAAAAGTAAAAAAAATGTGCTGCAGTATC
M C C S I 5
460  470  480  490  500  5 1 0  5 2 0  530  540
ACTCTTCTCTTTGCTTTATGGCTTACTCCAGTGTTTGGATCTAGTGAAAGTAACACAACAGGCTGCCGTATCATACACCCACCACGTGAT
6 T L L F A L W L T P V F G S S E S N T T G C R I I H P P R D 3 5
550 560 570 580 590 600 610 620 630
GGAGGGATACGTTACCGAGGTCTGACTCTCTCTCAGGTTAAAGCAGTTGAGGTCCTTCCCGTGGATTATGAAATTGAATTTGTTTGCCGC 
3 6 G G I R Y R G L T L S Q V K A V E V L P V D Y E I E F V C R 6 5
640 650 660 670 680 690 700 710 720
GGGGAGCGTGAGATTTCTGGTCCTAAAGTTAGAAAGTGTCAGCGGAATGGAACGTGGACAGATATGGACAAGCCCAGTCGATGCTTACAT 
6 6 G E R E I S G P K V R K C Q R N G T W T D M D K P S R C L H 9 5
7 3 0  74 0  7 5 0  76 0  7 7 0  7 8 0  7 9 0  800  810
ACCTGTTCCCGTATGCACTTAAAGTTAGAGAATGGACGAGCCGATGTAAGAGGGATGGGCCGTGTACCATTGGAGGGAACAAGTGTTCAG 
9 6 T C S R M H L K L E N G R A D V R G M G R V P L E G T S V Q  125
8 2 0  8 3 0  8 4 0  850  86 0  8 7 0  88 0  890  900
TTTGCATGTGATCCAGGCTTCCTACTTGTGGGTTCCAGTCACAGTCTGTGCACCAAGACAGGAAAATGGGACCATCCAAAACCAATATGT 
126  F A C D P G F L L V G S S H S L C T K T G K W D H P K P I C  155
910  920  930  940 950  96 0  97 0  980  990
CAAGTCAGGCGCTCAGATACTTCAATCAGGCACCCGGAATCTTCTCGTAAGAGAGCGCTGCACGTGGGTGCTCTATTCCCAATGAGTGGG 
1 56  Q V R R S D T S  I R H P E S S R K R A L H V G A L F P M S G  185
100 0  1 01 0  1 0 2 0  1 03 0  1 04 0  1 05 0  1 06 0  1 07 0  1080
GGATGGCCCGGTGGACAGGCCTGCCAGCCTGCTGCACAGATGGCTCTGGAGGATGTCAATAATAGACGGGACATCTTGCCGGAGTATGAA 
1 86  G W P G G Q A C Q P A A Q M A L E D V N N R R D I L P E Y E  21 5
109 0  11 0 0  1 11 0  1 1 2 0  1 1 3 0  114 0  1 1 5 0  1 1 6 0  1170
CTGAGGCTTATTCACCATGACAGCCAGTGTGACCCTGGCCAGGCAACACGATACCTATATGAGTTACTGTATAATGACCCCATAAAGATC 
2 1 6  L R L I H H D S Q C D P G Q A T R Y L Y E L L Y N D P I K I  24 5
118 0  11 9 0  1 20 0  1 21 0  1 2 2 0  123 0  1 2 4 0  1 2 5 0  126 0
ATGCTAATGCCAGGATGCAGCAGTGTCTCTACCCTAGTGGCAGAAGCAGCAAGAATGTGGCATCTTATTGTGCTCTCTTATGGGTCCAGC 
2 4 6  M L M P G C S S V S T L V A E A A R M W H L I V L S Y G S S  27 5
127 0  1 2 8 0  1 2 9 0  13 0 0  13 1 0  132 0  1 3 3 0  13 4 0  135 0
TCTCCAGCACTTTCAAACCGACAGAGATTCCCCACTTTCTTCCGCACTCATCCGTCAGCCACCTTACACAATCCTACCAGAGTACAGCTC 
2 7 6  S P A L S N R Q R F P T F F R T H P S A T L H N P T R V Q L  305
13 6 0  1 3 7 0  1 3 8 0  1 39 0  140 0  1 41 0  1 4 2 0  14 3 0  1440
TTCAAAAAGTGGGGATGGACTAAAATTGCCACCATACAGCAGACCACTGAGGTCTTCACTTCCACCCTGGATGATTTGGAAGAGCGAGTG
3 06 F K K W G W T K I  A T I  Q Q T T E V F T S T L D D L E E R V 335
145 0 1 4 6 0 147 0 148 0 149 0 1500 1 51 0 152 0 153 0
AAGGAAGCTGGCATTGAGATAACTTTTCGACAGAGCTTTTTCTCTGACCCAGTTATCCCAGTGAAAAACCTGAAGAGGCAAGATGCAAGA
336 K E A G I E I T F R Q S F F S D P V I  P V K N L K R Q D A R 365
1 54 0 155 0 1560 1570 158 0 1590 1 60 0 1 61 0 162 0
ATAATAGTTGGACTATTCTATGAAACTGAAGCACGAAAAGTCTTCTGTGAGGTTTATAAAGAACGTTTATTTGGTAAGAAATATGTGTGG
366 I I  V  G L F Y E T E A R K V F C E V Y K E R L F G K K Y V W 395
1 63 0 164 0 1650 1660 167 0 1680 1 69 0 1 7 0 0 1 71 0
TTTTTGATTGGCTGGTATGCAGACAACTGGTTTAAGATCCCTGACCCAGCCATTAACTGCACCGTGGAGGAAATGACACAGGCGGTGGAA
396 F L I  G W Y A D N W F K I P D P A I N C T V  E E M T Q A V  E 425
172 0 173 0 174 0 175 0 176 0 177 0 1 78 0 1 7 9 0 180 0
GGTCATGTGACCACAGAAATTGTCATGCTTAACCCCGAAAACACACGAGGAATCTCAAACATGACATCTCAGGAGTTCATGGAAAAGTTG
426 G H V  T T E I V M L N P E N T R G I S N M T S Q E F M E K L 455
181 0 182 0 183 0 184 0 18 5 0 186 0 1 87 0 188 0 1890
GAAAAACGTCTTGGAGAAAACCCAGAAATGACAGGGGGGTTACAAGAAGCTCCCCTCGCATATGATGCTATTTGGGCCCTTGCTCTTGCA
456 E K R L G E N P E M T G G L Q E A P L A Y D A I W A  L A L A 485
19 0 0 191 0 1920 193 0 19 4 0 195 0 1 9 6 0 1 97 0 198 0
CTTAATAAAACTGCCTATGAATTATCAAAGAAGGGTAAACGGTTGGAAGATTTCAATTATAACAATAAAATGATTAGTGAAGAAATCTAC
486 L N K T A Y E L S K K G K R L E D F N Y N N K M I S E E I  Y 515
continued overleaf.
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1990 2000 2010 2020 2030 2040 2050 2060 2070
AGGGCAATGAACTCCTCTTCATTTGATGGTGTTTCAGGTCATGTGGTCTTTGATGCCAGTGGTTCCAGAATGGCCTGGACTCTTATTGAA 
516 R A M N S S S F D G V S G H V V F D A S G S R M A W T L I E  545
2080 2090 2100 2110 2120 2130 2140 2150 2160
CAGCTACAAGGTGGTGTTTACAAGAAAATTGGGTATTATGACAGCACCAAGGACAACCTCTCGTGGTATAACAATGACAAGTGGATTGGA 
546 Q L Q G G V Y K K I G Y Y D S T K D N L S W Y N N D K W I G  575
2170 2180 2190 2200 2210 2220 2230 2240 2250
GGATCCCCTCCAGCTGACCACACCAAAGTGATCATTACATTCCGCTATGTCTCTCAGAAGCTTTTCATCTCTATCTCTGTGCTTGCTGGT 
576 G S P P A D H T K V I I T F R Y V S Q K L F I S I S V L A G  605
2260 2270 2280 2290 2300 2310 2320 2330 2340
CTTGGAATACTTCTGGGATTTGTGTGTCTGTCATTTAACATCTACAACAGTCATGTGAGGTATATCCAGAACTCTCAGCCCCATCTGAAT 
606 L G I L L G F V C L S F N I Y N S H V R Y I Q N S Q P H L N  635
2350 2360 2370 2380 2390 2400 2410 2420 2430
GATATGACTGCAGCAGGATGTATTTTGTCTCTCGCTGCTGTGTTTCCACTTGGTCTTGACGGACGCCACATTGAGACATGGCACTTTCCA 
636 D M T A A G C I L S L A A V F P L G L D G R H I E T W H F P  665
2440 2450 2460 2470 2480 2490 2500 2510 . 2520
CTTGTGTGTCAGGCACGTCTTTGGCTTCTAGGTCTGGGATTCAGTCTGGCATATGGCAGCATGTTTACCAAAATCTGGTGGATACATACA 
666 L V C Q A R L W L L G L G F S L A Y G S M F T K I W W I H T  695
2530 2540 2550 2560 2570 2580 2590 2600 2610
GCATTTACCAAGAAGGAAGATAAGAAGGAAAGGAGAAAGCTGTCCCAAACTCTAGAGCCATGGAAGCTCTACACTACAGTCTCACTTTTG 
696 A F T K K E D K K E R R K L S Q T L E P W K L Y T T V S L L  725
2620 2630 2640 2650 2660 2670 2680 2690 2700
CTGGGCCTGGATGTCATAACACTAGGGATCTGGCAGATAGTGGACCCCCTACAGCGTTCTATTGAGGAATTCACCAAAGAAGAACCTCGT 
726 L G L D V I T L G I W Q I V D P L Q R S I E E F T K E E P R  755
2710 2720 2730 2740 2750 2760 2770 2780 2790
GGTGACCTGGATGTTCTCATACTCCCGCAGCTGGAACACTGCAGTTCTCTCAAGATGAACACATGGCTTGGTATAGTATATGGCTCTAAA 
756 G D L D V L I L P Q L E H C S S L K M N T W L G I V Y G S K  785
2800 2810 2820 2830 2840 2850 2860 2870 2880
GGGCTACTCCTTTTGCTTGGTATATTCTTGGCCTATGAGACCAAGAGTGTTTCAACTGAGAAGATCAATGACCACCGTGCTGTGGGGATG 
786 G L L L L L G I F L A Y E T K S V S T E K I N D H R A V G M  815
2890 2900 2910 2920 2930 2940 2950 2960 2970
GCTATATACAATGTGGCTGTCCTTTGCCTCATCACCGCTCCAGTGACAATGATCCTCAGTAGCCAGCAGGACGCTTCCTTTGCATTCTCC 
816 A I Y N V A V L C L I T A P V T M I L S S Q Q D A S F A F S  845
2980 2990 3000 3010 3020 3030 3040 3050 3060
TCTCTTGCCATTGTATTCTCAGCCTACATCACTCTTGTTGTGCTCTTTGTGCCCAAGATGAGGCGCCTTATTACAAGAGGAGAGTGGCAG 
846 S L A I V F S A Y I T L V V L F V P K M R R L I T R G E W Q  875
3070 3080 3090 3100 3110 3120 3130 3140 3150
TCTGAACAACAGGACACCCTTAAGACTGGATCATCTACAAATAACAATGAGGAGGAGAAGTCTCGTCTATTGGAGAGAGAGAATCAGGAA 
876 S E Q Q D T L K T G S S T N N N E E E K S R L L E R E N Q E  905
3160 3170 3180 3190 3200 3210 3220 3230 3240
TTAGGAAGGATCATTGCTGAGAAAGAAGAAAGGGTCATGGAGCTTCGTCAGCAGCTGCGCTCCCGTAGGAGACCTTCTGTACCGGCCCGG 
906 L G R I  I A E K E E R V M E L R Q Q L R S R R R P S V P A R  935
3250 3260 3270 3280 3290 3300 3310 3320 3330
GAAAACTGTTCTGACAATCACTTCCCTAACTCTTCAGGGGCAGTTTCTTCTCTCTACCAGCCTGGCCTACCTCTTGCCAGGTGTCTTGTA 
936 E N C S D N H F P N S S G A V S S L Y Q P G L P L A R C L V  965
3340 3350 3360 3370 3380 3390 3400 3410 3420
GCAGAGGGAGGAGACAAACTGGGTAGGAATAGTTGTGATGGGAGCAGAGTGCACCTTTTGTACAAGTAGACCCTGAGAGTAGTGAGGCAA 
966 A E G G D K L G R N S C D G S R V H L L Y K *  987
3430 3440 3450 3460 3470 3480 3490 3500 3510
TATAGTCATGTACATAACTGTAAAAATACTGAGTCTCCTCTCTGTGTCTCTCTGCTGGCCAGTCTTTTCTTTCCTCTTGTTTGGCTTTTC
3520 3530 3540 3550 3560 3570 3580 3590 3600
CATTGCTGACAAGTCCCCCTTGCAGGTATAATTATTTTTCTGCCATTTAGCTTTAATTTCTATCCATTGATAGATGCCTTATTATTGCTT
3610 3620 3630 3640 3650 3660 3670 3680 3690
CCTATCAATGCCATCCCTCCCTTCTGGCTCTGCTGTTATAGTTCATGTATTCTTTCTTTATGTGCATCCAACTTTCTTGGCTTTTTGTTT
3700 3710 3720 3730 3740 3750 3760 3770 3780
TCCAATCCTGGATATCTTTATCAGTAAGGCCCCTTATATTTCATTCAAGCCAATTGCAAAAGCACCCACATAATACCCTGACTCCCCCCA
3790 3800 3810 3820 3830 3840 3850 3860 3870
CACACAGTCATATGATGCACTATTATTCTCCCCTTCTGCTGGAAGAAGTCACTTCCCCTCATCATTGATATCCCTTTTATAAGGAAAGCC
3880 3890 3900 . 3910 3920 3930 3940 3950 3960
AAACATCAACTTCTTAGTACAAAGGGACATCACTACATTAGCACTTGTCACCCTCCCAATGTTTTCTAAACTGTGATTGGCTGTTGCAAT
3970 3980 3990 4000
AAATACATTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Figure 3.6 The complete nucleotide sequence for the assembled cDNA clone encoding putative 
x/GABAB(ia), showing the deduced protein sequence. The 218 N-terminal amino acids encoded by the 
5’RACE product isolated in Section 3.2.4 (cDNA variant 1) are indicated ( b l u e  t e x t )
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3.2.5 Multiple sequence alignments of GABAB(i) protein orthologues
To determine whether the putative x/GABAB(i) receptor subunit isoforms, encoded by the 
cDNAs shown in Figures 3.5 and 3.6, represent genuine X.laevis orthologues of the 
corresponding mammalian proteins, the extent of the sequence identity shared at the 
amino acid level was determined by multiple sequence alignments with mammalian 
GABAB(ia> and GABAB(1b) protein sequences. These alignments were also used to 
evaluate whether residues important in the function of mammalian GABAB(1) proteins were 
conserved in the X.laevis orthologues.
Human, rat and mouse GABAB(1a) protein sequences (GenBank accession numbers: 
NP_001461, NP__112290 and NP_062312) were aligned against the deduced x/GABAB(1a) 
protein sequence shown in Figure 3.6. This multiple sequence alignment, annotated with 
key conserved features, is presented in Figure 3.7.
Human, rat and mouse GABAB(1b) protein sequences (GenBank accession numbers: 
NP_068703, CAA71399 and AAG29341) were aligned against the deduced x/GABAB(1b) 
protein sequence shown in Figure 3.5. This multiple sequence alignment, annotated with 
key conserved features, is shown in Figure 3.8.
Signal peptide sequences were predicted using PSORT II program (www.psort.oraT 
Protein sequences were aligned using ClustalW alignment program with Blosum similarity 
matrix and alignment parameters: Open Gap Penalty = 10.0, Extend Gap Penalty = 0.5.
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/.G A BAb,,., 1
rG ABAB|1„ 1
m G ABAa,,., 1
x /G ABAb,,.) 1
/.G A BA b,,., 100
/G A B A b,,., 99
fnGABAB„., 99
x /G ABAb,,., 97
/.G A BA b,,., 192
/G A B A b,,., 191
m G ABAa,,., 191
x /G ABAb,,., 197
/K )A BAb,,., 292
/G A B A b,,., 291
mGABAa,1., 291
x /G ABA b, , ., 297
/Ki AB A b,,., 392
/G A B A b,, ., 391
// /G A BA a,,., 391
x /G ABA b,,., 397
/.G A BA b,,., 492
/G A B A b„.) 491
/ / iu A B A b,,., 491
x /GABAb,,., 497
/.G A BA b,,., 592
/G A B A b,, ., 591
fr/GA B A b,, ., 591
x /GABAb,,., 597
-MLLLLLLLLFLRPLGAGGAQTPNVTSEGCQIIHPPWEGGIRYRGLIRDQVKAINFLPVDYEIEYVCRGEREWGPKVRKCLANGSWTDMDTPSRCVRI 98
signal peptide -sushi domain 1-
-ERRAVYIGALFPMSGGWPGGQACQPA 191 
-ERRAVYIGALFPMSGGWPGGQACQPA 190 
-ERRAVYIGALFPMSGGWPGGQACQPA 190
-sushi domain 2-
* * * * * * * * *
/.G A BA b,,., 692
/G A B A b,,., 691
mGABAa,,., 691
x /G ABA b,,., 697
/.G A B A b,,., 789
/G A B A b,,., 788
mGABAa,1.) 788
x /G ABAb,,., 797
/ i G ABA b,i .) 889
/G A B A b,, ,) 888
mGABAa,,., 888
x/G ABAb,,.) 897
* * * * * * * * * * * * * k * *  * * * * * * *  * *
TMVI
bcdefgabcdefgabcdefgabcdefga
coiled-coil domain
TMVI I
iQSRQQLRSRRHPPTPPEPSG----------------------------------------------- GLPRGPPEPPDRLSCDGSRVHLLYK* 961
-QSRQQLRSRRHPPTPPDPSG----------------------------------------------- GLPRGPSEPPDRLSCDGSRVHLLYK* 960
QSRQQLRSRRHPPTPPDPSG----------------------------------------------- GLPRGPSEPPDRLSCDGSRVHLLYK* 960
—  RQQLRSRRRPSVPARENCSDNHFPNSSGAVSSLYQPGLPLARCLVAEGGDKLGRNSCDGSRVHLLYK* 987
ER retention signal
Figure 3.7 Alignment of f7GABAB(ia), K5ABAB(ia), mGABAB(ia) and x/GABAs(ia) protein sequences, showing
putative signal peptide cleavage point (X), transmembrane domains (underlined, shaded), coiled-coil domain 
(underlined) annotated with heptad repeat, ER retention motifs (bold) and conserved ER retention signal 
(bold, shaded). Conserved residues important for sushi domain folding (Blein.S et al. 2004), ligand 
coordination (Galvez,T et al. 1999, 2000) and tertiary structure (Kniazeff.J et al. 2002) are shown ( red t e x t ). 
Known epitopes for commercially available antibodies are shown ( b lu e  t e x t ) . Conservative amino acid 
changes (.) and amino acid residues conserved in all species examined (*) are indicated.
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/>GABAe<ib) 1
iGABAeotb) 1
mGABAB(ib) 1
x/GABAU;|.) 1
/iGABAB(ib) 101
/GABAB(i b) 101
mGABAB(ib> 101
x/G ABAB(ib) 78
/)G A BAs,. 201
/G A B A B(1b) 201
mGABAB(1b, 201
xK3ABAB(ib) 178
/iGABAB(1b) 301
fGABAB,1b) 301
mGABAB(ib) 301
x/GA BAB(ib) 278
/)GABABl1b) 401
fGABAa(1b| 401
mGABAa(1b) 401
x/G AB Aa(1b| 378
/iGABAsub) 501
rGABAa(1b) 501
/rK3A B A a(lb) 501
x/G AB Ae(1b, 478
/)GABAB(1b) 598
/G A B A B(i b) 598
mGABAB(1b) 598
x/G AB AB(1b) 578
x/GABAs
X
MGPGAPFARVGWPLPLLWMAAGVAPVWASHSPHLPRPHSRVPPHPSSERRAVYIGALFPMSGGWPGGQACQPAVEMALEDVNSRRDILPDYELKLIHHD 100 
MGPGGPCTPVGWPLPLLLVMAAGVAPVWASHSPHLPRPHPRVPPHPSSERRAVYIGALFPMSGGWPGGQACQPAVEMALEDVNSRRDILPDYELKLIHHD 100
- KRALHVGAL FPMS GGW PGGQACQPAAQMALE DVNNRRDILPEYELRLIHHD 77
signal peptide
* * * * * * * * * * It * * * * * *  *
* * * * * * * * * * * * * * * * * * * k * * * * * * *
TMII TMIII
 GLLVGMDVLTLAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSSRKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVAV 697
 SLLLGLDVITLGIWQIVDPLQRSIEEFTKEEPRGDLDVLILPQLEHCSSLKMNTWLGIVYGSKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVAV 677 
TMIV TMV
abcdefgabcdefgabcdefgabcdef
/iGABAs^ b, 698
rt3ABAB(1b, 698
mGABA0(1b) 698
x/GABAS(1b) 678
/)GABAB(ib) 798
rt3ABAB(1b) 798
mGABAB(1b) 7 98
TMVI TMVII coiled-coil domain
LQSRQQLRSRRHPPTPPEPSG----------------------------------------------- GLPRGPPEPPDRLSCDGSRVHLLYK* 844
LQSRQQLRSRRH PPTPPDPSG----------------------------------------------- GLPRGPSEPPDRLSCDGSRVHLLYK* 84 4
LQSRQQIRSRRHPPTPPDPSG----------------------------------------------- GLPRGPSEPPDRLSCDGSRVHLLYK* 84 4
 RQQLRSRRRPSVPARENCSDNHFPNSSGAVSSLYQPGLPLARCLVAEGGDKLGRNSCDGSRVHLLYK* 842***'****'* * * " * ************
ER retention signal
Figure 3.8 Alignment of frG A B A B(ib), K 3A B A B(ib), m G A B A B(ib) and x/G ABAs^b) protein sequences, showing
putative signal peptide cleavage point (X), transmembrane domains (underlined, shaded), coiled-coil domain 
(underlined) annotated with heptad repeat, ER retention motifs (bold) and conserved ER retention signal 
(bold, shaded). Conserved residues important for ligand coordination (Galvez,T et al. 1999, 2000) and 
tertiary structure (Kniazeff.J et al. 2002) are shown (red te x t ). Known epitopes for commercially available 
antibodies are shown ( b lu e  t e x t ) .  Conservative amino acid changes (.) and amino acid residues conserved in
all species examined (*) are indicated.
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3.2.6 xlGABAB(i) proteins possess several amino acid sequences distinct from their
mammalian counterparts
Whilst the overall amino acid identity shared between human, rodent and X.laevis 
GABAB(d protein sequences is high, x/GABAB(ia) and x/GABAB(1b) possess several distinct 
features that distinguish them from their human and rodent counterparts. First, 
x/GABAB(ia) and x/GABAB(1b) proteins exhibit dissimilarity at their N-termini, and both 
possess distinct predicted signal peptide sequences compared to their human and rodent 
counterparts. This is perhaps indicative of a necessity for a distinct type of signal peptide 
sequence in amphibians compared to mammals, whilst sharing the overall requirement for 
a run of predominantly hydrophobic residues at the extreme N-terminus. Notably, the first 
sushi domain of x/GABAB(1a) is more highly conserved than the second, sharing 76% and 
52% amino acid identity with /7GABAB(ia) sushi domains 1 and 2 respectively. A recent 
study demonstrated that the two sushi domains of /7GABAB(1a) have markedly different 
structural properties, indicative of separate functions, and that the interaction between 
hGABAB(ia) and the extracellular matrix protein fibulin-2 was mediated by sushi domain 1 
and not 2 (Blein,S et al. 2004). It would appear that the x/GABAB(1a) protein sequence 
disclosed here supports the notion that sushi domain 1, but not 2, may have a conserved 
function in vertebrates. x/GABAB(1a) also possesses an insertion of seven amino acids 
(IRHPESS), in a putative linker region immediately downstream of sushi domain 2, which 
is not found in mammalian GABAB(ia) protein sequences. As the function of the sushi 
domains and this downstream linker region are not yet clear, it is impossible to infer any 
physiological implications of this insert, although the presence of additional amino acids 
here would presumably not affect the normal folding of the sushi complement modules.
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Second, both x/GABAB(i) isoforms also have an insert of three amino acids, LSQ, in their 
second intracellular loop, which is not present in the human and rodent protein 
sequences. As discussed in the Introduction of this thesis (see Section 1.1.3), the third 
intracellular loop of Family 3 GPCRs, not the second, contains the molecular determinants 
required for coupling to G-proteins, and so the latter insertion would probably not give rise 
to significant differences in receptor coupling.
Third, the x/GABAB(1) proteins isolated here are missing six amino acids found in 
mammalian GABAB(1) proteins, RHQLQS, corresponding to a deletion of the extreme C- 
terminal end of the coiled-coil domain upstream of the ER-retention signal. A recent study 
suggested that, in the case of GABAB(1), functionality of the ER-retention signal depends 
on residues in this region, and that the minimal ER retention sequence in /?GABAB(1) is 
comprised of the amino acids QLQSRQQLRSRR (Grunewald.S et al. 2002). The deletion 
observed in x/GABAB(1) here might be hypothesized to limit the effectiveness of the ER- 
retention signal and, hence, the proper assembly of GABAb(1/2) heterodimers in the ER. 
However, another study demonstrated that whilst secondary structure in this region was 
important, retention of GABAb(1) still occurred when the RSR(R) motif was moved N- or C- 
terminally of this sequence, casting doubt upon its significance (Gassmann, M et al. 
2005). The addition of a leucine residue immediately prior to the RSR(R) motif was often 
shown to be sufficient to rescue loss of retention, and other studies have shown that the 
presence of a hydrophobic residue at this position in RXR-type signals, as is the case in 
x/GABAB(1), is of primary importance for signal activity (Zerangue et al. 2001).
Finally, the x/GABAB(1) proteins described in this chapter also exhibit an insertion of 24 
amino acids in their C-terminal tail, SDNHFPNSSGAVSSLYQPGLPLAR, which is not 
found in mammalian GABAB(1) sequences. It has been demonstrated that the entire C-
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terminal tail of mammalian GABAB(i), downstream of the coiled-coil domain and ER- 
retention motif, may be deleted without affecting normal GABAb receptor function 
(Margeta-Mitrovic.M et al. 2001a) and, as such, this additional sequence may not be of 
physiological relevance. Indeed, the poor sequence conservation in this region, and the 
apparent truncation of the C-terminal tail during evolution from amphibian to mammalian 
sequences, may be seen to support the notion that it is a non-functional protein domain. 
Alternatively, the additional sequence observed here may represent a Xenopus-specific 
signal of hitherto unidentified function.
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3.3 Isolation and sequence analysis of X.laevis GABAB(2) cDNA
3.3.1 Homology searches to identify Xenopus ESTs sharing sequence identity with 
hGABAB(2)
The /?GABAB(2) protein sequence (GenBank accession number: NP_005449) was used as 
a query to search against the GenBank non-human, non-mouse expressed sequence tag 
(EST) database using TBLASTN 2.2, with the parameters used in Section 3.2.1, and an 
Expect threshold value of 1x1 O'50. Ten significant alignments with ESTs belonging to 
Xenopus cDNA clones were generated; EST GenBank Accession numbers and Clone IDs 
are listed in Table 3.7. Of the ten clones identified, seven belong to X.tropicalis and three 
to X.laevis. The clones identified come from cDNA libraries that were derived from 
embryos at a range of development stages from gastrulae to adult frogs.
The EST sequences belonging to the these clones map to the /?GABAB(2) coding region as 
shown in Figure 3.8. The X.laevis cDNA clone IMAGE:6947886, highlighted in Table 3.7, 
has a 5’ EST sequence that maps to the 5’ end of the /7GABAB(2) coding region (see 
Figure 3.8), and shares 83% identity with amino acids 68-245 of the /7GABAB(2) protein 
sequence when translated. The corresponding 3’ EST sequence shares 94% identity with 
amino acids 876-941 of the /7GABAB(2) protein when translated. It was thus considered 
likely that the IMAGE.6947886 cDNA clone contained an entire open reading frame 
encoding putative X.laevis GABAB(2), and so this clone was selected for sequencing.
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Clone ID Species cDNA library Dev. 5'EST 3'EST 5'EST 3'EST
(Xenopus) Stage Acc.# Acc.# e value e value
IMAGE:7656856 Tropicalis XGC adult brain adult CX828727 CX828726 none 7.0E-131
IMAGE:7793882 Tropicalis XGC adult brain adult CX886120 CX886119 none 2.0E-124
T G A S 042G 20^ Tropicalis XGC gastrulae 10J5-12 AL653551 n/a T 0 ^ 0 5 n/a
IMAGE:7029620 Tropicalis XGC all tissues 10,20,30 CF781749 n/a 5.0E-95 n/a
TNeu086o20 Tropicalis XGC neurulae 14-20 AL791931 n/a 2.0E-94 n/a
IMAGE:7587169 Tropicalis XGC tadpole 36-41 CX313014 CX313013 3.0E-83 none
IMAGE:6956951 Laevis XGC adult brain adult CD362386 CD361794 2.0E-65 3.0E-77
TTpA007e11 Tropicalis XGC tadpole 35-40 BX708428 BX708429 3.0E-64 none
IMAGE:6945549 Laevis XGC adult eye adult CD253409 n/a 3.0E-59 n/a
Table 3.9 Table summarising the Xenopus ESTs generating significant alignments with the /)GABAb(2) 
protein sequence, showing GenBank accession numbers (Acc.#) and Expect (e) values. IMAGE:6947886 
cDNA clone, selected for sequencing, is highlighted in blue.
PBP-like 7TM coiled-coil
domain domains domain
A 1
.. r ......_ ...... _..._ ....... x (  .................... . A
/jGABAb(2> ■ r a n a B D i K H D D C I I K I K S C E l E Z l H a i
\II
IMAGE:7656856
IMAGE:7793882
TGAS042G20
| IMAGE:6947886 — ——
IMAGE:7029620
TNeu086o20
IMAGE:7587169
IMAGE:6956951
TTpA007e11
IMAGE:6945549
1---- 1——1----1----1---- 1
—
Figure 3.10 Schematic diagram mapping the Xenopus ESTs against the /iGABAb(2) coding sequence.
Exons and principal protein domains of /?GABAB(2) are indicated. Location of orthologous region of each
EST is shown by thick blue bars. ESTs belonging to the same clone are connected by a thin black bar.
IMAGE:6947886 cDNA clone, selected for sequencing, is boxed. Scale bar shown represents 500bp.
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3.3.2 Sequence analysis of IMA GE.6947886 cDNA clone
The X.laevis cDNA clone IMAGE:6947886, highlighted in Figure 3.9, has 5’ and 3’ EST 
sequences that share 83% and 94% identity respectively with amino acids 68-245 and 
876-941 of the hGABAB{2) protein sequence when translated. This cDNA clone was 
acquired from the IMAGE Consortium and manually sequenced using the dideoxy method 
(see Section 2.1.12) with the oligonucleotide primers shown in Table 3.22C.
Sequence analysis revealed a 3253bp cDNA insert with an open reading frame encoding 
a protein 920 amino acids in length, sharing 82% amino acid identity with the hGABAB{2) 
protein sequence. The optimal translation initiation codon was identified using the ATGpr 
program (www.hri.co.ip/atgpr/). as described previously (see Section 3.2.3). The full 
cDNA sequence, showing the coding region with deduced protein sequence, is presented 
in Figure 3.11.
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10 20 30 40 50 60 70 80 90
GCTGCTGTTGCTGGTGGTGTTGAATCTGCCACCGGCGTCTCACCTAAACCTGCCATTCAGATGCCAATACTGCCTCCGCAATGCCTGCTG
M P I L P P Q C L L 1 0
100 110 120 130 140 150 160 170 180
CTGGTACTGGGTTTGGGATTGGGACCTGGTTTAGTTTATGGATCAAGGAGTACGACAATCGAACAGGCTGCCAATGGCACCTCGTTATCC
11 L V L G L G L G P G L V Y G S R S T T I E Q A A N G T S L S 40
190 200 210 220 230 240 250 260 270
ATCATGGGCTTGATGCCTCTCAACGAGACTGTAGCAAAGGGGAATATAGGCAGAGGCATCCTGCCTGCAGTACAACTGGCTATCGATCAG
41 I M G L M P L N E T V A K G N I  G R G I L P A V Q L A I D Q 70
280 290 300 310 320 330 340 350 360
ATCCGCAATATATCCCTCCTGCACCCTTACTTCTTGGACCTAAAGCTTTATGATACAGCGTGTGACAATGCACAAGGACTGAAAGCATTT
71 I R N I S L L H P Y F L D L K L Y D T A C D N A Q G L K A F 100
370 380 390 400 410 420 430 440 450
TACGATGCTATAAAATATGGACCTAATCACTTGATGGTATTTGGAGGTGTATGTCCATCTGTAACATCTATTATTGCCGAGTCTTTAAAA
101 Y D A I K Y G P N H L M V F G G V C P S V T S I I A E S L K 130
460 470 480 490 500 510 520 530 540
GGATGGAATTTAGTTCAGTTGTCATTCGCAGCAACAACTCCAGTTTTAGCAGATAAGAAAAAATATCCATACTTTTTCCGAACAGTTCCG
131 G W N L V Q L S F A A T T P V L A D K K K Y P Y F F R T V P 160
550 560 570 580 590 600 610 620 630
TCAGATAATGCAGTCAATCCAGCAATTGTAAAATTTCTTAAACATTTCAAGTGGAAAAGAGTAGGAACATTAACCCAAGATATACAGCGA
161 S D N A V N P A I  V K F L K H F K W K R V G T L T Q D I Q R 190
640 650 660 670 680 690 700 710 720
TTTTCAGAGGTGAGAAATGACTTAACCGGTGAACTGGAAGACTCTGCCATACAAATTGCAGACACTGAAAGTTTCTCTAATGATCCCTGC 
191 F S E V R N  D L T G E L E D S A I Q I A D T E S F S N D P C  220
730 740 750 760 770 780 790 800 810
ATCAGTGTAAAAAAGCTCAAGGGCAATGATGTTCGGATAATTATTGGGCAGTTTGATGAACATATGGCAGCTAAAGTCTTCTGTTGTGCT 
221 I  S V K K L K G N D V R I  I  I  G Q F D E H M A ' A K V F C C A  250
820 830 840 850 860 870 880 890 900
TTTGATGAAGACATGTATGGCAGTAAATACCAGTGGATCATCCCAGGATGGTATCAAGCATTATGGTGGCAGCAAGCTAACACATCCACA 
251 F D E D M Y G S K Y Q W I  I  P G W Y Q A L W W Q Q A N T S T  280
910 920 930 940 950 960 970 980 990
TGTTCCACTAAGAACCTGCTAACTGCTATGGAGGGATACATTGGAGTGGATTTTGAACCATTAAGCACAAAGCAAATCAAGACAATATCT
281 C S T K N L L T A M E G Y I G V D F E P L S T K Q I K T I S 310
1000 1010 1020 1030 1040 1050 1060 1070 1080
GGACGGACACCACAACAATATGAAAAAGAATACAATGAAAAACGGGCAGGTGTTGAGCCAAGCAAATTTCATGGGTATGCCTACGATGGA
311 G R T P Q Q Y E K E Y N E K R A G V E P S K F H G Y A Y D G 340
1090 1100 1110 1120 1130 1140 1150 1160 1170
ATATGGGTTATCGCCAAAACATTGCATCGAGCACTGGAATATCTTTATTCCTCCAAACAACGTCAGAGGATCCAGGATTTTAATTATACT 
341 I W V I A K T L H R A L E Y L Y S S K Q R Q R I Q D F N Y T  370
1180 1190 1200 1210 1220 1230 1240 1250 1260
GACCACAAGCTAGGAAAAATATTTTTGGATGCTATGAATGAAACAAATTTTTTTGGTGTAACGGGTCAAGTTGTGTTCAGAAATGGAGAG 
371 D H K L G K I  F L D A M N E T N F F G V T G Q V V F R N G E  400
1270 1280 1290 1300 1310 1320 1330 1340 1350
AGAATGGGCACAATCAAATTTACTCAGCTCCAAGATGGTAAAGAAGTGAAGGTGGGAGAGTATAATGCTGTAGCAGACAGCCTGGAATTG
401 R M G T I K F T Q L Q D G K E V K V G E Y N A V A D S L E L 430
1360 1370 1380 1390 1400 1410 1420 1430 1440
ATCAATGACACCATCAGATTTCAAGGTGCAGAACCTCCAAAAGATGAAACCTTCATCATAATGCAACGGCGTCAGATTCATCTACCACTT
431 I N O T I R F Q G A E P P K D E T F I  I  M Q R R Q I  H L P L 460
1450 1460 1470 1480 1490 1500 1510 1520 1530
TACAGTATTTTATCAACGATAACAATAATAGGGATGATAATGGCCAGTACATTTTTGTTCTTTAACATCAAAAATCGGAATCAGAAAATG
461 Y S I  L S T I T I  I G M I  M A S T F L F F N I  K N R N Q K M 490
1540 1550 1560 1570 1580 1590 1600 1610 1620
ATCAAGATGTCCAGCCCTTATATGAATAATCTTATCATTCTTGGGGGAATGCTTTCCTATGCATCAATATTCCTATTTGGTCTTGATGGA
491 I K M S s P Y M N N L I I  L G G M L S Y A S I  F L F G L D G 520
1630 1640 1650 1660 1670 1680 1690 1700 1710
TCTTTTGTCTCTGCAAATACCTTTGAAACGTTATGCACTGTAAGGACATGGATTTTGACTGTGGGCTACACAACTGCATTTGGTGCAATG
521 S F V S A N T F E T L C T V R T W I L T V G Y T T A F G A M 550
continued overleaf...
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1720 1730 1740 1750 1760 1770 1780 1790 1800
TTTGCAAAAACCTGGAGAGTTCATGCCATTTTTAAGAATGTAAAAATGAAGAAAAAGATTATTAAAGATCAAAAACTACTGATAATAGTT
551 F A K T W R V H A I  F K N V K M K K K I  I K D Q K L L I I  V 580
1810 1820 1830 1840 1850 1860 1870 1880 1890
GGAGGAATGTTGTTGATTGACCTGTGCATTTTAATTTGCTGGCAAATAGTGGATCCGCTGAAAAGAACAGTAGAGGAATATAACCTTGAG
581 G G M L L I  D L C I  L I  C W Q I  V D P L K R T V E E Y N L E 610
1900 1910 1920 1930 1940 1950 1960 1970 1980
CCAGACCCTGCTGGTAGAGACGTTGCAATTCGACCATTTCTGGAGCATTGTGAGAACACGCATATGACCATCTGGCTGGGAATAGTCTAT
611 P D P A G R D V A I R P F L E H C E N T H M T I W L G I V Y 640
1990 2000 2010 2020 2030 2040 2050 2060 2070
GCTTACAAAGGGCTTCTTATGTTGTTTGGATGCTTTTTGGCATGGGAAACTAGGAATGTAAGCATACCAGCGCTGAATGACAGCAAATAC
641 A Y K G L L M L F G C F L A W E T R N V S I  P A L N D S K Y 670
2080 2090 2100 2110 2120 2130 2140 2150 2160
ATAGGAATGAGTGTGTACAACGTGGGGATTATGTGCATAATAGGAGCAGCAGTTTCCTTCCTCACCAGAGACCAGCCTAATGTCCAGTTC
671 I G M S V Y N V G I  M C I  I G A A V S F L T R D Q P N V Q F 700
2170 2180 2190 2200 2210 2220 2230 2240 2250
TGCATTGTGGCATTAGTAATCATATTCTGCAGCACTATCACACTCTGTCTTGTTTTTGTGCCAAAGCTAATAACATTGAGGACAAATCCT
701 C I  V A L V I I F C S T I T L C L V F V P K L I T L R T N P 730
2260 2270 2280 2290 2300 2310 2320 2330 2340
GATGCAGCAACTCAGAACAGAAGATTTCAATTCACACACAATCAAAAGAAAGAGGACTCAAAGACATCGACATCAGTAACTAGCGTGAAC
731 D A A T Q N R R F Q F T H N Q K K E D S K T S T S V T S V N 760
2350 2360 2370 2380 2390 2400 2410 2420 2430
CAAGCTAGCACTTCTCGGTTAGAAGGACTACAGTCAGAAAATCACCGCTTAAGAATGAAAATCACAGAGTTGGACAAAGACCTTGAAGAG
761 Q A S T s R L E G L Q S E N H R L R M K I T E L D K D L E E 790
2440 2450 2460 2470 2480 2490 2500 2510 2520
GTCACAATGCAGCTTCAAGATACACCTGAAAAAACAACATATATCAAACAGAACCATTACCAGGACCTGAATGATATTCTAAGTATTCGA
791 V T M Q L Q D T P E K T T Y I K Q N H Y Q D L N D I  L S I  R 820
2530 2540 2550 2560 2570 2580 2590 2600 2610
AATTTCACAGACAATAAAGATGGTGAAAAGACGGTTTTAAAAAACCACCATGATCAAAAAGCGCCTACACAATGGAACACAATAGAAGCT
821 N F T D N K D G E K T V L K N H H D Q K A P T Q W N T I E A 850
2620 2630 2640 2650 2660 2670 2680 2690 2700
TCTAAAACCAATAAAGATCCTATAGAAGACATCAATTCTCCAGAGCATATACAGAGACGGCTCTCCTTACAACTACCCATATTACATCAT
851 S K T N K D P I E D I N S P E H I Q R R L S L Q L P I L H H 880
2710 2720 2730 2740 2750 2760 2770 2780 2790
GCCTACTTGCCATCAATTGGTGGTGTGGATGCCAGCTGTGCTAGCCCATGTGTAAGTCCTAGTGCCAGTCCACGACATAGACATGTGCAA
881 A Y L P S I  G G V D A S C A S P C V S P S A S P R H R H V Q 910
2800 2810 2820 2830 2840 2850 2860 2870 2880
CCATCTTTCCAAGTTATGGTCTCTGGTCTGTAGGAATAGGTAACACAGGCTTCTTGGACTGCTCCTGTAATCTCAAGAAGGTTTAGACTG 
911 P S F Q V M V S G L *  920
2890 290 0  2910 2920 2930 2940 .2950 2960 2970
CACAAACAAAAACTTTGCTACACACAAAACATTTGCTCTTAACACAGAGGAGAATAAAATCTTGCGACATCATCCCAAGAGTCCAAAATC
2980 2990 3000 3010 3020 3030 3040 3050 3060
AATCAGCGTGAGCAAGAAAAGTGAGAGATGCACAGAGACATACCTGGAGCCTTATCTGTGGAGTTTTTATTTCTTTACTCAGAGGACTAT
3070 3080 3090 3100 3110 3120 3130 3140 3150
GATGAATTCTTCCCAAAACTCTACGAGCATCAGATCAAGCTTAGAGAACCTATAATCTTGCACAAAAAGAAAATTACAGAAGATGAACTT
3160 3170 3180 3190 3200 3210 3220 3230 3240
TTTAACCCAAGTCACAAATCTAAATATATGGCTGCTATAAACAATGGTTAGTACCCTTTATACACACGTGATAATCTTAAAAAAAAAAAA
3250
AAAAAAAAAAAAA
Figure 3.11 The complete nucleotide sequence for IMAGE:6947886 cDNA clone encoding putative 
x/GABAB(2), showing the deduced protein sequence.
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3.3.3 Multiple sequence alignment of GABAB(2) protein orthologues
To determine whether the putative x/GABAb(2) receptor subunit, encoded by the cDNA 
shown in Figure 3.11, represents the genuine X.laevis orthologue of the corresponding 
mammalian proteins, the extent of the sequence identity shared at the amino acid level 
was determined by a multiple sequence alignment with mammalian GABAB(2) protein 
sequences. This alignment was also used to evaluate whether residues important in the 
function of mammalian GABAB(2) proteins were conserved in the X.laevis orthologue.
Human, rat and mouse GABAB(2) protein sequences (GenBank Accession numbers: 
NP_005449, NP_113990 and XP_143750) were aligned against the deduced x/GABAB(2) 
protein sequence shown in Figure 3.11. This multiple sequence alignment, annotated 
with key conserved features, is shown in Figure 3.12.
Signal peptide sequences were predicted using PSORT II program (www.psort.org). 
Protein sequences were aligned using ClustalW alignment program, with the parameters 
used in Section 3.2.5.
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X
/iG A BAB(2| 1 MASPRSSGQPGPPPPPPPPPARLLLLLLLPLLLPLAPOAWGWARGAPRPPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESLLRPYFLD 100
/GABA„(„  1 MASPPSSGQP-RPPPPPPPPARLLLPLLLSLLLWLAPGAWGWTRGAPRPPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESLLRPYFLD 99
mGABAB(2) 1 MASPPSSGQP-RPPPPPPPPARLLLPLLLSLLLSLAPqAWGWARGAPRPPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESLLRPYFLD 99
xfGABAB(2) 1  MPILPPQCLLLVLGLG------- LGPC^LVYGSSTTIEQAANGTSLSIMGLMPLNETVAKGNIGRGILPAVQLAIDQIRNISLLHPYFLD 82
signal peptide
AGABA^j, 101 LRLYDTECDNAKGLKAFYDAIKYGPNHLMVFGGVCPSVTSIIAESLQGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGT 200
fG AB AB,2, 100 LRLYDTECDNAKGLKAFYDAIKYGPNHLMVFGGVCPSVTSIIAESLQGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDNAVNPAILKLLKHFRWRRVGT 199
m GABAB(2) 100 LRLYDTECDNAKGLKAFYDAI KYGPNHLMVFGGVCPSVTS11 AES LQGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDNAVNPAILKLLKHFRWRRVGT 199
X/GABAB(2) 83 LKLYDTACDNAQGLKAFYDAI KYGPNHLMVFGGVCPSVTS 11 AES LKGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDNAVNPAIVKFLKHFKWKRVGT 182
AGABAb,2, 201 LTQDVQRFSEVRNDLTGVLYGEDIEISDTESFSNDPCTSVKKLKGNDVRIILGQFDQNMAAKVFCCAYEENMYGSKYQWIIPGWYEPSWWEQVHTEANSS 300
/G A B A b,2) 200 LTQDXQRFSEVRNDLTGVLYGEDIEISDTESFSNDPCTSVKKLKGNDVRIILGQFDQNMAAKVFCCAFEESMFGSKYQWIIPGWYEPAWWEQVHVEANSS 299
m G ABAB(2, 200 LTQDVQRFSEVRNDLTGVLYGEDIEISDTESFSNDPCTSVKKLKGNDVRI ILGQFDQNMAAKVFCCAFEESMFGSKYQWI IPGWYEPAWWEQVHVEANSS 299
x/G AB AB(2) 183 LTQDIQRFSEVRNDLTGELEDSAIQIADTESFSNDPCISVKKLKGNDVRIIIGQFDEHMAAKVFCCAFDEDMYGSKYQWIIPGWYQALWWQQANTST 279
* * * *  * * * * * * * * * * * *  *  *  *  * * * * * * * * * *  * * * * * * * * * * * * * * * * *  a  ^* * * * * * * * *   ^ ( *  *   ^ * * * * * * * * * * * *  * * _ *
AGABAb,2, 301 RCLRKNLLAAMEGYIGVDFEPLSSKQIKTISGKTPQQYEREYNNKRSGVGPSKFHGYAYDGIWVIAKTLQRAMETLHASSRHQRIQDFNYTDHTLGRIIL 400
/G A B A b,2) 300 RCLRRSLLAAMEGYIGVDFEPLSSKQIKTISGKTPQQFEREYNSKRSGVGPSKFHGYAYDGIWVIAKTLQRAMETLHASSRHQRIQDFNYTDHTLGKIIL 399
fflGABAB(2, 300 RCLRRSLLAAMEGYIGVDFEPLSSKQIKTISGKTPQQYEREYNSKRSGVGPSKFHGYAYDGIWVIAKTLQRAMETLHASSRHQRIQDFNYTDHTLGRIIL 399
X#GABAb<2) 280 -CSTKNLLTAMEGYIGVDFEPLSTKQIKTISGRTPQQYEKEYNEKRAGVEPSKFHGYAYDGIWVIAKTLHRALEYLYSSKQRQRIQDFNYTDHKLGKIFL 378
/|GABAb,2, 401 NAMNETNFFGVTGQWFRNGERMETIKFTQFQDSREVKVGEYNAVADTLEIINDTIRFQGSEPPKDKTIILEQLRKISLPLYSILSALTILGMIMASAFL 500
/G A B A b(2) 400 NAMNETNFFGVTGQWFRNGERMGTIKFTQFQDSREVKVGEYNAVADTLEIINDTIRFQGSEPPKDKTIILEQLRKISLPLYSILSALTILGMIMASAFL 499
m G ABAB(2, 400 NAMNETNFFGVTGQWFRNGERMGTIKFTQFQDSREVKVGEYNAVADTLEIINDTIRFQGSEPPKDKTIILEQLRKISLPLYSILSALTILGMIMASAFL 499
X/GABA^,) 379 DAMNETNFFGVTGQWFRNGERMGTIKFTQLQDGKEVKVGEYNAVADSLELINDTIRFQGAEPPKDETFIIMQRRQIHLPLYSILSTITIIGMIMASTFL 478
TMI
AGABAb(2) 501 FFNIKNRNQKLIKMSSPYMNNLIILGGMLSYASIFLFGLDGSFVSEKTFETLCTVRTWILTVGYTTAFGAMFAKTWRVHAIFKNVKMKKKIIKDQKLLVI 600
rGABAB(2) 500 FFNIKNRNQKLIKMSSPYMNNLIILGGMLSYASIFLFGLDGSFVSEKTFETLCTVRTWILTVGYTTAFGAMFAKTWRVHAIFKNVKMKKKIIKDQKLLVI 599
mGABAB(2) 500 FFNIKNRNQKLIKMSSPYMNNLIILGGMLSYASIFLFGLDGSFVSEKTFETLCTVRTWILTVGYTTAFGAMFAKTWRVHAIFKNVKMKKKIIKDQKLLVI 599
x/GABAs(2| 479 FFNIKNRNQKMIKMSSPYMNNLIILGGMLSYASIFLFGLDGSFVSANTFETLCTVRTWILTVGYTTAFGAMFAKTWRVHAIFKNVKMKKKIIKDQKL L I I  578
TMII TMIII
AGABAb,2) 601 VGGMLLIDLCILICWQAVDPLRRTVEKYSMEPDPAGRDISIRPLLEHCENTHMTIWLGIVYAYKGLLMLFGCFLAWETRNVSIPALNDSKYIGMSVYNVG 700
fGABAB(2) 600 VGGMLLIDLCILICWQAVDPLRRTVERYSMEPDPAGRDISIRPLLEHCENTHMTIWLGIVYAYKGLLMLFGCFLAWETRNVSIPALNDSKYIGMSVYNVG 699
fT>GABAB(2) 600 VGGMLLIDLCILICWQAVDPLRRTVERYSMEPDPAGRDISIRPLLEHCENTHMTIWLGIVYAYKGLLMLFGCFLAWETRNVSIPALNDSKYIGMSVYNVG 699
X/GABAb,2) 579 VGGMLLIDLCILICWQIVDPLKRTVEEYNLEPDPAGRDVAIRPFLEHCENTHMTIWLGIVYAYKGLLMLFGCFLAWETRNVSIPALNDSKYIGMSVYNVG 678
**************+* ****>**** * _******** 1^*** *****************************************+****+*********
TMIV TMV TMVI
  abcdefgabcdef
AGABAB(2) 701 IMCIIGAAVSFLTRDQPNVQFCIVALVIIFCSTITLCLVFVPKLITLRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQASTSRLEGLQSENHRLRM 800
/GABAb(2) 700 IMCIIGAAVSFLTRDQPNVQFCIVALVIIFCSTITLCLVFVPKLITLRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQASTSRLEGLQSENHRLRM 799
mGABAB,2) 700 IMCIIGAAVSFLTRDQPNVQFCIVALVIIFCSTITLCLVFVPKLITLRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQASTSRLEGLQSENHRLRM 799
X/GABAB(2) 679 IMCIIGAAVSFLTRDQPNVQFCIVALVIIFCSTITLCLVFVPKLITLRTNPDAATQNRRFQFTHNQKKEDSKTSTSVTSVNQASTSRLEGLQSENHRLRM 778
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  ^ * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
TMVI I coiled-coil
gabcdefgabcdefga
AGABAB(2) 801 KITELDKDLEEVTMQLQDTPEKTTYIKQNHYQELNDILNLGNFTESTDGGKAILKNHLDQNPQLQWNTTEPSRTCKDPIEDINSPEHIQRRLSLOLPILH 900
fGABAB(2) 800 KITELDKDLEEVTMQLQDTPEKTTYIKQNHYQELNDILSLGNFTESTDGGKAILKNHLDQNPQLQWNTTEPSRTCKDPIEDINSPEHIORRLSLOLPILH 899
mGABAB(2) 800 KITELDKDLEEVTMQLQDTPEKTTYIKQNHYQELNDILSLGNFTESTDGGKAILKNHLDQNPQLQWNTTEPSRTCKDPIEDINSPEHIORRLSLQLPILH 899
XfGABAa^j 779 KITELDKDLEEVTMQLQDTPEKTTYIKQNHYQDLNDILSIRNFTDNKDGEKTVLKNHHDQKAPTQWNTIEASKTNKDPIEDINSPEHIORRLSLQLPILH 878
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * _ * * * * *  _ * * * .  * *  * _ _ * * * *  * *  * * * *  * *_ *  * * * * * * * * * * * * * * * * * * * * * * * * *  
domain
AGABAb,2) 901 HAYLPSIGGVDASCVSPCVSPTASPRHRHVPPSFRVMVSGL* 941
/GABAb(2) 900 HAYLPSIGGVDASCVSPCVSPTASPRHRHVPPSFRVMVSGL* 940
/7lGABAB(2) 900 HAYLPSIGGVDASCVS PCVS PTAS PRHRHVP PS FRVMVSGL* 939
XK3ABAB(2) 87 9 HAYLPSIGGVDASCASPCVSPSASPRHRHVQPSFQVMVSGL* 920
* * * * * * * * * * * * * *  * * * * * *  * * * * * * * *  *  *  *  * * * * * *
ER retention signal
Figure 3.12 Alignment of /7GABAB(2), rGABAB(2), mGABAB(2) and x/GABAB(2) protein sequences, showing
(underlined) annotated with heptad repeat, ER retention motifs (bold) and conserved ER retention signal 
(bold, shaded). Conserved residues important for tertiary structure (Kniazeff.J et al. 2002) are shown ( red 
t e x t ) .  A known epitope for a commercially available antibody is shown ( blue  t e x t ) .  Conservative amino acid 
changes (.) and amino acid residues conserved in all species examined (*) are indicated.
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3.3.4 Mammalian and xIGABAB(2) protein sequences are highly conserved
In contrast to GABAB(i), GABAB(2) protein sequences are very highly conserved, with 
human and x/GABAB(2) sharing 82% identity at the amino acid level. Indeed, the only 
striking dissimilarity between mammalian and x/GABAB(2) protein sequences is at the 
extreme N-terminus, where x/GABAB(2) possesses a distinct putative signal peptide 
sequence and 17 N-terminal amino acids of the mature polypeptide. x/GABAB(2) also 
exhibits a deletion of four amino acids in the PBP-like domain, NSSR, with respect to its 
mammalian counterparts. Whilst the GABAB(2) subunit of the GABAb receptor does not 
appear to bind any endogenous ligands, the PBP-like domain of GABAB(2) has been 
shown to increase the agonist affinity of the GABAB(1) subunit, and is required for agonist- 
induced activation of the GABAb receptor (Galvez,T et al. 2001). As such, this deletion 
observed in x/GABAB(2) may modulate x/GABAb receptor activity, however, without 
characterisation of x/GABAb receptor pharmacology, the significance of this deletion is 
difficult to anticipate.
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3.4 Isolation and sequence analysis of X.laevis GABAbl cDNA
3.4.1 Homology searches to identify Xenopus ESTs sharing sequence identity with 
hGABABL
The /7GABABl protein sequence (GenBank accession number: NP_694547) was used as 
a query to search against the GenBank non-human, non-mouse expressed sequence tag 
(EST) database using TBLASTN 2.2, with the parameters used in Section 3.2.1, and an 
Expect threshold value of 1x1 O'10. One significant alignment with an EST belonging to a 
Xenopus laevis cDNA clone was generated; the EST GenBank accession number and 
Clone ID is listed in Table 3.13. This clone (XL024m02) belongs to a cDNA library derived 
from neurulae at stage 15 of development.
The 5’ EST sequence belonging to the XL024m02 cDNA clone maps to the hGABABL 
coding region as shown in Figure 3.14. The 3’ EST belonging to XL024m02 did not share 
sequence identity with the hGABABL protein when translated in any reading frame, 
suggesting that it may correspond to the 3’UTR downstream of the coding sequence.
Although mapping of the XL024m02 cDNA clone to the hGABABL coding region suggested 
that it may only contain a partial open reading frame encoding the C-terminus of putative 
xlGABAbl (see Figure 3.14), knowledge of this nucleotide sequence would permit the 
isolation of the presumptive missing x/GABAbl 5’ sequence by 5’RACE, and so this clone 
was selected for sequencing.
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Clone ID Species
(Xenopus)
cDNA library Dev.
Stage
5'EST
Acc.#
3'EST
Acc.#
5'EST 
e value
3'EST 
e value
XL024m02 NIBB neurulae 15 BJ035931 BJ050529 4.0E-31 none
Table 3.13 Table showing the X.laevis EST generating a significant alignment with the hGABAbl protein 
sequence, showing GenBank accession number (Acc.#) and Expect (e) value. XL024m02 cDNA clone,
selected for sequencing, is highlighted in yellow.
7TM
domains
coiled-coil
domain
/jGABAbl i l l a a a B B m ■ m
XL024m02
i— i— i— i— i— i
Figure 3.14 Schematic diagram mapping the X.laevis EST against the hGABAbl coding sequence. 
Exons and principal protein domains of /iGABAbl are indicated. Location of orthologous region of EST is 
shown by thick yellow bar. XL024m02 cDNA clone, selected for sequencing, is boxed.
Scale bar shown represents 500bp.
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3.4.2 Sequence analysis of XL024m02 cDNA clone
The X.laevis cDNA clone XL024m02, highlighted in Figure 3.13, has a 5’ EST that shares 
55% identity with amino acids 279-397 of the hGABABL protein when translated. This 
cDNA clone was acquired from the National Institute for Basic Biology, Japan, and 
manually sequenced using the dideoxy method (see Section 2.1.12) with the 
oligonucleotide primers shown in Table 3.22D.
Sequence analysis revealed a 1928bp cDNA insert with an open reading frame encoding 
a protein 524 amino acids in length, sharing 30% identity with amino acids 279-814 of the 
/7GABABl protein sequence. The full cDNA sequence, showing the coding region with 
deduced protein sequence, is presented in Figure 3.15.
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10 20 30 40 50 60 70 80 90
NCTCGTTTCTTCCCTGATTGGCCGAACCTGGTCTATGCAACAACATCAGGAAGCATCTTGATCTGTACAACCTCCATCAACTGCCTTATC
R F F P D W P N L V Y A T T S G S I L I C T T S I N C L I 2 9
100 110 120 130 140 150 160 170 180
TTCATCCCACAGTTGCTACAATCGAGGCAGTTTGAGGAGGAGCAGGTCCAGAGCACACAAATGACCAAGTATTTCAGTAGCCCCAGCAAG 
30 F I P Q L L Q S R Q F E E E Q V Q S T Q M T K Y F S S P S K 5 9
190 200 210 220 230 240 250 260 270
AGCTTCCGGTCCATGTACAGTGAGGAGCAGATCTACCACCTGCTGGGGGAAAACACGTCCATGAGAAAGCTCCTTTCAGAGCAAAATGCC 
60 S F R S M Y S E E Q I Y H L L G E N T S M R K L L S E Q N A 8 9
280 290 300 310 320 330 340 350 360
ATCATAGAAAGCCTCCAAGAGCAAGTGAGCAACGCTAAGGACAAGCTGGTGAAGCTATTAAAATCTGAGTGCAGCCTTGAAACCATTGAA 
90 I  I E S L Q E Q V S N A K D K L V K L L K S E C S L E T I E  119
370 380 390 400 410 420 430 440 450
g t g a c c a g c c t g tc t g t a t t a t c t g c tt c a a c g tt g g g c a tt c a g c a c c a t g tg g c c c c tg a a c a t a t g a a g a tc a t t g a g g a a c c t g c a  
120 V T S L S V L S A S T L A I Q H H V A P E H M K I  I E E P A  149
460 470 480 490 500 510 520 530 540
CCTCTTGATACTGTAGAGAACGTGGATCATGAAGCTGTCATTAAGGACACTCAGGAGGGTGATACTAACCATGGCACACAGAGTGATGTT 
150 P L D T V E N V D H E A V I K D T Q E G D T N H G T Q S D V  179
550 560 570 580 590 600 610 620 630
TTCGAGTCACCCAAGAACCATAATATACAGGAGTTAAAAGACAAGCCTCAAGAAGGGCCACAATGTACCAGCAAGCCTACTGAATACTCA 
180 F E S P K N H N I Q E L K D K P Q E G P Q C T S K P T E Y S  209
640 650 660 670 680 690 700 710 720
GTCTCAAAACAAGAGGACATGTCAACATCAGACTTCAGAAATGTGAGTTTTGCTGACAGTGTATCTAAAGCCCATTACCAGCACCAAGGG 
210 V S K Q E D M S T S D F R N V S F A D S V S K A H Y Q H Q G  239
730 740 750 760 770 780 790 800 810
GAACAGTCAGAGAGGACACATGAAGTTTTAGAGCAATTATCCAGGAAAGTGAATTATGTGAGCAGTGAGAAACTGCAAGAGATTCTCAAA 
240 E Q S E R T H E V L E Q L S R K V N Y V S S E K L Q E I L K  269
820 830 840 850 860 870 880 890 900
GAACTTGAGACAGTGTCAACCTGTGGCCACCAGTCTCCCAAAAGACAGAGATGTGCAAGTCACAGTGTGAACAGGGACCCTGGTTTGGCT 
270 E L E T V S T C G H Q S P K .  R Q R C A S H S V N R D P G L A  299
910 920 930 940 950 960 970 980 990
CCTTCAGAAGGAATTCAGAAAATGTGCCTCAGCTTGTCCCCTTATATGATGCGTAGAAGGCGAGGACCTTGCTACAGTCAGAGGAACCAA
300 P S E G I Q K M C L S L S P Y M M R R R R G P C Y S Q R N Q 329
1000 1010 1020 1030 1040 1050 1060 1070 1080
CACCCTTCCCATCACTTTCCAAATGCATTACCCCCACAGACTTGGTGCCTCTTAAACAAAGAAGCCAGAAACCGGAGTAATGGGGTAAAG
330 H P S H H F P N A L P P Q T W C L L N K E A R N R S N G V K 359
1090 1100 1110 1120 1130 1140 1150 1160 1170
AGAACAAGAAATGAAAGGCCGAGTCACACAGGAGAAGAGAGAACAGCAGAAGTTAATACGGGCCATGGGTATCATAATCCAAGTCTCTTA
360 R T R N E R P S H T G E E R T A E V N T G H G Y H N P S L L 389
1180 1190 1200 1210 1220 1230 1240 1250 1260
ACTAAGACCATGGAGCTGAGTGTTCATGGGAAAGAAGAAAATAGGACCAGAGTAGATAATGGAATATGGATGACCCCCAAATACTCAATT
390 T K T M E L S V H G K E E N R T R V D N G I  W M T P K Y S I 419
1270 1280 1290 1300 1310 1320 1330 1340 1350
TCACATCCTCCAGAGAACCCTTCTGGCTCTATTCCTACGAGCATCAGGAGACACACAGAAATACAAGCCCATGCAATGGTGACCTTAGCC
420 S H P P E N P S G S I P T S I R R H T E I Q A H A M V T L A 449
1360 1370 1380 1390 1400 1410 1420 1430 1440
GACCTCAGATCCCAAACTACTTACACAGAGACAGATTCAAGTAGCTCTGAGGGGACAATCTGCTACTGTCACAGGCCTTACTGCGAGTTG
450 D L R S Q T T Y T E T D S S S S E G T I C Y C H R P Y C E L 479
1450 1460 1470 1480 1490 1500 1510 1520 1530
TGCTTTCCAAATGAGTATGACTCAAGTGACAGCTCTGAAACAGATAGTGGTGACCAACTACATGGGTGGACAACCGAAAAAAAACCTCCA
480 C F P N E Y D S S D S S E T D S G D Q L H G W T T E K K P P 509
1540 1550 1560 1570 1580 1590 1600 1610 1620
CAATTGGTAGTTAATTTCAATGAAGATTTGACTCCAACTTTTGTTTAGAGGCATGACCATAACTGCCCCTCCTTAGCTTCTGGGGGAAGG
510 Q L V V N F N E D L T P T F V * 524
1630 1640 1650 1660 1670 1680 1690 1700 1710
GAACCTACATTCTATCTAACACGACGTACTGTATGTTTGATATCATTTTCTCCTGTAACTGTGTTTCATGCAAAGGAAGTGTTCAGTCAC
1720 1730 1740 1750 1760 1770 1780 1790 1800
TATAATCAAATATGCCCAAGCCCATCCCCAAGGAGGCACGTTATGTCAAGTTGATGAAGTTGGATGAAATTTCTTTCATACAGGAGATGC
1810 1820 1830 1840 1850 1860 1870 1880 1890
GTTTCACATGTTTTGCAGTTGTCTCTGTTAATGTTTGTGATGTGAACTTACCTCTGGTTACAGGCTGTGACATTGTGGTGTACCCAAAAT
1900 1910 1920
AAATTTCCCTGTTTCAACTTAAAAAAAAAAAAAAAAAAA
Figure 3.15 Nucleotide sequence for the XL024m02 cDNA clone encoding the C-terminus of putative 
x/GABAbl, showing the deduced protein sequence.
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3.4.3 Rapid amplification of cDNA ends to isolate putative x IG ABA bl 5’ sequence
Pairwise alignment of the deduced x/GABAbl protein sequence with the AGABAbl protein 
suggested that around 278 N-terminal amino acids may be missing from the former. In an 
effort to isolate the 5’ sequence missing from the XL024m02 cDNA clone (see Figure 
3.15), 5’RACE was carried out, as described in Section 2.1.11, using total RNA extracted 
from embryos at stage 36 of development, and gene specific oligonucleotide primers 
designed from the XL024m02 cDNA sequence. The oligonucleotide primers used for 
5’ RACE and subsequent dideoxy sequencing of the cloned product are shown in Table 
3.22E.
Sequence analysis of the cloned 5’RACE product uncovered a 515bp amplicon containing 
an open reading frame encoding putative x/GABABl N-terminal protein sequence. The 
deduced protein sequence was just 28 amino acids in length, and shared 29% identity 
with amino acids 1-28 of the AGABAbl protein. Assembly of a complete nucleotide 
sequence, using the cDNA isolated here by 5’RACE and the partial x/GABAbl cDNA clone 
shown in Figure 3.15, generated an open reading frame encoding a 535 amino acid 
protein that shared 21% sequence identity with the /7GABAbl protein. The optimal 
translation initiation codon was identified using the ATGpr program (www.hri.co.ip/ataDrA. 
as described previously (see Section 3.2.3). This assembled cDNA sequence, showing 
the coding region with deduced protein sequence, is presented in Figure 3.16.
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10 20 30 40 50 60 70 80 90
NTTACTATCCCAACTATAAGGACACTATGACTGCAAAGAAATAGGCTCAGCCAACAGGGCACAGGGATAGAAATGATCCCTTTAAACTGA
100 110 120 130 140 150 160 170 180
GTGCCCGTGCTCATAACACCAGTGCCCAACTGCCACCTAATTCAGTGCTTGTGAGGTCCAACCCATCTGCTGTGCCCATACAAATAAGAA
190 200 210 220 230  240 250 260 270
GTAGGCACACATAGGAAACATGGACACTTGCACTAGGACACCATCCATCCAGCCAGGGCACTGAGACTGGTATAGAAGTCCCGACTTACT
280 290 300 310 320 330 340 350 360
ACAGGGGGTGCAGGAGGATCACCTAGCAGGAGCAGGTCAGACTCCCCAGGCTGCAGACAATGTGTCTGTAGGCTGGAGCTATGAATAGTG
370 380 390 400 410 420 430 440 450
GGTGCTCTGTGCCAATCCCCCCCTGATTAGGGGCACCTTGTTCTGTGGGGGATCCCACAAGGGGCTCAGATCATGGAGCCGTCCCTGAAC
M E P S L N 6
460 470 480 490 500 510 520 530 540
TGCTCTGCACTGTTGAACAGCCACATTGATTGGCCGAACCTGGTCTATGCAACAACATCAGGAAGCATCTTGATCTGTACAACCTCCATC 
7 C S A L L N S H I D W P N L V Y A T T S G S I L I C T T S I 3 6
550 560 570 580 590 600 610 620 630
AACTGCCTTATCTTCATCCCACAGTTGCTACAATCGAGGCAGTTTGAGGAGGAGCAGGTCCAGAGCACACAAATGACCAAGTATTTCAGT 
3 7 N C L I  F I  P Q L L .  Q S R Q F E E E Q V Q S T Q M T K Y F S  66
640 650 660 670 680 690 700 710 720
AGCCCCAGCAAGAGCTTCCGGTCCATGTACAGTGAGGAGCAGATCTACCACCTGCTGGGGGAAAACACGTCCATGAGAAAGCTCCTTTCA 
6 7 S P S K S F R S M Y S E E Q I Y H L L G E N T S M R K L L S 9 6
730 740 750 760 770 780 790 800 810
GAGCAAAATGCCATCATAGAAAGCCTCCAAGAGCAAGTGAGCAACGCTAAGGACAAGCTGGTGAAGCTATTAAAATCTGAGTGCAGCCTT 
9 7 E Q N A I  I  E S L Q E Q V S N A K D K L V K L L K S E C S L 1 2  6
820 830 840 850 860 870 880 890 900
GAAACCATTGAAGTGACCAGCCTGTCTGTATTATCTGCTTCAACGTTGGCCATTCAGCACCATGTGGCCCCTGAACATATGAAGATCATT 
127 E T I E V T S L S V  L S A S T L A I Q H H V A P E H M K I I  156
910 920 930 940 950 960 970 980 990
GAGGAACCTGCACCTCTTGATACTGTAGAGAACGTGGATCATGAAGCTGTCATTAAGGACACTCAGGAGGGTGATACTAACCATGGCACA 
157 E E P A P L D T V E N V D H E A V I K D T Q E G D T N H G T  186
1000 1010 1020 1030 1040 1050 1060 1070 1080
CAGAGTGATGTTTTCGAGTCACCCAAGAACCATAATATACAGGAGTTAAAAGACAAGCCTCAAGAAGGGCCACAATGTACCAGCAAGCCT 
187 Q S D V F E S P K N H N I Q E L K D K P Q E G P Q C T S K P  216
•
1090 1100 1110 1120 1130 1140 1150 1160 1170
ACTGAATACTCAGTCTCAAAACAAGAGGACATGTCAACATCAGACTTCAGAAATGTGAGTTTTGCTGACAGTGTATCTAAAGCCCATTAC 
217 T E Y S V S K Q E D M S T S D F R N V S F A D S V S K A H Y  246
1180 1190 1200 1210 1220 1230 1240 1250 1260
CAGCACCAAGGGGAACAGTCAGAGAGGACACATGAAGTTTTAGAGCAATTATCCAGGAAAGTGAATTATGTGAGCAGTGAGAAACTGCAA 
247 Q H Q G E Q S E R T H E V L E Q L S R K V N Y V S S E K L Q  276
1270 1280 1290 1300 1310 1320 1330 1340 1350
GAGATTCTCAAAGAACTTGAGACAGTGTCAACCTGTGGCCACCAGTCTCCCAAAAGACAGAGATGTGCAAGTCACAGTGTGAACAGGGAC 
277 E I L K E L E T V S T C G H Q S P K R Q R C A S H S V N R D  306
continued overleaf...
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1360 1370 1380 1390 1400 1410 1420 1430 1440
CCTGGTTTGGCTCCTTCAGAAGGAATTCAGAAAATGTGCCTCAGCTTGTCCCCTTATATGATGCGTAGAAGGCGAGGACCTTGCTACAGT
307 P G L A P S E G I  Q K M C L S L S P Y M M R R R R G P C Y S 336
1450 1460 1470 1480 1490 1500 1510 1520 1530
CAGAGGAACCAACACCCTTCCCATCACTTTCCAAATGCATTACCCCCACAGACTTGGTGCCTCTTAAACAAAGAAGCCAGAAACCGGAGT
337 Q R N Q H P S H H F P N A L P P Q T W C L L N K E A R N R S 366
1540 1550 1560 1570 1580 1590 1600 1610 1620
AATGGGGTAAAGAGAACAAGAAATGAAAGGCCGAGTCACACAGGAGAAGAGAGAACAGCAGAAGTTAATACGGGCCATGGGTATCATAAT
367 N G V K R T R N E R P S H T G E E R T A E V N T G H G Y H N 396
1630 1640 1650 1660 1670 1680 1690 1700 1710
CCAAGTCTCTTAACTAAGACCATGGAGCTGAGTGTTCATGGGAAAGAAGAAAATAGGACCAGAGTAGATAATGGAATATGGATGACCCCC
397 P S L L T K T M E L S V H G K E E N R T R V D N G I  W M T P 426
1720 1730 1740 1750 1760 1770 1780 1790 1800
AAATACTCAATTTCACATCCTCCAGAGAACCCTTCTGGCTCTATTCCTACGAGCATCAGGAGACACACAGAAATACAAGCCCATGCAATG
427 K Y S I S H P P E N P S G S I P T S I  R R H T E 1 Q A H A M 456
1810 1820 1830 1840 1850 1860 1870 1880 1890
GTGACCTTAGCCGACCTCAGATCCCAAACTACTTACACAGAGACAGATTCAAGTAGCTCTGAGGGGACAATCTGCTACTGTCACAGGCCT
457 V T L A D L R S Q T T Y T E T D S S S S E G T I C Y C H R P 486
1900 1910 1920 1930 1940 1950 1960 1970 1980
TACTGCGAGTTGTGCTTTCCAAATGAGTATGACTCAAGTGACAGCTCTGAAACAGATAGTGGTGACCAACTACATGGGTGGACAACCGAA
487 Y C E L C F P N E Y D S S D S S E T D S G D Q L H G W T T E 516
1990 2000 2010 2020 2030 2040 2050 2060 2070
AAAAAACCTCCACAATTGGTAGTTAATTTCAATGAAGATTTGACTCCAACTTTTGTTTAGAGGCATGACCATAACTGCCCCTCCTTAGCT
517 K K P P Q L V V N F N E D L T P T F V * 535
2080 2090 2100 2110 2120 2130 2140 2150 2160
TCTGGGGGAAGGGAACCTACATTCTATCTAACACGACGTACTGTATGTTTGATATCATTTTCTCCTGTAACTGTGTTTCATGCAAAGGAA
2170 2180  2190 2200 2210 2220 2230 2240 2250
GTGTTCAGTCACTATAATCAAATATGCCCAAGCCCATCCCCAAGGAGGCACGTTATGTCAAGTTGATGAAGTTGGATGAAATTTCTTTCA
2260 2270  2280 2290 2300 2310 2320 2330 2340
TACAGGAGATGCGTTTCACATGTTTTGCAGTTGTCTCTGTTAATGTTTGTGATGTGAACTTACCTCTGGTTACAGGCTGTGACATTGTGG
2350 2360  2370 2380 2390
TGTACCCAAAATAAATTTCCCTGTTTCAACTTAAAAAAAAAAAAAAAAAAA
Figure 3.16 Nucleotide sequence for assembled cDNA clone encoding putative x/GABAbl, showing the 
deduced protein sequence. The 28 N-terminal amino acids encoded by the 5’RACE product isolated in 
Section 3.4.3 are indicated (blue text)
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3.4.4 RT-PCR to amplify alternative putative X.laevis GABA bl 5' sequence
Whilst the cDNA sequence obtained by 5’RACE in Section 3.4.3 appears to encode the 
28 N-terminal amino acids of the putative x/GABABl orthologue, pairwise alignment of the 
x/GABAbl protein sequence, deduced from the assembled cDNA clone shown in Figure 
3.16, and the hGABAbl protein sequence, suggests that around 267 amino acids 
encoding transmembrane domains l-VI may be missing from the former. To investigate 
whether an alternative x/GABAbl transcript might also exist, encoding a seven- 
transmembrane protein orthologous to /?GABAbl, oligonucleotide primers were designed, 
using the assembled cDNA clone shown in Figure 3.16, which flanked the proposed 
region of missing nucleotide sequence. Reverse transcriptase PCR (RT-PCR) was then 
carried out, using ACCUZYME™ proofreading DNA polymerase and template cDNA 
generated from mRNA extracted from embryos at stage 18 of development (see Section 
2.1.10), and the PCR product was sequenced by the dideoxy method (see Section 
2.1.12). The oligonucleotide primers used for RT-PCR and dideoxy sequencing are 
shown in Table 3.22F.
Sequence analysis of the cloned PCR product uncovered a 1573bp amplicon containing 
an open reading frame encoding an alternative putative x/GABAbl N-terminus. The 
deduced protein sequence was 510 amino acids in length, and shared 41% identity with 
amino acids 1-524 of the hGABABL protein. Assembly of a complete nucleotide sequence, 
using the cDNA isolated here by RT-PCR and the partial x/GABAbl cDNA clone shown in 
Figure 3.15, generated an open reading frame encoding a 798 amino acid seven- 
transmembrane protein, orthologous to /7GABAbl, that shared 38% sequence identity with 
the /7GABAbl protein overall. This assembled cDNA sequence, showing the coding region 
with deduced protein sequence, is presented in Figure 3.17.
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10 20 30 40 50 60 70 80 90
NGGCACCTTGTTCTGTGGGGGATCCCACAAGGGGCTCAGATCATGGAACCGTCCCTGAACTGCTCTGCACTGTTGAACAGCCACATTGAT
M E P S L N C S A L L N S H I D 1 6
100 110 120 130 140 150 160 170 180
ACCAGTCTGGAGAAGGAAGAGGCTGTAAAGGTTCTGCAGGAGCTGTGCAATGTCTCCTGGGCTCCACAGAGGAAACAGATCTCTACTGCT
17 T S L E K E E A V K V L Q E L C N V S W A P Q R K Q I S X A 46
190 200 210 220 230 240 250 260 270
CTCATGGGAATCTCAGGGGCCCTCCTGTCATTGGGGCTGTTACTCACTCTCTTCTTCTTCATCTTCACCCTTCGATTTCGCAGCAACAGG
47 L M a  i s G A L L S L G L L L X L F F F I F I L R F R s N R 76
280 290 300 310 320 330 340 350 360
ATAGTGAAGATGTCCAGCCCCAACCTGAACCTGGTGACCCTGGTTGGCAGTGCCCTCACTTATACCAGTGCTTTATTATTCCTGGTCCAG
77 I V K M S S P N L N L V I L V G S A L X Y I S A L L F L V Q 106
370 380 390 400 410 420 430 440 450
GAGCCCAATATCTCCATGGAAACCATCTTTCAGGTGCGGATCAGTCTGCTGTATCTGGGGGTCACGCTGGTGTTTGGGCCCCTGCTGGGG
107 E P N I S M E I I F Q V R I S L L Y L G V I L V F G P L L G 136
460 470 480 490 500 510 520 530 540
AAGAGCTGGAGGCTGCATCGAGTGTTCACCCACAGAGTTCCTGACAAACGTGTGATTATTAAAGACGTAACCCTGCTGAGTCTTGTGGCT
137 K s W R L H R V F X H R V P D K R V I I K D V I L L S L V A 166
550 560 570 580 590 600 610 620 630
GGACTTCTGTTCACTGATACCCTCTTACTCCTTATGTGGGTACTGTCCGACCCGGTGGTCTGTGCTAGGAGTGCCAGCGCCAGTATTCAG
167 G L L F T D X L L L L M W V L S D P V V c A R S A S A S I Q 196
640 650 660 670 680 690 700 710 720
GCGGCTGCTCGGGAGACACTGTACTCAGTCACCACCCGGTATTTCTGTGCTTCCAAATATAGCGACCTCTGGACCAGCCTCCTTGTTGGC
197 A A A R E X L Y S V I X R Y F C A s K Y S D L  W I S L L V G 226
730 740 750 760 770 780 790 800 810
TTTAAGGCTGCCCTGCTTATTTATGGATGTTACTTGGCTGGACTGACCAATAACATCAGCTCTCCACCAGTCAACCAGTCTCTGGCTATC
227 F K A A L L I Y G C Y L A G L X N N I s s P P V N Q S L A I 256
820 830 840 850 860 870 880 8 90 900
ATGGTTGGCAACGGCCTGGTGATGGCTGCCACTGGGGTGGTCTTCTTGGTTACTCGTTTCTTCCCTGATTGGCCGAACCTGGTCTATGCA
257 M V G N G L V M A A I G V V F L V X R F F P D W P N L V Y A 286
910 920 930 940 950 960 970 980 990
ACAACATCAGGAAGCATCTTGATCTGTACAACCTCCATCAACTGCCTTATCTTCATCCCACAGTTGCTACAATCGAGGCAGTTTGAGGAG
287 T T S G S I L I C X I S I N C L I F I P Q L L Q S R Q F E E 316
1000 1010 1020 1030 1040 1050 1060 1070 1080
GAGCAGGTCCAGAGCACACAAATGACCAAGTATTTCAGTAGCCCCAGCAAGAGCTTCCGGTCCATGTACAGTGAGGAGCAGATCTACCAC
317 E Q V Q S I Q M I K Y F S S P S K s F R S M Y S E E Q I Y H 34 6
1090 1100 1110 1120 1130 1140 1150 1160 1170
CTGCTGGGGGAAAACACGTCCATGAGAAAGCTCCTTTCAGAGCAAAATGCCATCATAGAAAGCCTCCAAGAGCAAGTGAGCAACGCTAAG
347 L L G E N X s M R K L L S E Q N A I I E S L Q E Q V s N A K 376
1180 1190 1200 1210 1220 1230 1240 1250 1260
GACAAGCTGGTGAAGCTATTAAAATCTGAGTGCAGCCTTGAAACCATTGAAGTGACCAGCCTGTCTGTATTATCTGCTTCAACGTTGGCC
377 D K L V K L L K S E C S L E X I E V X S L S V L s A S I L A 406
1270 1280 1290 1300 1310 1320 1330 1340 1350
ATTCAGCACCATGTGGCCCCTGAACATATGAAGATCATTGAGGAACCTGCACCTCTTGATACTGTAGAGAACGTGGATCATGAAGCTGTC
407 I Q H H V A P E H M K I I E E P A p L D I V E N V D H E A V 436
1360 1370 1380 1390 1400 1410 1420 1430 1440
ATTAAGGACACTCAGGAGGGTGATACTAACCATGGCACACAGAGTGATGTTTTCGAGTCACCCAAGAACCATAATATACAGGAGTTAAAA 
437 I K D X Q E G D I N H G I Q S D V F E S P K N H N I Q E L K  466
continued overleaf...
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1450 1460 1470 1480 1490 1500 1510 1520 1530
GACAAGCCTCAAGAAGGGCCACAATGTACCAGCAAGCCTACTGAATACTCAGTCTCAAAACAAGAGGACATGTCAACATCAGACTTCAGA 
467 D K P Q E G P Q C T S K P T E Y S V S K Q E D M S T S D F R  496
1540 1550 1560 1570 1580 1590 1600 1610 1620
AATGTGAGTTTTGCTGACAGTGTATCTAAAGCCCATTACCAGCACCAAGGGGAACAGTCAGAGAGGACACATGAAGTTTTAGAGCAATTA 
497 N V S F A D S V S K A H Y Q H Q G E Q S E R T H E V L E Q L  526
1630 1640 1650 1660 1670 1680 1690 1700 1710
TCCAGGAAAGTGAATTATGTGAGCAGTGAGAAACTGCAAGAGATTCTCAAAGAACTTGAGACAGTGTCAACCTGTGGCCACCAGTCTCCC 
527 S R K V N Y V S S E K L Q E I L K E L E T V S T C G H Q S P  556
1720 1730 1740 1750 1760 1770 1780 1790 1800
AAAAGACAGAGATGTGCAAGTCACAGTGTGAACAGGGACCCTGGTTTGGCTCCTTCAGAAGGAATTCAGAAAATGTGCCTCAGCTTGTCC
557 K R Q R C A S H S V N R D P G L A P S E G I Q K M C ' L S L S 586
1810 1820 1830 1840 1850 1860 1870 1880 1890
CCTTATATGATGCGTAGAAGGCGAGGACCTTGCTACAGTCAGAGGAACCAACACCCTTCCCATCACTTTCCAAATGCATTACCCCCACAG
587 P Y M M R R R R G P C Y S Q R N Q H P S H H F P N A L P P Q 616
1900 1910 1920 1930 1940 1950 1960 1970 1980
ACTTGGTGCCTCTTAAACAAAGAAGCCAGAAACCGGAGTAATGGGGTAAAGAGAACAAGAAATGAAAGGCCGAGTCACACAGGAGAAGAG
617 T W C L L N K E A R N R S N G V K R T R N E R P S H T G E E 646
1990 2000 2010 2020 2030 2040 2050 2060 2070
AGAACAGCAGAAGTTAATACGGGCCATGGGTATCATAATCCAAGTCTCTTAACTAAGACCATGGAGCTGAGTGTTCATGGGAAAGAAGAA
647 R T A E V N T G H G Y H N P S L L T K T M E L S V H G K E E 67 6
2080 2090 2100 2110 2120 2130 2140 2150 2160
AATAGGACCAGAGTAGATAATGGAATATGGATGACCCCCAAATACTCAATTTCACATCCTCCAGAGAAGCCTTCTGGCTCTATTCCTACG
677 N R T R V D N G I W M T P K Y S I S H P P E N P s G S I P T 706
2170 2180 2190 2200 2210 2220 2230 2240 2250
AGCATCAGGAGACACACAGAAATACAAGCCCATGCAATGGTGACCTTAGCCGACCTCAGATCCCAAACTACTTACACAGAGACAGATTCA
707 S I R R H T E I Q A H A M V T L A D L R S Q T T Y T E T D S 736
2260 2270 2280 2290 2300 2310 2320 2330 2340
AGTAGCTCTGAGGGGACAATCTGCTACTGTCACAGGCCTTACTGCGAGTTGTGCTTTCCAAATGAGTATGACTCAAGTGACAGCTCTGAA
737 S S S E G T I C Y C H R P Y C E L C F P N E Y D S S D S S E 766
2350 2360 2370 2380 2390 2400 2410 2420 2430
ACAGATAGTGGTGACCAACTACATGGGTGGACAACCGAAAAAAAACCTCCACAATTGGTAGTTAATTTCAATGAAGATTTGACTCCAACT
767 T D S G D Q L H G W T T E K K P P Q L V V N F N E D L T P T 796
2440 2450 2460 2470 2480 2490 2500 2510 2520
TTTGTTTAGAGGCATGACCATAACTGCCCCTCCTTAGCTTCTGGGGGAAGGGAACCTACATTCTATCTAACACGACGTACTGTATGTTTG 
797 F V * 798
2530 2540 2550 2560 2570 2580 2590 2600 2610
ATATCATTTTCTCCTGTAACTGTGTTTCATGCAAAGGAAGTGTTCAGTCACTATAATCAAATATGCCCAAGCCCATCCCCAAGGAGGCAC
2620 2630 2640 2650 2660 2670 2680 2690 2700
GTTATGTCAAGTTGATGAAGTTGGATGAAATTTCTTTCATACAGGAGATGCGTTTCACATGTTTTGCAGTTGTCTCTGTTAATGTTTGTG
2710 2720 2730 2740 2750 2760 2770 2780 2790
ATGTGAACTTACCTCTGGTTACAGGCTGTGACATTGTGGTGTACCCAAAATAAATTTCCCTGTTTCAACTTAAAAAAAAAAAAAAAAAAA
Figure 3.17 Nucleotide sequence for assembled cDNA clone encoding putative x/GABAbl, showing the 
deduced protein sequence. The 510 N-terminal amino acids encoded by the RT-PCR product isolated in 
Section 3.4.4 are indicated (blue text)
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3.4.5 Multiple sequence alignment of GABAbl protein orthologues
To determine whether the putative x/GABABl proteins, encoded by the cDNAs shown in 
Figures 3.16 and 3.17, represent genuine X.laevis orthologues of mammalian GABAbl 
proteins, the extent of the sequence identity shared at the amino acid level was 
determined by a multiple sequence alignment with mammalian GABAbl protein 
sequences. In order to distinguish between the two x/GABAbl transcript variants isolated 
here, the 798 amino acid seven-transmembrane protein, encoded by the cDNA shown in 
Figure 3.17, shall be referred to as x/GABABL(a) from this point onwards; the 535 amino 
acid single-transmembrane protein, encoded by the cDNA shown in Figure 3.16, shall be 
referred to as x/GABABL(b).
Human, rat and mouse GABAbl protein sequences (GenBank accession numbers: 
NP_694547, AAN03797 and NP_700443) were aligned against the deduced x/GABABL(a) 
and x/GABABL(b) protein sequences. This multiple sequence alignment, annotated with 
key conserved features, is presented in Figure 3.18.
Signal peptide sequences were predicted not to be present in either x/GABAbl protein 
using the PSORT II program (www.Dsort.ora). Protein sequences were aligned using 
ClustalW alignment program, with the parameters used in Section 3.2.5.
138
/ i G A B A bl 1
/G A B A bl 1
// iG A B A bl 1
x /G A B A bu,) 1
x/G A  B A Bi(b, 1
/i G A B A bl 97
/G A B A bl 97
// iG A B A bl 97
x /G A B A bl<«) 95
x/G AB ABL(b) 16
MEPEINCSELCDSFPGQELDR---------RPLHDLCKTTITSSHHSSKTISSLSPVLLGIVWTFLSCGLLLILFFLAFTIHCRKNRIVKMSSPNLNIVTLLGSC 96
MEPEINCSEFCDSFPGQELDR---------RPLHDLCKTTITDSQHGSADISPLSPALLGVIWTFLSCGLLLVLFFLAFTIRCRKNRIVKMSSPNLNIVTLLGSC 9 6
MEPEINCSEFCDSFPGQELDR---------RPLHDLCKTTITESQHSSTAASPLSPALLGIMWTFLSCGLLLVLFFLAFTIRCRKNRIVKMSSPNLNWTLLGSC 96
MEPSLNCSALLNSHIDTSLEKEEAVKVLQELCNVSWAPQRK-------------QISTALMGISGALLSLGLLLTLFFFIFTLRFRSNRIVKMSSPNLNLVTLVGSA 94
MEPSLNCSALLNSHID-----------------------------------------------------------------------------------------------------------------------------------------------------------------------  16
TMI TMII
!/* + *****■*
TMIII TM IV
/i G A B A bl 197
/G A B A bl 197
// iG A B A bl 197
x /G A B A 8l(.) 93
x /G A B A blo,) 16
h G A B A b l 
rt3ABABL 
// iG A B A bl 
x K3ABA8l(>) 
x/GA BA BL(b>
-WPNLVYATTSGSI 29
TMV TMVI
abcdefgabcdef gabcde fgabcde fga
/ i G A B A bl 297
/G A B A bl 297
// iG A B A bl 297
x /G A B A bl<i ) 293
x/G A B A BL(bi 30
TMVI I coiled-coil domain
397 EGAAPPASSPNKDVQAVASVHTLAAAQGPSGHLSDFQNDPGMAAR DSQCTSGPSSYAQSLEGPGKDSSFSPGKEEKISDSKDFSDHLDSGCSQKP 491
397 EWAVPAAASAG--------------------------------GPAECXATSEKESGAAAE--------- DSLPASAASQHMQGPGASRRDXSPSPDQKY-DMPLKQFCDHLDMGCSQKP 474
397 EWAVPDAASARG---------------------- LALPGPSECPAVSENESGAAAR--------- DSLHVPAACQHVQGPGASRRDTSPSPAQQD-NMPLKQYCDHLDTGCNQKP 479
393 EVTSLSVLSAST----------------------LAIQHHVAPEHMKIIEEPAPLDTVENVDHEAVIKDTQEGDTNHGTQSDVFESPKNHN-IQELKDKPQEGPQ-CTSKP 479
130 EVTSLSVLSAST--------------------- LAIQHHVAPEHMKIIEEPAPLDTVENVDHEAVIKDTQEGDTNHGTQSDVFESPKNHN-IQELKDKPQEGPQ-CTSKP 216
/iG A B A b l 492 WTEQSLGPERGDQVPMNPSQSLLPDRGGSDPQRQR----- HLENSEEPPERRSRVSSVIREKLQEVLQDLGLGPEASLSTAPS— CHQQTWKNSAAFSPQKM 58 6
/G A B A b l 475 KAEQSEGPERGNQEPMAPGQSLMTDGVACEPHRPR-----------QNSEVLPERLPRVSSWREKLQEVLQELDLGTEAPLSPLP-----CPQQPWKSNTSGSPQKL 566
/ / /G A B A b l 480 KAEQREGPERGDQEPMAPSQRLMADGVACEPHKP-----------RQSPEGLPKKLPGVSSWREKLQEVLQELDLGSEAPLSPLP-----CPQQLWKSTTSRSPRKL 571
X/GABAbl<,) 480 -TEYSVSKQE-DMSTSDFRNVSFADSVSKAHYQHQGEQSERTHEVLEQLSRKVNYVSSEKLQEILKELETVSTCGHQSPKRQRCASHSVNRDPGLAPSEG 577
XK3ABABL(b) 217 -TEYSVSKQE-DMSTSDFRNVSFADSVSKAHYQHQGEQSERTHEVLEQLSRKVNYVSSEKLQEILKELETVSTCGHQSPKRQRCASHSVNRDPGLAPSEG 314
/ iG A B A bl 587
/G A B A bl 567
// iG A B A bl 572
x /G A B A Bl(j) 578
x/G AB ABUb) 315
/i G A B A bl 681
/G A B A bl 660
// iG A B A bl 665
x /G A B A Bl(») 673
x /G A B A BL(b) 410
/IG A B A bl 780
/G A B A bl 758
/rG A B A bl 764
x /G A B A B i. 768
x/G A B A SL(b) 505
-AAQRARSHFPGSAPSSVGHRANRTVPGAHSRLHVQNGDSPSLAPQTTDSRVRRPSSRKPSLPSDPQDRPGTLEGSKQ 680 
-AAQRARSRIPGSVGLKMGHQANNTVSGSQNGLIVQNRDSPRLDHHNARSKEPRSSSVKPSPISAPHQRRGSLEGSKQ 659 
-AAQRARSHIPGSVGLNVGHQANSTVSSSQSGLIIQNRDSPRQDHHNARSKVPRSSSVKPSPLSEPRRKQGTLEGSKQ 664
ER retention signal
-LHGWTTEKKPPQLWNFNEDLTPTFV* 535
Figure 3.18 Alignment of ^G A B A bl, aGABAbl, hiGABAbl, x/GABAblo) and x/GABAbl^) protein sequences, 
showing putative transmembrane domains (underlined, shaded), coiled-coil domain (underlined) annotated 
with heptad repeat, ER retention motifs (bold) and conserved ER retention signal (bold, shaded). The 
epitope for a known antiserum is shown (blue text). Conservative amino acid changes (.) and amino acid 
residues conserved in all species examined (*) are indicated.
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3.4.6 The C-terminus of GABAbl is poorly conserved and contains multiple RXR-type 
ER-retention motifs
In contrast to the GABAB(i) and GABAB(2) protein orthologues, the amino acid sequence for 
GABAbl is poorly conserved X.laevis and the mammalian species examined here. The C- 
terminal intracellular tail of GABAbl, downstream of the coiled-coil domain, is particularly 
poorly conserved, with just 25% amino acid identity shared between human and X.laevis 
sequences in this region, rising to 54% and 56% between human and mouse, and human 
and rat, respectively. There are, however, several short and highly conserved amino acid 
sequences in the C-terminus that may be of functional importance, such as EKLQE(IA/)L, 
SPY(MA/)(MA/)RRR, SSSS and CHRPYCE(IA/)C (see Figure 3.18). These conserved 
sequences would make attractive targets for future mutagenesis studies, should 
functionality of the GABAbl protein ever be demonstrated.
Strikingly, human, rodent and x/GABAbl sequences each possess multiple RXR-type ER- 
retentions motifs in their C-terminal tails. The locations of many of these motifs are not 
conserved across the species, and many are not immediately preceded by a hydrophobic 
residue, casting doubt as to their significance as retention signals in vivo. However, the 
location of one motif is highly conserved, (M/V)RRR(R), and may function as a bona fide 
RXR-type ER-retention signal in vivo.
The presence of these multiple signals in the GABAbl C-terminus, and the lack of an N- 
terminal secretion peptide sequence, suggests that the GABAbl protein might be retained 
on intracellular membranes post-translation. Indeed, subsequent to cloning, Calver and 
colleagues experienced difficulty expressing the human GABAbl orthologue at the cell 
surface in HEK-293 cells without the addition of an N-terminal signal peptide (Calver,A.R
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et al. 2003). It is possible that these ER-retention signals might be masked in vivo 
through interactions with other proteins, resulting in the trafficking of a GABABi_-protein 
complex to the plasma membrane. Indeed, the GABAbl subunit may yet be found to 
function as a non ligand-binding partner in a heterodimeric receptor, analogous to its 
closely related cousin, GABAB(2). The extended C-terminal tail of GABAbl, unusually long 
even for a Family 3 GPCR, may also be indicative of interactions with multiple intracellular 
factors or receptor subunits, perhaps as part of a larger oligomeric GPCR assembly.
3 .4 .7  x IG ABA blm  ar,d  x lG A B A BL(b) transcripts encode proteins that possess a different 
number of transmembrane domains
The isolation of two distinct x/GABAbl transcript variants here is intriguing, since the 
existence of distinct GABAbl isoforms has been postulated previously. A number of 
hGABABL transcripts of different length have been identified in the human testis by 
northern analysis (Calver,A.R et al. 2003), and the nucleotide sequence for a hGABABL 
transcript variant, encoding a single-transmembrane protein, termed here hGABABL(b), is 
deposited in GenBank (accession number: AB209362) (Totoki.Y et al. 2005) (see Figure 
1.3). The assembled x/GABABL(a) cDNA clone, shown in Figure 3.17, encodes a seven- 
transmembrane protein orthologous to mammalian GABAbl proteins; the x/GABABL(b) 
cDNA clone, shown in Figure 3.16, encodes a identical protein except for the deletion of 
262 amino acids corresponding to transmembrane domains l-IV of x/GABABUa). Whilst the 
significance of this deletion is not yet clear, the similarity in receptor topology to that 
encoded by the /7GABABL(b) transcript variant suggests that this phenomenon may be 
conserved between human and X.laevis. However, analysis of the deduced hGABABL{b) 
and x/GABABL(b) protein sequences reveals that, whilst the latter lacks transmembrane
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domains l-VI with respect to its seven-transmembrane homologue, the hGABABL(b) lacks 
transmembrane domains I l-VI I, suggesting that they are unlikely to be generated by a 
comparable RNA splicing mechanism. Furthermore, the canonical splicing event that 
generates the f?GABABL(b) variant causes a frameshift which results in the deletion of 
almost the entire C-terminal intracellular tail and, as such, it is difficult to imagine that 
/7GABABL(b) and x/GABABL(b) proteins would perform analogous roles if expressed in vivo. 
The exon organisation of the x IG A B A Bl gene presently remains undisclosed and, as such, 
there is no evidence to suggest that the x/GABABL(b) transcript assembled here could be 
generated by canonical RNA splicing events. In the absence of this evidence, it was 
decided that pursuit of the functional characterisation of x/GABABL(a), and not x/GABABL(b), 
would be favourable in the first instance, since the former isoform was orthologous to 
mammalian GABAbl proteins and possessed seven-transmembrane domains, reminiscent 
of a GPCR.
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3.5 Subcloning of X.laevis GABAb receptor cDNAs into expression vectors
3.5.1 Identification of plasmid vectors suitable for the generation of X.laevis GABAb 
receptor expression constructs
Following the identification and isolation of x/GABAb receptor cDNAs, a number of 
applications for these clones were envisaged. The first was to use these cDNAs as a 
template from which to transcribe x/GABAB-specific antisense cRNA probes that could be 
used to perform in situ hybridization experiments (see Section 5.3). The IMAGE:6948709 
and IMAGE:6947886 cDNA clones, containing complete open reading frames for 
x/GABAB(1b) and x/GABAB(2) respectively, were acquired from libraries constructed using 
the pCMV-SPORT6 (Invitrogen) plasmid vector; the XL024m02 cDNA clone, containing a 
partial open reading frame encoding the C-terminus of x/GABAbl (see Figure 3.15) was 
acquired from a library constructed using the pBlueScript® II SK(-) (Stratagene) phagemid 
vector. Since both of these vectors contain two promoter regions flanking either side of 
the polylinker, these constructs were ideally suited for the transcription of antisense, and 
sense, x/GABAB(i), x/GABAB(2) or x/GABABL-specific cRNA probes.
The second application envisaged for the x/GABAb receptor cDNAs was the in vitro 
transcription of sense cRNAs, suitable for microinjection into X.laevis embryos, to facilitate 
x/GABAB(1a), x/GABAB(1b), x/GABAB(2) and x/GABABL(a) protein overexpression experiments 
(see Sections 6.2-5). These experiments required not only the assembly of full-length 
cDNAs encoding x/GABAB(1a) and x/GABABL(a), but also the use of specialised plasmid 
expression vectors designed to maximise expression of the cRNAs transcribed from them.
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The pSp64T.clon plasmid vector, derived from the pSp64 expression vector (Promega), 
was originally constructed by Dr Rodolpho. M. Albano (Dept of Biochemistry, State 
University of Rio de Janeiro, Rio de Janeiro, Brazil) and was kindly donated by Dr Leslie 
Dale (Dept of Anatomy and Developmental Biology, University College London, London, 
UK). pSp64T.clon was generated by replacing the Bglll site in pSp64T with the additional 
restriction sites Sma/, Kpn/, Sac/, EcoRl, Not/, XmaIII, offering a greater range of cloning 
options. cDNAs cloned into this polylinker are flanked by the 5’UTR and 3’UTR of the 
X.laevis (3-globin gene, known to be efficiently translated in vivo. A second polylinker 
downstream of the 3’UTR allows for linearization of the plasmid prior to in vitro 
transcription with Sp6 RNA polymerase.
The pCS2+ plasmid vector, derived from the pBluescript II KS(+) vector (Promega), was 
originally constructed by Dr David Turner (University of Michigan, Ann Arbor, Ml, USA) 
and was kindly donated by Dr Leslie Dale. pCS2+ contains the simian CMV IE94 
promoter followed by a polylinker into which cDNAs may be cloned, followed by a SV40 
poly-adenylation sequence. A second polylinker downstream of the SV40 signal allows 
for linearization of the plasmid prior to in vitro transcription with Sp6 RNA polymerase.
Whilst both of these plasmid vectors were, in principle, suitable for the generation of the 
x/GABAb receptor expression constructs, cloning options were limited by the presence of 
multiple endonuclease recognition sequences within the x/GABAb receptor coding 
sequences. The rationale developed in order to subclone these cDNAs demanded the 
use of the pSp64T.clon plasmid vector to generate the x/GABAB(ia), x/GABAB(1b) and 
x/GABAB(2) expression constructs, and the pCS2+ plasmid vector to generate the 
x/GABABL(a) expression construct.
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3.5.2 Subcloning of X.laevis GABAb receptor cDNAs into pSp64T.clon vector
In the case of x/GABAB(ia) and x/GABAB(1b), it was necessary to remove a significant 
portion of their 5’UTR prior to subcloning into pSp64T.clon, due to the presence of several 
short open reading frames upstream of the initiation codons corresponding to the 
x/GABAB(1a) and x/GABAB(1b) open reading frames. Failure to eliminate these short open 
reading frames may have resulted in the translation of alternative polypeptides in 
reticulocyte lysate reactions, or in oocytes and embryos following microinjection of 5’- 
capped, polyadenylated cRNAs transcribed from these constructs.
To generate the x/GABAB(ib) expression construct, the 3653bp x/GABAB(1b) cDNA shown in 
Figure 3.5 was first subcloned into Kpn I (5’) and Not I (3’) sites in the mammalian 
expression vector pcDNA3.1(+) Neo (Invitrogen). This construct was then used as a 
template from which to amplify a 3180bp fragment, corresponding to nucleotides 473- 
3653 of the x/GABAB(1b) cDNA clone, by RT-PCR (see Section 2.1.10) using 
ACCUZYME™ proofreading DNA polymerase and the oligonucleotide primers shown in 
Table 3.19A. This fragment was digested with Asp 7181 (5’) and Not I (3’) (see Section 
2.1.7) and ligated into the Kpn I (5’) and Not I (3’) sites in the pSp64T.clon vector (see 
Section 2.1.15). The nucleotide sequence for this construct was verified by dideoxy 
sequencing (see Section 2.1.12).
To generate the x/GABAB(1a) expression construct, a 720bp fragment, corresponding to 
nucleotides 368-1088 of the x/GABAB(1a) cDNA clone isolated by 5’RACE, shown in Figure 
3.6, was amplified by RT-PCR (see Section 2.1.10) using ACCUZYME™ proofreading 
DNA polymerase and the oligonucleotide primers shown in Table 3.19B. This fragment 
was digested with Asp718l (5’) and StuI (3’) (see Section 2.1.7) to yield a 641 bp fragment
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encoding the 191 N-terminal amino acids of x/GABAB(1a). Next, the newly completed 
pSp64T.clon x/GABAB(1b) construct, described in this section, was also digested with 
Asp7181 (5’) and StuI (3’) to release an 18.9bp fragment encoding the 46 N-terminal amino 
acids ofx/GABAB(1b). This fragment was discarded and the 641 bp fragment encoding the 
191 N-terminal amino acids of x/GABAB(1a) was ligated into the Asp 7181 (5’) and Stu I (3’) 
sites in the linearised pSp64T.clon x/GABAB(ib) construct (see Section 2.1.15), to yield a 
new pSp64T.clon construct containing an assembled x/GABAB(1a) cDNA clone. The 
nucleotide sequence for this construct was verified by dideoxy sequencing (see Section
2 . 1. 12).
The generation of the x/GABAB(2) expression construct was simplified by the absence of 
any short open reading frames in its 5’UTR. Here, the complete 3253bp x/GABAB(2) 
cDNA, shown in Figure 3.11, was subcloned directly into Kpn I (5’) and Not I (3’) sites in the 
pSp64T.clon vector to generate the expression construct.
3.5.3 Subcloning of X.laevis x IG ABA blm cDNA into pCS2+ vector
To generate the x/GABABL(a) expression construct, site-directed mutagenesis was 
performed (see Section 2.1.13) to mutate the BglII restriction site at position 167 in the 
x/GABABL(a) cDNA isolated by RT-PCR, shown in Figure 3.17, using the oligonucleotide 
primers shown in Table 3.19C. The mutated clone was then digested with EcoRl (5’) and 
BglII (3’) (see Section 2.1.7) to yield a 1069bp fragment encoding the 342 N-terminal 
amino acids of x/GABABL(a). Next, the partial cDNA clone encoding the C-terminal end of 
x/GABAbl, shown in Figure 3.15, was digested with BglII (5’) and XhoI (3’) to yield a 
1719bp fragment encoding the 456 C-terminal amino acids of x/GABAbl. Both fragments
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were then ligated into EcoRl (5’) and XhoI (3’) sites in the pCS2+ vector (see Section 
2.1.15) to yield a pCS2+ construct containing an assembled x/GABABi_(a) cDNA clone. The 
nucleotide sequence for this construct was verified by dideoxy sequencing (see Section
2. 1. 12).
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A
cDNA Primer Nucleotide Sequence
Loc
(bp) Strand
x/G ABAe(ib) xGB1 b-AMP-fwdO 5 ' -CCACCACTTTCGCTGCCTTC-31 398 plus
BGH-rev1 (vector) 5 ’-TAGAAGGCACAGTCGAGG-3 ' n/a minus
B
x/GABAe(ia) xGB1a-AMP-fwd2 5 ' - GGACATAAAGCACTAAAGAAGT-3 ' 368 plus
xGB1-SEQ-rev3 5 ' -AGCCTCAGTTCATACTCCG-31 1088 minus
c
x/GABAana) xGBL-5'SDM-1wd 1 5 ’ -ACAGAGGAAACAGAT TCTACTGCTCTCATGG-3 ' 156 plus
xGBL-5'SDM-rev1 5 ' -CCATGAGAGCAGTAGA ATCTGTTTCCTCTGT-3' 187 minus
Table 3.19 Oligonucleotide primers used during the subcloning of cDNAs encoding A. x/GABAe(ib), B. 
x/GABAe(ia), and C. x/GABAeL(a) into expression vectors, showing binding loci (bp) and strand, where 
applicable, relative to the cDNA sequences shown in Figures (A) 3.5, (B) 3.6, and (C) 3.17.
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3.5.4 In vitro transcription and translation of X.laevis GABAb receptor cDNAs from 
expression constructs
In order to demonstrate the proper construction of the pSp64T.clon and pCS2+ x/GABAb 
receptor expression constructs, 5’-capped polyadenylated cRNAs were transcribed from 
these plasmid templates using Sp6 RNA polymerase, as described in Section 2.1.20, and 
translated into radiolabelled protein through incubation with reticulocyte lysate (see 
Section 2.2.1). As a positive control, cRNA and protein products were also generated 
from a pCS2+ construct containing a cDNA insert encoding the N-terminal extracellular 
domain (ECD) of f?GABAB(1a), described in the main thesis Discussion (see Section 7.5.1). 
As a negative control, the products from a reticulocyte lysate reaction containing no cRNA 
template were also analysed. The expected sizes of the cRNA (kb) and protein (kDa) 
products from these constructs are shown in Table 3.20. Denatured cRNA and 
radiolabelled protein products are shown in Figure 3.21.
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Construct Expected size 
cRNA (kb)
Expected size 
Protein (kDa)
pSp64T.clon x/GABAB(1a) 3.9 111.6
pSp64T.clon x/GAE3AB<ib) 3.6 95.2
pSp64T.clon x /GABAB(2) 3.7 103.8
pCS2+ x/GABABL(a) 3.0 89.3
pCS2+ /7 G A B A B(ia)ECD 2.0 67.4
Table 3.20 Table showing approximate expected cRNA (kb) and protein (kDa) sizes
generated by each construct.
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Figure 3.21 Denatured cRNA products, from in vitro transcription (upper), and 
denatured radiolabelled protein products, from in vitro translation (lower), generated 
by each construct, showing -cRNA control. Molecular weight of fragments observed
are shown in each case.
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A Loc
cDNA Primer Nucleotide Sequence (bp) Strand
x /GABAb(i b) T7 promoter 5'-TAATACGACTGACTATAGGG-3' n/a plus
& xGB1-SEQ-fwd1 5'-TGCTCTATTCCCAATGAGTG-3' 621 plus
x/GABAB(ia) xGB1-SEQ-fwd3 5'-TTCTCTGACCCAGTTATCCC-3' 1132 plus
5* end xGB1-SEQ-fwd4 5 ' -ATTATGACAGCACCAAGGAC-3’ 1757 plus
xGB1-SEQ-fwd2 5 ' -GGGACTACTCCTTTTGCTTG-3' 2442 plus
xGB1-SEQ-rev3 5'-AGCCTCAGTTCATACTCCG-3' 740 minus
xGB1-AMP-rev1 5 ' -TGCCTGTGTCATTTCCTCCACG-3' 1356 minus
xGB1-SEQ-rev1 5 1-GACACACAAATCCCAGGAG-3' 1930 minus
xGB1-SEQ-rev2 5 »-CAAAGGACAGCCACATTG-3' 2558 minus
Sp6 promoter 5'-GATTTAGGTGACACTATAG-3' n/a minus
B 5'-GGCCACGCGTCGACTAGTAC
x/GABAa<ia) 5’RACE AAP* GGGIIGGGIIGGGIIG-3' n/a plus
5’ end AUAP* 5'-GGCCACGCGTCGACTAGTAC-3' n/a plus
xGB1-SEQ-rev3 (GSP2)* 5 ' -AGCCTCAGTTCATACTCCG-31 740 minus
xGB1-AMP-rev1 (GSP1)* 5 ' -TGCCTGTGTCATTTCCTCCACG-3' 1356 minus
xGB1a-AMP-fwd3 5 1 -ATCATGGGACATAAAGCACT-3 ' 362 plus
xGB1a-SEQ-rev1 5 ' -CAAACACTGGAGTAAGCC-3' 487 minus
Sp6 promoter 5 1-GATTTAGGTGACACTATAG-3' n/a minus
^  x /GABAb<2) T7 promoter 5'-TAATACGACTGACTATAGGG-31 n/a plus
xGB2-SEQ-fwd1 5'-TGAACTGGAAGACTCTGCC-3' 660 plus
xGB2-SEQ-fwd3 5'-GCAGAACCTCCAAAAGATGAAACC-3 1378 plus
xGB2-SEQ-fwd2 5 •-TTTTGACCGTGGGCTACAC-3' 1673 plus
xGB2-SEQ-fwd4 5'-CAGTTTCCTTCCTCACCA-31 2120 plus
xGB2-AMP-rev1 5'-TGGAGTTGTTGCTGCGAATGAC-3' 492 minus
xGB2-SEQ-rev3 5'-AACACAACTTGACCCGTTAC-3' 1247 minus
xGB2-SEQ-rev2 5'-GGTCAATCAACAACATTCCTC-3' 1822 minus
xGB2-SEQ-rev4 5'-GGCACAAAAACAAGACAGAGTG-3' 2222 minus
Sp6 promoter 5 1-GATTTAGGTGACACTATAG-3' n/a minus
D x /GABAblo T3 promoter 5'-ATTAACCCTCACTAAAGGGA-3' n/a plus
3’ end xGBL-SEQ-fwd1 5'-CACACAGAGTGATGTTTTCG-3' 525 plus
& xGBL-SEQ-fwd2 5'-GAACCCTTCTGGCTCTATTC-3' 1275 plus
x/GABAenb) xGBL-SEQ-rev2 5'-TGCTGGTAATGGGCTTTAG-31 713 minus
3* end xGBL-SEQ-rev1 5'-TGGGCTTGTATTTCTGTGTG-3' 1331 minus
T7 promoter 5'-TAATACGACTGACTATAGGG-3' n/a minus
E 5'-GGCCACGCGTCGACTAGTAC
x/GABABL(b> 5’RACE AAP* GGGIIGGGIIGGGIIG-31 n/a plus
5’ end AUAP* 5'-GGCCACGCGTCGACTAGTAC-3' n/a plus
xGBL-SEQ-rev3 (GSP2)* 5'-AGCCTCAGTTCATACTCCG-3' 53 minus
xGBL-SEQ-rev2 (GSP1)* 5'-TGCCTGTGTCATTTCCTCCACG-3' 712 minus
Sp6 promoter 5'-GATTTAGGTGACACTATAG-3' n/a minus
^ x/GABABL(a) xGBL-AMP-fwd2* 5'-GGCACCTTGTTCTGTGGG-3' 391 plus
5’ end xGBL-SEQ-rev2* 5'-TGCTGGTAATGGGCTTTAG-3' 713 minus
T7 promoter 5'-TAATACGACTGACTATAGGG-3' n/a plus
xGBL-SEQ-fwd4 5 ' -AACCCTGCTGAGTCTTGTG-3' 518 plus
xGBL-SEQ-fwd5 5 ' -TCCCACAGTGCTACAATCG-3' 955 plus
xGBL-SEQ-rev4 5 ' -AGTGAACAGAAGTCCCAGC-31 554 minus
xGBL-SEQ-rev5 5 ' -TGGTCATTTGTGTGCTCTG-3 ' 1017 minus
Sp6 promoter 5'-GATTTAGGTGACACTATAG-3' n/a minus
Table 3.22 Oligonucleotide primers used for sequencing cDNAs encoding A. x/GABAB(it» and 
x/GABAsoa) 3’ end, B. x/GABAB(ia) 5’ end, C. x/GABAB(2), D. x/GABABL(a) and x/GABAsL(b) 3 ’ end, E. 
x/GABABL(b) 5’ end and F. x/GABAelo) 5’ end, showing binding loci (bp) and strand where applicable. 
Primers also used for amplification of cDNA by 5’RACE or RT-PCR are denoted with an asterix (*).
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3.6 Discussion
In this chapter, a combination of homology searches, 5’RACE, RT-PCR and molecular 
cloning techniques were used to isolate cDNAs encoding x/GABAb receptors which were 
then subcloned into expression vectors for localisation and overexpression studies. 
Recombinant proteins were translated from cRNA transcribed from these constructs, and 
the size of these products was consistent with that of the deduced x/GABAb receptor 
proteins. Multiple sequence alignments were used to compare the degree of identity and 
the conservation of structurally and functionally important residues between mammalian 
and X.laevis GABAb receptor proteins. Key findings from the data presented in this 
chapter are evaluated below.
3.6.1 Identification of X.laevis GABAb receptor orthologues
Four of the cDNAs isolated here, shown in Figures 3.5, 3.6, 3.11 and 3.17, contain open 
reading frames encoding putative seven transmembrane proteins that exhibit striking 
homology to human or rodent GABAB(1b), GABAB(1a), GABAB(2) and GABAbl respectively. A 
fifth cDNA isolated here, termed x/GABABL(b) (see Figure 3.16), encodes a protein that 
also exhibits homology to human or rodent GABAbl, but which is predicted to possess 
only a single transmembrane domain. Pairwise sequence alignments reveal that 
/?GABAB(1a) and x/GABAB(ia) coding sequences share 69% nucleotide identity and 76% 
amino acid identity respectively; /7GABAB(1b) and x/GABAB(1b) coding sequences share 
71% nucleotide identity and 78% amino acid identity respectively, and hGABAB(2) and 
x/GABAB(2) coding sequences share 72% nucleotide identity and 82% amino acid identity
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respectively. Analysis of the multiple sequence alignments presented in Figures 3.7, 3.8, 
3.12 and 3.18 also shows that, in addition to key GABAb receptor features such as sushi 
domains, transmembrane and coiled-coil domains and ER-retention signals being 
conserved, residues shown to be important for both ligand coordination and tertiary 
structure of the PBP-like domain in human and rat GABAb receptors (Galvez,T et al. 1999, 
Galvez,T et al. 2000, Kniazeff.J et al. 2002), are also conserved in the x/GABAb(1) and 
x/GABAB(2) protein sequences deduced here. Taken together, these data strongly suggest 
that the X.laevis cDNAs isolated here encode the X.laevis orthologues of the mammalian 
GABAB(ia), GABAB(1b) and GABAB(2) receptor proteins.
The sequence conservation between hGABAbl and x/GABABL(a) coding sequences is 
markedly lower, sharing 53% nucleotide identity and 38% amino acid identity overall. 
However, analysis of the multiple sequence alignment presented in Figure 3.18 shows 
that much of the dissimilarity between the human, rodent and X.laevis GABABL(a) protein 
sequences resides in the C-terminal intracellular tail. Pairwise sequence alignment 
reveals that the amino acid identity shared between /?GABAbl and x/GABAbl rises to 57% 
across the putative seven-transmembrane and coiled-coil domains. Despite the low 
sequence conservation in the C-terminal tail, several short amino acid sequences, such 
as EKLQE(IA/)L, SPY(MA/)(MA/)RRR, SSSS and CHRPYCE(IA/)C, are highly conserved 
between human, rodent and X.laevis GABAbl proteins (see Figure 3.18). Taken together 
with the high level of sequence conservation observed at the extreme N- and C-termini 
and similar overall open reading frame length across the species, these data suggest that 
the X.laevis GABABL(a) cDNA isolated here encodes the X.laevis orthologue of the 
mammalian GABAbl proteins.
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3.6.2 Some mammalian GABAbl and GABAbl receptor subunit protein sequences
are not conserved in their X.laevis counterparts
Whilst the multiple sequence alignments shown in Figures 3.7, 3.8 and 3.12 demonstrate 
that many features known to be important for mammalian GABAb receptor function are 
conserved in X.laevis GABAB(i) and GABAB(2) receptor subunits, there are a some striking 
differences between these proteins and their mammalian counterparts. Firstly, 
x/GABAB(1a), x/GABAB(1b) and x/GABAB(2) proteins all possess putative N-terminal signal 
peptide sequences that are distinct from their mammalian orthologues, suggesting that a 
distinct type of signal peptide sequence may be required in mammals compared to 
amphibians. Alternatively, the poor sequence conservation here may be indicative of a 
lack of selective evolutionary pressure at this location, implying that the secretion signal 
depends only upon the hydrophobic nature of the N-terminal residues and not necessarily 
any specific amino acid sequence. Similarly, the divergence observed in the C-terminus 
of x/GABAb(1) proteins may indicate either the presence of mammalian or amphibian- 
specific signals in this region, or a lack of functionality of this domain; the latter notion is 
supported by experiments demonstrating that GABAB(1) proteins with C-terminal deletions 
or mutations still exhibit wild-type activity (Margeta-Mitrovic.M et al. 2001a). Perhaps the 
most functionally significant difference observed between mammalian and X.laevis GABAb 
receptor proteins is the deletion of six amino acids at the C-terminal end of the coiled-coil 
domain of x/GABAB(1) proteins, just upstream of the of the ER-retention signal, RSR(R). 
Several studies have demonstrated that deletions or mutations at this location modulate 
the trafficking of mammalian GABAB(1) subunits to the plasma membrane (Grunewald.S et 
al. 2002, Gassmann, M et al. 2005), and so it is postulated that x/GABAB(1) proteins may 
exhibit distinct trafficking properties from their mammalian counterparts.
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3.6.3 Some commercially available antibodies are unlikely to recognise X.laevis 
GABAb receptor proteins
The epitopes for various GABAB(1) and GABAB(2) antibodies that are available 
commercially are highlighted in Figures 3.7, 3.8, 3.12 and 3.18. These include N-terminal 
GABAB(1a), GABAB(1b> and GABAB(2)-specific antisera, and a C-terminal GABAB(1) antibody. 
Whilst much of the epitope for N-terminal GABAB(1a) antibodies is conserved in 
x/GABAB(ia), the epitopes for N-terminal GABAB(1b) and GABAB(2) antibodies are not found 
in the x/GABAB(1b) and x/GABAB(2) protein sequences shown here. More than half of the 
epitope sequence recognised by C-terminal PAN-GABAB(1) antibodies is present in 
x/GABAB(1) protein, including most of the charged residues. Taken together, these data 
suggest that whilst N-terminal GABAB(1a) and C-terminal PAN-GABAB(1) antibodies may 
recognise x/GABAB(ia) and x/GABAB(1) respectively, N-terminal GABAB(ib) and GABAB(2) 
antibodies are unlikely to detect x/GABAB(1b) and x/GABAB(2) proteins. A GABABL-specific 
antiserum was raised against the amino acid sequence highlighted in Figure 3.18 
(Calver,A.R et al. 2003), which is partially conserved in x/GABAbl proteins. Whilst this 
antiserum may be able to detect x/GABAbl proteins, it is not commercially available.
3.6.4 Proteins of the correct predicted molecular mass are translated from the X.laevis 
GABAb receptor constructs produced here
The data shown in Figure 3.17 demonstrate that 5’-capped polyadenylated cRNAs, 
transcribed from the X.laevis GABAb receptor constructs produced here (see Section 3.5), 
give rise to proteins of the correct predicted molecular weight when translated in 
reticulocyte lysates. These constructs should be suitable for use in a variety of
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applications designed to investigate x/GABAb receptor functions, facilitating both the 
design of oligonucleotide primers and probes, and providing a template for the 
transcription of x/GABAB-specific cRNA probes or synthetic mRNA for the manipulation of 
x/GABAb receptor gene expression in developing X.laevis embryos.
3.6.5 Data accompanying the ESTs identified here may provide information about
gene expression
The ESTs identified in this chapter by homology searches, shown in Tables 3.1, 3.3, 3.9 
and 3.13, provide initial insight into the spatiotemporal expression pattern of X.laevis 
GABAb receptor gene products. ESTs from Xenopus GABAB(1b) cDNA clones were 
identified in cDNA libraries derived from tissues in the brain, eye, head, oviduct or whole 
embryo, at developmental stage 25 (tailbud) up to adult. ESTs from X.tropicalis GABAB(1a) 
cDNA clones were identified in cDNA libraries derived from adult heart and brain tissues. 
ESTs from Xenopus GABAB(2) cDNA clones were identified in cDNA libraries derived from 
tissues in the brain, eye or whole embryo, at developmental stage 10.5 (gastrulae) up to 
adult frogs. A single EST from a X.laevis GABAbl cDNA clone was identified in a cDNA 
library derived from whole neurulae.
Since the number of ESTs identified here is very small, these data are unlikely to provide 
a very accurate picture of the spatiotemporal expression pattern of x/GABAb transcripts in 
the Xenopus embryo, particularly in the case of GABAbl where only a single clone was 
identified. Whilst a relationship between the location of the ESTs identified here and the 
relative abundance of x/GABAb transcripts in those tissues is likely, these data point 
toward some controversial conclusions. For example, 43% of the X.laevis GABAB(1b)
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ESTs come from cDNA libraries derived from the adult eye, whereas none of the twelve 
X.tropicalis GABAB(ia) ESTs identified came from the adult eye. This suggests that 
GABAB(ib> transcripts are abundantly expressed in the X.laevis eye, but not in that of the 
very closely related frog X.tropicalis, which seems somewhat unlikely. However, these 
data do identify developmental stages when x/GABAb transcripts are expressed, where 
further characterisation of expression patterns, by the use of sensitive molecular methods, 
might be most informative.
3.6.6 Summary
In this chapter, full-length cDNAs encoding x/GABAb receptor subunits were isolated and 
subcloned into expression vectors. The deduced protein sequences were compared with 
known orthologues by multiple sequence alignments, and translation of x/GABAb receptor 
proteins of the correct predicted molecular weight was demonstrated. Whilst the multiple 
sequence alignments of x/GABAb protein orthologues provide a fascinating insight into the 
conservation of these sequences during evolution, these data do not provide information 
regarding the structure of the xIGABAb genes or conservation of untranslated sequences 
or intron-exon boundary locations. The latter data would be required in order to evaluate 
the significance of the x/GABABL(b) transcript isolated here, which encodes a putative 
single-transmembrane GABAbl protein that has not previously been reported. The recent 
progress made in X.tropicalis genome projects may facilitate the elucidation of xIGABAb 
gene structure through mapping of the cDNAs isolated here onto X.tropicalis genomic 
sequences, and this approach will be explored in Results Chapter Two.
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Data accompanying the ESTs identified in this chapter provide a little insight into the 
expression of the xlGABAB(1)l xIGABAB(2) and xIGABAbl genes during X.laevis 
development (see Section 3.6.5), but further analysis using molecular methods is 
necessary in order to uncover detailed spatiotemporal expression patterns, and this 
approach will explored in Results Chapter Three.
Whilst the high degree of amino acid sequence conservation exhibited between 
mammalian and X.laevis GABAb receptors is highly indicative of conserved function, the 
expression constructs produced in this chapter (see Section 3.5) will permit the 
characterisation of these newly isolated orthologues, by overexpression in X.laevis 
embryos, which may uncover functional differences between mammalian and X.laevis 
GABAb receptors. Furthermore, overexpression of xlGABABL(a) in X.laevis embryos might 
bring about developmental changes in this organism that could provide some insight into 
the function of this orphan GPCR.
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Results
Chapter Two
Analysis of Xenopus tropicalis genomic sequence and 
comparisons of orthologous GABAb receptor gene structure
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4.1 Introduction
4.1.1 Background
The recent advances made in sequencing the genomes of numerous model organisms 
have facilitated the annotation of thousands of cloned eukaryotic genes. The mapping of 
cDNA clones to assembled genomic sequences now permits the rapid identification of the 
chromosomal location of the cloned gene, and a determination of the size, number and 
location of the exons and introns present. However, prior to the publication of this 
sequence information, the identification of gene loci in chromosomal DNA was typically 
achieved through restriction mapping and nucleic acid hybridization techniques.
GABAB(i) cDNAs were isolated by expression cloning in 1997, four years prior to the 
publication of the first assembly of the human genome. The location of the GABAB(1) gene 
was initially identified through cDNA hybridization selection on genomic DNA clones 
spanning the 6p21.3 region of human chromosome 6: a genetic locus for schizophrenia, 
juvenile myoclonic epilepsy (JME), and dyslexia (Goei.V.L et al. 1998, Grifa.A et al. 1998). 
Initial analysis of the human GABAB(d gene revealed that it spanned at least 18kb and 
contained 22 exons, however, a subsequent study suggested that at least one additional 
untranslated exon must exist, corresponding to the 5-UTR of the GABAB(ia) transcript 
variant (Peters,H.C et al. 1998). The GABAB(ib) transcript variant was shown to derive 
from transcriptional initiation at an alternative site residing within intronic sequence 
downstream of exon 1a4, resulting in the extension of exon 1 at its 5’ end and the 
encoding of 47 unique amino acid residues (Peters,H.C et al. 1998, Martin,S.C et al. 2001, 
Steiger,J.L et al. 2004). The existence of several other reported GABAB(1) transcript
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variants are readily explained by variations in intron splicing events consistent with the 
reported structure of the GABAB(1) gene (see Section 1.4.3).
The location of the human GABAB(2) gene on chromosome 9 was identified through 
searches of GenBank genomic DNA databases, using the GABAB(2) cDNA sequence as a 
query (Martin,S.C et al. 2001). Mapping of GABAB(2) cDNAs to genomic sequence 
revealed that the GABAB(2) gene contained 19 exons and spanned more than 350 kb. 
Alignments of two reported transcript variants, GABAB(2b) and GABAB(2C), with GABAB(2) 
genomic sequences, provided no evidence for their generation through canonical splicing 
events and, as such, these cDNAs are now thought to have been generated by cloning 
artefacts. Comparison of the GABAB(1) and GABAB(2) genes shows that they have a 
related genomic organisation and share many intron/exon boundary locations, indicating 
that they most probably derive from a common ancestral gene (Martin,S.C et al. 2001).
Unlike GABAB(d and GABAB(2), there are no reported studies into the structure of the 
GABAbl gene. However, automatic annotation of the human genome, incorporated in 
relational databases such as Ensembl (www.ensembl.org). reveals that the human 
GABAbl gene resides on chromosome 3, spans at least 97kb and contains 9 translated 
exons (Hubbard,T.J.P et al. 2007). Whilst it has been demonstrated that certain regions of 
the cloned GABAbl cDNAs share sequence identity with GABAb receptor nucleotide 
sequences (Calver.A.R et al. 2003), comparison between the organisation of the GABAbl 
and GABAb receptor genes has not been published.
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4.1.2 Cloned xIGABAb receptors
The identification and characterisation of GABAb receptor protein orthologue sequences, 
presented in Results Chapter One, revealed a number of striking dissimilarities between 
X.laevis and mammalian GABAb receptor proteins (see Figures 3.7, 3.8, 3.12 and 3.18). 
Most notably, the x/GABAB(1) receptor protein sequences contained stretches of additional 
amino acid sequences not present in their human or rodent counterparts (see Section 
3.2.6). Whether these differences derive from alternative splicing mechanisms or from a 
distinct GABAB(i) gene organisation has not been elucidated.
During the cloning of xlGABAb receptor cDNAs (see Section 3.2), several distinct 
transcript variants were isolated when carrying out rapid amplification of 5’-cDNA ends 
(5’RACE). For example, three distinct cDNA clones encoding the N-terminal domain of 
x/GABAB(ia) isolated using this method were found to differ in sequence downstream of 
their sushi domains (see Section 3.2.4). In addition, a truncated x/GABAbl transcript 
variant, encoding a protein predicted to possess only a single transmembrane domain, 
termed here x/GABABL(b), was also isolated by 5’RACE (see Section 3.2.9). The latter is 
intriguing in that, although GenBank database searches do not retrieve any other similarly 
truncated GABAbl sequences, the encoded protein would exhibit a similar morphology, as 
a single-pass membrane protein, to that encoded by a reported human GABAbl transcript 
variant, termed here /7GABABL(b) (see Section 1.4.5). The generation of /?GABABL(b) is 
readily explained by canonical splicing events, but it is presently unclear whether the 
same is true of x/GABABL(b) and the x/GABAB(1a) N-terminal transcript variants isolated here 
by 5’RACE.
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4.1.3 The X. tropicalis genome
Recently, significant progress has been made in sequencing the genome of the African 
frog X.tropicalis, a close relative of X.laevis that is increasingly being used as a model 
organism for vertebrate development in preference to the latter. X.tropicalis offers a 
distinct advantage over X.laevis for use in experimental genetics in that it is a true diploid 
organism, whereas X.laevis is pseudotetraploid and possesses four copies of many of its 
genes as two distinct pairs of alleles (Showed,C et al. 2007). The close relationship 
between the two frogs does, however, allow the effective mapping of cDNA sequences 
isolated from X.laevis to X.tropicalis genomic DNA, permitting the annotation of the 
X.tropicalis genome and providing insight into the exon structure of cloned X.laevis 
genes.
The mapping of the x/GABAb receptor cDNA sequences, isolated in Results Chapter One, 
to the X.tropicalis genome will facilitate the elucidation of X.tropicalis GABAb receptor 
exon organisation, and hence an understanding of the structure of x/GABAb receptor pre- 
RNA transcripts. This information could then be used as evidence to support or contend 
an RNA splicing model for the generation of the various x/GABAb receptor transcript 
variants isolated in Results Chapter One.
4.1.4 Comparisons of vertebrate and invertebrate GABAb receptor genes
The x/GABAb receptor cDNAs described in Results Chapter One are the first non­
mammalian vertebrate GABAb receptors to have been cloned and, as such, their 
sequences provide an interesting point of reference, from an evolutionary perspective,
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between the mammalian and invertebrate GABAb receptor sequences already identified. 
Comparison of the human and D.melanogaster GABAB(2) genes demonstrates that many, 
but not all, intron/exon boundary locations are conserved (Martin,S.C et al. 2001). A 
similar analysis of human and D.melanogaster GABAB(i) genes is lacking. Comparison 
between invertebrate and vertebrate GABAb receptor genes might be improved by 
including in the analysis, for the first time, genomic sequence from a non-mammalian 
vertebrate species. In this way, the structure of the X.tropicalis GABAb receptor genes, 
deduced by mapping the X.laevis cDNAs isolated here onto the X.tropicalis genome, may 
provide further insight into the evolution of GABAb receptor genes.
4.1.5 Aims
The principal objective of this chapter is to determine the exon structure of the X.tropicalis 
GABAb receptor genes through mapping of the cDNA sequences isolated in Results 
Chapter One onto X.tropicalis genomic DNA. These structures will then to be used to 
clarify whether the differences observed between mammalian and deduced X.laevis 
GABAb receptor protein sequences derive from a distinct genomic organisation, and to 
test an RNA splicing hypothesis for the generation of the X.laevis GABAb receptor 
transcript variants isolated. A comparison of human, rat, X.tropicalis and D.melanogaster 
GABAb receptor genomic organisation will permit an investigation of the conservation of 
intron/exon boundary locations between vertebrate and invertebrate GABAb receptor 
genes. Finally, comparisons made between GABAB(1), GABAB(2) and GABAbl exon 
organisation will allow an investigation of the relationship between these three genes.
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4.2 Analysis of X.tropicalis GABAb receptor gene structure
4.2.1 Mapping xlGABAB(ij cDNAs to X. tropicalis genomic sequences
The assembled cDNA sequence encoding x/GABAB(ia), shown in Figure 3.6, was used as 
a query to search against the U.S. Department of Energy Joint Genome Institute (JGI) 
X.tropicalis genomic assembly database v4.1 using BLASTN with Blosum62 similarity 
matrix and an Expect threshold value of 1x1 O'5. This search retrieved 32 hits on 
Scaffold_396 between positions 1,023,940 and 1,091,778, corresponding to significant 
alignments between the x/GABAB(ia) cDNA and X.tropicalis genomic sequences. These 
data were used as a guide to locate GABAB(1a) exonic sequences, and intron/exon 
boundary locations in the X.tropicalis GABAb l  gene were identified manually, based upon 
pairwise alignments between Scaffold_396 and x/GABAB(1a) or x/GABAB(1b) cDNA 
sequences. The 5’ EST sequence of the X.tropicalis cDNA clone IMAGE.7663085 
(GenBank accession number: CX845730) was used to map to position of the most 5’ 
GABAB(1a)-specific exon, exon -1a2, and the 5’ EST sequence of the X.tropicalis cDNA 
clone IMAGE:7662364 (GenBank accession number: CX844645) was used to map to 
position of the most 5’ GABAB(1b)-specific exon, exon 1b.
The X.tropicalis GABAB(1) gene was found to contain 23 exons spanning at least 68kb (see 
Figure 4.1A). Intron and exon sizes and the location of intron/exon boundaries are shown 
in Table 9.1. A summary of these data, showing the 5’-donor and 3’-acceptor sequences 
at each splice junction in the X.tropicalis GABAB(1) gene, is shown in Figure 4.1 B. Once 
assembled, the translated exon sequences for x/GABAB(1a) and xfGABAB(1b), deduced from 
Scaffold_396, generate open reading frames homologous to those encoded by the
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x/GABAB(ia) and x/GABAB(ib) cDNAs, shown in Figures 3.5 and 3.6, respectively. 
xfGABAB(1a) and x/GABAB(1a) share 94% nucleotide and 97% amino acid sequence 
identity; xKBABAB(1b) and x/GABAB(1b) share 95% nucleotide and 98% amino acid 
sequence identity.
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Figure 4.1 A. Schematic diagram showing location of the 24 exons (not to scale) in the X.tropicalis 
GABAb(d gene. GABAB(ia)-specific (green) and PAN-GABAe(i) (red) exons are indicated. Introns are 
drawn to scale. B. Table showing location of splice junctions in the X.tropicalis GABAbl gene with the 
corresponding 5’-donor and 3’-acceptor sequences. Exon sequences are in upper case; intron sequences 
are in lower case. 5’-donor and 3’-acceptor dinucleotide motifs in introns are shown in bold.
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4.2.2 Mapping xIGABAB(2) cDNA to X. tropicalis genomic sequences
The cDNA sequence encoding x/GABAB(2), shown in Figure 3.11, was used as a query to 
search against the X.tropicalis genomic assembly database v4.1 using BLASTN with the 
parameters defined in Section 4.2.1. This search retrieved 20 hits on Scaffold_140 
between positions 100,888 and 450,686, corresponding to significant alignments between 
the x/GABAB(2) cDNA and X.tropicalis genomic sequences. Intron/exon boundary 
locations in the X.tropicalis GABAbl gene were identified manually, based upon pairwise 
alignments between Scaffold_140 and the x/GABAB(2) cDNA sequence. The 5’ EST 
sequence of the X.tropicalis cDNA clone IMAGE:7659488 (GenBank accession number: 
CX839001) was used to map the position of the most 5’ exon, exon 1.
The X.tropicalis GABAb(2) gene was found to contain 19 exons spanning at least 346kb 
(see Figure 4.2A). Intron and exon sizes and the location of intron/exon boundaries are 
shown in Table 9.2. A summary of these data, showing the 5’-donor and 3’-acceptor 
sequences at each splice junction in the X.tropicalis GABAb(2) gene, is shown in Figure 
4.2B. Once assembled, the exon sequences for the x/GABAB(2) transcript deduced from 
Scaffold_140 generates an open reading frame homologous to that encoded by the 
x/GABAB(2) cDNA isolated in Results Chapter One. xfGABAB(2) and x/GABAB(2) share 94% 
nucleotide and 97% amino acid sequence identity across the coding region.
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11 133 . . . T T T A T G C A C T g t a a t t g t a t . . . 11 5,035 . . . t g t a t a a a a g G T A A G G A C A T . . .
12 108 . . .G A A G A A A A A G g t g a g t c t t t . . . 12 6,238 . . . t t g c c c t t a g A T T A T C A A A G . . .
13 123 . . . T A A T C T T G A G g t a a g t t a t g . . . 13 55,351 . . . t a t t t t t c a g C C G G A C C C T G .. .
14 111 . . . G C T T C T T A T G g t a a g a g a a a 14 684 . . . c t c t t a a t a g T T G T T T G G G T . . .
15 225 . . .T G T G C C A A A G g t g a g t g a t t . . . 15 3,050 . . . t a c t t t c t a g C T A A T A A C A C . . .
16 183 . . A A T C A C A G A G g t n n n n n n a t . . . 16 3,479 . . . t a t t t t a c a g T G G A C A A A G A . .
17 130 . . .G A C A A T A A A G g t a a t g g g c a . . . 17 1,700 . . . t t a c t t a c a g A T G G T G A G A A . .
18 118 . . .C T C C A G A G C A g t a a g t a t c a . . . 18 6,000 . . . t t c t t c a t a g T A T A C A G A G A . .
19 595
Figure 4.2 A. Schematic diagram showing location of the 19 exons (not to scale) in the X.tropicalis 
GABAb(2) gene. Introns are drawn to scale except where indicated by breaks {//). B. Table showing 
location of splice junctions in the X.tropicalis GABAbl gene with the corresponding 5’-donor and 3’- 
acceptor sequences. Exon sequences are in upper case; intron sequences are in lower case. 5’-donor 
and 3’-acceptor dinucleotide motifs in introns are shown in bold.
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4.2.3 Mapping xlGA B A bl cDNAs to X. tropicalis genomic sequences
The assembled cDNA sequence encoding x/GABABL(a), shown in Figure 3.17, was used 
as a query to search against the X.tropicalis genomic assembly database v4.1 using 
BLASTN with the parameters defined in Section 4.2.1. This search retrieved 13 hits on 
Scaffold_692 between positions 198,727 and 206,659, corresponding to significant 
alignments between the x/GABABL(a) cDNA and X.tropicalis genomic sequences. 
Intron/exon boundary locations in the X.tropicalis GABA bl gene were identified manually, 
based upon pairwise alignments between Scaffold_692 and x/GABABL(a) or x/GABABL(b) 
cDNA sequences. Pairwise alignments identified a splice junction eight nucleotides 
upstream of the initiation codon of x/GABAbl, at position 198,728 on Scaffold_692, 
indicating the existence of an additional 5’ untranslated exon. However, BLASTN 
searches of the X.tropicalis genome using the outstanding 424 nucleotides in the 5’UTR of 
the cloned x/GABABL(b) cDNA retrieve no significant matches. In addition, sequences 
homologous to this region are not generated by exon prediction programmes, such as 
GENESCAN (http://qenes.mit.edu/GENSCAN.html) and GrailEXP
(http://qrail.lsd.ornl.gov/qrailexp/). when using the remaining upstream sequence in 
Scaffold_692 (nucleotides 1 to 198,727) as a query. Characterisation of this untranslated 
region of the x(GABAbl transcript is currently precluded by the absence of any 
homologous X.tropicalis ESTs with which to map onto the genomic DNA, as demonstrated 
by the homology searches performed in Section 3.2.7.
The X.tropicalis G A B A bl gene was found to contain 9 translated exons spanning at least 
8.3kb (see Figure 4.3A). Intron and exon sizes and the location of intron/exon boundaries 
are shown in Table 9.3. A summary of these data, showing the 5’-donor and 3’-acceptor 
sequences at each splice junction in the X.tropicalis GABAbl gene, is shown in Figure
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4.3B. Exonic sequence from the X.tropicalis GABAbl gene contains an open reading 
frame homologous to that encoded by the x/GABABi_(a) cDNA sequence, shown in Figure 
3.17, sharing 87% nucleotide and 85% amino acid sequence identity.
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K- 8,299bp
B Exon Intron Exon
No. Size (bp) 3’-junction 5’-donor No. Size (bp) 3’-acceptor 5’-junction
. . . g t c c c a c a a g C T C A G A A C A T . . .
1 116 . . .G G T G T C C T G G g t a a g g g c a a . . . 1 2,938 . . . t a t c t t g c a g G C G C C A C A G C . . .
2 119 . . .G C A G C A A C A G g t g a g t c g c t . . . 2 175 . . . c a t c t c c c a g G A T A G T G A A G . . .
3 124 . . . C A T C T T C C A G g t c a g t g a t g . . . 3 94 . . . g t t t g c c c a g G T G C G G A T C A . .
4 111 . . .C A A A C G A G T G g t g a g c a a t a . . . 4 1,560 . . . t g c c c c a c a g A T T A T T A A G G . . .
5 126 . . . C A G C A T T A A G g t g a g t a t g g . . . 5 104 . . . a t c c t t c c a g G C G G C T G C T C . . .
6 96 . . . T G G C T T T A A G g t a g g c a t t t . . . 6 196 . . . t t c c t c c c a g G C T G C C C T G C . . .
7 237 . . . C A T T C C A C A G g t a c a g c t g t . . . 7 266 . . . a t a t c t g t a g T T G C T C C A A T . . .
8 159 . . .C C T G T C A G A G g t g a g g a a c c . . . 8 210 . . . t t t c t g a c a g A A A A A T G C C A . .
9 1,668
Figure 4.3 A. Schematic diagram showing location of the 9 exons (not to scale) in the X.tropicalis 
GABAbl gene. Introns are drawn to scale. B. Table showing location of splice junctions in the X.tropicalis 
GABAbl gene with the corresponding 5’-donor and 3’-acceptor sequences. Exon sequences are in upper 
case; intron sequences are in lower case. 5’-donor and 3’-acceptor dinucleotide motifs in introns are
shown in bold.
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4.3 Evaluation of possible alternative splicing mechanisms in X.tropicalis GABAb 
genes
4.3.1 Analysis of the genetic basis for differences between mammalian and xIGABAB(1) 
proteins
The multiple sequence alignment of human, rat, mouse and X.laevis GABAB(ib) protein 
sequences, shown in Figure 3.8, reveals several differences between mammalian and 
x/GABAB(i) proteins. To address whether these differences might occur as a result of 
distinct RNA splicing mechanisms, the nucleotide sequences encoding these regions 
were compared with the X.tropicalis GABAB(i) exon organisation deduced in Section 4.2.1.
Analysis of the multiple sequence alignment in Figure 3.8 shows that x/GABAB(1) proteins 
possess an additional sequence, LSQ, in their second intracellular loop, which is not 
present in the mammalian orthologues. Mapping of the x/GABAB(1b) cDNA sequence, 
shown in Figure 3.5, against the X.tropicalis GABAB(1) gene reveals that these nucleotides 
constitute a 9bp extension of exon 11 at its 3’ end. The equivalent location of the 
mammalian splice junction in x/GABAB(1) lacks the necessary canonical intron dinucleotide 
sequence gt due to the presence of the CTG leucine codon, giving rise to this 9bp 
extension with respect to the mammalian GABAb(1) transcripts. However, analysis of the 
X.tropicalis GABAB(1) gene shows that this dinucleotide sequence is conserved in the 
X.tropicalis orthologue, due to the presence of the GTG valine codon (see Figure 4.1), 
suggesting that xfGABAB(1) proteins may not possess the equivalent additional amino acid 
sequence, VSQ. Since none of the X.tropicalis ESTs identified by homology searches in 
Section 3.2.2 span this region (see Figure 3.4), it is not presently possible to resolve this
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contention and, as such, the X.tropicalis GABAB(d exon 11 is shown in Figure 4.1 with the 
9bp extension, demonstrably present in the x/GABAB(ib) cDNA sequence (see Figure 3.5).
Analysis of the X.tropicalis GABAbl gene reveals that the sequence encoding the 24 
amino acids SDNHFPNSSGAVSSLYQPGLPLAR, present in x/GABAB(i) but not 
mammalian GABAB(i) proteins, and the site of deletion of the amino acid sequence 
RHQLQS, present in mammalian GABAB(1) but not in x/GABAB(1) proteins, are both located 
within exon 18 and are thus not generated by canonical RNA splicing events. The 
possibility that the former sequence is deleted from mammalian GABAB(1) transcripts by a 
cryptic splicing event, thus representing a ‘cryptic intron’, is discounted by the absence of 
this sequence in human or rat genomic DNA. These data demonstrate that alternative 
RNA mechanisms are not responsible for the differences observed between the C-termini 
of mammalian and X.laevis GABAB(1) proteins. This divergence may instead be indicative 
of a lack of functionality of the GABAB(1) C-terminal domain in vertebrates, consistent with 
the observation that deletion of this domain in recombinant hGABAB(1) does not affect 
normal GABAb receptor function (Margeta-Mitrovic.M et al. 2001a).
4.3.2 Analysis of xlGABAB(1a) transcript variants isolated by 5’RACE
The multiple sequence alignment of human, rat, mouse and X.laevis GABAB(1a) protein 
sequences shown in Figure 3.11 reveals that, in addition to the differences discussed in 
Section 4.3.1, x/GABAB(1a) also possesses seven additional amino acids in its N-terminal 
domain that are not present in the mammalian GABAB(1a) orthologues (see Figure 3.7). 
When performing 5’RACE in Section 3.2.4, three alternative cDNA variants encoding the 
N-terminal domain of x/GABAB(1a) were isolated that exhibited variability about this region.
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The assembled x/GABA8(ia) cDNA clone shown in Figure 3.6, termed here x/GABAB(ia) 
variant 1, encodes the fourteen residues VRRSDTSIRHPESS just downstream of its 
second sushi domain. An alternative clone isolated by 5’RACE, termed x/GABAB(ia) 
variant 2, encodes only the latter seven residues, IRHPESS, and an further alternative 
clone, termed x/GABAB(1a) variant 3, does not encode any of these fourteen residues. 
Mapping of cloned x/GABAB(1a) cDNA sequences to the X.tropicalis GABAB(i) gene reveals 
that the latter seven residues, IRHPESS, are encoded by a 21 bp GABAB(1a)-specific exon 
located at position 1,057,404 of Scaffold_396, termed here 1a4j8. However, no significant 
matches are obtained with the X.tropicalis genome when using the 21 bp cDNA sequence 
encoding the first seven residues, termed here exon 1a4cr, as a query. In addition, 
pairwise alignment of exon 1a4or with the 17,843bp X.tropicalis intron -2, downstream of 
exon 1a4/3, does not reveal any region of identity corresponding to an additional putative 
exon. Pairwise sequence alignments between the x/GABAB(1a) exons 1a4cr and 1a4j3 and 
the human GABAB(1a) exon 1a4 sequence indicate that the latter is more closely related to 
exon 1a4cr than exon 1a4/3; GABAB(1a) exon 1a4 shares 38.1% nucleotide and 42.9% 
amino acid sequence identity with x/GABAB(1a) exon 1a4cr, compared with 28.0% 
nucleotide and 37.5% amino acid sequence identity with x/GABAB(1a) exon 1a4/3.
Analysis of the cloned mammalian GABAB(1) transcript variants, summarised in Figure 
1.3A, shows that the presence of two exons at this location, as observed in x/GABAB(1a) 
variant 1, has not been reported previously. x/GABAB(1a) variant 2 contains only one exon 
at this location, analogous to the vast majority of the cloned mammalian GABAB(1a) 
transcript variants, although, intriguingly, it is in possession of the less closely related 
exon 1a4/3. x/GABAB(1a) variant 3 has an identical exon organisation to the rat-specific 
splice variant /GABAB(1f) reported previously (Isomoto.S et al. 1998, Wei,K et al. 2001a), 
lacking both exons 1a4cr and 1a4/3. These data strongly support an alternative RNA
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splicing model for the generation of the cloned x/GABAB(1a) cDNA variants, and suggest 
the presence of the 21 bp exon 1a4cr in intron -2. A multiple sequence alignment, showing 
this region of the cloned X.laevis GABAB(1a) cDNA variants with the corresponding region 
in human and rat GABAB(1a) transcript variants, is shown in Figure 4.4A.
The pairwise sequence alignment, shown in Figure 4.4B, reveals that Xenopus GABAB(ia) 
exons 1a4cr and 1a4/3 are of identical length and share 66.7% nucleotide sequence 
identity. Given that both exons share a similar level of sequence identity with the human 
exon 1a4, these data provide compelling evidence that exons 1a4 and 1a4’ are closely 
related, and may have derived from an exon duplication event. The absence of 
X.tropicalis genomic sequence corresponding to X.laevis exon 1a4cr may be readily 
explained by sequencing errors in the 17,843bp intron -2, which contains several 
stretches of degenerate nucleotide sequence. Analysis of this intron sequence reveals 
multiple consensus sequences for eukaryotic RNA lariat branch points, TACT(A/G)A(T/C), 
suggesting that exonic sequences may be hidden within the degenerate regions of this 
intron sequence (Harris,N.L et al. 1990, Wessagowit.V et al. 2005).
Homology searches conducted in Section 3.2.1 uncovered, six X.tropicalis cDNA clones 
with ESTs sharing sequence identity with the /7GABAB(1a) N-terminus (see Figure 3.2), of 
which only three have sequence spanning the exon 1a4 region. A multiple sequence 
alignment of these ESTs with the assembled X.laevis GABAB(1a) cDNA sequence, 
presented in Figure 4.4C, shows that all of these clones possess both exon 1a4cr and 
1a4j6, analogous to the x/GABAB(1a) variant 1. These data suggest that x/GABAB(1a) variant 
1 might represent the principal isoform expressed in Xenopus, and so this variant was 
used to assemble a full-length x/GABAB(1a) cDNA clone for use in all subsequent 
experiments (see Section 3.5.2).
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Exon 1a4/3
905 TCAGGCGCTCAGATACTTCAA 925
92 6 TCAGGCACCCGGAATCTTCTC 947 
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CX840283 870 ATATGCCCAGTCAGGCGCCCAGATACTTCCATCA------------------- ;---------  903
DN004963 863 ATATGCCAAGTCAGGCGCCCAGATACTTCTATCAGGCACC------------- !---------  902
CX843223 253 ATATGCCAAGl'CAGGCGCCCAGATACTTCAA.'TCAGGCACCCGGAATCTTCAcbTAAGAGAGC 314
x/GABAsfia) 8 95 ATATGTCAAGTCAGGCGCTCAGATACTTCAATCAGGCACCCGGAATCTTCTCGTAAGAGAGC 956
Exon 1a3 Exon 1a4or Exon 1a4/3 Exon 1a
Figure 4.4 A. Multiple sequence alignment of human and rat GABAe(ia)CDNA sequences with the rat 
splice variant GABAe(if). and the three putative x/GABAe(ia) transcript variant cDNAs isolated by 5’RACE, 
spanning exons 1a4a and 1a4/3. B. Pairwise sequence alignment of X.laevis exons 1a4a and 1a4/3 
showing shared sequence identity. C. Multiple sequence alignment showing three X.tropicalis ESTs, 
spanning exons 1a4cr and 1a4j6, with the corresponding region in the cloned x/GABAe(ia)CDNA sequence. 
Nucleotide sequences were aligned using ClustalW alignment program with Blosum similarity matrix and 
standard alignment parameters: Open Gap Penalty = 100, Extend Gap Penalty = 0.5.
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4.3.3 Analysis ofxlGABABL transcript variants isolated by 5’RACE
In Section 3.4.3, 5’RACE was carried out to isolate upstream x/GABABl exons missing 
from the partial cDNA clone XL024m02. Using this method a x/GABABl transcript was 
isolated, termed x/GABABL(b), which encoded a truncated GABAbl N-terminus predicted to 
contain only a single transmembrane domain (see Figure 3.16). An additional GABAbl 
cDNA, which encoded a seven-transmembrane protein orthologous to mammalian 
GABAbl receptors when assembled with the XL024m02 clone, was subsequently isolated 
by RT-PCR, and termed x/GABABL(a). Alignment of x/GABABL(a) and x/GABABL(b) protein 
sequences, in Figure 3.18, indicated that the x/GABABL(b) isoform lacked a 262 amino acid 
region containing transmembrane domains l-VI. It was hypothesised that this deletion 
might derive from an RNA splicing event and so an analysis was carried out in order to 
identify putative splice junctions that might give rise to the cloned x/GABABL(b) transcript 
variant.
Analysis of the X.tropicalis GABAbl exon organisation, summarised in Figure 4.3, 
indicates that the putative splice junctions required to generate the x/GABABL(b) transcript 
would reside within exons 1 and 7 (see Figure 4.5A), and would thus also contain putative 
5’-donor and 3’-acceptor intron sequences, respectively. Surprisingly, alignment of 
x/GABABL(a) and x/GABABL(b) cDNA sequences reveals that there are five possible sites 
within exons 1 and 7 where potential intron/exon boundaries could be located, due to the 
presence of the repeated sequence TGAT at this location in both exons (see Figure 4.5B). 
The five possible 5’-donor and 3’-acceptor intron sequences generated by these boundary 
locations are shown in Figure 4.5C. Consensus sequences at mammalian canonical and 
non-canonical splice junctions are shown in Figure 4.5D, showing the approximate 
percentage abundance in mammalian genomes as estimated by Burset.M et al. 2000.
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Comparison of these two figures reveals that, of the five possible boundary locations 
shown in Figure 4.5C, none would generate the dinucleotide motifs found in canonical and 
non-canonical 5’-donor and 3’-acceptor sites and, as such, it is not possible to accurately 
assign a putative splice junction with the available information. These data suggest that, 
should the x/GABABL(b) transcript exist in vivo, it might be generated by a cryptic RNA 
splicing event (Wessagowit.V et al. 2005). Intriguingly, despite the absence of the 
expected dinucleotide motifs known to be of primary importance at splice junctions, the 
predicted 3’-acceptor sequences shown in Figure 4.5C each possess a run of pyrimidines 
immediately upstream of the putative splice junction, and thus exhibit compelling 
homology to the 3’-acceptor consensus sequence found at canonical GT-AG splice 
junctions. Should the x/GABABL(b) transcript indeed be generated by cryptic RNA splicing 
in vivo, it is possible that splicosome machinery might be targeted to this location by virtue 
of this sequence.
These data strongly suggest that, unlike the x/GABAB(1a) transcript variants isolated in this 
project (see Section 4.3.2), the x/GABABL(b) transcript encoding a truncated GABAbl 
receptor protein is not generated by canonical RNA splicing, casting doubt as to the 
physiological relevance of this isoform. Whilst the expression of this transcript variant in 
vivo cannot be ruled out, it is perhaps more likely that the isolation of this cDNA by 
5’RACE occurred as a result of a cloning artefact, as discussed in Section 4.7.2.
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Figure 4.5 A. Schematic diagram of x/GABAbl and x/GABABL(b) coding sequences showing locations of 
exons and principal protein domains. The locations of putative splice junctions necessary for generation of 
x/GABABL(b> transcript variant are indicated (A). B. Alignment of x/GABAbl and x/GABAblo?) cDNA 
sequences showing five possible locations of the splice junctions in exon 1 and exon 7. C. Table showing 
5’-donor and 3’-acceptor sequences at the five possible splice junctions. D. Diagram showing consensus 
sequences at canonical (*) and non-canonical splice junctions, showing approximate percentage 
abundance in mammalian genomes. Exon sequences are in upper case; intron sequences are in lower 
case. 5’-donor and 3’-acceptor dinucleotide motifs in introns are shown in bold.
M= A or C, R/r= G/g or A/a, y= t or c, n= any nucleotide.
180
4.4 Comparisons between mammalian, invertebrate and X.tropicalis GABAb genes
4.4.1 Analysis o f intron and exon sizes in vertebrate and invertebrate GABAb genes
Analysis of the exon organisation of the X.tropicalis GABAb genes, deduced in Section 
4.2, indicates that there are differences in the number of exons compared with their 
mammalian and invertebrate counterparts. To aid direct comparison between these 
genes, tables of values were produced listing the intron and exon sizes and locations 
within human, rat, X.tropicalis and D.melanogaster GABAB(1)> GABAb(2), and GABAbl 
genomic sequences (see Sections 9.1, 9.2 and 9.3). Exon sizes for human GABAB(1) and 
GABAB(2) genes, and the D.melanogaster GABAB(2) gene have been reported previously 
(Goei.V.L et al. 1998, Grifa.A et al. 1998, Peters,H.C et al. 1998, Martin,S.C et al. 2001), 
but not for rat GABAB(1) and GABAB(2), D.melanogaster GABAB(1), or any GABAbl genes. 
The Ensembl Genome Browser (www.ensembl.org). a relational database that 
automatically annotates cloned eukaryotic genes, was used as a primary source to 
identify genomic sequences and act as a guide to locate exonic sequence. However, all 
intron and exon sizes were verified by pairwise alignments between cDNA and genomic 
DNA sequences.
Ensembl gene ID and GenBank accession numbers for the genomic sequences identified:
H.sapiens GABAB(1): ENSG00000204681, AL645936.5 
H.sapiens GABAB(2): ENSG00000136928, AL353782.23 
H.sapiens GABAbl: ENSG00000175697, AC092897.6 
R.norvegicus GABAB(1): ENSRNOG00000000774, AABR03116854.1 
R.norvegicus GABAB(2): ENSRNOG00000008431, AABR03040519.1 
R.norvegicus GABAbl\ ENSRNQG00000002797, AABR03081639.1
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D.melanogaster GABAB(1): CG15274-RA (Flybase Gene ID), NT_033779.4 
D.melanogaster GABAB(2): CG6706-RB (Flybase Gene ID), NT_033777.2
Initial analysis of the data indicates that, whilst exon sizes in the human, rat and 
X.tropicalis GABAB(1) genes are very similar, many of the introns in the X.tropicalis gene 
are significantly longer that their mammalian counterparts. A notable example is the 
GABAB(iarspecific intron -2, postulated to contain an additional exon termed 1a4cr, which 
is around 15 times longer than the comparable human or rat intron sequence. In contrast, 
except for the presence of an additional untranslated exon at its 5’ end, and the proposed 
exon 1a4or, the X.tropicalis GABAB(1) gene exhibits an identical exon organisation to that of 
the human and rat GABAB(1) genes. The D.melanogaster GABAB(i} gene, however, 
exhibits dissimilarity to its vertebrate counterparts and contains just 15 exons, compared 
with the 23 and 24 encoded by mammalian and X.tropicalis GABAB(1) genes respectively. 
The D.melanogaster GABAB(1) gene also contains much shorter intronic sequences, and 
10 of its 14 introns are less than 100bp in length.
The X.tropicalis GABAB(2) gene has an exon organisation identical to that of its human and 
rat counterparts, and also exhibits a very similar average intron length of 19,255bp, 
compared with 23,074bp and 20,280bp for the human and rat GABAB(2) genes 
respectively. The D.melanogaster GABAB(2) gene, however, has a dissimilar gene 
organisation compared to its vertebrate counterparts and contains just 12 exons, 
compared with the 19 encoded by the vertebrate GABAB(2) genes. As with the 
corresponding GABAB(1) gene, D.melanogaster GABAB(2) contains much shorter introns 
than the orthologous vertebrate genes, with an average length of just 128bp.
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The X.tropicalis GABAbl gene has an exon organisation identical to that of its human and 
rat counterparts, containing 9 exons. In contrast, the average intron size for the 
X.tropicalis GABAbl gene is much smaller than that of its vertebrate counterparts at just 
693bp, compared with 9,328bp and 7,802bp for the human and rat GABAbl genes 
respectively.
4.4.2 Alignment and comparison of vertebrate and invertebrate GABAb exons
Using the data in Sections 9.1-3, figures were produced to facilitate the direct comparison 
of vertebrate and invertebrate GABAb exon organisation. Using the H.sapiens genomic 
sequences as a reference, pairwise sequence alignments were carried out to determine 
the percentage sequence identity shared with the corresponding exons in the 
R.norvegicus, X.tropicalis and D.melanogaster GABAb genes. Schematic diagrams 
showing the exon organisation of the GABAB(i), GABAB(2) and GABAbl genes, and the 
sequence identity shared with the human orthologue in each case, are presented in 
Figures 4.6, 4.7 and 4.8 respectively.
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Figure 4.6 Schematic diagram showing the exon organisation of the human (h), rat (r), X.tropicalis (xf) and D.melanogaster (d) GABAb( v genes, showing GABAadar 
specific (green) and GABAB(ib)-spec\f\c (red) exon sequences in the vertebrate genes. Coding exon sequences are shown in dark colour, untranslated regions are 
shown in lighter colour. Exons are drawn to scale, introns are not. Percentage sequence identity shared between the rat, X.tropicalis or D.melanogaster GABAam 
sequences and the human GABAan) (reference) sequence is shown across the coding regions indicated. Scale bar shown corresponds to 1000bp.
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Figure 4.7 Schematic diagram showing the exon organisation of the human (/?), rat (r), X.tropicalis (xf) and D.melanogaster (d) GABAbl genes. Coding exon 
sequences are shown in dark grey, untranslated regions are shown in lighter grey. Exons are drawn to scale, introns are not. Percentage sequence identity shared 
between the rat, X.tropicalis or D.melanogaster GABAbl sequences and the human GABAB(2) (reference) sequence is shown across the coding regions indicated.
Scale bar shown corresponds to 1000bp.
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Figure 4.8 Schematic diagram showing the exon organisation of the human (h), rat (r) and X.tropicalis {xt) 
GABAbl genes. Coding exon sequences are shown in dark grey, untranslated regions are shown in lighter 
grey. Exons are drawn to scale, introns are not. Percentage sequence identity shared between the rat or 
X.tropicalis GABAbl sequences and the human GABAbl (reference) sequence is shown across the coding 
regions indicated. Scale bar shown corresponds to 1000bp.
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4.5 Investigating synteny of the GABAbl gene
4.5.1 Identification of genes neighbouring GABAbl in human, rat and X. tropicalis
genomic sequences
Analysis of the cDNAs isolated in Results Chapter One showed that the proteins encoded 
by the cloned x/GABAB(1a), x/GABAB(1b> and x/GABAB(2) transcripts exhibit striking homology 
to their mammalian orthologues, sharing 76%, 78% and 82% amino acid identity with 
human GABAB(1a), GABAB(1b) and GABAB(2) proteins respectively. In contrast, the protein 
encoded by the cloned x/GABABL(a) cDNA exhibits markedly lower homology to its 
mammalian orthologues, sharing just 38% amino acid sequence identity with the human 
GABAbl protein. The low sequence identity between hGABABL and x/GABABL(a) may 
indicate that the latter transcript is derived from a related, yet distinct, gene, which may 
perform a separate function. To determine whether the cloned x/GABABL(a) cDNA is 
encoded by the true orthologue of the mammalian G ABAbl genes, the genes neighbouring 
the GABAbl gene in human, rat and X.tropicalis genomic sequences were identified and 
compared. Human, rat and X.tropicalis GABAbl cDNAs were mapped onto H.sapiens 
chromosome 3, region q12.33, R.norvegicus chromosome 11, region q21, and X.tropicalis 
Scaffold_692 respectively.
The H.sapiens G A B A bl gene is found at positions 121362775-121445877 of chromosome 
3, region q13.33, and has 5’ flanking genes encoding the nuclear receptor subfamily 1, 
group 1, member 2 (NR1I2) at positions 120984236-121020021, and glycogen synthase 
kinase-3(3 (GSK-3/3) at positions 121028238-121295954, and 3’ flanking genes encoding 
leucine rich repeat containing protein 58 (LRRC58) at positions 121531624-121550876,
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and follistatin-like protein 1 (FSTL1) at positions 121595817-121652533. The 
R.norvegicus GABAbl gene is found at positions 64506980-64571771 of chromosome 11, 
region q21, and has 5’ flanking genes encoding NR1I2 at positions 64239917-64276701, 
and GSK-3/3 at positions 64284731-64428698, and 3’ flanking genes encoding LRRC58 at 
positions 64637642-64646930, and FSTL1 at positions 121,595,817-121,652,533. The 
X.tropicalis GABAbl gene is found at positions 198728-207026 of Scaffold_692, and has 
5’ flanking genes encoding NR112 at positions 289804-295904, and GSK-3/3 at positions 
215590-280575, and 3’ flanking genes encoding LRRC58 at positions 184567-188993, 
and FSTL1 at positions 158107-168651.
These data strongly suggests that the x/GABABL(a) cDNA clone, shown in Figure 3.17, was 
transcribed from the gene representing the true Xenopus orthologue of mammalian 
GABAbl genes, due to the highly conserved synteny of this gene across the species, and 
thus presumably encodes a protein of similar or identical function.
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A H.sapiens
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3q12.33
NR1I2 GSK-3/3 GPR156 LRRC58 FSTL1
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Figure 4.9 Schematic diagram showing approximate location of genes (light grey) neighbouring the 
GABAbl (GPR156) gene (yellow) in A. human, B. rat, and C. X.tropicalis genomic sequences. Genes are 
given their official symbols here to aid comparison between the species.
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4.6 Comparisons of GABAB(d, GABAB(2), and GABAbl gene organisation
4.6.1 Identification and alignment of corresponding exons found in the H.sapiens
GABAB(i), GABAB(2), and GABAbl genes
The human and rodent GABAbl cDNAs cloned previously were reported to share 
sequence identity with GABAB(i) and GABAB(2) and encoded several similar features, 
including a seven-transmembrane domain and coiled-coil motif (Calver,A.R et al. 2003). 
Analysis of GABA bl gene organisation was, however, lacking, and exon and intron sizes 
and locations in mammalian and X.tropicalis GABAbl genes is reported here for the first 
time (see Sections 4.2.3 and 4.4.1). In an effort to gain further insight into the relationship 
between the GABAB(i), G A B A b l  and GABA bl genes, comparisons were made within the 
exons encoding the regions sharing sequence identity to determine whether the 
intron/exon boundary locations and exon sizes were also conserved between these three 
genes. The results of these comparisons are presented in Figure 4.10.
Analysis of these data reveals that the GABAB(i), GABAb l  and GABAbl genes share 
multiple intron/exon boundary locations and exhibit similar exon sizes across the region 
encoding the seven-transmembrane and coiled-coil domains. Pairwise sequence 
alignments between these corresponding exons also reveal that GABAbl shares a 
percentage nucleotide sequence identity with GABAbl (37%) and GABAB(2) (39%) similar 
to that shared between GABAB(i) and GABAb l  (44%) across this region. The GABAbl 
and GABAB(2) genes share the same number of exons across this region, whereas 
GABAb l  contains an additional exon. However, the GABAB(i) and GABAbl genes exhibit 
a more similar exon organisation at their 3’ end and share the same terminal exon, albeit
190
with the termination codon occurring much earlier in GABAB(i) exon 18 than in the 
corresponding G A B A bl exon 9.
In summary, these data show that the GABAbl gene is closely related to the GABAB(i), 
GABAB(2) genes and shares both significant nucleotide sequence identity and similar exon 
organisation across the region encoding the seven-transmembrane, coiled-coil and C- 
terminal protein domains, suggesting that GABAB(i), GABAB(2) and GABAbl most likely 
derive from a common ancestral gene. Whilst GABAB(2) and GABAbl are marginally more 
closely related than GABAB(i) and GABA bl in terms of sequence identity, the latter two 
genes exhibit a more similar 3’ exon organisation and, as such, it is difficult to hypothesize 
which of the G A B A b genes G A B A bl may have descended from based upon this 
information. Perhaps most importantly, the GABAbl gene does not contain 5’ exons, 
found in both the GABAB(i) and GABA bl genes, which encode an N-terminal PBP-like, or 
‘venus-flytrap’, domain. This domain is characteristic of almost all other Family 3 GPCRs 
and is identified as the site of ligand-binding for the GABAb receptor (Malitschek.B et al. 
1999), the metabotropic glutamate receptors (mGluRs) (O’Hara,P.J et al. 1993), the 
calcium-sensing receptor (CaSR) (Brauner-Osborne.H et al. 1999b), and the promiscuous 
L-a-amino acid receptor, GPRC6A (Wellendorph.P et al. 2005). The absence of an N- 
terminal venus-flytrap domain in the GABAbl protein implies that, should it bind 
endogenous ligands, it would do so in a manner unlike other Family 3 GPCRs, perhaps by 
means of a hydrophilic pocket formed by its transmembrane domains, analogous to 
Family 1a GPCRs. Alternatively, and perhaps more likely, GABAbl may be a non ligand- 
binding partner in a hitherto unidentified receptor hetero-oligomer, modulating downstream 
signalling cascades in response to ligand-binding to an associated receptor, analogous to 
its most closely related cousin, GABAB(2).
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Figure 4.10 Schematic diagrams showing exon organisation across corresponding regions of H.sapiens 
A. GABAb(1) and GABAb(2), B. GABAbci) and GABAbl> 3nd C. GABAb(2) 3nd GABAbl genes. 
Coding exon sequences are shown in dark grey, untranslated regions are shown in lighter grey.
Exon sizes fbp) are shown above or below each exon. Exons are drawn to scale, except where indicated 
by breaks {//). Introns are not drawn to scale. Percentage sequence identity shared between the regions 
indicated is shown. Scale bars shown correspond to 200bp.
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4.7 Discussion
In this chapter, the X.laevis GABAb receptor cDNA sequences isolated in Results Chapter 
One were mapped onto the X.tropicalis genome and the exon organisation of the 
X.tropicalis GABAB(i), GABAB(2) and GABAbl genes was determined. These gene 
structures were then used to evaluate the mechanisms by which the x/GABAB(ia) and 
x/GABAbl transcript variants isolated may have been generated. Comparisons were 
made between mammalian, invertebrate and X.tropicalis GABAb exon organisation, 
revealing a high level of conservation between the vertebrate genes, and a comparison 
was also made between the structure of the human GABAB(1)i GABAB(2) and GABAbl 
genes. Key findings from the data presented in this chapter are evaluated below.
4.7.1 X.tropicalis GABAb genes have a similar exon organisation to mammalian 
GABAb genes
The sizes and locations of exons and introns found in the X.tropicalis GABAB(1), GABAB(2) 
and GABAbl genes are reported here for the first time and exhibit many similarities to their 
human and rat counterparts. X.tropicalis GABAB(2) and GABAbl possess an identical 
number of exons to human and rat GABAB(2) and GABAbl genes and share very similar 
exon sizes. The structure of the X.tropicalis GABAB(1) gene is similar, with the exception 
of an additional 5’-untranslated exon, -1a2, which is not found in mammalian GABAB(1) 
genes, and the proposed existence of two closely related Xenopus-specific 21 bp exons, 
analogous to mammalian GABAB(ia) exon 1a4, termed here 1a4or and 1a4/3. These data
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indicate that, whilst GABAb exon organisation is highly conserved, the Xenopus GABAB(i) 
gene possesses unique exons not previously identified in mammals.
Intron sizes in GABAb genes are generally not well conserved between the species, 
although corresponding introns in human and rat GABAb genes are often related in size. 
The average intron size in the X.tropicalis GABAB(1) gene is longer than that of its 
mammalian counterparts. In contrast, introns are comparatively smaller in the X.tropicalis 
GABAbl gene, and of a similar size in the X.tropicalis GABAB(2) gene, compared with the 
human and rat orthologues. Intron sequences in D.melanogaster GABAB(1) and GABAB(2) 
genes are generally much smaller than those found in their mammalian counterparts. 
These data suggest that, whilst invertebrate intron sequences tend to be shorter, there is 
no consistent rule to describe the differences observed between mammalian and non­
mammalian vertebrate intron sizes.
4.7.2 Evidence supporting the existence ofxlGABAB(1a) splice variants but not the 
xlGABABL(b) transcript variant
Mapping of x/GABAB(1a) cDNA sequences to the X.tropicalis genome suggests the 
existence of two closely related GABAB(ia)-specific exons termed here 1a4or and 1a4/3. 
Whilst the exon 1a4a sequence cannot presently be found in X.tropicalis genomic 
sequences, this exon is demonstrably present in both x/GABAB(1a) cDNA isolated here and 
in 5’ ESTs belonging to putative xfGABAB(1a) cDNA clones, providing compelling evidence 
for the existence of this distinct exon. Exon 1a4cr is predicted to reside within the 
17,843bp X.tropicalis intron -2, which contains several degenerate sequences that most 
likely derive from sequencing errors. Analysis of this intron sequence reveals multiple
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consensus sequences for eukaryotic RNA lariat branch points, suggesting that exonic 
sequences may be hidden within the degenerate regions of this intron sequence. Future 
revisions of the X.tropicalis genome may reveal the identity of these nucleotide sequences 
and uncover the 21 bp exon 1a4cr sequence within this intron.
Whilst the existence of exon 1a4cr in X.tropicalis genomic DNA is not directly 
demonstrated, further evidence to support the notion that 1a4cr and 1a4/3 are distinct 
exons is provided here through the isolation of three distinct x/GABAB(ia) transcript 
variants, 1, 2 and 3, containing either the two exons 1a4cr and 1a4j8, 1a4/3 alone, or 
containing neither exon. Analysis of the cloned mammalian GABAB(i) transcript variants, 
summarised in Figure 1.3A, shows that alternative splicing of the GABAB(1) gene at exon 
1a4 has been reported previously, since the skipping of this exon is responsible for the 
deletion of 7 amino acids in the rat-specific rGABAB(1f) protein isoform (Isomoto.S et al. 
1998, Wei,K et al. 2001a). Taken together, these data suggest that the 1a4or nucleotide 
sequence represents a bona fide exon that is alternatively spliced in the X.tropicalis 
GABAbl gene, and does not occur as a result of ‘slippage’ during transcription. The 
identical size and high level of sequence identity shared between exons 1 a4cr and 1 a4/3 
strongly suggests that the two are closely related, and it is postulated here that they may 
have derived from an exon duplication event during evolution. This phenomenon appears 
to be unique to the Xenopus GABAB(1) gene and constitutes the first time an additional 
translated exon has been discovered in any vertebrate GABAb gene.
The amino acids encoded by exon 1a4 are of unknown function, but it is postulated here 
this sequence might represent a ‘linker’ peptide connecting the sushi domains and PBP- 
like domain. Variability in the length of this peptide, occurring as a result of the alternative 
splicing of exon 1a4 proposed here, and demonstrated previously (Isomoto.S et al. 1998,
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Wei.K et al. 2001a), might modulate the function of the sushi domains in the GABAB(1a) 
protein by bringing them closer or further away from the ligand-binding domain. Whilst the 
role of the sushi domains in GABAB(ia) remains unidentified, however, the significance of 
the variability of exon 1a4 remains unclear.
Comparison of the x/GABABL(a) and x/GABABL(b) cDNAs, shown in Figures 3.17 and 3.16 
respectively, with the X.tropicalis G ABA bl exon organisation deduced here, did not 
provide evidence to support the generation of the latter variant through canonical RNA 
splicing mechanisms. The presence of a run of pyrimidines in X.tropicalis GABAbl exon 7, 
analogous to a canonical intron 3’-acceptor sequence, does add some credibility to the 
notion of a cryptic splice site at this location. However, the requirement for RNA splicing 
to occur at two cryptic sites in order to generate this transcript makes its proposed 
existence in vivo highly controversial, and thus without additional evidence of endogenous 
expression of x/GABABL(b), a physiological role seems unlikely.
It is perhaps more likely that this transcript represents an artefact of the cDNA synthesis 
carried out as the initial phase of the 5’RACE method used to isolate it. Analysis of 
possible locations for the putative splice junctions required to generate this transcript in 
vivo revealed the presence of a short repeated sequence, TGAT, at both sites. 
Intriguingly, similarly repeated sequences, CCAC and ACAGA, were found at the putative 
splice junctions required for the mammalian GABAB(2b) and GABAB(2C) transcripts isolated 
previously, which were also discounted as artefacts of cDNA synthesis (Clark,J.A et al 
2000, Martin,S.C et al. 2001).
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4.7.3 Evidence fora relationship between GABAB(i), GABA b l  and GABAbl genomic 
organisation
The proteins encoded by the mammalian GABAbl cDNAs isolated previously, and the 
x/GABAbl transcript variants isolated here, exhibit features known to be of importance to 
GABAb receptor functions. The identity shared between GABAB(i), GABAB(2) and GABAbl 
sequences indicate that their genes are related and might share a similar genomic 
organisation. The results shown here demonstrate that, whilst the GABAbl gene lacks 5’ 
exons encoding a venus-flytrap domain, it exhibits a similar exon organisation to GABAb 
genes across the sequences encoding the seven-transmembrane domains, coiled-coil 
motif and C-terminal tail. These data provide evidence .to suggest that GABAB(i), GABAB(2) 
and GABAbl derive from a common ancestral gene, and the absence of an invertebrate 
GABAbl orthologue indicates that G ABA bl may have diverged from the GABAb genes 
during the evolution of vertebrates.
4.7.4 Summary
The data presented in this chapter show that the organisation of exons in GABAB(i), 
GABAB(2) and G A B A bl genes is highly conserved in the vertebrate species analysed here. 
Mapping of the x/GABAB(ia) cDNA sequence shown in Figure 3.6 onto the X.tropicalis 
genome, however, uncovered an additional 5’ untranslated exon in the X.tropicalis 
GABAB(i) gene that is not found in mammalian GABAB(i) genes, and indicated that an a 
hitherto unreported translated 21 bp exon may reside within intron -2. Analysis of the 
deduced X.tropicalis GABAB(i) and G ABA bl gene structures provided evidence to support 
a canonical RNA spicing model for the generation of three x/GABAB(ia) N-terminal
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transcript variants shown in Figure 4.4, but not for the truncated x/GABAbl transcript 
variant shown in Figure 3.16, termed x/GABABL(b), casting doubt on the physiological 
significance of the latter. Comparison of the genomic sequences flanking human, rat and 
X.tropicalis GABAbl genes revealed that the synteny of this gene is highly conserved in 
these vertebrates, providing evidence to suggest that the protein encoded by the 
x/GABABL(a) cDNA shown in Figure 3.17 represents the true X.laevis orthologue of 
mammalian GABAbl proteins, despite the relatively low amino acid sequence 
conservation between the species. Finally, the pairwise sequence alignments made here 
between human GABAB(1), GABAB(2) and GABAbl exon sequences show that these genes 
have a related genomic organisation, suggesting that they may derive from a common 
ancestral precursor.
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Results
Chapter Three
Temporal and spatial expression patterns of GABAb receptor 
mRNAs during Xenopus laevis embryonic development
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5.1 Introduction
5.1.1 Background
In order to gain a better understanding of the role of X.laevis GABAb receptors, the 
expression pattern of x/GABAb receptor genes was investigated during development. 
Data accompanying the x/GABAb receptor ESTs identified by homology searches (see 
Tables 3.1, 3.3, 3.9 and 3.13) included information regarding the source of mRNA used to 
generate cDNA libraries from which the ESTs derive, providing insight into where and 
when x/GABAb receptor transcripts can be found. However, a detailed understanding of 
the spatial and temporal expression pattern of x/GABAb receptors is not possible without 
the use of sensitive molecular methods designed to detect x/GABAb receptor gene 
products in the developing embryo.
Several techniques are available to today’s researcher to detect mRNA, offering a range 
of sensitivity, versatility and easy of use. Reverse transcriptase PCR (RT-PCR) is a 
versatile method that involves the conversion of mRNA to complementary DNA (cDNA), 
by an RNA-dependent DNA polymerase, from which specific DNA sequences may be 
amplified by PCR. Unlike northern analysis, RT-PCR requires only very small quantities 
of mRNA and can be used to obtain partial or full-length cDNA clones or detect the 
presence of specific transcripts in RNA preparations, even when they are of particularly 
low abundance. Although the use of RT-PCR to measure gene expression is widespread, 
accurate quantification is technically complex due to the numerous enzymatic steps 
involved and the associated variability between individual reactions. When quantification 
is not strictly necessary, researchers frequently adopt internal controls for RT-PCR, such
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as the concomitant amplification of an unrelated endogenous mRNA from within the same 
RNA sample. Whilst such controls are not ideal, there are adequate to demonstrate the 
activity of the assay, and RT-PCR remains an appropriate method for analysing gene 
expression.
Whilst northern analysis and RT-PCR are capable of providing some information 
regarding the spatial expression pattern of specific gene products, through analysis of 
RNA sourced from distinct tissues, techniques such as in situ hybridization and 
immunohistochemistry provide unrivalled insight as to the location of gene products in a 
particular tissue, through detection of specific mRNAs or protein in situ. The former 
method involves the hybridization of a labelled antisense cRNA probe, typically 
transcribed from a plasmid vector, to endogenous mRNAs present in the tissue of interest, 
and subsequent visualisation by means of colorimetric, fluorescent or auto-radiographic 
analysis. With the development of wholemount protocols in recent years (see 
Harland.R.M 1991) in situ hybridization has emerged as the method of choice among 
researchers aiming to uncover spatial mRNA expression patterns in developing Xenopus 
embryos.
5.1.2 Aims
The aim of this chapter was to use a combination of the RT-PCR and in situ hybridization 
techniques discussed here to uncover the temporal and spatial expression patterns of 
x /GABAb receptor transcripts in the developing embryo.
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5.2 Temporal expression patterns of x /GABAb receptor mRNAs during embryonic 
development
5.2.1 Detection of xIGABAb receptor mRNAs by RT-PCR and Southern blotting
The identification of x/GABAe receptor ESTs in Results Chapter One (see Tables 3.1, 3.3, 
3.9 and 3.13) permitted the design of x/GABAb receptor-specific oligonucleotide primers. 
However, upon the cloning and sequencing of the full-length x/GABAb receptor cDNAs, 
shown in Figures 3.5, 3.6, 3.11, 3.16 and 3.17, it became possible to design primer pairs 
capable of distinguishing between distinct transcript variants. These primer pairs could be 
used to detect the presence of x/GABAB(1a), x/GABAB(1b), x/GABAB(2), x/GABABL(a) and 
x/GABABL(b) transcripts in RNA preparations by RT-PCR.
Total RNA was extracted from embryos a t a range of developmental stages, as described 
in Section 2.1.8, including blastulae (stages 5 and 7), gastrulae (stages 9 and 12), 
neurulae (stage 17) and from tailbud (stages 22, 26, 32, 36) and tadpole (stage 40) 
embryos. RT-PCR was performed as described in Section 3.1.10, using the 
oligonucleotide primers and optimal annealing temperatures shown in Table 5.1. The 
DNA fragments amplified by RT-PCR are shown in Figure 5.2.
In order to verify the identity of the fragments amplified by RT-PCR, DNA was transferred 
to nylon membranes by Southern blotting and analysed using radiolabelled probes, as 
described in Section 2.1.24. The hybridized DNA fragments are shown in Figure 5.3.
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Transcript Primers Nucleotide Sequence
Loc
(bp)
Size
(bp) °C
x/GABAs(ia) xGB1 a-AMP-fwdO 
xG B1 a/b-AM P-revO
5'-CGTGAGATTTCTGGTCCCAAAG-3' 
5'-ACATTCTTGCTGCTTCTGCCAC-3'
637
1228
592 57.2
x/GABAe(ib) xGB1 b-AMP-fwdO 
xGB1 a/b-AM P-revO
5'-CCACCACTTTCGCTGCCTTC-3'
5 ' -ACATTCTTGCTGCTTCTGCCAC-3'
398
880
483 57.4
x /GABAb(2) xGB2-SEQ-fwd3
xGB2-SEQ-rev4
5 ' -GCAGAACCTCCAAAAGATGAAACC-3 
5 ' -GGCACAAAAACAAGACAGAGTG-3'
1378
2222
845 53.2
x /GABAq L(a> xGBL-SEQ-fwd4
xGBL-SEQ-rev5
5 ' -AACCCTGCTGAGTCTTGTG-3' 
5 ' -TGGTCATTTGTGTGCTCTG-3'
518
1017
500 55.1
x /GABAb L(b> xGBL-1TM-AM P-fwd 1 
xGBL-SEQ-rev2
5'-GAACAGCCACATTGATTGG-31 
5'-TGCTGGTAATGGGCTTTAG-3'
464
1174
711 54.1
x/ODC xODC-fwd1
xODC-rev1
5'-CAGCTAGCTGTGGTGTGG-3'
5'-CAACATGGAAACTCACACC-3'
674
883
228 53.1
Table 5.1 Summary of oligonucleotide primers used for RT-PCR. Binding loci (bp), amplicon sizes (bp) 
and annealing temperatures used (°C) are shown. Optimum °C were calculated using MacVector 7.2 
(Accelrys), expect for x/ODC primers (see Agius.E. et al. 2000).
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12 17 22 26 32
x/GABAe(ia)
x/GABA8(ib)
x /G A B A b(2)
x /G A B A blo)
x/GABAeLfb)
x/ODC
36 40 5 12 26 40
-RT -RT -RT -RT
Figure 5.2 DNA fragments generated by RT-PCR from reverse-transcribed total RNA from stage 
5,7,9,12,17,22,26,32,36 and 40 embryos, showing -RT controls for stages 5, 12, 26 and 40.
5 7 9 12 17 22 26 32 36 40 5 12 26 40
-RT -RT -RT -RT
M  592bp 
M  403bp
M  483bp 
M  845bp 
500bp 
M  711 bp 
M  228bp
Figure 5.3 Southern blot analysis of RT-PCR amplification products shown in Figure 5.2
x/GABAe(ia)/(ic)
x/GABAi
x/GABA,
x/GABABL(a)
x/GABABL(b>
x/ODC
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5.2.2 xlGABAB(i) receptor subunit mRNAs exhibit distinct temporal expression 
patterns during X.laevis embryonic development
Analysis of the data shown in Figure 5.2 reveals that, whilst fragments corresponding to 
x/GABAB(ia) were not visualised on the ethidium bromide gel in any of the stages tested, 
x/GABAB(ib) transcripts are readily detected by RT-PCR in from late neurulation (stage 17) 
onwards. Southern blot analysis, which was used to confirm, by hybridization, that the 
amplified fragments corresponded to the predicted gene products, indicated that 
x/GABAB(1b) transcripts could also be detected at stage 12 (see Figure 5.3). Using a 
x/GABAB(1a)-specific probe, two distinct fragments were identified by Southern analysis. 
These were estimated to be approximately 600bp and 400bp in length and were detected, 
at stages 9, 26, 32, 36 and 40, only after prolonged exposure to photographic film (see 
Figure 5.3). Whilst the larger fragment appears to correspond to the expected 592bp 
x/GABAB(1a) amplicon, the smaller fragment does not appear to correspond to any of the 
x/GABAB(1) transcript variants isolated in Results Chapter One. However, analysis of the 
X.tropicalis GABAB(i) gene organisation, shown in Figure 4.1, reveals that deletion of the 
189bp exon 1a3 would yield a x/GABAB(1) transcript from which a 403bp fragment could be 
amplified by RT-PCR using the same x/GABAB(1a)-specific oligonucleotide primers shown 
in Table 5.1. As discussed in Section 1.4.3, the skipping of exon 1a3 from the GABAB(1) 
gene in humans generates the transcript variant /7GABAB(1c): an isoform that exhibits an 
expression pattern roughly parallel to that of hGABAB(1a). Taken together, these data 
suggest that the ~400bp fragment amplified here by RT-PCR, and detected by a 
x/GABAB(1a)-specific radiolabelled probe (see Figure 5.3), may correspond to a hitherto 
unreported x/GABAB(1) transcript variant, orthologous to hGABAB(iC), termed here 
x/GABAb(1c).
205
The temporal expression patterns for x/GABAB(ia) and x/GABAB(iC) are similar (see Figure 
5.3). Both transcripts are detectable during early gastrulation (stage 9) and in all stages 
tested from stage 26 onwards, during which time the x/GABAB(1c) signal strength remains 
quite uniform. The signal corresponding to the detection of x/GABAB(ia) transcripts is 
somewhat irregular, with very strong signal observed at stage 36. Whilst the RT-PCR 
method used here was not necessarily quantitative, the requirement for around 500-fold 
greater exposure time to generate comparable signal to the other blots, shown in Figure
5.3, suggests that the x/GABAB(1a) and x/GABAB(1C) transcripts might be less abundant than 
the other x/GABAb receptor transcripts detected here, notably x/GABAB(1b).
5.2.3 xIGABAB(2) receptor subunit mRNA is expressed throughout X.laevis embryonic 
development
x/GABAB(2) transcripts are readily detectable by RT-PCR in all developmental stages 
tested (see Figure 5.2). Southern blot analysis using a x/GABAB{2)-specific probe confirms 
this expression pattern, although minor contamination by template in the -RT negative 
control reactions is evident (see Figure 5.3). Unlike x/GABAB(1), it is possible to detect the 
expression of ‘maternal’ x/GABAB(2) transcripts in total RNA extracted from blastulae 
(stages 5 and 7). However, from gastrulation (stage 9) onwards the xlGABAB(i) and 
xIGABAB(2) genes appear to be temporally co-expressed. Interestingly, these expression 
patterns suggest that any functional x/GABAb receptors expressed during gastrulation 
(stages 9 to 12) would be predominantly GABAB(1a/2) or GABAB(1c/2) heterodimers, whereas 
a combination of GABAB(1a/2), GABAB(1b/2), and GABAB(1c/2)' heterodimeric receptors could 
potentially be expressed thereafter.
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5.2.4 x IG A B A blw but not xlGABABL(b) transcripts are detected by RT-PCR
x/GABABL(a) transcripts are readily detectable by RT-PCR in all developmental stages 
tested from late neurulation (stage 17) onwards (see Figure 5.2). Southern blot analysis 
using a x/GABABL-specific probe confirms this expression pattern, although minor 
contamination by template in the -RT negative control reactions is visible (see Figure 5.3). 
The data shown in Figure 5.3 indicate that the fragments corresponding to the transcript 
variant x/GABABi_(b) are not detected in any stages tested, even following exposure of the 
Southern blot to photographic film for up to three weeks. These data indicate that the 
x/GABABL(b) transcript variant is either absent at the developmental stages tested here or 
is expressed at a particularly low level and, as such, a temporal expression pattern for the 
x/GABABL(b) transcript during development remains elusive.
Despite the use of these sensitive detection methods, the existence of the x/GABABL(b) 
transcript in X.laevis total RNA has only been directly demonstrated once, through 
molecular cloning and sequencing of a 515bp amplicon isolated by 5’RACE in Section
3.4.3 (see Figure 3.16). Analysis of the X.tropicalis GABAbl gene organisation also 
showed that the generation of this transcript in vivo would depend upon the occurrence of 
two simultaneous cryptic slicing events, casting doubt over the physiological relevance of 
this variant (see Figure 4.5). Taken together with the data presented in Figure 5.3, these 
data strongly suggest that x/GABABL(b) is not a bona fide transcript variant expressed in 
vivo, and thus almost certainly derived from an artefact of cDNA synthesis during 
molecular cloning.
207
5.2.5 Detection of xIGABAblw mRNAs in neurulae by RT-PCR
To further investigate the temporal expression pattern of x/GABABL(a) mRNA during 
neurulation, and to identify the developmental stage at which x/GABABi_(a) could be first 
detected, RT-PCR was used to amplify x/GABABL(a) fragments from total RNA extracted 
from embryos at stages 12, 13, 14, 15, 16 and 17, as described in Section 12.1.8. RT- 
PCR was carried out, as described in Section 2.1.10, using the oligonucleotide primers 
shown in Table 5.1. The DNA fragments amplified are shown in Figure 5.4.
These data show that x/GABABL(a) transcripts are readily detected from stage 14 of 
development, indicating that x/GABABL(a) protein might be expressed from mid-neurulation 
onwards.
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Figure 5.4 RT-PCR amplification of products of reverse-transcribed total RNA from stage 12, 13, 14, 
15, 16 and 17 embryos (bottom), showing -RT control for stage 15. The expression pattern previously
uncovered in Section 5.2.1 is shown (top).
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5.3 Spatiotemporal expression patterns of x/GABAb receptor mRNAs during 
embryonic development
5.3.1 Analysis of spatial xIGABAb expression patterns by RT-PCR
In order to obtain some initial information about the spatial expression pattern of x/GABAb 
transcripts at different stages of development, RT-PCR was used to amplify x/GABAB(1b), 
x/GABAB(2) and x/GABABL(a) fragments from total RNA extracted from anterior, posterior, 
dorsal and ventral explants, as described in Section 2.1.8, at stages 14, 21 and 30 of 
development. These total RNA samples were chosen for analysis as the data shown in 
Figures 5.3 and 5.4 indicate that x/GABAB(1b), x/GABAB(2) and x/GABABL(a) transcripts are 
temporally co-expressed at these stages of development. RT-PCR was carried out, as 
described in Section 2.1.10, using the oligonucleotide primers shown in Table 5.1. The 
DNA fragments amplified are shown in Figure 5.5A\ the boundaries of anterior, posterior, 
dorsal and ventral explants at the stages tested as shown in Figure 5.5B.
These data show that, whilst x/GABAB(ib) transcripts are detected in anterior, dorsal and 
posterior tissues at stages 21 and 30, x/GABAB(2) transcripts are not readily detected until 
stage 30 in anterior and dorsal tissues. Whilst the RT-PCR method used here is not 
strictly quantitative, these data also suggest that x/GABAB(1b) and x/GABAB(2) mRNA is 
most abundant in anterior tissues at stage 30, and that x/GABAB(1b) transcripts greatly 
outnumber those of x/GABAB(2) at this stage. In contrast, the data shown in Figure 5.5A 
indicate that x/GABABL(a) transcripts are uniformly expressed in anterior, posterior, dorsal 
and ventral tissues at the developmental stages analysed here.
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Figure 5.5 A. RT-PCR amplification of products of reverse-transcribed total RNA from anterior, dorsal, 
posterior and ventral explants from stage 14, 21 and 30 embryos, showing -RT controls for anterior 
explants from each stage. B. Diagram showing approximate boundaries of anterior (a), dorsal (P), 
posterior (y) and ventral (6) regions isolated from stage 14, 21 and 30 embryos.
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5.3.2 Detection of xIGABAb receptor mRNAs by wholemount in situ hybridization
In order to produce sense and antisense DIG-labelled cRNA probes for use in in situ 
hybridization experiments, in vitro transcription was performed, as described in Section 
2.1.16, using the dual-promoter plasmid vectors containing cDNA clones encoding 
x/GABAB(ib), x/GABAB(2) and the C-terminus of x/GABAbl, shown in Figures 3.5, 3.11, and 
3.15 respectively. Wholemount in situ hybridization was performed, as described in 
Section 2.3.5, on embryos fixed at various stages of development (see Section 2.3.4), 
using DIG-labelled PAN-x/GABAB(1), x/GABAB(2) and PAN-x/GABABL-specific sense and 
antisense cRNA probes, the former acting as a negative control in each case. As a 
positive control, wholemount in situ hybridization was performed using a DIG-labelled 
antisense cRNA probe transcribed from the muscle-specific Xenopus alpha skeletal actin 
gene (xa-actin). A selection of fixed embryos showing in situ staining of hybridized PAN- 
x/GABAB(1), x/GABAB(2) and PAN-x/GABABL-specific cRNA probes is shown in Figures 5.6, 
5.7 and 5.8 respectively.
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Figure 5.6 Wholemount in situ hybridization using DIG-labelled A-C. antisense PAN- 
x /G ABA b(i > cR N A  probe, D. antisense xa-actin cRNA probe, and E. sense PAN- 
x/GABAB(i) cRN A  probe. A. Overall in situ staining patterns. B. Enlarged images 
showing in situ staining in anterior region. C. Transverse (a, P) and lateral (y) sections 
showing in situ staining. Abbreviations: db (developing brain), do (diencephalon), fb 
(forebrain), hb (hindbrain), mb (midbrain), mhb (midbrain-hindbrain boundary), mus 
(muscle), ob (olfactory bulb), ov (otic vesicle), r2 (rhombomere 2), sc (spinal cord), tn
(trigeminal nerve).
18 lateral 20 lateral
18 dorsal 20 dorsal
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5.3.3 xIGABAB(i) transcripts are expressed in multiple brain regions of the developing
X.laevis embryo
x/GABAB(i) transcripts are detected by in situ hybridization from late neurulation (stage 18) 
onwards (see Figure 5.6A). At stage 18, specific staining of DIG-labelled antisense 
x/GABAB(i) probe is visible in neural tissues in the developing brain and spinal cord and, 
upon further differentiation of the CNS, is clearly visible in the hindbrain and trigeminal 
nerve at stage 20 and 23. By stage 30, staining is visible in the forebrain, and by stage 34 
strong signal is visible in multiple brain regions. Analysis of lateral and dorsal views of the 
head at stage 34 shows that staining is pronounced in restricted segments of the midbrain 
and hindbrain, notably at the isthmus, or midbrain-hindbrain boundary, and in 
rhombomere 2 at the root of the trigeminal nerve (see Figure 5.6B). Faint staining is also 
visible at the posterior edge of the otic vesicle in the stage 34 embryo. Transverse (a, P) 
and lateral (y) sections of stage 34 embryos confirm the presence of x/GABAB(1)-specific 
staining throughout the midbrain, hindbrain, trigeminal nerve and spinal cord, but also 
reveal prominent staining in the diencephalon and olfactory bulb (see Figure 5.6C).
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Figure 5.7 Wholemount in situ hybridization using DIG-labelled A-C. antisense 
x/GABAB(2) cRNA probe, D. antisense xa-actin cRNA probe, and E. sense x/GABAb(2> 
cRNA probe. A. Overall in situ staining patterns. B. Enlarged images showing in situ 
staining in anterior region. C. Transverse (a, 3) and lateral (y) sections showing in situ 
staining. Abbreviations: cn (cranial nerves), db (developing brain), dc (diencephalon), 
fb (forebrain), hb (hindbrain), mb (midbrain), mus (muscle), ob (olfactory bulb), sc 
(spinal cord), tn (trigeminal nerve).
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5.3.4 xIGABAB(2) transcripts are expressed in multiple brain regions of the developing
X.laevis embryo
x/GABAB(2) transcripts are detectable by in situ hybridization from stage 21 onwards (see 
Figure 5.7A). At stage 21, faint staining of DIG-labelled antisense x/GABAB(2) probe is 
visible in the developing brain and spinal cord and, upon further differentiation of the CNS, 
is clearly visible in the trigeminal nerve (stage 26). By stage 30, staining is visible in the 
forebrain, and by stage 34 signal is also visible in the midbrain and hindbrain. Analysis of 
lateral and dorsal views of the head at stage 34 shows that, unlike x/GABAB(i), x/GABAB(2) 
transcripts are not detectable in dorsal regions of the midbrain and hindbrain by in situ 
hybridization, and signal is notably absent in rhombomere 2 (see Figure 5.7B). 
Transverse (a, p) and lateral (y) sections of stage 34 embryos confirm the presence of 
x/GABAB(2)-specific staining throughout the midbrain, hindbrain, trigeminal nerve and 
spinal cord, but also reveal staining in the diencephalon, olfactory bulb and along the 
facial cranial nerve (see Figure 5.7C).
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Figure 5.8 Wholemount in situ 
hybridization using DIG-labelled 
A-D. antisense PAN-x/GABAbl 
cRNA probes, E. antisense xa- 
actin cRNA probe, and F. sense 
PAN-x/GABAbl cRNA probe. A. 
Overall in situ staining patterns. B. 
Enlarged images showing in situ 
staining in anterior region. C. Transverse (a) and lateral (P) sections showing in situ 
staining. D. In situ staining in neurulae, including transverse (y) and lateral (5) sections. 
Abbreviations: ar (archenteron roof), cn (cranial nerves), fb (forebrain), hb (hind-brain), 
mb (midbrain), mhb (midbrain-hindbrain boundary), mus (muscle), oc (oral cavity), ov
(otic vesicle).
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5.3.5 xIGABAbl transcripts are expressed primarily in the otic vesicle and hindbrain of
the developing X.laevis embryo
x/GABAbl transcripts are detectable by in situ hybridization from stage 27 onwards (see 
Figure 5.8A). At stage 27, specific staining of DIG-labelled antisense x/GABABl probe is 
visible around the posterior edge of the otic vesicle, and by stage 30 is also visible in a 
restricted location at the anterior end of the hindbrain, near to the mid-hindbrain boundary. 
At stage 34, faint signal is observed in other brain tissues, and analysis of lateral and 
dorsal views of the head reveals that this staining is most prominent in proximal regions of 
the forebrain, midbrain and hindbrain (see Figure 5.8B). Transverse (a) sections through 
stage 34 embryos confirm this observation and show that x/GABABL-specific staining is 
concentrated at the proximal edge of the neural tissue surrounding the brain ventricle in 
the midbrain and hindbrain (see Figure 5.8C). A lateral (p) section of the head at stage 34 
suggests that the staining observed in the oral cavity in transverse sections might 
correspond to cranial nerves, such as the oculomotor, throchlear or facial nerve. 
x/GABAbl transcripts are not detectable in the spinal cord by in situ hybridization at any of 
the stages tested here.
A determination of the spatial expression pattern for x/GABAbl in neurulae proved 
elusive. Whilst strong staining of DIG-labelled antisense x/GABAbl probe was visible 
around the anterior neural plate of stage 14 embryos, transverse (y) and lateral (5) 
sections revealed that the signal was located in non-neuronal tissue along the roof of the 
archenteron (see Figure 5.8D). Whilst expression of x/GABAbl in these tissues is 
possible, trapping of probe and hybridization buffer in the archenteron during wholemount 
in situ hybridization is not uncommon and could generate a false positive signal. 
However, a signal was repeatedly detected by in situ hybridization at the archenteron roof,
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even when holes were introduced into neurulae prior to hybridization to aid the penetration 
of probe and wash solutions. This phenomenon also appears to be probe-specific, as 
none of the other probes used here generated this specific signal in neurulae, including 
the DIG-labelled sense x/GABAbl cRNA probe. When RT-PCR was performed using total 
RNA extracted from anterior, dorsal, ventral and posterior neurulae explants, x/GABABl 
transcripts were detectable in all four regions, providing little insight into where they might 
be predominantly localised. It should be noted that x/GABAbl transcripts were detected by 
RT-PCR in all four of the tissue explants analysed at stages 21 and 30, despite in situ 
hybridization data demonstrating that x/GABAbl expression was restricted to the anterior 
region at these stages. These data suggest that, whilst x/GABAbl mRNA may be 
concentrated in certain differentiated anterior tissues during embryo development, such as 
the otic vesicle, transcripts may still be expressed in other tissues at a level detectable by 
RT-PCR.
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5.4 Discussion
In this chapter, a combination of RT-PCR and in situ hybridization techniques were used 
to explore the spatiotemporal expression patterns of x/GABAb receptor mRNAs during 
X.laevis embryo development. cDNA was prepared from total RNA extracted from 
embryos at a range of developmental stages from 5-40 for RT-PCR analysis, and in situ 
hybridization was performed on gastrulae, neurulae, tailbud and tadpole embryos using 
PAN-x/GABAB(i), x/GABAB(2) and PAN-x/GABABL-specific cRNA probes. Key findings from 
the data presented in this chapter are evaluated below.
5.4.1 xIGABAb receptor subunit mRNAs are differentially expressed during X.laevis
embryonic development
Analysis of the data presented in Figures 5.2 and 5.3 reveals that x/GABAb receptor 
subunit mRNAs exhibit distinct temporal expression patterns between stage 5 and stage 
40 of embryo development. x/GABAB(2) transcripts were detected in all stages tested 
including stage 5 and 7 blastulae. This suggests that maternally transcribed x/GABAB(2) 
mRNAs are present in X.laevis oocytes prior to fertilisation, since zygotic gene 
transcription is not thought to begin until gastrulation. In contrast, x/GABAB(1) transcripts 
were not detected until early gastrulation (stage 9), in agreement with findings from 
previous studies in rats suggesting that x/GABAB(1) and x/GABAB(2) gene expression is not 
co-ordinately regulated during development (Martin,S.C et al. 2004). These data are 
consistent with a role for GABAB(2), in the absence of GABAB(1), during the very early 
stages of vertebrate development.
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Whilst Southern analysis using a x/GABAB(ib)-specific probe revealed that x/GABAB(1b) 
transcripts are not expressed until stage 12 of X.laevis development, hydridization of a 
x/GABAB(1a).specific probe uncovered the expression of two related transcripts, postulated 
here to be x/GABAB(1a) and the X.laevis orthologue of the human GABAB(1) splice variant, 
GABAB(1c), during early gastrulation (stage 9). The expression pattern of these two 
transcripts was found to be near identical, consistent with the notion that GABAB(1a) and 
GABAB(1c) are regulated by the same promoter.
The differential expression patterns for x/GABAB(1a) and x/GABAB(1b) transcripts uncovered 
here are consistent with the findings of previous studies, which suggest that x/GABAB(1a) is 
the primary GABAB(1) isoform expressed during early development (Malitschek.B et al. 
1998, Fritschy.J.M et al. 1999, Fritschy.J.M et al. 2004, Martin,S.C et al. 2004, Steiger,J.L 
et al. 2004). These data are indicative of a role for x/GABAB(1a/2) receptor heterodimers, 
during gastrulation, prior to the transcription of x/GABAB(1b) mRNAs, during neurulation.
Whilst a temporal expression pattern for the x/GABABL(b) transcript variant was not 
detected here, the data shown in Figures 5.2 and 5.3 show that x/GABABL(a) transcripts are 
expressed from stage 17 of development onwards. However, further analysis of 
x/GABABL(a) expression during neurulation revealed that x/GABABL(a) transcripts were first 
detectable at stage 14 using this method (see Figure 5.4).
Spatial expression patterns for x/GABAb receptor subunit mRNAs were analysed here by 
RT-PCR and in situ hybridization experiments. The former showed that, whilst x/GABAB(1) 
and x/GABAB(2) transcripts are principally expressed in anterior and dorsal tissues in 
tailbud embryos, x/GABABL(a) transcripts could be amplified from anterior, posterior, dorsal 
and ventral regions of the embryo at all developmental stages tested. In situ hybridization
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revealed that x/GABAB(1) and x/GABAb(2) mRNA expression was indeed restricted to the 
CNS and that these transcripts were co-expressed in most brain regions of the tailbud 
embryo, consistent with the proposal that both subunits are required for normal GABAb 
receptor function. However, there were areas of unique x/GABAB(i) transcript expression, 
most notably in dorsal regions of the midbrain and in rhombomere 2 of the hindbrain, 
where strong x/GABAB(1)-specific signal was observed in the absence of a x/GABAB(2) 
signal at stage 34 (see Figures 5.6B and 5.7B). These data are consistent with a role for 
x/GABAB(1) in these developing brain regions in the absence of x/GABAB(2). In situ 
hybridisation revealed that x/GABAbl transcripts are concentrated in the otic vesicle and at 
a restricted location at the anterior end of the hindbrain near to the isthmus (see Figure 
5.8). x/GABABL-specific staining is also visible in proximal regions of the forebrain, 
midbrain and hindbrain, along the anteroposterior axial midline, at stage 34. Unlike 
x/GABAB(1) and x/GABAb(2), x/GABAbl transcripts are not detected in the spinal cord of the 
developing embryo by in situ hybridisation.
5.4.2 The x IG A B A blw transcript variant is unlikely to be expressed in vivo
The data presented in Figures 5.2 and 5.3 show that x/GABABL(b) transcripts are not 
detected in any of the developmental stages tested, even following exposure of the blot to 
photographic film for period of three weeks. Taken together with the findings from the 
genomic analysis carried out in Section 4.3.3, which showed that generation of this 
putative splice variant would require two simultaneous cryptic splicing events to occur 
(see Figure 4.5), these data strongly suggest that the x/GABABL(b) transcript variant shown 
in Figure 3.16 is unlikely to be expressed in vivo, and was most probably generated as a 
result of errors during cDNA synthesis.
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5.4.3 Summary
The results described in this results chapter provide a detailed insight into the 
spatiotemporal expression pattern of GABAb receptor mRNAs during X.laevis embryonic 
development. These data show that, whilst GABAb receptor mRNAs are differentially 
expressed during X.laevis development, there are significant areas of overlapping 
expression in the brain, particularly in the case of x/GABAB(1) and x/GABAb(2) gene 
products. Interestingly, both RT-PCR and in situ hybridization data appear to show 
x/GABAB(1) transcript levels exceeding those of x/GABAB(2) in most brain regions, in 
agreement with data described previously in rats (Martin,S.C et al. 2004); however, it must 
be noted that neither of the techniques used here are strictly quantitative. The co­
expression of x/GABAB(1) and x/GABAB(2) transcripts in these brain regions is indicative of 
the expression of functional GABAb receptor heterodimers at the cell surface, and 
suggests a role for metabotropic GABA signalling during the development of the X.laevis 
CNS. Whilst the function of the GABAbl receptor is presently unknown, the in situ 
hybridization data shown here are indicative of a role for x/GABABL(a) during the 
development of the X.laevis brain and ear.
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Results
Chapter Four
Overexpression of GABAb receptor proteins during 
laevis embryonic development
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6.1 Introduction
6.1.1 Manipulation of gene expression in Xenopus embryos
With recent advances in molecular genetics, numerous approaches have now been 
developed that allow the manipulation of gene expression in Xenopus embryos. One 
method involves the microinjection of synthetic mRNA into cleavage-stage embryos 
(blastulae), resulting in overexpression and increased activity of a gene of interest during 
embryonic development. Similarly, a loss-of-function approach is made possible through 
microinjection of synthetic mRNA encoding a polypeptide that interferes with the protein of 
interest in a dominant negative fashion, or by microinjection of an antisense morpholino (a 
synthetic oligonucleotide analogous to RNA with a morpholine phosphorodiamidate 
backbone) that contains sequence complimentary to the 5’UTR of the gene of interest and 
interferes with its translation through steric blocking of the ribosomal complex. The 
manipulation of gene expression using these approaches can bring about reproducible 
changes to the morphology or behaviour of embryos that can aid in elucidating the role of 
a protein of interest during development.
Phenotypes arising from the increased activity of a protein through overexpression can be 
extremely informative, and may indicate the normal function of the gene in Xenopus 
embryos. However, there are a number of limitations associated with this approach that 
should be taken into consideration when interpreting results. Microinjection of synthetic 
mRNA typically results in the immediate translation of large amounts of protein in the 
absence of any temporal and spatial regulation of expression, and this distinctly non- 
physiological scenario can produce ambiguous results through non-specific effects. Large
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quantities of RNA or protein can be toxic and inhibit physiological processes, and early 
activity of a particular protein may produce unrepresentative phenotypes and preclude 
analysis of later effects of the same protein. Furthermore, ectopic activity of the 
overexpressed protein may interfere with developmental processes that it would not 
normally be associated with in vivo, and so care must be taken when interpreting results 
to avoid drawing inaccurate conclusions about the endogenous function of the protein of 
interest using this assay.
The injection of a ‘neutral’ synthetic mRNA, encoding a protein, which brings about no 
detectable changes to the morphology of the developing embryo, represents a satisfactory 
control to demonstrate the toxicity of high concentrations of RNA, or lack thereof. Also, 
the co-injection of synthetic mRNA with a freely diffusible lineage tracer, such as dextran- 
fluorescein, results in the labelling of the injected cell’s progeny without affecting cell fate, 
and can demonstrate that injected cells are both viable and contribute to differentiated 
structures in the embryo.
Synthetic mRNA injected into blastulae can be targeted to particular tissues in the later 
embryo by exploiting the 32-cell stage Xenopus fate map (Dale,L et al. 1987), which 
describes the fate of each blastomere in terms of tissue types and spatial localisation. 
Whilst exact targeting is problematic, due to mixing of cell populations, the fate map can 
be used to direct transcripts toward dorsal or ventral structures through microinjection at 
the 4 or 8-cell stage. This approach has been used previously to demonstrate the 
differential effects of a several genes in dorsal or ventral tissues (Sokol,S et al. 1991, 
Jones,C.M et al. 1992, Dale.L et al. 1992).
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Explants taken from different regions of the embryo may be used to investigate the effect 
of a gene of interest on events occurring in distinct tissues of the embryo, such as the 
animal cap (prospective ectoderm), the marginal zone (prospective mesoderm and 
endoderm), and the vegetal zone (prospective endoderm). Such explants, particularly 
animal caps, retain many of their characteristics when removed from the embryo and will 
give a robust response to inducing factors, providing an ideal bioassay with which to study 
the effects of signalling molecules or receptors.
6.1.2 Rationale for GABAb receptor gene overexpression in Xenopus embryos
The use of a gain-of-function approach, by overexpression of a protein of interest in 
Xenopus embryos, has contributed to the elucidation of developmental functions for a host 
of vertebrate genes (Moon.R.T et al. 1993, Heasman.J et al. 1994, Yang.S et al. 1998, 
Godfrey,E.W et al. 1999, Pohl.B.S et al. 2001). Whilst the suitability of this bioassay for 
investigating the functions of secreted factors or intracellular signalling components is well 
established, the analysis of receptor function in this way may be complicated by 
differences in the temporal and spatial availability of the endogenous ligands required for 
receptor activation. Previous studies have demonstrated the widespread presence of 
endogenous GABA in Xenopus embryos at early stages of development, prior to the 
formation of synapses (Roberts,A et al. 1987, Perrins,R et al. 2002, Mueller,T et al. 2006), 
thus permitting the analysis of heterodimeric x/GABAb receptor signalling using this assay. 
Similarly, the abundance of endogenous GABA will permit the analysis of any ligand- 
dependent effects of monomeric x/GABAB(i) subunit overexpression in the developing 
embryo. Since GABAB(2) and GABAbl do not bind any known ligands, any observable 
effects when x/GABAb(2) or x/GABABL(a) proteins are overexpressed in isolation may be
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considered to be non ligand-dependent and derived from constitutive G-protein coupling 
activity of these proteins or, perhaps, from interactions with other endogenous factors.
The spatiotemporal expression patterns of x/GABAb receptor mRNAs uncovered in 
Results Chapter Three suggest a role for metabotropic GABA signalling in the developing 
X.laevis embryo. It was hypothesised here that overexpression of x/GABAb receptor 
heterodimers during X.laevis development might lead to an increase in metabotropic 
GABA signalling, and thus inhibition of neuronal circuits in the developing embryo. This 
might be predicted to manifest itself in terms of reduced locomotion, swimming activity or 
response to stimulus in tailbud and tadpole embryos, or perhaps changes in embryo 
morphology, indicative of an endogenous role for metabotropic GABA signalling in the 
regulation of morphogenetic events during development (Roberts,A et al. 1987, Perrins,R 
et al. 2002, Mueller,T et al. 2006). The lack of temporal or spatial regulation of expression 
in this assay might result in metabotropic GABA signalling in tissues that are not normally 
responsive to GABA, producing distinctive morphogenetic effects that might provide 
insight into the developmental functions of endogenous x/GABAb receptors. Previous 
studies have suggested roles for individual GABAb receptor subunits when expressed 
alone (Kaupmann.K et al. 1998b, Ng,G.Y et al. 1999, Martin,S.C et al. 1999, Fritschy.J.M 
et al. 2004, Gassmann,M et al. 2004). Whilst it is difficult to predict the nature of any 
phenotypic changes that might occur as a result of individual x/GABAb receptor subunit 
overexpression, this assay may uncover observable morphogenetic effects that provide 
insight into the possible individual contributions of GABAB(1) and GABAB(2) subunits to 
vertebrate development. GABAbl is a protein of hitherto unknown function and, as such, it 
is difficult to predict the likely effect of x/GABABL(a) subunit overexpression during X.laevis 
embryogenesis. However, the expression pattern of mammalian GABAbl transcripts is 
consistent with a role in development (Calver,A.R et al. 2003, Martin,S.C et al. 2004) and,
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as such, this assay may represent an ideal method for demonstrating functionality of this 
orphan receptor.
6.1.3 Aims
The aim of this chapter is to adopt a gain-of-function approach to assess the functional 
contributions of individual x/GABAb receptor subunits or heterodimers to X.laevis 
embryonic development. Where reproducible morphological phenotypes are observed in 
embryos overexpressing x/GABAb receptor protein, further analysis of the morphogenetic 
and/or biochemical effects of this protein will be performed in an effort to gain insight into 
any specific functions of the protein during development.
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6.2 Overexpression of x/GABAb subunit proteins during X.laevis embryonic 
development
6.2.1 Overexpression of individual xlGABAB(i) and xIGABAB(2) subunits during 
embryonic development
In Results Chapter One, cDNA clones encoding x/GABAB(1a), x/GABAB(1b) and x/GABAB(2) 
were assembled and subcloned into expression vectors (see Section 3.5). In vitro 
transcription of 5’-capped polyadenylated cRNAs from these constructs yielded transcripts 
of the expected size, which generated proteins of the correct predicted molecular weight 
when translated in vitro (see Figure 3.21). To assess the possible functional contributions 
of individual GABAb receptor subunits to the development of X.laevis embryos, 5’-capped 
polyadenylated cRNAs were transcribed from the verified constructs, as described in 
Section 2.1.17, and used for microinjections into 2-cell or 8-cell blastulae, as described in 
Section 2.3.7, in order to overexpress individual x/GABAB(1a), x/GABAB(1b) and x/GABAB(2) 
subunit proteins during embryonic development.
In the first instance, 1.6ng cRNA was injected into around fifty 2-cell blastulae per 
construct, 0.8ng per blastomere, from the same batch of fertilised embryos per 
experiment. After initial optimisation using several different cRNA preparations, a single 
preparation was produced and experiments were performed three times. Representative 
batches of stage 40 embryos were selected for photographing. Photographs showing the 
phenotypes observed, following microinjection of x/GABAB(1a), x/GABAB(1b) and x/GABAB(2) 
subunit cRNAs at the 2-cell stage, are shown in Figure 6.1.
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In order to target the expression of these GABAb receptor subunit proteins towards the 
tissues of the developing embryonic CNS, 1.6ng cRNA was injected into the dorsal 
blazoners of around 50 8-cell blastulae per construct, 0.8ng per dorsal blastomere, from 
the same batch of fertilised embryos. These experiments were performed three times and 
representative batches of stage 40 embryos were selected for photographing. 
Photographs showing the phenotypes observed, following microinjection of x/GABAB(ia), 
x/GABAB(1b) and x/GABAB(2) subunit cRNAs at the 8-cell stage, are shown in Figure 6.2. A 
selection of injected embryos exhibiting significant morphological defects at stage 40, 
compared to the uninjected wild-type embryos, is shown in Figure 6.3.
In order to quantify the phenotypic variation observed in stage 40 embryos, following 
microinjection of x/GABAB(1a), x/GABAB(1b) and x/GABAB(2) subunit cRNAs at both the 2-cell 
and 8-cell stage, embryos were scored according to the system described in Section 2.3.9 
(for an example see Figure 2.1). The percentage proportion of embryos scoring 1-4 within 
each batch was calculated (shown in Tables 9.4A and B), and these data were used to 
generate the stacked column charts shown in Figure 6.4.
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xlGABAB(ib> 1 -6ng score = 1
Figure 6.1 Phenotypes observed in stage 40 (tadpole) embryos 
following microinjection of 1.6ng A. x/GABAB(ia), B. x/GABAB(ib) or 
C. x/GABAb(2) cRNAs into 2-cell blastulae. D. Uninjected controls at
stage 40.
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xIGABAb(w) 1 -6ng score = 1
x IGABAb(2> 1 6ng u n in je c te d
Figure 6.2 Phenotypes observed in stage 40 (tadpole) embryos 
following microinjection of 1.6ng A. x/GABAe(ia), B. x/GABA8(ib) or 
C. x/GABAB(2) cRNAs into 8-cell blastulae. D. Uninjected controls at 
stage 40. Merged images show location of lineage tracer (green).
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Figure 6.3 Phenotypes observed in stage 40 (tadpole) embryos scoring 2, 3 or 4 following microinjection 
of1.6ng A. x/GABAeda). B. x/GABAe<ib) or C. x/GABAb<2) cRNAs into 8-cell blastulae Images show
location of lineage tracer (green).
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Figure 6.4 Stacked column charts showing the percentage proportion of embryos scoring 1( ), 2( ), 
3(*i) or 4 (* ) , at stage 40, following microinjection of 1.6ng x /G A B A B(ia), x/GABAe(ib) orx/GABAe(2) cRNAs 
into 2-cell (left) o r 8-cell (right) blastulae. Uninjected controls are shown in each case.
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6.2.2 Embryos overexpressing xlGABAB(i) and xIGABAB(2) subunits exhibit a 
predominantly wild-type phenotype
Initial analysis of the data shown in Figures 6.1 and 6.4 reveals that 100% of embryos 
injected with 1.6ng x/GABAB(ia) or x/GABAB(ib) subunit cRNAs, at the 2-cell stage, 
developed into stage 40 tadpoles that exhibited no observable morphological defects, 
compared to 96% of those injected with 1.6ng x/GABAb(2) cRNA. Injected embryos also 
displayed wild-type swimming behaviour, in response to stimulus, and developed at the 
same rate as uninjected control embryos. These data suggest that overexpression of 
individual x/GABAB(1a), x/GABAB(1b) or x/GABAb(2) subunit proteins across all regions of the 
developing embryo does not adversely affect the normal morphology or overt behaviour of 
X.laevis embryos.
Analysis of the data shown in Figures 6.2 and 6.4 shows that 77% of embryos injected 
with 1.6ng x/GABAB(1a) cRNA, into dorsal blastomeres at the 8-cell stage, developed into 
stage 40 tadpoles that were indistinguishable from their uninjected wild-type counterparts, 
compared to 81% and 76% of those injected with x/GABAB(ib) and x/GABAB(2) cRNA 
respectively. These embryos also displayed wild-type swimming behaviour, in response 
to stimulus, and developed at the same rate as uninjected control embryos. The lineage 
tracer, visible in injected embryos, also indicates that cells overexpressing x/GABAB(1a), 
x/GABAB(ib) or x/GABAB(2) subunits are viable and contribute to differentiated structures in 
these tadpole embryos. However, analysis of the data shown in Figure 6.3 shows that, for 
each construct, the remaining injected embryos exhibited a range of morphological 
defects, from moderate to severe, and were assigned scores of 2, 3 and 4. These data 
show that overexpression of x/GABAB(2) in the developing CNS induced the most marked 
deviation from wild-type morphology, with 7% of x/GABAB(2)-injected embryos exhibiting
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major truncation and a total loss of recognisable head and tail features, scoring 4, 
compared with 4% and 3% of embryos injected with x/GABAB(1a) and x/GABAB(ib) cRNA 
respectively.
Whilst the frequency of x/GABAB(1a), x/GABAB(1b) or x/GABAB(2)-injected embryos scoring 2- 
4 was similar in all experiments carried out, the morphological defects observed were not 
reproducible and, as such, it was not possible to ascribe any specific phenotype to 
overexpression of any particular x/GABAb receptor subunit. Also, the percentage 
proportion of embryos scoring 2-4 in each case is small, with around 80% of injected 
embryos developing normally. Where normal muscle anatomy was preserved, embryos 
scoring 2 or 3 retained wild-type swimming behaviour, and even those scoring 4 exhibited 
some visible motor activity in response to stimulus. Thus, despite the phenotypic 
variability described here, these data suggest that, overall, a high level overexpression of 
x/GABAB(1a), x/GABAB(1b) or x/GABAB(2) subunit proteins in developing dorsal tissues does 
not adversely affect the normal morphology or overt behaviour of X.laevis embryos.
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6.2.3 Co-overexpression of xlGABAB(i) and xIGABAB(2) subunits during embryonic
development
To assess the possible functions of GABAb receptor heterodimers during the development 
of X.laevis embryos, transcribed x/GABAB(ia) and x/GABAB(ib) cRNAs were combined 
separately with x/GABAB(2) cRNA, in a 1:1 ratio, and used for microinjections into 2-cell or 
8-cell blastulae, as described in Section 2.3.7, in order to overexpress x/GABAB(1a/2) or 
x/GABAB(ib/2) heterodimers during embryonic development.
In the first instance, a total of 1.6ng cRNA was injected into around fifty 2-cell blastulae 
per co-injection, 0.8ng per blastomere, from the same batch of fertilised embryos per 
experiment. Experiments were performed three times using the same cRNA preparations 
used in Section 6.2.1. Representative batches of stage 40 embryos were selected for 
photographing. Photographs showing the phenotypes observed, following co­
microinjection of x/GABAB(1a/2) or x/GABAB(1b/2) cRNAs at the 2-cell stage, are shown in 
Figure 6.5.
In order to target the expression of GABAb receptor heterodimers towards the tissues of 
the developing embryonic CNS, a total of 1,6ng cRNA was injected into the dorsal 
blastomeres of around fifty embryos at the 8-cell stage per co-injection, 0.8ng per 
blastomere, from the same batch of fertilised embryos. These experiments were 
performed three times and representative batches of stage 40 embryos were selected for 
photographing. Photographs showing the primary phenotype observed in embryos at 
stage 25 (tailbud) and stage 40 (tadpole), following co-microinjection of x/GABAB(1a/2) or 
x/GABAB(1b/2) cRNAs at the 8-cell stage, are shown in Figure 6.6. A selection of injected
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embryos exhibiting significant morphological defects at stage 40, compared to the 
uninjected wild-type embryos, is shown in Figure 6.7.
In each case, batches of embryos were scored at stage 40, as described in Section 2.3.9, 
the percentage proportion of embryos scoring 1-4 within each batch was calculated 
(shown in Tables 9.4A and B), and these data were used to generate the stacked column 
charts shown in Figure 6.8.
xlGABAeaax, 1.6ng score = 1 uninjected
Figure 6.5 Phenotypes observed in stage 40 (tadpole) embryos following co-microinjection of a total of 
1.6ng A. x/GABAe<ia/2) or B. x/GABAb<iw2 ) cRNAs into 2-cell blastulae. C. Uninjected controls at stage 40.
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Figure 6.6 Phenotypes observed in stage 25 (tailbud) embryos following co-microinjection of 1.6ng A. 
x/GABAB(ia/2) or B. x /G A B A B(it>/2) cRNAs into 8-cell blastulae. Phenotypes observed in stage 40 (tadpole) 
embryos following co-microinjection of 1.6ng A. x/GABAe(ia/2) or B. x/GABAe(ib/2> cRNAs into 8-cell 
blastulae. Uninjected controls are shown at C. stage 25, and F. stage 40. Merged images show location
of lineage tracer (green).
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Figure 6.7 Phenotypes observed in stage 40 (tadpole) embryos 
scoring 2, 3 or 4 following co-microinjection of a total of 1.6ng 
A. x/GABAB(ia/2> or B. x/GABAe(ib/2) cRNAs into 8-cell blastulae. 
Images show location of lineage tracer (green).
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Figure 6.8 Stacked column charts showing the percentage proportion of embryos scoring 1( ), 2(  ), 
3 ( B )  or 4(B), at stage 40, following co-microinjection of a total of 1.6ng x /G A B A B(ia/2) o rx /G A B A B(ib/2) 
cRNAs into 2-cell (left) or 8-cell (right) blastulae. Uninjected controls are shown in each case.
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6.2.4 Embryos overexpressing xlGABAB(ia/2) or xlGABAB(1b/2) receptor heterodimers
exhibit a predominantly wild-type phenotype
Analysis of the data shown in Figures 6.5 and 6.8 shows that 77% of embryos co-injected 
with a total of 1.6ng x/GABAB(1a/2) cRNA, at the 2-cell stage, developed into stage 40 
tadpoles that were indistinguishable from their uninjected wild-type counterparts, 
compared to 59% of those co-injected with 1.6ng x/GABAB(ib/2) cRNA. These embryos 
also displayed wild-type swimming behaviour, in response to stimulus, and developed at 
the same rate as uninjected embryos. Whilst none of the embryos injected exhibited 
sufficiently severe defects to be assigned a score of 4, these data show that co-injection 
of x/GABAB(ib/2) cRNA at the 2-cell stage produced the most marked changes in embryo 
morphology, with 12% exhibiting severe microcephaly and scoring 3 at stage 40, 
compared to just 5% of embryos overexpressing x/GABAB(1a/2) heterodimers. Whilst 30% 
of x/GABAB(1b/2)-injected embryos were assigned a score of 2, these embryos were 
generally very well differentiated but for a significant kink in the tail, and all of the embryos 
injected here retained wild-type swimming activity in response to stimulus. Thus, these 
data suggest that overexpression of x/GABAB(1a/2) or x/GABAB(1b/2) receptor heterodimers 
across all regions of the developing embryo does not adversely affect the normal 
morphology or overt behaviour of X.laevis embryos.
Analysis of the data shown in Figures 6.6 and 6.8 reveals that 60% of embryos co-injected 
with a total of 1.6ng x/GABAB(1a/2) cRNA, into dorsal blastomeres at the 8-cell stage, 
developed into stage 40 tadpoles that exhibited no observable morphological defects, 
compared to 62% of embryos co-injected with 1.6ng x/GABAB(ib/2) cRNA. These embryos 
also displayed wild-type swimming behaviour, in response to stimulus, and developed at 
the same rate as uninjected control embryos. The lineage tracer, visible in injected
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embryos, also indicates that cells overexpressing x/GABAB(ia/2) or x/GABAB(ib/2) 
heterodimers are viable and contribute to differentiated structures in these tadpole 
embryos. However, a small number of injected embryos exhibited minor abnormalities at 
stage 25 (see Figures 6.6A and 6.6B) which had developed into moderate or severe 
morphological defects by stage 40, scoring 2, 3 or 4 (see Figure 6.7). For example, 20% 
of embryos co-injected with 1.6ng x/GABAB(ia/2> cRNA at the 8-cell stage exhibited a total 
loss of identifiable head structures, or acephaly, at stage 40, and were assigned a score 
of 4. Where normal muscle anatomy was preserved, however, these embryos still 
retained wild-type swimming activities. Overexpression of x/GABAB(1b/2) heterodimers in 
the developing CNS gave rise to less severe defects, with just 15% exhibiting 
microcephaly or body truncation at stage 40, scoring 3, and none scoring 4.
Whilst these results suggest that overexpression of heterodimeric x/GABAb receptors in 
the developing CNS, particularly x/GABAB(1a/2) heterodimers, can bring about 
morphogenetic effects in developing X.laevis embryos, the majority of injected embryos, 
typically 60%, were indistinguishable from the uninjected controls and, as such, a 
x/GABAb receptor-specific effect seems unlikely. Furthermore, the differential effects of 
x/GABAB(ia/2) versus x/GABAB(1b/2) heterodimer overexpression, described here, were not 
always reproducible, casting doubt upon the functional relevance of these apparent 
x/GABAB(1) isoform-specific effects. Thus, despite the phenotypic variability observed, 
these data suggest that a high level overexpression of x/GABAB(1a/2) or x/GABAB(1b/2) 
receptor heterodimers in developing dorsal tissues does not affect normal morphology or 
behaviour in the majority of X.laevis embryos. As such, further exploration of this avenue 
of investigation was dropped in favour of the pursuit of evidence of functionality of the 
orphan receptor, x/GABABL(a), by use of this gain-of-function assay.
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6.2.5 Overexpression of xlGABABL(a) during embryonic development
In Results Chapter One, a cDNA clone encoding the seven-transmembrane protein 
x/GABABL(a) was assembled and subcloned into an expression vector (see Section 3.5.3). 
In vitro transcription of 5-capped polyadenylated cRNA from this construct yielded a 
transcript of the expected size, which generated a protein of the correct predicted 
molecular weight when translated in vitro (see Figure 3.21). To investigate the functions 
of GABAbl during the development of X.laevis embryos, 5’-capped polyadenylated 
x /GABAblo) cRNA was transcribed from the verified construct, as described in Section 
2.1.17, and used for microinjections into 2-cel! or 8-cell blastulae, as described in Section 
2.3.7, in order to overexpress x/GABABL(a) protein during embryonic development.
In the first instance, 1.6ng x /GABAblo cRNA was injected into at least fifty 2-cell blastulae 
per experiment, 0.8ng per blastomere, to achieve overexpression of x/GABABL(a) protein in 
all regions of the embryo during development. After initial optimisation using several 
different cRNA preparations, a single preparation was produced and experiments were 
performed three times. Representative batches of stage 40 embryos were selected for 
photographing. Photographs showing the phenotypes observed in injected embryos at 
stage 23 are shown in Figure 6.9A\ phenotypes observed at stage 40 are shown in 
Figures 6.9C and E.
In an effort to uncover any tissue-specific effects of x/GABABL(a) overexpression in 
developing embryos, x/GABABL(a) cRNA was targeted towards either dorsal or ventral 
tissues through microinjection of x/GABABL(a) cRNA into dorsal or ventral blastomeres at 
the 8-cell stage, 0.8ng per blastomere. Around fifty embryos were injected per 
experiment, which were performed three times, and representative batches of embryos
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were selected for photographing. Photographs showing the phenotypes observed in 
stage 40 embryos overexpressing x/GABABL(a) in dorsal or ventral tissues, following 
microinjection of x/GABABi_(a) cRNA at the 8-cell stage, are shown in Figure 6.10.
To investigate any cRNA concentration-dependent effects of x/GABABL(a) overexpression, 
a dose response assay was performed whereby a total of 0.2ng, 0.4ng, 0.8ng or 1.6ng 
cRNA was injected into embryos at the 2-cell stage. Around twenty 2-cell blastulae were 
injected, per cRNA concentration analysed, using a common batch of fertilised embryos to 
account for possible batch variability. This experiment was repeated and representative 
batches of embryos were selected for photographing. Photographs showing the 
phenotypes observed in these injected embryos at stage 40 are shown in Figure 6.11.
For each of the experiments described above, batches of embryos were scored at stage 
40, as described in Section 2.3.9, and the percentage proportion of embryos scoring 1-4 
within each batch was calculated (shown in Tables 9.4A, B and C). These data were 
used to generate the stacked column charts shown in Figure 6.12.
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xlG ABAsti, 1 6ng
Figure 6.9 Phenotypes observed in embryos, following microinjection of 1.6ng x/GABAbl cRNA into 2-cell 
blastulae, at A. stage 23, and at C, E. stage 40 (tadpole). Uninjected controls are shown at B. stage 23, 
and D. stage 40. Abbreviations: yolk plug (yp), cyclopia (eye).
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Figure 6.10 Phenotypes observed in stage 40 (tadpole) embryos 
following microinjection of 1.6ng x/GABAena) cRNA into A. dorsal 
blastomeres, and B. ventral blastomeres, at the 8-cell stage.
C. Phenotypes observed in stage 40 (tadpole) embryos following 
microinjection of 0.8ng x/GABABL(a) cRNA into a single dorsal 
blastomere at the 8-cell stage, showing opposing lateral views a and p. 
D. Uninjected controls at stage 40. Merged images show location of 
lineaqe tracer (green). Abbreviations: cvclopia (cvc).
xIGABAblo) 0.2ng score = 1
xIGABAblo) 0.4ng xlGABABL(a) 0.4ng score = 2
x IGABAblis) 0.8ng score = 3
xIGABAblo) 1 -6ng score = 3xlGABAeua) 1 -6ng
uninjected
Figure 6.11 A. Dose response showing phenotypes observed in 
stage 40 (tadpole) embryos, following microinjection of 0.2ng, 0.4ng, 
0.8ng or 1.6ng x/GABAblo) cRNA at the 2-cell stage.
B. Uninjected controls at stage 40.
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Figure 6.12 Stacked column charts showing the percentage proportion of embryos scoring 1( ), 2( ), 3(B) or 4(B), at stage 40, following 
A. microinjection of 1.6ng x/GABAeL(a) cRNA into 2-cell (left) or 8-cell (right) blastulae, and B. microinjection of 0.2ng, 0.4ng, 0.8ng or 1.6ng
x/GABAeL(a) cRNA at the 2-cell stage. Uninjected controls are shown in each case.
251
6.2.6 Embryos overexpressing xlGABABL(a) exhibit a reproducible body truncation 
phenotype
Initial analysis of the data shown in Figures 6.9 and 6.12A reveals that 100% of embryos 
injected with 1.6ng x/GABABL(a) cRNA at the 2-cell stage exhibit around 30% shorter body 
length, at stage 23, and around 50% shorter body length, at stage 40, than their 
uninjected wild-type counterparts. Minor gastrulation defects are visible in some stage 23 
embryos, in the form of small ‘yolk plugs’ emanating from the blastopore (see Figure 
3.9A), and at stage 40, where many injected embryos possess open neural plates or split 
tails (see Figure 3.9B). Effective wild-type swimming activity was precluded by the lack of 
correctly developed fin and tail structures in 100% of injected embryos, although all 
exhibited some visible motor activity in response to stimulus. These data suggest that 
overexpression of x/GABABL(a) protein across all regions of the developing embryo gives 
rise to gastrulation defects and a reproducible body truncation phenotype post- 
neurulation.
6.2.7 Some embryos overexpressing xlG A B A BL(a) exhibit eye defects and cyclopia
Analysis of the data presented in Figure 6.9E shows that, in addition to the body 
truncation phenotype, some embryos injected with x/GABABL(a) cRNA at the 2-cell stage 
exhibit eye defects, such as cyclopia, indicative of failures in the correct separation of the 
eye field during development. Decreased eye size, or total loss of eye specification, is 
observed in other x/GABABL(a)-injected embryos, see Figures 6.10C and 6.11 A, and thus 
represents a reproducible phenotypic manifestation of overexpression of x/GABABL(a) in 
X.laevis embryos.
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6.2.8 Embryos exhibit distinct phenotypes depending on site of xIGABAblm 
overexpression
Analysis of the data shown in Figures 6.10A and 6.12A reveals that 100% of stage 40 
embryos injected with x/GABABL(a) cRNA, into dorsal blastomeres at the 8-cell stage, 
exhibit a comparable body truncation phenotype and gastrulation defects to those injected 
at the 2-cell stage (see Figure 6.9C). However, failures in eye separation or specification 
appear to be more prevalent in embryos injected at the 8-cell stage, with 67% exhibiting 
cyclopia or complete eye loss at stage 40, compared to just 23% of those injected at the 
2-cell stage. These data suggest that this phenotype might be associated with a high 
level of x/GABABL(a) protein expression in dorsal tissues, such as the developing CNS. 
This observation is supported by the data shown in Figure 6.10C, which show that micro­
injection of 0.8ng x/GABABL(a) cRNA into a single dorsal blastomere, at the 8-cell stage, 
brings about loss of eye specification on the injected side of the embryo, but not on the 
uninjected side. Interestingly, embryos injected in this way also exhibit a milder truncation 
phenotype, compared with embryos injected with 0.8ng x/GABABL(a) cRNA into two dorsal 
blastomeres (see Figure 6.10A), indicating that the determinants giving rise to the 
truncation phenotype also reside in dorsal tissues.
The data shown in Figure 6.1 OB reveal that embryos injected with 1.6ng x/GABABL(a) 
cRNA into ventral blastomeres, at the 8-cell stage, develop into tadpoles that exhibit no 
observable morphological defects and are indistinguishable from their uninjected wild-type 
counterparts. These data demonstrate that the distinct morphology observed in injected 
embryos occurs when x/GABABL(a) protein is overexpressed in dorsal tissues, and that 
overexpression in ventral tissues has no observable effect on X.laevis embryo 
development.
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6.2.9 The phenotypic effects observed in xlG A B A BL(a) overexpressing embryos are
cRNA concentration-dependent
The data presented in Figures 6.11 and 6.12B show that stage 40 embryos, injected with 
x/GABABL(a) cRNA at the 2-cell stage, exhibit morphological defects even at significantly 
reduced cRNA concentrations. When 0.2ng x/GABABi_(a) cRNA is injected into 2-cell 
blastulae, embryos exhibit minimal morphological defects at stage 40, with just 24% 
deviating from the wild-type phenotype, scoring 2 or 3. However, when 0.4ng x/GABABL(a) 
cRNA is injected, this percentage proportion increases to 86%. When 0.8ng or 1.6ng 
x/GABABL(a) cRNA is injected, 100% of embryos exhibit morphological defects at stage 40, 
whilst embryo viability drops from 100%, when 0.4ng cRNA is injected, to around 60% or 
45%, when 0.8ng or 1.6ng cRNA is injected. These data strongly suggest that the 
phenotype observed in these injected embryos occurs as a result of x/GABABL(a) 
overexpression, and that these effects are observed even at significantly reduced cRNA 
concentrations.
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6 .3  Characterisation of the phenotypes arising from x/G A B A BL(a) overexpression
during embryo development
6.3.1 Investigating the effect of xIGABAblm overexpression on convergent extension
The data shown in Figures 6.9, 6.10 and 6.11 indicate that a prominent and reproducible 
phenotype occurring in tailbud and tadpole embryos, as a result of x/GABABi_(a) 
overexpression, is body truncation. Convergence and extension of mesodermal tissue 
has been shown to be critical for anteroposterior axial elongation in Xenopus embryos, 
and is regulated by the non-canonical Wnt/PCP signalling pathway during gastrulation 
(Tada.M et al. 2000, Wallingford,J.B et al. 2000, Wallingford, J.B et al. 2001) (see Section 
1.1.4). It was postulated here that a reduction in axial elongation of tailbud embryos 
overexpressing x/GABABL(a) might occur as a result of earlier failures in the regulation of 
cell movements and polarity during gastrulation.
In order to investigate the effect of x/GABABL(a> overexpression on mesodermal induction 
and convergent extension, and thus assay the biological activity of x/GABABL(a) protein 
during gastrulation, animal caps explanted from x/GABABL(a)-injected and uninjected 
embryos were incubated in the presence and absence of the mesoderm-inducing growth 
factor, activin A, as described in Section 2.3.9. This experiment was performed twice, and 
representative caps and embryos were selected for photographing. Photographs showing 
x/GABABL(a)-overexpressing animal caps at stage 21, following incubation with or without 
activin, are shown in Figures 6.13A and C; uninjected animal caps at stage 21, following 
incubation with or without activin, are shown in Figures 6.13D and E. x/GABABL(a)-injected 
and uninjected stage 21 embryos are shown in Figures 6.13E and F respectively.
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Figure 6.13 A. Animal caps at stage 21 following micro-injection with 1.6ng 
x/GABAblo) cRNA at 2-cell stage. B. Uninjected control animal caps at 
stage 21. C. Animal caps at stage 21 following micro-injection with 1.6ng 
x/GABAeua) cRNA at 2-cell stage and incubation with activin A.
D. Uninjected control animal caps at stage 21 following incubation with 
activin A. E. Embryos at stage 21 following micro-injection with 1.6ng 
x/GABABL(a) cRNA at 2-cell stage. F. Uninjected embryos at stage 21.
Abbreviations: Act (activin A)
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6.3.2 xIGABAblw overexpression interferes with convergent extension in animal caps
The data shown in Figures 6.13C and D indicate that animal caps explanted from 
embryos overexpressing x/GABABL(a), following microinjection of 1.6ng x/GABABL(a) cRNA 
at the 2-cell stage, respond differently to caps explanted from uninjected wild-type 
embryos, following incubation with the mesoderm-inducing growth factor, activin A. 
Following explantation, in the absence of activin, both sets of animal caps healed to form 
spheroidal clumps of epidermal tissue (see Figures 6.13A and B). In the presence of 
activin, cells were observed to differentiate into presumptive mesodermal tissue in both 
sets of caps by stage 12. By stage 21 this tissue had become markedly elongated in the 
wild-type caps, but not in those overexpressing x/GABABL(a) (see Figures 6.6C and D). 
These data indicate that, whilst the initial induction of mesodermal tissue by activin 
appears to be unaffected, the subsequent elongation of mesoderm by convergent 
extension, in caps overexpressing xlGABABL(a), is limited compared to that observed in 
induced wild-type caps.
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6 .3 .3  Investigating the effect of x lG A B A BL(a) overexpression on the transcriptional 
regulation o f mesoderm-specific markers
In order to confirm the presence of mesodermal tissue in the animal caps incubated with 
activin A in Section 6.3.1, and to investigate the biochemical activity of x/GABABL(a) in this 
assay, reverse-transcriptase PCR (RT-PCR) was used to detect mRNAs transcribed from 
genes known to be upregulated following mesoderm induction. Six such mesoderm- 
specific markers were chosen for investigation. Xenopus brachyury (xBra), a transcription 
factor widely expressed in the mesoderm that is necessary for convergent extension and 
notochord differentiation (Smith,J.C et al. 1991, Conlon,F.L et al. 1996, Smith,J.C et al. 
1997), type-ll collagen (xColl-2), a major structural component of the outer sheath of the 
notochord (Bieker,J.J et al. 1992, Su.M.W et al. 1991), lysyl oxidase-like 3 (xLoxl-3), a 
putative amine oxidase specifically expressed in the notochord (Geach.T et al. 2005), 
aipha cardiac actin (xa-actin), a marker of cardiac muscle differentiation induced by activin 
A (Logan,M et al. 1993), sox-2 (xSox-2), a transcription factor involved in neural induction 
(Mizuseki.K et al. 1998), and endodermin (xEndo), an endoderm-specific marker that is 
also expressed in the notochord during neurulation (Ahmed,N et al. 2004). Detection of 
the uniformly expressed Xenopus orthinine decarboxylase (x/ODC), an essential 
metabolic enzyme present in all embryonic cells, was used as control in this assay.
Total RNA was extracted from x/GABABL(a)-injected and uninjected caps, following 
incubation in the presence or absence of activin A, and x/GABABL(arinjected and 
uninjected embryos, at stage 21, as described in Section 2.1.8. RT-PCR was carried out, 
as described in Section 2.1.10, using the oligonucleotide primers and annealing 
temperatures shown in Table 6.14. The DNA fragments amplified by RT-PCR are shown 
in Figure 6.15.
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Transcript Primers Nucleotide Sequence
Loc
(bp)
Size
(bp) °C
Reference
xBra xBra-fwd1 5 1-GCTGGAAGTATGTGAATGGAG-3 ' 433 319 52.0 Agius.E et al.
xBra-rev1 5'-TTAAGTGCTGTAATCTCTTCA-3' 731 2000
xColl-2 xColl-2-fwd1 5'-AGGCTTGGCTGGTCCTCAAGGT-3 ' 3470 398 52.0 Sasai.Y et al.
xColl-2-rev1 5'-TGTAACGCATAGGGTCGGGTCC-3 ' 3846 1996
xLoxl-3 xl_oxl-3-fwd1 5'-CAAGGAATCACAGTAGGATGCTG-3' 616 243 52.0 Geach.T et al.
xLoxl-3-rev1 5 ’-ACGCTTATTTGCTTCTTCGCTG-3' 859 2005
xa-actin xa-actin-fwd1 5 ’-TCCCTGTACGCTTCTGGTCGTA-3' 480 253 52.0 Stutz.F et al. .
xa-actin-rev1 5'-TCTCAAAGTCCAAAGCCACATA-3' 711 1986
xSox-2 xSox-2-fwd1 5'-GAGGATGGACACTTATGCCCAC-3 ' 484 214 52.0 DeRobertis.E.M
xSox-2-rev1 5'-GGACATGCTGTAGGTAGGCGA-3' 677 etal. 1997
xEndo xEndo-fwd1 5'-AGCAGAAAATGGCAAACACAC-31 1521 386 52.0 Sasai.Y et al.
xEndo-rev1 5'-GGTCTTTTAATGGCAACAGGT-3' 1868 1996
x/ODC xODC-fwd1 5 1-CAGCTAGCTGTGGTGTGG-3' 674 228 52.0 Agius.E et al.
xODC-rev1 5'-CAACATGGAAACTCACACC-3' 883 2000
Table 6.14 Summary of oligonucleotide primers used for RT-PCR. Binding loci (bp), amplicon sizes (bp), 
annealing temperatures used (°C), and references are shown.
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Figure 6.15 DNA fragments generated by RT-PCR from reverse-transcribed total RNA from
x/GABAeL(a)-injected and uninjected stage 21 animal caps, following incubation with or without activin, and
embryos. -RT controls for embryos are shown.
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6.3.4 xlGABABL(a) overexpression does not interfere with mesoderm induction
The data shown in Figure 6.15 indicate that transcripts encoding six markers of activin- 
induced mesoderm formation are readily detected by RT-PCR in both wild-type and 
x/GABABL(a)-overexpressing induced animal caps and embryos. In contrast, only x/ODC 
transcripts are detected in un-induced wild-type and x/GABABL(a)-overexpressing animal 
caps. These data indicate that the differentiated tissue, observed in both the induced 
wild-type and x/GABABL(a)-overexpressing animal caps (see Figures 6.13C and D), is 
indeed mesodermal, and demonstrate that overexpression of x/GABABL(a) does not affect 
the transcriptional regulation of the mesoderm-specific markers examined here in 
response to induction by activin A.
Taken together, the data shown in Figures 6.13 and 6.15 strongly suggest that 
xlGABABL(a) is a biologically active protein that interferes with mesodermal convergent 
extension, but not induction, when overexpressed in X.laevis animal cap explants.
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. 6.3.5 Examination of internal structures of embryos overexpressing x IGABAblw
The data shown in Figures 6.9, 6.10 and 6.11 indicate that overexpression of x/GABABL(a) 
during embryonic development generates a reproducible body truncation phenotype in 
embryos that otherwise exhibit many wild-type features, such as differentiated head, tail 
and fin structures. In addition, the data shown in Figures 6.13 and 6.15 indicate that the 
morphogenetic effects of x/GABABL(a) overexpression occur without affecting the 
transcriptional regulation of markers of mesoderm differentiation, suggesting that key 
internal structures such as the notochord, derived from chordamesoderm, and the 
somites, derived from paraxial mesoderm, would be developed in x/GABABL(a)- 
overexpressing tailbud or tadpole embryos.
To investigate the internal morphology of X.laevis embryos overexpressing x/GABABL(a), 
transverse wax sections of injected and uninjected stage 40 embryos were cut and 
stained, as described in Section 2.3.6. Photographs of sections cut from representative 
embryos are shown in Figure 6.16, and enlarged photographs showing sections of interest 
are presented in Figure 6.17.
262
x IGABAblo) 1 6ng u n in je c t e d
msc
xlGABABL(a) 1 6ng
msc
u n in je c t e d
Figure 6.16 A. Stage 40 embryo, injected with 1.6ng x/GABAbl(3 ) cR N A  at the 2-cell stage, showing 
location of transverse sections a, p, y. 6 ar|d £ B Uninjected wild-type embryo at stage 40, showing 
location of transverse sections a, p, y, 6 and e. C. Transverse wax sections of a stage 40 embryo, 
injected with 1.6ng x /G A B A BL(a> cRNA at the 2-cell stage. D. Transverse wax sections of an uninjected 
wild-type embryo at stage 40. Abbreviations: bv (brain ventricle), df (dorsal fin), eye (eye), gut (gut), In 
(lens), msc (mesencephalon), not (notochord), nt (neural tube), oc (oral cavity), ov (otic vesicle), rbc 
(rhombencephalon), som (somite). Scale bars shown represent 200pm.
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som
xlGABAaL(a) 1.6ng
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Figure 6.17 Enlarged transverse wax sections y and 6 from A. a stage 40 embryo injected with 1.6ng 
x /G A B A BL(a) cRNA at the 2-cell stage, and B. an uninjected wild-type embryo at stage 40. Abbreviations: 
not (notochord), np (neural plate), nt (neural tube), rbc (rhombencephalon), som (somite).
Scale bars shown represent 200pm.
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6.3.6 Embryos overexpressing xlG A B A Bi_(a) exhibit brain, eye, notochord and neural 
plate defects
The data shown in Figures 6.16 and 6.17 reveal several differences between the internal 
morphology of embryos overexpressing x/GABABL(a) and wild-type embryos at stage 40. 
Whilst most differentiated internal structures are present in x/GABABL(arinjected embryos, 
such as the brain, neural plate, notochord and somites, there are marked differences in 
the morphology of these structures, particularly anteriorly, compared to wild-type embryos. 
Like many embryos overexpressing x/GABABL(a), the animal sectioned here is cyclopean 
and possesses a single eye that contains a lens but which exhibits a distinct morphology 
from the wild-type embryonic eye (see Figures 6.16Ca and p). This animal also exhibits 
distinct morphology in anterior regions of the brain, such as the mesencephalon and 
rhombencephalon, and lacks a visible brain ventricle. However, consistent with the 
observation that eye defects occur sporadically in x/GABABL(aroverexpressing embryos 
(see Figures 6.9, 6.10 and 6.11), other injected embryos sectioned here display wild-type 
eye morphology, even when cyclopean, and possess brain ventricles.
A consistent observation made in all x/GABABL(a)-overexpressing embryos sectioned here 
was the presence of a markedly enlarged notochord and neural tube, across the left-right 
axis, and a more open neural plate with respect to wild-type embryos (see Figures 6.17A 
and B). In addition, the cells inside the notochord of injected embryos appeared larger 
and more vacuolated than their wild-type counterparts. Taken together with the fact that 
x/GABABL(a)-overexpressing embryos are truncated, the data shown in Figures 6.17A and 
B indicate that the notochord must be considerably shorter and broader in injected 
embryos than in wild-type embryos. These data support the hypothesis, based upon the 
results from the animal cap experiments carried out in Section 6.3.1, that x/GABABL(a)-
overexpression induces morphological defects in differentiated mesodermal structures, 
such as the notochord, that give rise to the phenotypic effects observed in injected 
embryos.
266
6.4 Discussion
In this chapter, 5’-capped polyadenylated cRNAs, in vitro transcribed from x/GABAB(ia), 
x/GABAB(1b), x/GABAB(2) and x/GABABL(a) expression constructs in Section 3.5, were 
microinjected into cleavage stage embryos to achieve overexpression of the encoded 
proteins during X.laevis embryonic development. In each case, the morphogenetic and 
behavioural effect of overexpression of these individual proteins, and co-expression of the 
x/GABAB(1) and x/GABAB(2) receptor subunit proteins, was evaluated, and the former was 
also quantified by means the scoring system developed in Section 2.3.9. The effect of 
targeting overexpression of these proteins towards distinct developing tissues was 
investigated, and the reproducible phenotypes derived from x/GABABL(a) expression were 
further characterised by means of a animal cap mesoderm elongation assay, and by 
analysis of wax-sections from x/GABABL(a)-injected embryos. The key findings from the 
data presented in this chapter are evaluated below.
6.4.1 Overexpression ofxlGABAB receptor subunits or heterodimers during X.laevis
development does not generate a reproducible morphological phenotype
In Sections 6.2 of this chapter, x/GABAB(1) and x/GABAb(2) receptor subunit cRNAs were 
microinjected into X.laevis blastulae, either in isolation or in combination, to induce the 
overexpression of x/GABAb receptor subunits or heterodimers during embryonic 
development, respectively. It was hypothesized here that overexpression of x/GABAb 
receptor heterodimers might increase GABA-ergic inhibition of neural circuits and reduce 
embryo locomotion, swimming activity or response to stimulus. It was further postulated
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that x/GABAB(i) and x/GABAB(2) receptor subunit or heterodimer overexpression might 
produce observable changes in morphology, indicative of a role for these proteins in the 
morphogenetic events occurring during embryogenesis. However, the results presented 
here provide no evidence to support these hypotheses, and demonstrate that 
overexpression of x/GABAb receptor subunits or heterodimers has a very limited effect of 
the morphology and overt behaviour of developing embryos, even when expressed at a 
high level in the developing CNS.
The data presented in Figure 6.4 show that stage 40 embryos, injected with x/GABAB(1a), 
x/GABAB(1b) or x/GABAB(2) subunit cRNAs at the 2-cell stage, exhibit wild-type morphology 
and score similarly to uninjected stage 40 embryos. When x/GABAB(1a), x/GABAB(1b) or 
x/GABAB(2) subunit cRNAs are concentrated in dorsal tissues, following microinjection into 
8-cell blastulae, around 10% of embryos exhibited moderate or severe morphological 
defects at stage 40, scoring 3 or 4, but around 80% were indistinguishable from wild-type 
embryos at stage 40 and scored 1. These data strongly suggest that overexpression of 
x/GABAb receptor subunits during X.laevis development does not bring about any 
significant morphogenetic effect.
The data presented in Figure 6.8 indicate that co-microinjection of x/GABAB(1a/2) or 
x/GABAB(1b/2) cRNAs into 2-cell blastulae gives rise to increased deviation from wild-type 
morphology at stage 40, compared to that of the component subunit cRNAs, with 23% 
x/GABAB(1a/2)-injected and 41% x/GABAB(1b/2)-injected embryos exhibiting morphological 
defects. When x/GABAB(ia/2) or x/GABAB(1b/2) cRNAs are concentrated in dorsal tissues, 
following co-microinjection into 8-cell blastulae, these percentages increase to around 
40%. Intriguingly, 20% of embryos overexpressing x/GABAB(1a/2) heterodimers exhibited 
severe morphological defects at stage 40, such as acephaly, and were assigned a score
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of 4; this is in contrast to those overexpressing x/GABAB(1b/2) heterodimers, of which none 
scored the maximum of 4. Whilst it is tempting to speculate that this might represent an 
isoform-specific morphogenetic effect, perhaps mediated by the extracellular sushi 
domains unique to x/GABAB(1a), the acephaly recorded here was not always observed 
when experiments were repeated, although defects were generally more severe in 
x/GABAB(1a/2)-overexpressing embryos in these experiments. Thus, since it was not 
possible to infer any specific reproducible phenotype from these data, and given that the 
majority of x/GABAB(ia/2) or x/GABAB(1b/2)-injected embryos exhibit wild-type morphology, 
the data presented in this chapter suggest that overexpression of x/GABAb receptor 
heterodimers during X.laevis development does not bring about any reproducible 
morphogenetic effect.
6.4.2 Overexpression of x IG A B A blw during X.laevis embryonic development generates
a reproducible morphological phenotype
In Section 6.2 of this chapter, x/GABABL(a) cRNA was microinjected into X.laevis blastulae 
to induce the overexpression of x/GABABL(a) protein during embryonic development. The 
data presented in Figure 6.12A show that 100% of embryos, injected with x/GABABL(a) 
cRNA at the 2-cell stage, exhibit moderate or severe body truncation at stage 40, and 
score 3 or 4. When x/GABABL(a) cRNA in concentrated in dorsal tissues, following 
microinjection into 8-cell blastulae, a similar result is obtained except that the proportion of 
severely truncated embryos, scoring the maximum of 4, increases from 23% to 67%. 
These data strongly suggest that overexpression of x/GABABL(a) during X.laevis 
development reproducible gives rise to body truncation. In addition, some x/GABABL(a)- 
injected embryos also exhibited head or eye defects, such as cyclopia, and some
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exhibited more general failures during gastrulation giving rise to acephaly, open neural 
plates and split tails. Further experimentation revealed that overexpression of x/GABABL(a) 
in ventral tissues has no observable morphogenetic effect, indicating that the 
determinants giving rise to these phenotypes must reside in dorsal tissues (see Figure
6.1 OB). The data shown in Figures 6.11 and 6.12B demonstrated that the phenotypes 
observed in x/GABABL(arinjected embryos manifest themselves in a cRNA concentration- 
dependent manner, and that the principal truncation phenotype was observed even at 
relatively low cRNA concentrations, further strengthening the case for a x/GABABL(a)- 
specific morphogenetic effect.
The biological activity of x/GABABL(a) was directly demonstrated here by means of an 
animal cap assay, whereby activin-induced elongation of mesodermal tissue by 
convergent extension was shown to be restricted in animal caps overexpressing 
x/GABABL(a), compared to that observed in wild-type caps (see Figure 6.13). Further 
analysis of these animal cap explants revealed that the transcription regulation of six 
genetic markers of mesoderm induction was unaffected by x/GABABL(a) overexpression, 
suggesting that the morphogenetic effects observed here do not occur as a result of 
x/GABABL(a)-induced missexpression of these genes. Indeed, the animal sections shown 
in Figures 6.16 and 6.17 demonstrate that the differentiation of principal mesodermal 
structures in the tadpole embryo, such as the notochord and somites, which derive from 
chordamesoderm and paraxial mesoderm respectively, is unaffected by x/GABABL(a) 
overexpression. However, these sections do show that the notochord in x/GABABL(a)- 
injected embryos is generally shorter and broader than in uninjected embryos, and that 
the cells of the notochord tend to appear larger and more vacuolated (see Figure 6.17). 
jh eSe effects are consistent with the overt body truncation phenotype observed in 
injected embryos and suggests that overexpression of x/GABABL(a) interferes with the
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normal axial elongation of the notochord. The irregular organisation of cells in the 
differentiated notochord may be attributed to earlier aberrations in the regulation of 
mesodermal cell motility or polarity during gastrulation, bringing about failures in the 
convergent extension movements that are critical for establishing the anteroposterior 
tissue polarity required for normal axial elongation of the tailbud ewnbryo (Adams,D.S et al. 
1990, Wallingford,J.B et al. 2000, Wallingford,J.B et al. 2001, Tadia.M et al. 2002).
Consistent with the notion that GABABL(a) is a putative orphan GPCR (Calver.AR et al. 
2003, Charles,K.J et al. 2003, Martin,S.C et al 2004), these data indicate that x/GABABL(a) 
may be mediating its effects by signal transduction. Furthermore, the demonstration that 
x/GABABL(a) overexpression specifically disrupts mesodermal convergent extension is 
highly indicative of interference in the non-canonical Wnt/PCP siginalling pathway (Tada.M 
et al. 2000, Wallingford,J.B et al. 2000, Wallingford, J.B et al. 2001) (see Section 1.1.4). 
Thus, it is postulated that, when overexpressed in X.laevis embryos, x/GABABL(a) couples 
to G-proteins and activates intracellular signalling cascades tha t directly or indirectly 
disrupt the non-canonical Wnt/PCP pathway, modulating cell movements or polarity 
during gastrulation without necessarily affecting cell fate.
6.4.3 Summary
The data presented in this chapter provide strong evidence for ^  specific morphological 
phenotype in embryos overexpressing x/GABABL(a), but not x/GABAb receptor subunits or 
heterodimers. The demonstration that x/GABAb receptor heterodimer overexpression in 
the CNS does not bring about reproducible changes in X /aev/s embryo morphology 
during development is consistent with the results from previous animal studies, which
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revealed that knock-out of either of the GABAB(i) and GABAB(2) genes in mice does not 
adversely affect the normal development of mouse embryos (Prosser,H.M et al. 2001, 
Schuler,V et al. 2001, Queva.C et al. 2003, Gassmann,M et al. 2004). These data 
suggest that metabotropic GABA signalling does not play a major role during vertebrate 
embryogenesis. The demonstration that overexpression of x/GABABi_(a) during X.laevis 
development generates a reproducible body truncation phenotype, and inhibits 
mesodermal convergent extension in explanted animal caps, suggests that the 
x/GABABL(a) cDNA clone isolated in Section 3.4 (see Figure 3.17) encodes a functional 
protein that acts in a manner reminiscent of a GPCR, by modulating intracellular signal 
transduction cascades such as the non-canonical Wnt/PCP signalling pathway.
Discussion
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7.1 Vertebrate GABAb receptor genes are highly conserved
7.1.1 X.laevis GABAB(i) and GABAB(2) receptor proteins exhibit striking homology to 
their mammalian orthologues
In Results Chapter One of this thesis, three X.laevis cDNA clones encoding amino acid 
sequences that shared identity with human GABAB(i), GABAB(2) and GABAbl protein 
sequences were identified by homology searches. Sequence analysis of these clones 
uncovered open reading frames encoding putative full-length x/GABAB(1b) and x/GABAb(2), 
and the C-terminus of putative x/GABAbl, shown in Figures 3.5, 3.11 and 3.15 
respectively. Using a combination of 5’RACE, RT-PCR and site-directed mutagenesis, 5’ 
exons encoding the N-termini of putative x/GABAB(1a) and x/GABAbl were isolated and 
used to assemble the full-length x/GABAB(1a) and x/GABAbl cDNA clones shown in Figures
3.6 and 3.17. Using 5’RACE, three distinct x/GABAB(1a) N-terminal variants were isolated 
(see Figure 4.4), as was a cDNA encoding a truncated x/GABAbl protein that was 
predicted to possess only a single transmembrane domain, termed here x/GABABL(b) (see 
Figure 3.16).
Multiple sequence alignments of human, rodent and X.laevis GABAb receptor protein 
sequences uncovered striking homology across GABAB(ia), GABAB(1b) and GABAB(2) 
functional domains, with the human and X.laevis orthologues sharing 76%, 78% and 82% 
amino acid sequence identity respectively. Dissimilarities were observed between 
mammalian and X.laevis N-terminal secretion signal peptide sequences, and x/GABAB(1) 
proteins were also found to possess an 24 amino acid insert in their intracellular C- 
terminal tails, in a region previously demonstrated to be non-essential for normal GABAb
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receptor function (Margeta-Mitrovic.M et al. 2001a) (see Figures 3.7 and 3.8). Analysis of 
the X.tropicalis GABAB(1) exon structure, shown in Figure 4.1, demonstrated that the latter 
sequence was found within exon 18, and is thus not generated by a novel splicing 
mechanism. This insertion constitutes the most marked divergence from the mammalian 
GABAB(i) receptor protein sequences.
The overall high level of amino acid sequence identity shared between mammalian and 
X.laevis GABAB(i) and GABAB(2) receptor proteins, particularly across the PBP-like, 
transmembrane and coiled-coil domains demonstrated to be essential for normal GABAb 
receptor function, is highly indicative of a conserved role for these subunit proteins, and 
thus heterodimeric X.laevis GABAb receptors.
7.1.2 X.laevis GABAB(i) subunit proteins may be more readily trafficked to the plasma 
membrane than their mammalian counterparts
A notable distinction between mammalian and X.laevis GABAb(1) proteins, with intriguing 
physiological implications, is the deletion of six amino acids at the C-terminal end of the 
coiled-coil domain just upstream of the RSR(R) ER-retention motif in x/GABAB(1). The 
multiple sequence alignments shown in Figures 3.7 and 3.8 suggest that this deletion 
would give rise to a truncation of the coiled-coil domain in x/GABAB(1) by one complete turn 
in the alpha helix (approximately four amino acid residues). However, analysis of the 
amino acid sequence immediately downstream of this deletion in x/GABAB(i) reveals that 
the resulting N-terminal shift would bring the next leucine residue, in the subsequent 
sequence RQQL, into position a of the coiled-coil heptad repeat, thereby reconstituting the 
deleted C-terminal turn in the coiled-coil motif. The net result of this deletion thus appears
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to be the translocation of the RSS(R) ER-retention motif proximally to the coiled-coil 
domain by six amino acids, with respect to mammalian GABAB(i) proteins. Whilst there is 
contention as to whether the specific amino acid sequence upstream of the ER-retention 
motif is of major significance to the function of this signal (Grunewald.S et al. 2002, 
Gassmann.M et al. 2005) (see Section 3.2.6), the latter study by Gassmann and 
colleagues demonstrates that translocation of the RRS(R) motif in GABAB(i) closer to the 
plasma membrane dramatically reduces its effectiveness, consistent with the model that 
RXR-type ER-retention motifs require a certain distance from the plasma membrane to 
function properly (Shikano.S et al. 2003).
It is hypothesized here that, as a result of this deletion, the RSR(R) signal in x/GABAB(1) 
may not function as efficiently as that found in mammalian GABAB(1) proteins, and so 
x/GABAB(1) proteins might be more readily trafficked to the plasma membrane in the 
absence of the x/GABAB(2) subunit, challenging the accepted paradigm that GABAb 
receptor heterodimerization is regulated by this trafficking checkpoint (Margeta-Mitrovic.M 
et al. 2000, Pagano.A et al. 2001). Whilst an investigation into the significance of this 
deletion was outside the scope of this project, the cloning of the x/GABAB(1) cDNAs here 
would facilitate a comparative study of mammalian and x/GABAB(1) subunit trafficking that 
would also provide an interesting point of reference for future studies into the function of 
RXR-type ER retention signals.
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7.1.3 X.laevis GABAB(ia) N-terminal variants may give rise to GABAb receptor 
heterogeneity in vivo
The three x/GABAB(1a) N-terminal variants isolated here by 5’RACE were shown to exhibit 
variability at exon 1a4, upon the elucidation of X.laevis GABAB(1) exon organisation in 
Section 4.2.1. x/GABAB(1a) variant 1 was shown to possess two exons at this location, 
whereas x/GABAB(ia) variant 2 possess a single exon, analogous to mammalian GABAB(1a) 
receptor sequences (see Figure 4.4). x/GABAB(ia) variant 3 was characterised by the 
skipping of exon 1 a4, analogous to the rat GABAB(1a) splice variant, GABAB(1f) reported 
previously (Isomoto.S et al. 1998, Wei,K et al. 2001a). Whilst the exon 1a4 ‘doublet’ 
observed in x/GABAB(1a) variant 1 has not been reported previously, the alternative splicing 
of exon 1a4 observed in both mammalian and X.laevis sequences suggests the possibility 
of functional heterogeneity within GABAB(1a/2) receptor heterodimer populations.
The amino acids encoded by exon 1a4 reside immediately C-terminally of the sushi 
domains, which represent the only major structural dissimilarity between GABAB(1a) and 
GABAB(1b) proteins and are assumed to be responsible for all GABAB(1a)-specific functions 
(Bettler.B et al. 2006). Until recently, the separation of GABAB(1a) and GABAB(1b) proteins 
by functional means was not possible, however, it is now demonstrated that GABAB(1a/2) 
heterodimers form predominantly presynaptic heteroreceptors and are largely excluded 
from dendritic spines where post-synaptic GABAB(1b/2) receptors are found (Vigot.R et al, 
2006, Perez-Garci.E et al. 2006). This process of exclusion is presumably mediated by 
interactions between the sushi domains and hitherto unidentified extracellular factors. 
This discovery has since rekindled interested in the various GABAB(ia) splice variants 
reported previously, such as /7GABAB(1c), which is characterised by the skipping of exon 
1a3 and encodes a protein lacking the second sushi domain of hGABAB(1a) (Calver,A.R et
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al. 2001, Martin.S.C et al. 2001). Interest in this variant is further compounded by the 
demonstration that the two sushi domains in GABAB(ia) exhibit markedly distinct structural 
properties, implying that they may interact with distinct factors in vivo (Blein.S et al. 2004). 
It is postulated here that GABAB(ia) N-terminal variants may contribute to GABAB(ia/2) 
receptor heterogeneity through differential interaction with the factors regulating GABAB(1a) 
subunit-specific trafficking and exclusion, perhaps giving rise to subtle variation in sub- 
cellular localisation or association with other cell-surface proteins. Whilst it is difficult to 
hypothesize the physiological significance of the variability at exon 1a4 reported here, in 
the absence of a model describing the mechanism by which GABAB(1a) sushi domains 
function, any future comprehensive investigation into the contribution of GABAB(1a) N- 
terminal variants to GABAb receptor heterogeneity might benefit from the inclusion of 
these x/GABAB(1a) transcript variants in the study. It is postulated here the amino acids 
encoded by exon 1a4 represent a ‘linker’ region connecting the sushi domains to the 
ligand-binding domain, and that variations in the length of this peptide might modulate 
GABAB(1a) function through changes in the relative proximity of these domains.
7.1.4 The X.laevis GABABl cDNA isolated here encodes a genuine orthologue of 
mammalian GABAbl proteins
Multiple sequence alignments of human, rodent and X.laevis GABAbl protein sequences 
uncovered homology across the transmembrane and coiled-coil domains, with human 
GABAbl and X.laevis GABABL(a) sharing 57% amino acid identity across this region (see 
Figure 3.18). However, this percentage drops dramatically to 24% across the residues C- 
terminally to the coiled-coil domain, and as a result human GABAbl and X.laevis 
GABAblo) proteins share just 38% amino acid identity overall. This lack of absolutely
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compelling sequence homology led to the postulation that the X.laevis cDNA clone 
isolated here might have been transcribed from a distinct, yet closely related, gene that 
might also have a distinct function. However, the demonstration that the synteny of this 
gene is highly conserved in human, rat and X.tropicalis genomes provides very strong 
evidence to suggest that the clone isolated here encodes the bona fide X.laevis GABAbl 
orthologue (see Figure 4.9). This notion is further supported by the similar overall open 
reading frame length encoded by the mammalian and Xenopus G ABA bl genes, highly 
conserved extreme N- and C-termini, and the presence of several short, highly conserved 
amino acid sequences in the C-terminal tail (see Section 3.4.6). The latter sequences are 
particularly intriguing as they reside in an otherwise very poorly conserved region, and 
may therefore be of functional significance.
Taken together, these data suggest that the x/GABABL(a) protein characterised in this 
thesis is orthologous to the mammalian GABAbl proteins studied previously (Calver.A.R et 
al. 2003, Charles,K.J et al. 2003, Martin,S.C et al 2004), and thus the biological activity of 
x/GABABL(a) demonstrated in Results Chapter Four is likely also to be representative of 
mammalian GABAbl proteins.
7.1.5 Vertebrate GABAb exon organisation is highly conserved, although X. tropicalis 
GABAB(d possesses novel additional exons
The comparison of human, rat and X.tropicalis GABAb genomic organisation, undertaken 
in Section 4.4, uncovered many striking similarities between these vertebrate GABAb 
genes. Vertebrate GABAb exon sizes are well conserved and the GABAB(2) and GABAbl 
genes studied here contain the same number of exons across the species, although an
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additional unidentified 5’ untranslated X.tropicalis GABAbl exon corresponding to 5’-UTR 
of the x/GABABL(b) cDNA clone, shown in Figure 3.16, is predicted to exist. The 
organisation of the GABAB(1) gene is not so well conserved between the vertebrate 
species analysed here and, although most exon sizes and locations are similar, the 
X.tropicalis GABAB(i) gene possesses two additional exons that are not present in the 
mammalian orthologues (see Figure 4.6). The first is exon -1a2, which is a 5’ 
untranslated exon readily identified by a pairwise alignment between the x/GABAB(ia) 
cDNA sequence, shown in Figure 3.6, and X.tropicalis genomic sequences. The second 
novel exon, termed here 1a4cr, is predicted to reside within the 17,843bp X.tropicalis 
GABAB(1) intron -2, and encodes the first 7 amino acids of the putative linker region, 
discussed previously (see Section 7.1.3), found in x/GABAB(ia) variant 1 and all available 
X.tropicalis GABAB(1a) ESTs (see Figure 4.4). This exon is perhaps more controversial, as 
direct demonstration of its existence is currently precluded by poor sequence integrity in 
the published X.tropicalis GABAB(1) intron -2  sequence. However, the presence of exons 
1a4or and 1a4/3 in expressed transcripts provides compelling evidence of the existence of 
these two closely related Xenopus-spec\T\c 21 bp exons, analogous to mammalian 
GABAB(1a) exon 1a4, and represents the first the first time an additional translated exon 
has been discovered in any vertebrate GABAb gene. Whilst time constraints restricted 
any further experimentation as part of this project, future investigation into this 
phenomenon would benefit from the elucidation of the full nucleotide sequence for intron -  
2 in order to directly demonstrate the presence of exon 1a4cr in X.tropicalis genomic DNA.
Invertebrate GABAb genes exhibit a distinct genomic organisation that is related to the 
mammalian genes, but which is characterised by having fewer exons that are often 
greater in length. Mapping of the cloned dGABAB(1) cDNA against D.melanogaster 
genomic sequences reveals that this transcript is very closely related to mammalian
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GABAB(ib) transcripts in terms of its exon structure (see Figure 4.6). Comparison of 
mammalian and D.melanogaster GABAB(2) genes reveals that the latter possesses 3’ 
exons that do not have corresponding mammalian counterparts, and encode a divergent 
GABAB(2) C-terminus that is specific to invertebrates (see Figure 4.7). The absence of a 
D.melanogaster GABAbl orthologue suggests that this gene is not present in 
invertebrates, implying that the G A B A bl gene evolved later than the GABAb genes.
7.1.6 Genomic analysis provides evidence for a relationship between GABAbl and the 
GABAb genes
The significant amino acid sequence identity shared between the GABAb receptors and 
GABAbl is highly indicative of a genetic relationship, however, direct comparison of 
GABAB(i), GABAB(2) and G A B A bl gene organisation has not been reported previously. The 
data shown in Figure 4.10 reveal that the exons encoding hGABAbl exhibit and almost 
identical organisation to those encoding the C-termini of /7GABAB(d and hGABAB(2). 
Furthermore, the nucleotide sequence identity shared between G A B A bl and GABAso) or 
GABAB(2) exons, across this region, is comparable to that shared between GABAB(i) and 
GABAB(2) themselves, suggesting that these three genes may derive from the same 
ancestral precursor. Taken together with evidence that the G A B A bl gene is not found in 
invertebrates, but is present in non-mammalian vertebrates such as Xenopus, it is 
postulated here that G A B A bl may have diverged from one of the G A B A b genes during the 
early evolution of vertebrate species.
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7.2 X.laevis GABAb receptor mRNAs are expressed during embryonic 
development
7.2.1 X.laevis GABAB(i) and GABAB(2) receptor subunit mRNAs are differentially 
expressed during embryonic development
In Results Chapter Three of this thesis, the temporal and spatial expression patterns of 
x/GABAb receptor subunit mRNAs during X.laevis embryonic development were 
investigated using a combination of RT-PCR and in situ hybridization techniques. Initial 
analysis by RT-PCR revealed that x/GABAb receptor subunit mRNAs exhibit distinct 
temporal expression patterns between stage 5 and stage 40 of development (see Figures
5.2 and 5.3).
x/GABAB(2) transcripts were detected in all stages tested including stage 5 and 7 blastulae, 
indicating that maternally transcribed x/GABAB(2) mRNAs must be present in X.laevis 
oocytes prior to fertilisation. By contrast x/GABAB(1) transcripts were not detected until 
early gastrulation (stage 9), demonstrating that x/GABAB(1) and x/GABAB(2) gene products 
are not co-expressed during early development, despite the proposed requirement for 
both subunits for normal GABAb receptor activity. These data suggest a role for GABAB(2), 
in the absence of GABAB(1), during the very early stages of vertebrate development prior 
to gastrulation, perhaps in conferring the future GABA-ergic fate of neuronal precursor cell 
populations.
Whilst fragments corresponding to x/GABAB(1b) transcripts were readily visualised on an 
ethidium bromide gel, from late neurulation (stage 17) onwards, x/GABAB(1a) transcripts
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were only detected by Southern analysis following prolonged exposure the blot to 
photographic film. Intriguingly, two distinct fragments were detected using a x/GABAB(1a)- 
specific radiolabelled probe at stages 9, 26, 36 and 40 of development (see Figure 5.3). 
The larger of the two fragments, detected, was of the correct predicted size and almost 
certainly corresponded to x/GABAB(1a); the second fragment was some 200bp smaller. 
Analysis of the mammalian GABAB(1) transcript variants isolated previously suggests that 
this fragment may correspond to the X.laevis orthologue of f?GABAB(1C), a minor isoform 
which lacks a second sushi domain and exhibits a similar expression pattern to 
/7GABAB(1a). Whilst the identity of this amplicon was not verified here directly, though 
dideoxy sequencing of a gel-purified fragment, both the expression pattern and specific 
detection of this amplicon by a x/GABAB(ia)-specific radiolabelled probe, are highly 
indicative of this fragment corresponding to x/GABAB(1c). This is the first indication of the 
existence of a non-human GABAB(1c) orthologue.
The RT-PCR evidence presented here suggests a role for x/GABAB(1a/2) receptor 
heterodimers, during gastrulation, prior to the transcription of x/GABAB(1b) mRNAs, during 
neurulation, which is consistent with the evidence reported previously suggesting that 
x/GABAB(1a) is the primary GABAB(1) isoform expressed during early development 
(Malitschek.B et al. 1998, Fritschy.J.M et al. 1999, Fritschy.J.M et al. 2004, Martin,S.C et 
al. 2004, Steiger,J.L et al. 2004). However, the visualisation of x/GABAB(1b) but not 
x/GABAB(1a) transcripts on an ethidium bromide gel suggests that the former may be 
expressed at a much higher level upon the onset of their transcription during neurulation, 
becoming the principal GABAB(1) isoform expressed. Furthermore, x/GABAB(1b) transcripts 
appear to greatly outnumber those of x/GABAB(2) post-organogenesis (at stages 36 and 
40) (see Figure 5.2), in agreement with results published previously (Martin,S.C et al. 
2004, Steiger,J.L et al. 2004). However, despite these indications, it should be noted that
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the RT-PCR method used here was not quantitative and that band intensity is not 
necessarily related to transcript number. Efforts to investigate the expression patterns of 
x/GABAb receptor gene products quantitatively, by northern analysis, were ultimately 
unsuccessful and are not included in this thesis. In retrospect, however, it is clear that 
northern analysis would have most likely lacked the sensitivity required to detect the 
x/GABAB(ia) and putative x/GABAB(iC) transcripts amplified here by RT-PCR, and as such 
the latter technique has proved to be entirely appropriate for the purposes of obtaining 
meaningful expression pattern data in this case. In pursuit of more quantitative temporal 
expression data, a logical progression of this research would be to utilize quantitative real­
time RT-PCR to comprehensively explore the differential expression of the transcript 
variants identified in this study during X.laevis development.
Spatial expression patterns for x/GABAb receptor subunit mRNAs were analysed here by 
RT-PCR and in situ hybridization experiments, which revealed further differences between 
the expression of x/GABAB(1) and x/GABAB(2) gene products. RT-PCR again shows that 
x/GABAB(1b) mRNAs are more readily detected than those of x/GABAB(2), and are found in 
anterior, dorsal and posterior tissues, whereas x/GABAB(2) transcripts were only detected 
at stage 30 in anterior and dorsal tissues using this technique (see Figure 5.5). In situ 
hybridization experiments uncovered very similar spatial expression patterns for 
x/GABAB(1) and x/GABAb(2) transcripts throughout the developing CNS, although the 
antisense x/GABAB(1) cRNA probe consistently generated a stronger signal that the 
x/GABAB(2) probe, again possibly indicative of a greater transcript number (see Figures 5.6 
and 5.7). x/GABAB(1) and x/GABAB(2) transcripts were detected in the developing CNS 
from around stage 18 and 21 respectively, and were both found to be concentrated in the 
trigeminal nerve, hindbrain and spinal cord of the developing tailbud embryo. By stage 34 
x/GABAB(i) and x/GABAB(2) gene products were shown to be largely co-expressed
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throughout most brain regions, consistent with the proposal that both subunits are 
required for normal GABAb receptor function. However, there were areas of unique 
x/GABAB(i) transcript expression, most notably in dorsal regions of the midbrain and in 
rhombomere 2 of the hindbrain, where strong x/GABAB(1)-specific signal was observed in 
the absence of a x/GABAB(2) signal at stage 34. These x/GABAB(1)-specific signals are 
particularly intriguing as they are found in regions that have yet to differentiate into 
neuronal tissue at stage 34. The rhombomeres running along the anteroposterior midline 
of the hindbrain at this stage may be best described as paired segments of tissue 
functioning to compartmentalise distinct and mutually exclusive areas of neuronal 
development. Rhombomere 2, to which the x/GABAb(i} signal is restricted, is found at the 
root of the trigeminal nerve, and is likely to be associated with its interface with the CNS. 
The abundance of x/GABAb(1) transcripts in this region is indicative of a function for 
x/GABAB(1) subunit proteins in the differentiation of neuronal tissue in the hindbrain, prior 
to the formation of synapses and in the absence of x/GABAB(2). These data are in 
agreement with previous studies that have uncovered areas of unique x/GABAb(1) 
expression in the mammalian CNS, and supports the notion that x/GABAB(1) subunits may 
exhibit biological activity in regions lacking x/GABAB(2) (Calver.A.R et al. 2000, Charles,K.J 
et al. 2001, Kulik.A et al. 2002, Sands,S.A et al. 2003, Fritschy.J.M et al. 2004, Lopez- 
Bendito.G et al. 2004, Martin,S.C et al 2004, Gassmann.M et al. 2004).
In situ hybridisation indicates that x/GABAB(2) transcripts are expressed in the absence of 
x/GABAB(1) in what appear to be craniofacial nerves beneath the diencephalon, however 
further anatomical analysis would be necessary to confirm this as x/GABAB(2)-specific 
signal lies very close to ventral regions of the brain. Should x/GABAB(2) subunits indeed 
be expressed here, in the absence of x/GABAB(1), they might function by modulating signal
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transduction cascades through constitutive G-protein coupling activity, as proposed by 
other studies (Kaupmann.K et al. 1998b, Martin,S.C et al. 1999).
Despite these areas of unique expression, the in situ hybridisation patterns presented in 
this thesis demonstrate that x/GABAB(i) and x/GABAB(2) gene products are largely co­
expressed in the developing CNS of X.laevis, consistent with the notion that both subunits 
are required for canonical GABAb receptor activity. The marked presence of both 
x/GABAb(1) and x/GABAB(2) mRNAs in the trigeminal nerve is indicative of a function for 
metabotropic signalling in the regulation of sensory signals from the eye and cement 
gland, perhaps in concert with ionotropic GABAa receptors which are also expressed in 
these regions (Perrins,R et al. 2002, Li,W-C et al. 2003, Lambert,T.D et al. 2004). 
Furthermore, the broad expression pattern of these mRNAs throughout the most brain 
regions is commensurate with the function of GABAb receptors as ubiquitous transducers 
of the principal inhibitory neurotransmitter signal, GABA.
The RT-PCR data presented in this thesis uncovered distinct temporal expression 
patterns for x/GABAB(1a) and x/GABAB(1b) transcript variants, and as such distinct spatial 
expression patterns during embryonic development were considered possible. In situ 
hybridisation experiments were repeatedly performed, using fluorescently-labelled 
antisense oligonucleotide probes specific to x/GABAB(1a) and x/GABAB(1b), although these 
were ultimately unsuccessful and are not included in this thesis. Whilst these experiments 
were abandoned on technical grounds, due to high background fluorescence, the RT-PCR 
and Southern blot data suggest that x/GABAB(1a) transcripts are considerably less 
abundant than those of x/GABAB(1b). In retrospect, it seems likely that this in situ 
hybridisation method would have lacked the sensitivity required to detect x/GABAB(1a) 
transcripts without amplification, and as such, the x/GABAB(1)-specific staining observed in
286
Figure 5.6 may be considered representative primarily of x/GABAB(ib) transcript 
expression.
7 .2.2 The expression pattern for x lG A B A BL(a) suggests a distinct function from
xIGABAb receptors during vertebrate development
The RT-PCR and Southern blot data shown in Figures 5.2 and 5.3 demonstrated that 
x/GABABL(a) transcripts were not detected until stage 17 of development. However, further 
analysis of x/GABABL(a) expression during neurulation revealed that x/GABABL(a) transcripts 
were in fact first detectable at stage 14 using this method (see Figure 5.4). Initial analysis 
of the  spatial expression of x/GABABL(a) by RT-PCR revealed that transcripts were readily 
amplified from anterior, posterior, dorsal and ventral tissues of all stages tested (see 
Figure 5.5) suggesting that, unlike the x/GABAb receptor subunits, x/GABABL(a) mRNAs are 
ubiquitously expressed throughout the developing X.laevis embryo and are not restricted 
to the  CNS.
As with the x/GABAb receptor subunit mRNAs, the specific detection of x/GABAbl 
transcripts in neurulae by in situ hybridisation proved to be difficult, despite the fact that 
the RT-PCR data were indicative of widespread x/GABABL(a) expression at stage 14. 
Taken together, these data suggest that x/GABAbl transcripts are not sufficiently 
concentrated in any one location at this stage to permit detection by in situ hybridisation.
In s itu  hybridisation revealed that x/GABAbl transcripts are markedly concentrated in the 
otic vesicle in tailbud embryos, and at a restricted location at the anterior end of the 
hindbrain near to the isthmus (see Figure 5.8). This is in contrast to the x/GABAb receptor
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subunit mRNAs, which are readily detected in multiple brain regions by in situ 
hybridization at stage 30. By stage 34, x/GABABi_-specific staining is visible in proximal 
regions of the forebrain, midbrain and hindbrain, along the anteroposterior axial midline, 
and in the otic vesicle. x/GABAbl is co-expressed with x/GABAB(i) in parts of the otic 
vesicle at stage 34 in the absence of x/GABAB(2), as x/GABAB(1)-specific staining is also 
visible at a very restricted site at the ventral extremity of the otic vesicle (see Figure 5.6B). 
The expression pattern of x/GABAbl transcripts in the CNS also overlaps that of the 
x/GABAb receptor subunit mRNAs at stage 34, however, transverse sections reveal that 
x/GABAB(i) and x/GABAB(2)-specific staining is strongest in brain regions that are distal to 
the midline, whereas x/GABABL-specific staining is restricted to the proximal edge of the 
neural tissue surrounding the brain ventricle (see Figure 5.8C). x/GABAbl transcripts are 
also not detected in the spinal cord of the developing embryo by in situ hybridisation, 
where x/GABAB(1) and x/GABAB(2)-specific staining is prominent.
Taken together, the RT-PCR and in situ data presented in Results Chapter Three suggest 
that x/GABABl  transcripts have a distinct spatial expression pattern from x/GABAb receptor 
gene products in the developing X.laevis embryo, suggesting that the functions of GABAbl 
and GABAb receptors during vertebrate development may not be related. The expression 
of x/GABABl  at the isthmus at stage 30, and in central brain regions along the 
anteroposterior axial midline at stage 34, is indicative of involvement in proximal 
processes during the differentiation of the embryonic brain, whereas the relative 
abundance of x/GABABl  mRNA in the developing otic vesicle is indicative of a function for 
x/GABAbl in the vertebrate ear, a region where metabotropic GABA signalling has not 
previously been implicated.
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7.2.3 The absence of an expression pattern for xIGABAblm suggests that this 
transcript variant does not exist in vivo
In Results Chapter One of this thesis, a cDNA encoding a truncated x/GABABl protein, 
predicted to possess only a single transmembrane domain, was isolated by 5’RACE and 
termed x/GABAbl^) (see Figure 3.16). The notion that a single-transmembrane isoform of 
GABAbl might expressed in vivo in Xenopus was intriguing, as a human cDNA clone 
encoding a similarly truncated GABAbl protein of unknown function had recently been 
isolated (Totoki.Y et al. 2005). It was postulated that if such isoforms were expressed at 
the protein level, they might play a role in modulating GABAbl receptor activity, perhaps by 
functioning in a dominant negative manner, and so further characterisation of the 
x/GABABL(b) variant was considered desirable. Alignment of this nucleotide sequence 
X.tropicalis G A B A bl genomic sequences, however, revealed that generation of this 
putative transcript variant by RNA splicing required two novel internal splice junctions 
within X.tropicalis G A B A bl exon 1 and 7 (see Figure 4.5A). Further analysis of these 
sequences revealed that there were five possible locations for these putative splice 
junctions, due to the presence of a short repeated sequence, TGAT, at the corresponding 
location in both exons (see Figure 4.5B). However, it was demonstrated that none of 
these putative junctions generated canonical or non-canonical intron/exon boundary 
consensus sequences, implying that the x/GABABL(b) transcript variant would be only be 
generated in vivo as a result of two simultaneous cryptic splicing events (see Figure 4.5C- 
D).
Analysis of the temporal expression pattern of this putative transcript variant during 
X.laevis development was performed by RT-PCR, using a nested oligonucleotide primer 
spanning the novel splice junction identified in Section 4.3.3. Using this method, DNA
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fragments were not visible on an ethidium bromide gel in any of the stages tested, and 
hybridization of a radiolabelled x/GABABL-specific probe following Southern blotting 
uncovered no specific signal, even after the blot was exposed to photographic film for 
three weeks. Taken together with the results from the genomic analysis, these data 
strongly suggest that the x/GABABL(b) transcript either does not occur in vivo, or is 
expressed at such low levels during development that it is outside the range of detection 
by RT-PCR and subsequent Southern analysis using a radiolabelled probe. The latter 
possibility seems highly unlikely as both of these techniques are extremely sensitive, and 
indeed the molecular cloning of this variant was facilitated by the use of an RT-PCR 
method (5’RACE). It therefore seems more likely that this cDNA was generated by an 
error occurring during first strand synthesis or cDNA amplification, and is thus of no 
physiological relevance.
It was noted that similarly repeated sequences were found at the putative splice junctions 
required for the mammalian GABAB(2b) and GABAB(2C) transcripts isolated previously, which 
were also discounted as artefacts of cDNA synthesis (Clark,J.A et al 2000, Martin,S.C et 
al. 2001). It is possible that these short repeated sequences may in some way be 
required, or indeed responsible, for the skipping of template RNA sequences by the 
reverse transcriptase enzyme during cDNA synthesis. Whilst an investigation into the 
sequence-specific nature of errors reverse transcriptase errors was outside the scope of 
this project, it is postulated here that this phenomenon might occur as a result of 
secondary structure forming in the template RNA, bringing together like sequences across 
which the reverse transcriptase enzyme could pass, thus generating truncated cDNAs 
containing deletions with respect to their RNA templates.
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7.3 Overexpression of x/GABABL(a), but not x/GABAb receptors, generates a 
morphological phenotype in developing X.laevis embryos
7.3.1 No evidence for an essential role for metabotropic GABA signalling during 
X.laevis embryonic development
The expression of GABAB(1) and GABAB(2) receptor subunit mRNAs during X.laevis 
development, demonstrated in Results Chapter Three, is indicative of a role for these 
proteins, and thus metabotropic GABA signalling, during vertebrate embryogenesis. In 
Results Chapter Four of this thesis, a gain of function approach was adopted to 
investigate these potential functions using X.laevis frogs as a model organism. The 
molecular cloning of cDNAs encoding X.laevis orthologues of the mammalian GABAb 
receptors permitted the generation of expression constructs suitable for the purpose of 
transcribing 5’capped, polyadenylated cRNAs (see Section 3.5). These ‘synthetic mRNAs’ 
were then used in microinjections into cleavage stage embryos to induce overexpression 
of these proteins during X.laevis embryonic development (see Sections 6.2 and 6.3).
The rationale behind this approach was that overexpression of x/GABAb receptor 
heterodimers might increase GABA-ergic inhibition of neural circuits, reduce embryo 
locomotion, swimming activity or response to stimulus, or generate observable changes in 
morphology indicative of a role for these receptors in embryogenesis. Similarly it was 
postulated that overexpression of individual x/GABAb receptor heterodimers might amplify 
or interfere with any separate functions of these proteins, such as those proposed of 
GABAB(2) in X.laevis blastulae, in a manner that might manifest itself as an observable 
morphological phenotype. These latter experiments were also design to acts as controls
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for the heterodimer overexpression assays by permitting the evaluation of the individual 
contribution of each subunit to any morphological changes observed.
The data generated by these experiments, however, provided little evidence of any 
specific morphogenetic effects derived from overexpression of x/GABAb receptor subunits 
or heterodimers during X.laevis embryogenesis, even when expressed at a high level in 
the developing CNS (see Figures 6.4 and 6.8). Although striking morphological 
abnormalities were occasionally observed, such as acephaly in some embryos 
overexpressing x/GABAB(1a/2> heterodimers (see Figure 6.7A), these phenotypes were not 
reproducible and only occurred in a very small number of injected embryos, the majority 
being indistinguishable from their wild-type counterparts in every experiment (see Figure 
6.6D).
Although translation of proteins of the correct predicted size was demonstrated for the 
cRNAs preparations used in these experiments using an in vitro reticulocyte lysate kit (see 
Section 3.5.4), a key limitation of the experiments performed here was the absence of 
confirmation of translation of the recombinant proteins inside the X.laevis embryo. Whilst 
existing mammalian GABAb receptor antibodies are either unlikely to detect X.laevis 
GABAb receptor proteins (see Section 3.6.3) or do not perform sufficiently well to permit 
immunodetection on blotted membranes (see Section 7.5.1), the modification of the 
xIGABAb receptor constructs produced in Section 3.5 to incorporate hemagglutinin (HA), 
poly-histidine or myc epitope tags would avoid these complications and would thus 
represent a useful modification to the experiment.
The gain-of-function approach adopted here involved the use of an assay particularly 
suited to the detection of gross changes in animal behaviour or morphology in response to
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manipulation of gene expression. Subtle changes occurring at the cellular level of 
developing tissues may not be obvious using this assay, and so it is possible that 
x/GABAb receptor subunit or heterodimer overexpression might have brought about 
changes in the development of neuronal tissue in X.laevis embryos that was not detected 
here. Also, embryos were only studied until they reached stage 40 of development, thus 
precluding any analysis of post-metamorphic effects in adult frogs, when earlier changes 
occurring within neural tissues might manifest themselves as diagnosable neurological 
conditions. Indeed, it has been shown previously that both GABAB(1) and GABAB(2)- 
deficient mice, which lack canonical GABAb receptor responses, do not exhibit any overt 
morphological defects during development yet exhibit spontaneous seizures, 
hyperalgesia, impaired memory and hyperlocomotion in adulthood (Prosser,H.M et al. 
2001, Schuler,V et al. 2001, Queva.C et al. 2003, Gassmann.M et al. 2004). Taken 
together with these results, the data presented in Section 6.2 provide evidence to support 
the notion that metabotropic GABA signalling does not play an essential role during 
vertebrate embryogenesis.
7.3.2 xlGABAsL(a) overexpression disrupts mesodermal convergent extension and 
notochord elongation in developing X.laevis embryos
In contrast to the results from the x/GABAb receptor gain-of-function assays, 
overexpression of x/GABABL(a) gave rise to a reproducible morphological phenotype during 
X.laevis embryonic development (see Figure 6.9). Whilst a number of defects were 
apparent in these embryos, the principal phenotype observed as a result of x/GABABL(a) 
overexpression was body truncation. Further experimentation using this gain-of-function 
approach revealed that x/GABABL(a) had no morphogenetic effect when overexpressed
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exclusively in ventral tissues, suggesting that the determinants responsible for the body 
truncation phenotype most probably reside in dorsal tissues (see Figure 6.10). In 
addition, dose-response overexpression assays revealed that phenotypic changes 
occurred in injected embryos in a x/GABABi_(a) cRNA concentration-dependent manner, 
further strengthening the case for x/GABABL(a)-specific effect (see Figure 6.11).
A direct demonstration of the specific biological activity of x/GABABL(a) was achieved by 
means of the animal cap assays performed in Section 6.3.1. Here, x/GABABL(a) was 
shown to specifically interfere with the morphogenetic processes required for mesodermal 
extension, in response to induction of mesoderm differentiation by the growth factor 
Activin A, without necessarily affecting cell fate. Analysis of gene expression in these 
animal caps by RT-PCR showed that the transcription of six markers of mesoderm 
induction and convergent extension were unaffected by x/GABABL(a) overexpression, thus 
verifying the presence of mesodermal tissue in the induced caps and implying that 
structures such as the notochord and somites, derived from mesoderm, should be present 
in x/GABABL(a)-injected embryos (see Figure 6.15). Wax-sectioning and histological 
staining of x/GABABL(a)-overexpressing tailbud embryos confirmed this, and showed that 
the both the notochord and the overlying neural plate were much broader in these 
embryos compared to their wild-type counterparts (see Figure 6.17).
Axial elongation in Xenopus tailbud embryos is driven primarily by the anteroposterior 
extension of the notochord, which occurs primarily as a result of an increase in osmotic 
pressure within its vacuolated cells between stages 21 and 25 (Adams,D.S et al. 1990). 
The observed shortening and broadening of the notochord in x/GABABL(a)-injected 
embryos, and the overt body truncation phenotype, suggests that axial elongation is 
restricted in these embryos as a result of abnormal elongation of the notochord. A
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candidate protein responsible for this defect might be type-ll collagen, which is the primary 
component of the outer sheath of the notochord and provides the mechanical properties 
required for elongation (Smith,J.C et al. 1985, Bieker.J.J et al. 1992, Stemple.D. 2005). 
However, embryos injected with x/GABAbl cRNA appear truncated prior to stage 21, 
indicating that the morphogenetic effects of x/GABABL(a) overexpression occur as a result 
of earlier processes. Furthermore, RT-PCR data demonstrate that transcription of type-ll 
collagen is not affected by x/GABABL(a) overexpression in animal caps, casting doubt upon 
its significance in this case. Indeed, the absence of any apparent biochemical differences 
between wild-type and x/GABABL(a)-overexpressing animal caps, whist exhibiting markedly 
distinct morphology in response to mesoderm induction, suggests that x/GABABL(a) does 
not mediate its effects by inducing misexpression of the mesodermal markers analysed. 
Consistent with the proposal that GABAbl is a putative orphan GPCR (Calver.A.R et al. 
2003, Charles,K.J et al. 2003, Martin,S.C et al 2004), it was postulated here that 
x/GABABL(a) may be mediating its effects by signal transduction. The demonstration that 
morphogenetic cell movements are disrupted in x/GABABL(a)-overexpressing animal caps 
is consistent with this notion, since these events are regulated by G-protein signalling. 
The pathway most implicated in the regulation of convergence and extension in 
vertebrates is the non-canonical Wnt/PCP pathway, and is characterised by Wnt-5 or Wnt- 
11 ligands binding to Frizzled receptors and activating downstream small GTPases such 
as RhoA and cdc42 (Heisenberg,C.P et al. 2000, Wallingford,J.B et al. 2000, Darken,R.S 
et al. 2002, Park,M et al. 2002, Tada,M et al. 2002, Wallingford,J.B et al. 2002, Kilian.B et 
al. 2003, Takeuchi.M et al. 2003, Veeman.M.T et al. 2003, Sheldahl.L.C et al. 2003, 
Wang,J et al. 2006). These G-proteins regulate such processes as tissue separation, 
cytoskeleton rearrangements, cell adhesion, and activation of c-Jun N-terminal kinase 
(JNK), and misexpression of these genes results in gastrulation failures and body 
truncation in Xenopus embryos (Winklbauer.R et al. 2001, Choi,S.C et al. 2002, Habas.R
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et al. 2003, Penzo-Mendez et al. 2003). Overexpression of either wild-type or dominant 
negative cdc42, for example, interferes with convergent extension in both embryos and 
activin-induced animal caps without affecting mesoderm specification (Choi,S.C et al. 
2002), a phenotype analogous to that observed upon overexpression of x/GABABL(a). It is 
thus postulated that x/GABABL(a) may be directly or indirectly interfering with the non- 
canonical Wnt/PCP pathway when overexpressed in X.laevis embryos, bringing about 
aberrations in the regulation of convergent extension movements and cell polarity, and 
restricting the normal narrowing and lengthening of the notochordal mesoderm and 
overlying neural plate during gastrulation. These resultant irregularities in tissue polarity 
and patterning of the extracellular matrix would then presumably preclude the organised 
antero-posteriorly oriented cell division and elongation of the notochord, giving rise to the 
overt body truncation phenotype observed in x/GABABL(a)-overexpressing X.laevis tailbud 
and tadpole embryos.
7.3.3 xIGABAblo) overexpression occasionally results in eye and brain defects
In addition to the principal body truncation phenotype, observed in 100% of embryos 
injected with 0.8ng x/GABABL(a) cRNA or more (see Figure 6.11 A), a significant minority of 
x/GABABL(a)-overexpressing embryos also exhibited eye and head defects. Whilst it may 
be difficult to resolve possible x/GABABL(a)-specific head or defects and those brought 
about by more generalised severe gastrulation defects, there is some evidence to suggest 
that x/GABABL(a) overexpression causes cyclopia in otherwise well differentiated tadpole 
embryos (see Figures 6.9E and 6.10C). The initial specification of the vertebrate eye field 
is known to be highly dependent upon the activity of the transcription factor Pax-6, as 
mutations in this gene generate ‘small eye’ and ‘eyeless’ phenotypes in mouse and
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Drosophila respectively (Hill.R.E et al. 1991, Quiring.R et al. 1994), and overexpression 
gives rise to fully differentiated ectopic eyes in Xenopus embryos (Chow.R.L et al. 1999). 
The primary cause for cyclopia in vertebrates, however, is the incomplete separation of 
the eye field into two separate eye primordia, a process that is thought to occur from 
around stage 16 in Xenopus when the extending prechordal plate reaches its most 
anterior aspect (Li,H et al. 1997). Whilst the molecular mechanisms responsible for this 
process are not yet clear, there is evidence to suggest that, in addition to Pax-6, both 
retinoic acid (RA) and Wnt signalling may be involved (Cavodeassi,F et al. 2005, De 
longh.R.U et al. 2006). It has been also been suggested that Dishevelled (Dsh) may 
mediate ephrinBI signalling in the Xenopus eye field via the PCP pathway, further 
implicating this signalling pathway in vertebrate eye development (Lee,H-S et al. 2005). 
Whilst it is tempting to postulate that the proposed interference with non-canonical 
Wnt/PCP signalling by x/GABABL(a) might also be responsible for the cyclopia occasionally 
observed, it is not presently possible to incorporate the PCP pathway into a rational model 
to explain this phenomenon. It is possible that restricted separation of the eye field may 
have occurred as a secondary effect of inhibition of convergent extension in the 
chordamesoderm, resulting in restricted movement of the prechordal plate anteriorly 
towards the eye field during separation.
In order to further characterise this apparent x/GABABL(a)-specific phenotype, additional 
experiments would need to be carried out. Whilst time constraints made these unviable 
for the purposes of this project, initial analyses might include in situ hybridization 
experiments using a probe specific to Pax-6, to assess whether x/GABABL(a)- 
overexpression was having an effect on the spatiotemporal expression of this established 
marker of vertebrate eye field development.
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7.3.4 An endogenous role for xIGABAblw in the regulation of mesodermal
convergent extension is unlikely
The functional data presented in this thesis demonstrate that, when overexpressed in 
developing X.laevis embryos, x/GABABi_(a) is capable of specifically disrupting mesodermal 
convergent extension (see Section 6.3). This discovery was intriguing as it suggests that 
x/GABABL(a) might have a similar role in vivo. However, the spatiotemporal expression 
patterns for endogenously-expressed x/GABABL(a), uncovered by RT-PCR and in situ 
hybridization, do not support this notion (see Section 7.2.2). Whilst x/GABABL(a) transcripts 
were detectable in across the whole embryo by RT-PCR, x/GABABL-specific signal was 
found to be strongest in the otic vesicle of the tailbud embryo by in situ hybridization, 
suggesting a probable role in the amphibian or vertebrate ear. Staining was also 
prominent in dorsal tissues along the anteroposterior midline, which is perhaps a more 
promising location for a gene postulated to be involved in convergent extension (see 
Figure 6.8). However, the temporal expression pattern for x/GABABL(a), uncovered by RT- 
PCR and further analysed by Southern blotting with a radiolabelled probe, clearly 
demonstrated that x/GABABL(a) transcripts were not detected until neurulation (stage 14), 
many hours after the cessation of mesodermal convergent extension movements in the 
embryo. These data therefore strongly suggest that x/GABABL(a) does not normally play a 
role in the regulation of vertebrate convergent extension in vivo.
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7.4 First evidence of functionality of the putative orphan GPCR, GABAbl
7.4.1 The x IG A B A blo) cD N A  isolated here encodes a functional protein
The data presented Section 6.2 of this thesis demonstrate that overexpression of 
x/GABABL(a) during early X.laevis development brings about gross morphological changes 
in tailbud and tadpole embryos, further characterised and shown to occur as a result of 
x/GABABL(a)-specific interference with mesodermal convergent extension movements 
during gastrulation (see Section 6.3). Taken together with the demonstration that these 
reproducible morphogenetic effects manifest themselves in a x/GABABL(a) cRNA 
concentration-dependent manner (see Figure 6.11), these data indicate that the 
x/GABABL(a> cDNA shown in Figure 3.17 encodes a functional protein. This is the first 
reported evidence of functionality of this putative orphan GPCR. The demonstration that 
functional effects are observed as a result of overexpression of GABAbl will be of great 
interest to researchers investigating orphan Family 3 GPCRs since, despite the efforts of 
several research groups, previous studies have failed to demonstrate G-protein coupling 
activity for any of these proteins (Cheng,Y et al. 1998, Robbins,M.J et al. 2000, Brauner- 
Osborne.H et al. 2001, Calver.A.R et al. 2003, Bettler,B et al. unpublished observations).
7.4.2 Orphan Family 3 GPCRs may not bind endogenous ligands
Although most closely related to the GABAb receptors, GABAbl shares a common overall 
receptor topology with members of subfamily 5 of the Family 3 GPCRs (GPRC5 
receptors). There are presently four known members of the GPRC5 family of receptors:
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GPRC5A was first isolated using a differential display technique to identify retinoic acid- 
regulated genes in UMSCC-22B cells, and was originally termed retinoic acid-induced 
gene 1 (RAIG1) (Cheng,Y et al. 1998). Three other closely related retinoic acid-inducible 
receptors have subsequently be cloned and named GPRC5B, GPRC5C and GPRC5D 
(Robbins,M.J et al. 2000, Brauner-Osborne.H et al. 2001). Unlike most Family 3 GPCRs, 
GABAbl and the GPRC5 family of receptors possess short N-termini, and lack the large 
extracellular venus-flytrap modules characterised as the site of ligand-binding in the 
GABAb receptors (Malitschek.B et al. 1999), the mGluRs (O’Hara,P.J et al. 1993), 
GPRC6A (Wellendorph.P et al. 2005), and the calcium-sensing receptor (CaSR) (Brauner- 
Osborne.H et al. 1999b). Furthermore, efforts to identify endogenous ligands for these 
receptors have so far proved unsucessful (Calver,A.R et al. 2003, Brauner-Osborne.H et „ 
al. unpublished observations). Whilst it is tempting to speculate that these short N- 
terminal Family 3 GPCRs might coordinate ligands in a hydrophilic pocket formed by their 
seven transmembrane domains, in a manner analogous to the Family 1a GPCRs, this 
seems highly unlikely since the transmembrane domains of the five main GPCRs families 
are not related to each other by homology, and are thus unlikely to perform a similar 
function. Taken together with the accepted paradigm that all other Family 3 GPCRs bind 
ligands in their venus-flytrap domain, it now seems likely that neither GABAbl nor the 
GPRC5 family of GPCRs function as ligand-binding receptors.
Whilst the lack of ability to specifically bind ligands might appear to challenge the classical 
interpretation of what is considered a ‘receptor’, there are numerous examples of non 
ligand-binding seven-transmembrane proteins that perform ligand-independent roles and, 
as such, the contributions that such proteins may make to the pharmacological diversity of 
GPCRs in vivo is increasingly being evaluated (Levoye.A et al. 2006a). A well- 
characterised example is the GABAbl subunit of the GABAb receptor: a non ligand-
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binding receptor protein that couples to G-proteins in an agonist-dependent manner 
through transactivation by the ligand-binding receptor subunit with which it 
heterodimerizes. Another is the Family 5 GPCR Smoothened (Smo): a constitutively 
active non ligand-binding receptor whose coupling efficacy is modulated by the activity of 
an associated ligand-binding transmembrane protein. However, recently it has been 
demonstrated that a number of orphan receptors are capable of modulating both the 
downstream signalling cascades and internalisation of other independently functional 
GPCRs. For example, the orphan GPCR MrgE (Mas-related gene, subtype E) is capable 
of heterodimerizing with the related receptor MrgD in HEK293 cells and has been shown 
to increase the potency of MrgD to phosphorylate extracellular-signal-regulated kinase 1 
(ERK1) and ERK2, sustain elevated concentrations of intracellular calcium for a longer 
period following receptor activation, and reduce agonist-induced internalization of the 
receptor compared to when MrgD is expressed alone (Milasta,S et al. 2006). Similarly, 
the orphan receptor GPR50 has been shown to heterodimerize with the MTt melatonin 
receptor, inhibit high-affinity agonist binding and Gors coupling to adenylate cyclase, and 
dramatically reduce (3-arrestin-binding to the MT  ^promoter (Levoye.A et al. 2006b). These 
effects were demonstrated to be dependent upon the large (>300 amino acid) C-terminal 
intracellular tail of GPR50, thought to interfere with interactions between the MT-i receptor 
subunit and intracellular factors though steric hinderence. As discussed previously, the C- 
terminal tail of GABAbl is also unusually long for a GPCR (at around 480 amino acids), 
and might function in a similar fashion to that of GPR50.
The activity of the x/GABABL(a) protein in X.laevis embryos following overexpression, 
demonstrated in Sections 6.2 and 6.3, may be thought to arise as a result of four possible 
scenarios. First, should GABAbl indeed be an orphan GPCR, the observed activity of 
x/GABABL(a) may have be agonist-induced, and thus dependent on the co-localisation of
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the overexpressed x/GABABL(a) protein and its endogenous ligand in the embryo. Second, 
the overexpression of x/GABABi_(a) protein, which contains numerous putative RXR-type 
ER retention motifs, in the absence of normal physiological regulation of temporal and 
spatial expression might induce phenotypic changes in the embryo by retaining binding 
partners, with which it would not normally be co-expressed in vivo, on intracellular 
membranes. This model implies that the morphological changes observed here in 
x/GABABL(a)-overexpressing embryos did not occur directly as a result of the biological 
activity of x/GABABL(a), but rather as a result of inhibition of the normal function of other 
factors involved in the regulation of convergent extension. Third, should GABAbl function 
as a genuine partner in a hitherto unidentified GPCR hetero-oligomer, the observed 
activity would presumably have been dependent upon the co-expression of the 
x/GABABL(a) protein with both its receptor subunit partner(s) and their endogenous 
ligand(s) during these experiments. Finally, should x/GABABL(a) exhibit a basal level of 
constitutive activity at the cell surface when expressed at normal physiological levels, the 
frequency of G-protein coupling would presumably have been amplified by 
overexpression, and may have induced a sufficient level of signal transduction in 
overexpressing cells as to trigger physiologically significant downstream effects. Since it 
is postulated that GABAbl is a non ligand-binding seven-transmembrane protein, the latter 
three scenarios are favoured here, however, the notion of constitutive activity is perhaps 
easier to reconcile since it does not require both the spatiotemporal co-expression of other 
receptor proteins and the abundance of specific extracellular signals. Indeed, the 
observation that a robust morphogenetic response is observed even when x/GABABL(a) is 
overexpressed at relatively low levels in the embryo (see Figure 6.11 A) is perhaps 
indicative of x/GABABL(a) functioning as a constitutively active GPCR in vivo, and these 
findings are consistent with a model that expression of x/GABABL(a) without the normal
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spatiotemporal controls and in the absence of its endogenous attenuating factors gives 
rise to unregulated coupling to G-protein signalling cascades.
Should the assumption be made that GABAbl, and indeed the GPRC5 family of receptors, 
are non ligand-binding proteins, future research would benefit from diverting attention 
away from trying to identify extracellular ligands for these receptors, and instead pursuing 
their ‘de-orphanisation’ through characterisation of intracellular interactions with other 
membrane-bound or cytosolic factors. Rational approaches to achieve this aim are briefly 
discussed in Sections 7.5.3 and 7.5.4.
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7.5 Future research
7.5.1 A knock-down approach to investigate the role of GABA signalling during 
X.laevis development
During the course of this project, several approaches were explored in order to investigate 
the effects of knock-down of GABA signalling on the development of X.laevis embryos. 
Firstly, experiments were carried out where wild-type embryos were allowed to develop in 
medium containing the GABAa receptor antagonist, bicuculline, or the GABAb receptor 
antagonist CGP35348, or a combination of both; the aim of these experiments being to 
specifically knock-down ionotropic or metabotropic GABA signalling in the developing 
embryo. However, in these experiments, embryos were found to develop perfectly 
normally, even when antagonist concentrations of up to 200pM were used, suggesting 
that knock-down of GABA signalling might not give rise to major morphogenetic or 
behavioural effects in developing embryos.
Secondly, an alternative approach was explored that was designed to reduce the 
concentration of GABA in the extracellular fluid whilst simultaneously specifically inhibiting 
GABAb receptor activity. A construct was produced, using the pCS2+ plasmid vector, 
which contained an insert encoding a polypeptide corresponding to the mature N-terminal 
extracellular domain (ECD) of /7GABAB(1a); the construct was also used as a control in the 
in vitro translation experiments performed in Section 3.5.4 (see Figure 3.21). This 
construct was almost identical to that used by Malitshek and colleagues to demonstrate 
that the ECD of GABAB(1) is soluble and sufficient to bind agonists and antagonists 
(Malitshek,B et al. 1999), except for the inclusion of nucleotide sequence encoding the N-
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terminal signal peptide sequence for X.laevis bone morphogenetic protein 1 (x/BMP-1), 
which was ligated in-frame at the 5’ end of the mature hGABAB(1a)ECD sequence and 
designed to promote secretion of the translated protein when expressed in X.laevis 
embryos. cRNA transcribed from this construct was injected into cleavage stage embryos 
in a series of experiments performed alongside the GABAb receptor overexpression 
experiments described in Section 6.2. The rationale behind this study was that, should 
the overexpressed hGABAB(1a)ECD protein indeed be secreted, it would bind endogenous 
GABA present in the extracellular fluid with a greater affinity than wild-type GABAb 
receptors, as demonstrated previously (Malitshek,B et al. 1999), thus reducing the 
probability of agonist-induced activation of GABAb receptors at the cell surface. In 
addition, overexpression of the f7GABAB(1a)ECD protein was intended to further inhibit 
GABAb receptor activity, in a dominant negative fashion, through heterodimerization with 
the N-termini of endogenously expressed GABAB(2) receptor subunits, as was 
demonstrated for the similarly truncated GABAb(1) receptor isoform, /?GABAB(ie) 
(Schwarz,D.A et al. 2000). Ultimately, these experiments were abandoned on technical 
grounds, as efforts to reproducibly demonstrate translation and secretion of the protein 
from X.laevis oocytes, embryos or animal cap explants by western analysis failed. 
Nonetheless, these overexpression assays also generated a predominantly wild-type 
phenotype in injected embryos, consistent with the notion that aberrations in GABAb 
receptor signalling during development may not give rise to gross morphological or 
behavioural changes in developing embryos.
In order to optimise this experiment a number of modifications could be made. For 
example, the construct could be modified to include signal peptide sequences from more 
robustly secreted proteins than BMP-1, such as Activin A. The recombinant protein could 
also be tagged with a hemagglutinin (HA), poly-histidine or myc epitope, in order to
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optimise the detection of the translated protein by western analysis, and avoid reliance 
upon the N-terminal GABAB(ia) polyclonal antibody used here. With these modifications, 
this approach might represent a novel and elegant method of effectively silencing GABA 
signalling in the CNS of developing embryos.
7.5.2 A knock-down approach to investigate the role of xlGABABL(a) endogenously 
expressed during X.laevis development
Following the demonstration that overexpression of x/GABABL(a) protein during 
development brings about reproducible morphogenetic effects in X.laevis embryos (see 
Section 6.2), a loss-of-function approach designed to knock-down endogenous 
x/GABABL(a) expression was considered, and some laboratory work was carried out with 
respect to this proposal. A rationale was developed whereby a synthetic antisense RNA 
analogue (or morpholino), with sequence complimentary to that of the region spanning the 
initiation codon of x/GABABL(a), was to be synthesized and injected into cleavage-stage 
X.laevis embryos in an effort to block the translation of endogenously expressed 
x/GABABL(a), and thus determine the effects of knock-down of this gene during 
development. An alternative x/GABABL(a) expression construct was also produced, using 
the pCS2+ plasmid vector, which contained nine silent mutations in the region of the 
5’UTR and initiation codon, such that the morpholino would be unlikely to form a duplex 
with cRNA transcribed from this template. A series of experiments were planned whereby 
the morpholino was to be co-injected with this alternative x/GABABL(a) cRNA into cleavage- 
stage embryos, in an effort to rescue any specific morphogenetic phenotypes observed as 
a result of the morpholino-induced knock-down of endogenous x/GABABL(a) expression. 
Whilst time constraints meant that these experiments could not be performed as part of
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this project, this approach represents an ideal method to gain insight into the in vivo 
functions of x/GABABi_(a) expressed during X.laevis embryo development, and the findings 
from these experiments would be highly complementary to the data presented in this 
thesis. Indeed, these data would almost certainly be deemed necessary to permit the 
publication of the results from this project in a quality peer-reviewed journal and, as such, 
obtaining them would be a priority for any future research into the functionality of this 
protein.
7.5.3 Selective G-protein knock-down approach to investigate signal transduction by 
x IG A B A blo) when overexpressed in developing X.laevis embryos
In Section 6.4.2 it was postulated that the morphogenetic effects observed as a result of 
x/GABAblo) overexpression might be attributed to the activation of intracellular signalling 
cascades. However, GABAbl remains a putative GPCR whose cognate G-protein has yet 
to be identified and, as such, it is not possible to satisfactorily integrate the experimental 
findings of this project into a rational model to describe x/GABABL(a) signalling in vivo. 
Given that functionality has been demonstrated for GABAbl using this gain-of-function 
approach, it may now be possible to develop an assay based upon this system that would 
facilitate the identification of the downstream signal transduction pathway to which 
x/GABABL(a), or indeed any other GPCR which elicits a function response when 
overexpressed in X.laevis embryos, couples to in vivo. This approach would first focus on 
the development, or where possible, acquisition, of dominant negative isoforms of 
Xenopus Ga subunit G-proteins and small GTPases, analogous to the Ga0 and Gai2 
mutants generated by Slepak and colleagues previously (Slepak.V.Z et al. 1993, 
Slepak.V.Z et al. 1995), capable of knocking-down the activity of their endogenously
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expressed counterparts when overexpressed in X.laevis embryos. Following optimisation 
of this assay, through the demonstration of the knock-down of specific G-protein signal 
transduction cascades in response to activation of previously characterised GPCRs, 
experiments could then be performed whereby x/GABABi_(a) was co-overexpressed with 
each dominant negative G-protein separately. Rescue of the body truncation phenotype, 
normally associated with X.laevis embryos overexpressing x/GABABi_(a), though co­
expression with one of these G-proteins would provide strong evidence of a functional 
association, and might serve to identify which signal transduction pathway(s) x/GABABL(a) 
mediates its effects through in vivo. Furthermore, if successful, a valuable product of this 
research would be a tool-box of dominant negative Xenopus G-proteins that could be 
used to characterise a host of other GPCRs expressed using this system.
Based upon the evidence that x/GABABL(a) appears to specifically interfere with the non- 
canonical Wnt/PCP pathway when overexpressed in X.laevis embryos and animal cap 
explants (see Section 6.4.2), the x/GABABL(a) protein might be expected to directly or 
indirectly regulate the activity of small GTPases like RhoA, Rac1 and cdc42, which have 
been identified previously as downstream effectors of the Wnt/PCP pathway (Sheldahl.L.C 
et al. 2003). Indirect regulation might occur as a result of x/GABABL(a)-induced activation of 
a heterotrimeric G-protein that positively or negatively regulates Dishevelled (Dsh), 
bringing about the activation or deactivation of the downstream small GTPases and c-Jun 
N-terminal kinase (JNK) in the Wnt/PCP pathway (see Figure 1.2). Another possibility is 
that x/GABABL(a> activates heterotrimeric G-proteins containing Ga^mz subunits, which 
have recently been shown to directly regulate RhoA and its downstream effects by binding 
to and activating RhoGEFs (Kozasa.T wt al. 1998, Hart.M.J et al. 1998, Sah.V.P et al. 
2000). In addition to the application of the G-protein knock-down assay described above 
pull-down assays could also be performed, using antibodies specific for activated (GTP-
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bound) RhoA, Rac1 and cdc42, to compare the relative levels of each activated G-protein 
in wild-type and x/GABABL(a)-overexpressing embryos, as described previously 
(Unterseher.F et al. 2004). These data would provide insight into the effects of 
x/GABABL(a) overexpression upon the activation or inhibition of specific small GTPases, 
and thus help to further characterise the nature of the signal transduction pathway(s) to 
which x /GABAblo) couples. Ultimately, it might be possible to carry out functional studies 
whereby the downstream effects of x/GABAbl^) activation could be investigated in an 
agonist-dependent fashion. This could be achieved through the development of a 
chimeric receptor protein containing the N-terminal ECD from a related ligand-binding 
Family 3 GPCR, such as x/GABAB(i), and the seven-transmembrane and intracellular C- 
terminal domains of x/GABABL(a); a similar chimeric receptor containing the N-terminal 
ECD of the CaSR and the seven-transmembrane and C-terminal domains of mGluRI was 
shown to be pharmacologically indistinguishable from the wild-type CaSR (Brauner- 
Osbourne,H et al. 2001).
7.5.4 Rational approaches to identify GABABL-interacting factors
In Section 7.4.2 it was suggested that GABAbl and the other short N-terminal Family 3 
GPCRs may not function as ligand-binding receptors in vivo, and that future research 
might benefit from focussing attention upon the characterisation of the intracellular 
interactions of these orphan receptors. As discussed in Section 7.5.3, the proposed 
coupling of x/GABABL(a> to downstream G-protein signalling cascades could be thought to 
occur either as a result of transactivation, by another ligand-binding receptor partner with 
which it heterodimerizes, or through ligand-independent constitutive activity of the 
recombinant protein when overexpressed in X.laevis embryos. Given that GABAbl protein
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possesses an extremely extracellular short N-terminal domain, it is likely that any 
heterodimerization interfaces with other GPCR partners would reside within either the 
transmembrane a-helices or the extended C-terminal intracellular tail of GABAbl- Should, 
GABAbl function in an ligand-independent fashion in vivo, as a constitutively active homo- 
oligomeric GPCR, its downstream signalling activity would presumably still be regulated 
by other intracellular factors through the attenuation of G-protein coupling in response to 
specific cellular events. Thus, the identification of proteins that specifically interact with 
GABAbl at the plasma membrane, whether they be membrane-anchored or cytosolic, 
would permit the characterisation of the ligand-independent properties of this putative 
GPCR, and help to build a model to explain the functional effects observed as a result of 
overexpression of the x/GABABL(a) protein in X.laevis embryos. At best, this approach 
might lead to the discovery of a novel and pharmacologically distinct GPCR hetero­
oligomer, or a previously uncharacterised cell signalling mechanism, which enhances our 
understanding of an important disease state.
Two approaches that could be explored in order to identify specific GABAbl C-terminal- 
interacting factors are considered here. The first would be to screen for interactions using 
the yeast-2-hybrid system, whereby the intracellular C-terminal tail of GABAbl would be 
used as a ‘bait’ protein to identify interacting proteins encoded by cDNA clones from a 
library: an approach that has been used previously to identify GABAB(i) C-terminal- 
interacting proteins (Nehring.R.B et al. 2000, Vernon,E et al. 2001, White,J.H et al. 2000, 
Sauter.K et al. 2001, Couve.A et al. 2001, Couve.A et al. 2004), and to demonstrate the 
existence of a specific heterodimerization interface between the C-terminal domains of the 
GABAB(i ) and GABAB(2) receptor subunits (White,J et al. 1998, Kuner.R et al. 1999, 
White,J et al. 2002). One limitation of this technique is that it is unsuitable for the 
identification of weak or transient protein-protein interactions and, as such, many specific
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and physiologically important associations may not be detected using this approach. 
Another disadvantage is that the screening of a cDNA library, encoding the entire 
complement of genes expressed by a particular tissue, could give rise to potentially 
misleading positive results where, for example, a strong specific interaction is 
demonstrated between the GABAbl C-terminus and a protein that would never normally 
come into contact with cell-surface receptors by virtue of the compartmentalisation of the 
cell in vivo. Indeed, the specific interactions between the C-terminus of GABAB(i) and the 
RNA-binding protein Marlin-1, or the ATF/CREB family of transcription factors, identified 
previously by yeast-2-hybrid experiments (Nehring,R.B et al. 2000, Vernon,E et al. 2001, 
White,J.H et al. 2000, Couve.A et al. 2004), may not prove to be of any physiological 
relevance; there is presently no evidence to suggest that any of these proteins are 
capable of modulating GABAb receptor activity, and it remains difficult to incorporate them 
into a coherent model to explain any demonstrable aspect of GABAb receptor biology.
A second and, potentially, much more sensitive approach would be to express and purify 
sufficient recombinant GABAbl C-terminal protein to permit the synthesis of a GABAbl C- 
terminal affinity chromatography column. Cell lysates from tissues that normally express 
GABAbl, such as the hypothalamus or the pyramidal cell layers of the hippocampus 
(Charles,K.J et al. 2003), could then be passed through the column to pull out potential 
cytosolic GABABl C-terminal-interacting factors. Once eluted from the column, short 
amino acid sequences from fragments of these proteins could be elucidated by mass 
spectrometry, and then used as queries to search GenBank databases to reveal the 
identity of the interacting gene products. Once identified, cDNAs encoding these proteins 
could be cloned, and the interactions between GABAbl and these recombinant proteins 
characterised by yeast-2-hybrid and co-immunoprecipitation experiments. A primary 
objective would be to map the location of any specific interactions using a series of
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GABAbl C-terminal deletion constructs, and identify critical amino acid residues through 
mutagenesis studies. As discussed in Section 3.4.6, whilst exhibiting very poor sequence 
conservation overall, the C-terminal tail of GABAbl possesses several highly conserved 
amino acid sequences, such as EKLQE(IA/)L, SPY(MA/)(MA/)RRR, SSSS and 
CHRPYCE(IA/)C (see Figure 3.18). Specific interactions involving these sequences 
would presumably be conserved throughout the vertebrate kingdom, and might be of great 
physiological relevance.
A research project is thus conceived, using the approaches described here, to evaluate 
the hypothesis that G ABA bl and the GPRC5 family of orphan receptors are non ligand- 
binding seven-transmembrane proteins that couple to intracellular signal transduction 
cascades via G-proteins, and whose activity is regulated by hitherto unidentified 
associated factors. An initial assumption would be that these proteins function as the G- 
protein coupling component of a GPCR hetero-oligomer, and are activated in an agonist- 
dependent manner by a ligand-binding receptor partner, analogous to GABAB(2). 
However, an alternative model would be that these proteins represent constitutively active 
GPCRs who function as part of larger oligomeric GPCR assemblies to modulate the 
signalling properties of other receptors with which they are associated.
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Table 9.1 Intron/exon sizes and locations in GABAB(1) genes
G A B A b(i )
Chromosome
Sequence
Strand
Exon/lntron
H.sapiens
6
A L645936.5.1 .155874  
minus
size (bp)
start (bp) end (bp)
R.norvegicus
20
AA B R 03116854.1 
minus
size (bp)
start (bp) end (bp)
X.tropicalis
not available 
Scaffold _396  
plus
size (bp)
start (bp) end (bp)
Exon -1a2 531
1,023,756 1,024,286
Intron -6 8,719
1,024,287 1,033,005
Exon -1a1 311 181 117
29,708 ,916  29,708 ,606 1,582,398 1,582,218 1,033,006 1,033,122
Intron -5 464 420 282
29,708 ,605  29,708 ,142 1,582,217 1,581,798 1,033,123 1,033,404
Exon 1a1 85 82 76
29,708,141 29,708 ,057 1,581,797 1,581,716 1,033,405 1,033,480
Intron -4 701 645 534
29,708 ,056  29,707 ,356 1,581,715 1,581,071 1,033,481 1,034,014
Exon 1a2 204 204 204
29,707 ,355  29,707,152 1,581,070 1,580,867 1,034,015 1,034,218
Intron -3 752 749 5,153
29,707,151 29,706 ,400 1,580,866 1,580,118 1,034,219 1,039,371
Exon 1a3 186 186 189
29,706 ,399  29,706 ,214 1,580,117 1,579,932 1,039,372 1,039,560
Intron -2 1,350 1,177 17,843
29,706 ,213  29,704 ,864 1,579,931 1,578,755 1,039,561 1,057,403
Exon 1a4 21 21 21
29,704 ,863  29,704,843 1,578,754 1,578,734 1,057,404 1,057,424
Intron -1 1,440 1,199 3 ,167
29,704 ,842  29,703,403 1,578,733 1,577,535 1,057,425 1,060,591
Exon 1a 161 161 161
29,703 ,402  29,703,242 1,577,534 1,577,374 1,060,592 1,060,752
Exon 1b 553 504 829
29,703 ,794  29,703,242 1,577,877 1,577,374 1 ,059,924 1,060,752
Intron 1 3,461 2,934 1,413
29,699,781 29,703,241 1,577,369 1 ,574,436 1,060,753 1,062,165
Exon 2 135 135 135
29,699 ,780  29,699646 1,574,435 1,574,301 1 ,062,164 1,062,298
Intron 2 414 394 837
29,699 ,645  29,699,232 1,574,300 1,573,907 1,062,299 1,063,135
Exon 3 171 171 171
29,699,231 29,699,061 1,573,906 1,573,736 1 ,063,136 1,063,306
Intron 3 1,099 891 1,868
29,699,060 29,697,962 1 ,573,735 1 ,572,845 1,063,307 1,065,174
D.melanog aster
2L
N T .0 33 7 79
plus
size (bp)
start (bp) end (bp)
243
15,013,083
3,695
15,013,326
255
15,017,021
4,043
15,017,276
135
15,021,319
90
15,021,454
171
15,013,325
15,017,020
15,017,275
15,021,318
15,021,453
15,021,543
15,021,544 1 5,021,714
61
Exon -1
Intron -1
Intron 3
15,021,715 15,021,775
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Exon 4 102 102 102
29,697,961 29,697,860 1,572,844 1,572,743 1,065,175 1,065,276
Intron 4 286 295 3,702 |
29,697 ,859  29,697,574 1,572,742 1,572,448 1,065,277 1,068,978
Exon 5 66 66 69
2 9,697 ,573  29,697,508 1,572,447 1,572,382 1,068,979 1,069,047
Intron 5 459 531 267
2 9,697 ,507  29,697,049 1,572,381 1,571,851 1,069,048 1,069,314
Exon 6 192 192 189
2 9,697 ,048  29,696,857 1,571,850 1,571,659 1,069,315 1,069,503
Intron 6 7 ,615 5,347 124
29,696 ,856  29,689,242 1,571,658 1,566,312 1,069,504 1,069,627
Exon 7 243 243 243
29,689,241 29,688 ,999 1,566,311 1,566,069 1,069,628 1,069,870
Intron 7 628 588 1,050
29,688 ,998  29,688,371 1,566,068 1,565,481 1,069,871 1,070,920
Exon 8 64 64 64
29,688 ,370  29,688 ,307 1,565,480 1,565,417 1,070,921 1,070,984
Intron 8 1,549 1,307 2,296
29,688 ,306  29,686 ,758 1,565,416 1,564,110 1,070,985 1,073,280
Exon 9 78 78 79
29,686 ,757  29,686 ,680 1,564,109 1,564,032 1,073,281 1,073,359
Intron 9 1,544 2,662 1,326
29,686 ,679  29,685 ,136 1,564,031 1,561,370 1,073,360 1,074,685
Exon 10 151 151 152
29,685 ,135  29,684 ,985 1,561,369 1,561,219 1,074,684 1,074,835
Intron 10 495 430 382
29,684 ,984  29,684 ,490 1,561,218 1,560,789 1,074,836 1,075,217
Exon 11 133 133 133
29,684 ,489  29,684 ,357 1,560,788 1,560,656 1,075,218 1,075,350
Intron 11 1,382 1,826 303
29,684 ,356  29,682 ,975 1,560,655 1,558,830 1,075,351 1,075,653
Exon 12 117 117 126
29,682 ,974  29,682 ,858 1,558,829 1,558,713 1,075,654 1,075,779
Intron 12 97 202 12,169
29,682 ,857  29,682,761 1,558,712 1,558,511 1,075,780 1,087,948
Exon 13 108 108 105
29,682 ,760  29,682,653 1,558,510 1,558,403 1 ,087,949 1,088,053
Intron 13 412 545 533
29,682 ,652  29,682,241 1,558,402 1,557,858 1 ,088,054 1,088,586
Exon 14 94 94 97
29,682 ,240  29,682,147 1,557,857 1,557,764 1 ,088,587 1,088,683
Intron 14 694 568 224
29,682 ,146  29,681,453 1,557,763 1,557,196 1,088,684 1,088,907
Exon 15 128 128 129
29,681,452 29,681,325 1 ,557,195 1 ,557,068 1,088,908 1,089,036
Intron 15 580 1,346 423
29,681 ,324  29,680,745 1,557,067 1,555,722 1,089,037 1,089,459
Exon 16 129 129 129
29,680,744 29,680 ,616 1,555,721 1 ,555,593 1 ,089,460 1,089,588
217_________ j
15,021,776 15,021,992
92
15,021,993 15,022,084
166
15,022,085 15,022,250
63
15,022,251 15,022,313
244
15,022,314 15,022,557
59
15,022,558 15,022,616
150
15,022,617 15,022,766
2,751
15,022,767 15,025,517
143
15,025,518 15,025,660
58
15,025,661 15,025,718
124
15,025,719 15,025,842
71
15,025,843 15,025,913
117
15,025,914 15,026,030
63
15,026,031 15,026,093
208
15,026,094 15,026,301
57
15,026,302 15,026,358
257
15,026,359 15,026,615
60
15,026,616 15,026,675
Intron 4
Exon 5
Intron 5
Exon 6
Intron 6
Exon 7
Intron 7
Exon 8
Intron 8
Exon 9
Intron 9
Exon 10
Intron 10
Exon 11
Intron 11
Exon 12
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Intron 16 222
29,680,394
105
1,555,488
1,097
1,090,68529,680 ,615 1,555,592 1,089,589
Exon 17 144 144 144 138
29,680 ,393 29,680,250 1,555,487 1,555,344 1,090,686 1,090,829 15,026,676 15,026,813
Intron 17 566 161 1,118
29,680 ,249 29,679 ,473 1,555,343 1,554,778 1,090,830 1,090,990 15,026,814 15,027,931
Exon 18 1,489 1,466 818 189
29,679 ,472 29,677 ,984 1,554,777 1,553,312 1,090,991 1,091,808 15,027,932 15,028,120
Z exon (bp) 4,512 (1a) 4,356 (1a) 4,184 (1a) 2,757 |
4 ,097 (1b) 4,025 (1b) 3,714 (1b)
I  intron (bp) 26,421 (1a) 24,727 (1a) 63,873 (1a) 12,281
21,714 (1b) 20,537 (1b) 28,175 (1b)
Exon 13 
Intron 13 
Exon 14
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Table 9.2
G A B A b(2i
Chromosome
Sequence
Strand
Exon/lntron
Exon 1
Intron 1
Exon 2
Intron 2
Exon 3
Intron 3
Exon 4
Intron 4
Exon 5
Intron 5
Exon 6
Intron 6
Exon 7
Intron 7
Exon 8
Intron 8
Exon 9
Intron/exon sizes and locations in GABAB(2) genes
H.sapiens
9
AL353782 23.1 .165358  
minus
size (bp)
start (bp) end (bp)
R. norvegicus
5
AABR03040519.1
minus
size (bp)
start (bp) end (bp)
X.tropicalis
not available 
Scaffold_140 
plus
size (bp)
start (bp) end (bp)
781 468 702
98,551 ,034  98,550,254 63,611 ,907  63,611,440 100,516 101,217
130,344 115,045 100,617
98,550 ,253  98,419,910 63,611 ,439  63,496,395 101,218 201,834
138 138 138
9 8,419 ,909  98,419,772 63,496 ,394  63,496,257 201,835 201,972
35,891 31,342 46,944
98,419,771 98,383,881 63,496 ,256  63,464,915 201,973 248,916
171 171 171
98,383 ,880  98,383,710 63,464 ,914  63,464,744 248,917 249,087
45,358 30,514 19,573
9 8,383 ,709  98,338,352 63,464,743 63,434,230 249,088 268,660
102 102 102
98,338,351 98,338,250 63,434,229 63,434,128 268,659 268,760
15,415 13,545 5,658
98,338 ,249  98,322,835 63,434,127 63,420,583 268,761 274,418
66 66 66 |
98,322 ,834  98,322,769 63,420,582 63,420,517 274,419 274,484
7,585 5,593 4,829
98,322 ,768  98,315,184 63,420,516 63,414,924 274,485 279,313
201 201 189
98,315 ,183  98,314,983 63,414,923 63,414,723 279,314 279,502
18,928 11,292 2,210
98,314,982 98,296,055 63,414,722 63,403,431 279,503 281,712
237 237 237
98,296 ,054  98,295,818 63,403,430 63,403,194 281,711 281,947
47,839 60,811 45,856
98,295,817 98,247,979 63,403,193 63,342,383 281,948 327,803
61 61 61
98,247,978 98,247,918 63,342 ,382  63,342,322 327,804 327,864
11,825 20,790 35,637
98,247,917 98,236,093 63,342,321 63,321,532 327,865 363,501
81 81 81
98,236,092 98,236,012 63,321,531 63,321,451 363,502 363,582
D.melanog aster
3R
NT_033777
minus
size (bp)
start (bp) end (bp)
100
17,601,562 17,601,463
393
17,601,462 17,601,070
263
17,601,069 17,600,807
176
17,600,806 17,600,631
482
17,600,630 17,600,149
61
17,600,148 17,600,088
Exon -1
Exon 1
Intron 1
Exon 2
Intron 2
181
17,600,087
55
17,599,906
219
17,599,851
55
17,599,632
296
17,599,577
60
17,599,907
17,599,633
17,599,578
17,599,282
17,599,281 17,599,222
Exon 3
Intron 3
Intron 4
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Intron 9 
Exon 10 
Intron 10 
Exon 11 
Intron 11 
Exon 12 
Intron 12 
Exon 13 
Intron 13 
Exon 14 
Intron 14 
Exon 15 
Intron 15 
Exon 16 
Intron 16 
Exon 17 
Intron 17 
Exon 18 
Intron 18 
Exon 19
Z exon (bp) 
£ Intron (bp)
5,170
98,236,011
151
98,230,841
98,230,690
133
98,227,609
14,068
98,227,476
108
98,213,408
8,626
98,213,300
123
98,204,674
51,509
98,204,551
111
98,153,042
4,749
98,152,931
225
98,148,182
2,697
98,147,957
183
98,145,260
3,887
98,145,077
130
98,141,190
5,321
98,141,060
118
98,135,739
3,035
98,135,621
2,666
98,230,842
98,230,691
98,227,610
98,227,477
98,213,409
98,213,301
98,204,675
98,204,552
98,152,932
98,148,183
98,147,958
98,145,261
98,145,078
98,141,191
98,141,061
98,135,740
98,135,622
98,132,587
98,132,586 98,129,921
3,416
63,321,450
63,318,034
2,163
63,317,883
133
63,315,720
9,339
63,315,587
108
63,306,248
6,624
63,306,140
123
63,299,516
37,246
63,299,393
111
63,262,147
2,689
63,262,036
225
63,259,347
3,512
63,259,122
183
63,255,610
2,810
63,255,427
130
63,252,617
5,799
63,252,487
118
63,246,688
2,506
63,246,570
2,668
63,318,035
63,317,884
63,315,721
63,315,588
63,306,249
63,306,141
63,299,517
63,299,394
63,262,148
63,262,037
63,259,348
63,259,123
63,255,611
63,255,428
63,252,618
63,252,488
63,246,689
63,246,571
63,244,065
63,244,064 63,241,397
3,510
363,583
151
367,093
207
367,244
133
367,451
108
372,623
6,238
372,731
123
378,969
55,351
379,092
111
434,443
225
435,238
3,050
435,463
438,513
3,479
438,696
130
442,175
1,700
442,305
118
444,005
6,000
444,123
595
367,092
367,243
367,450
367,583
372,622
372,730
378,968
379,091
434,442
434,553
435,237
435,462
438,512
438,695
442,174
442,304
444,004
444.122
450.122
450,123 450,717
5,786 3,624
| 415,328 365,036 346,582
364 Exon 6
17,599,221 17,598,858
Intron 662
17,598,857 17,598,796
111 Exon 7
17,598,795 17,598,685
Intron 766
17,598,684 17,598,619
225 Exon 8
17,598,618 17,598,394
Intron 8424
17,598,393 17,597,970
346 Exon 9
17,597,969 17,597,624
Intron 965
17,597,623 17,597,559
103 Exon 10
17,597,558 17,597,456
Intron 1057
17,597,455 17,597,399
467 Exon 11
17,597,398 17,596,932
Intron 1161
17,596,931 17,596,871
816 Exon 12
17,596,870 17,596,055
I 3,973 
| 1,535
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Table 9.3 Intron/exon sizes and locations in GABAbl genes
G A B A bl
Chromosome
Sequence
Strand
Exon/lntron
H.sapiens
3
AC092897.6.1.127044 
minus
size (bp)
start (bp) end (bp)
R .norvegicus
11
AABR03081639.1 
minus
size (bp)
start (bp) end (bp)
X.tropicalis
not available 
Scaffold_692 
plus
size (bp) 
start (bp) end (bp)
Exon 1 338 96 116
121,445,877 121,445,540 64,571,771 64,571,676 198,728 198,843
Intron 1 226 1,619 2,938
121,445,539 121,445,314 64,571,675 64,570,057 198,844 201,781
Exon 2 137 137 119
121,445,313 121,445,177 64,570,056 64,569,920 201,782 201,900
Intron 2 50,215 33,336 | 175
121,445,176 121,394,962 64,569,919 64,536,584 201,901 202,075
Exon 3 130 130 124
121,394,961 121,394,832 64,536,583 64,536,454 202,076 202,199
Intron 3 245 210 94
121,394,831 121,394,587 64,536,453 64,536,244 202,200 202,293
Exon 4 111 111 111
121,394,586 121,394,476 64,536,243 64,536,133 202,294 202,404
Intron 4 6,155 12,130 1,560 |
121,394,475 121,388,321 64,536,132 64,524,003 202,405 203,964
Exon 5 126 126 126
121,388,320 121,388,195 64,524,002 64,523,877 203,965 204,090
Intron 5 1,263 879 104
121,388,194 121,386,932 64,523,876 64,522,998 204,091 204,194
Exon 6 96 96 96
121,386,931 121,386,836 64,522,997 64,522,902 204,195 204,290
Intron 6 3,937 3,043 196
121,386,835 121,382,899 64,522,901 64,519,859 204,291 204,486
Exon 7 237 237 237
121,382,898 121,382,662 64,519,858 64,519,622 204,487 204,723
Intron 7 7,654 5,319 266
121,382,661 121,375,008 64,519,621 64,514,303 204,724 204,989
Exon 8 159 159 159
121,375,007 121,374,849 64,514,302 64,514,144 204,990 205,148
Intron 8 4,927 5,877 210
121,374,848 121,369,922 64,514,143 64,508,267 205,149 205,358
Exon 9 1,454 1,287 1,668
121,369,921 121,368,468 64,508,266 64,506,980 205,359 207,026
E exon (bp) 2,788 2,379 I 2,756
I  intron (bp) 74,622 62,413 I 5,543
Table 9.3 Intron/exon sizes and locations in GABAbl genes
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Table 9.4 Data from scoring of microinjected embryos
2-cell blastulae 
A microinjections
x /G A B A e (ia ) x /G A B A e(ib ) x /G A B A b(2> x /G  A B A b(13/2) x /G A B A B(ib/2) x /G A B A s n a ) un-in jected
Score n % n % n % n % n % n % n %
1 15 100.0 20 100.0 22 95.7 17 77.3 10 58.8 0 0.0 23 95.8
2 0 0.0 0 0.0 1 4.3 4 18.2 5 29.4 0 0.0 1 4.2
3 0 0.0 0 0.0 0 0.0 1 4.5 2 11.8 24 77.4 0 0.0
4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 7 22.6 0 0.0
Total 15 100.0 20 100.0 23 100.0 22 100.0 17 100.0 31 100.0 24 100.0
8-cell blastulae 
B microinjections
X /G A B A B(ia) x /G A B A s c ib ) x /G A B A b(2> X /G A B A B(1a/2) x / G A B A B(ib/2) x /G A B A bloi un-injected
Score n % n % n % n % n % n % n %
1 20 76.9 26 81.3 22 75.9 9 60.0 8 61.5 0 0.0 23 95.8
2 3 11.5 3 9.4 4 13.8 2 13.3 3 23.1 0 0.0 1 4.2
3 2 7.7 2 6.3 1 3.4 1 6.7 2 15.4 4 33.3 0 0.0
4 1 3.8 1 3.1 2 6.9 3 20.0 0 0.0 8 66.7 0 0.0
Total 26 100.0 32 100.0 29 100.0 15 100.0 13 100.0 12 100.0 24 100.0
2-cell blastulae microinjections 
C  (x /G A B A e u a )  dose response)
Score
0 .2
n %
0 .4
n %
0 .8
n %
1 .6
n %
un -in jec ted
n %
1 13 76.5 3 13.6 0 0.0 0 0.0 18 100.0
2 3 17.6 2 9.1 2 16.7 1 11.1 0 0.0
3 1 5.9 9 40.9 3 25.0 3 33.3 0 0.0
4 0 0.0 8 36.4 7 58.3 5 55.6 0 0.0
Total 17 100.0 22 100.0 12 100.0 9 100.0 18 100.0
Table 9.4 Data from scoring of microinjected embryos
